

PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME

RELATED APPLICATIONS

This application claims priority to U.S.S.N. 60/248,153, filed November 13, 2000;
5 U.S.S.N. 60/249,598, filed November 17, 2000; U.S.S.N. 60/264,240, filed January 26, 2001;
U.S.S.N. 60/266,127, filed February 2, 2001; U.S.S.N. 60/269,562, filed February 16, 2001;
U.S.S.N. 60/304,348, filed July 10, 2001; U.S.S.N. 60/309,261, filed July 31, 2001, and
U.S.S.N. 60/313,283, filed August 17, 2001 each of which is incorporated by reference in its
entirety.

10 FIELD OF THE INVENTION

The invention relates to polynucleotides and the polypeptides encoded by such
polynucleotides, as well as vectors, host cells, antibodies and recombinant methods for
producing the polypeptides and polynucleotides, as well as methods for using the same.

BACKGROUND OF THE INVENTION

15 The present invention is based in part on nucleic acids encoding proteins that are new
members of the following protein families: Membrane protein/neuropilin/metalloproteinase-
like protein-like, Fibrillin-like, KIAA1589-like, WD 40 motif-like, Opioid Binding Cell Adhesion
Molecule-like, Triacylglycerol lipase-like, IGE Receptor Beta Subunit-like, Munc 18-like,
Immunoglobulin-like and Type II Cytokeratin-like. More particularly, the invention relates to
20 nucleic acids encoding novel polypeptides, as well as vectors, host cells, antibodies, and
recombinant methods for producing these nucleic acids and polypeptides.

Neuropilins play an active role in angiogenesis as they are receptors for VEGF and
may regulate VEGF-induced angiogenesis. Neuropilins are also expressed by tumor cells and
may play a role in tumor angiogenesis. Neuropilins also play a role in axon guidance as they
25 bind to semaphorins and in combination with plexins regulate the signal transduction
events in neurons. Hence neuropilin-like molecules play an important role in embryonic
development and the dedifferentiation events seen in cancer. These molecules probably play an
important role in regulation of angiogenesis, cancer, development and neurological conditions.
The MAM domain is characteristic of the extracellular region of membrane associated
30 proteins such as meprin (a cell surface glycoprotein); A5 antigen (a developmentally-regulated
cell surface protein); and receptor-like tyrosine protein phosphatase. These proteins although

functionally diverse; resemble receptors comprising a signal peptide, an N-terminal extracellular domain, a single transmembrane domain and an intracellular domain. The MAM domain might play a role in cell adhesion.

5 Fibrillin is a very large molecule whose primary structure is now known from the cloning and sequencing of 10 kb of cDNA. Fibrillin is the major component of extracellular microfibrils and is widely distributed in connective tissue throughout the body. Mutations in the fibrillin-1 (FBN1) gene, on chromosome 15q21.1, have been found to cause Marfan syndrome, a dominantly inherited disorder characterised by clinically variable skeletal, ocular, and cardiovascular abnormalities. Fibrillin-1 mutations have also been found in several other
10 related connective tissue disorders, such as severe neonatal Marfan syndrome, dominant ectopia lentis, familial ascending aortic aneurysm, isolated skeletal features of Marfan syndrome, and Shprintzen-Goldberg syndrome (PMID: 9401003, PMID: 8575254, PMID: 7584608).

Opioid binding cell adhesion molecules (OBCAMs) are members of the cell adhesion
15 molecule family with homology to the immunoglobulin protein superfamily. OBCAMs are seen both in the developing nervous system as well as in the mature adult brain. They may play a role in neuronal outgrowth and development, probably by modulating cell-cell interactions. In addition, OBCAMs are known to affect the regulation and functioning of opioid receptors. Chronic morphine treatment downregulates the expression of at least one
20 member of this family. Therefore, these proteins could mediate long-term effects on brain function by opioid usage and may be used as a therapeutic in that context.

The assimilation of dietary fats into the body requires that they be digested by lipases. One lipase, pancreatic triglyceride lipase, is essential for the efficient digestion of dietary fats. Pancreatic triglyceride lipase is the archetype of the lipase gene family that includes two
25 homologues of pancreatic triglyceride lipase, pancreatic lipase-related proteins 1 and 2. The cDNA sequences encoding pancreatic triglyceride lipase and the related proteins have been described. Furthermore, the tertiary structure of human pancreatic triglyceride lipase has been determined alone and in a complex with colipase, a pancreatic protein required for lipase activity in the duodenum (Lowe, Molecular mechanisms of rat and human pancreatic
30 triglyceride lipases. J Nutr 127(4):549-57, 1997).

The high-affinity receptor for immunoglobulin E, Fc epsilon RI, is found exclusively on mast cells and basophils. When multivalent allergens bind to the receptor-bound IgE, the consequent aggregation of the receptors leads to the release of mediators responsible for allergic symptoms. In rodents Fc epsilon RI is a tetrameric complex of non-covalently

attached subunits: one IgE-binding alpha subunit, one beta subunit and a dimer of disulphide-linked gamma subunits (Blank et al., Complete structure and expression in transfected cells of high affinity IgE receptor. *Nature* 337(6203):187-9, 1989). IgE receptors of mast cells, Fc epsilon RI, localize to coated pits and internalize after cross-linking. Studies have investigated whether any one of the receptor's four distinctive cytoplasmic domains regulates these phenomena. The conclusion of these studies was that no single cytoplasmic domain of the Fc epsilon RI uniquely controls its ligand-induced localization to coated pits and internalization (Mao et al., Effects of subunit mutation on the localization to coated pits and internalization of cross-linked IgE-receptor complexes. *J Immunol* 151(5):2760-74, 1993).

Sec1 family proteins are regulators of diverse exocytic processes, from yeast to man. Three mammalian homologues, Munc18-1, -2, and -3 have been described. The Munc18-2 gene comprises 19 exons whose sizes range from 50 to 158 bp, with a total gene size of approximately 11 kb. A single transcript of 2.1 kb is expressed in multiple non-neuronal murine tissues. Munc18-2 has a striking resemblance to Munc18-1 in structure despite only 60% sequence identity, suggesting a recent gene duplication event (Agrawal et al., Gene structure and promoter function of murine Munc18-2, a nonneuronal exocytic Sec1 homolog. *Biochem Biophys Res Commun* 276(3):817-22, 2000).

SUMMARY OF THE INVENTION

The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, NOV4, NOV5, NOV6, NOV7, NOV8, NOV9 and NOV10 nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "NOVX" nucleic acid or polypeptide sequences.

In one aspect, the invention provides an isolated NOVX nucleic acid molecule encoding a NOVX polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47. In some embodiments, the NOVX nucleic acid molecule will hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a NOVX nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,

38, 40, 42, 44, 46 and 48. The nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47.

Also included in the invention is an oligonucleotide, *e.g.*, an oligonucleotide which includes at least 6 contiguous nucleotides of a NOVX nucleic acid (*e.g.*, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47) or a complement of said oligonucleotide. Also included in the invention are substantially purified NOVX polypeptides (SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48). In certain embodiments, the NOVX polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human NOVX polypeptide.

The invention also features antibodies that immunoselectively bind to NOVX polypeptides, or fragments, homologs, analogs or derivatives thereof.

In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.

In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a NOVX nucleic acid, under conditions allowing for expression of the NOVX polypeptide encoded by the DNA. If desired, the NOVX polypeptide can then be recovered.

In another aspect, the invention includes a method of detecting the presence of a NOVX polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the NOVX polypeptide within the sample.

The invention also includes methods to identify specific cell or tissue types based on their expression of a NOVX.

Also included in the invention is a method of detecting the presence of a NOVX nucleic acid molecule in a sample by contacting the sample with a NOVX nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a NOVX nucleic acid molecule in the sample.

In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample that includes the NOVX polypeptide with a compound that binds to the NOVX polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, *e.g.*, a small molecule, such as a nucleic acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, *e.g.*, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, Tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, behavioral disorders, addiction, anxiety, pain, actinic keratosis, acne, hair growth diseases, alopecia, pigmentation disorders, endocrine disorders, connective tissue disorders, such as severe neonatal Marfan syndrome, dominant ectopia lentis, familial ascending aortic aneurysm, isolated skeletal features of Marfan syndrome, Shprintzen-Goldberg syndrome, genodermatoses, contractural arachnodactyly, inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer, leukemia or pancreatic cancer; blood disorders; asthma; psoriasis; vascular disorders, hypertension, skin disorders, renal disorders including Alport syndrome, immunological disorders, tissue injury, fibrosis disorders, bone diseases, Ehlers-Danlos syndrome type VI, VII, type IV, S-linked cutis laxa and Ehlers-Danlos syndrome type V, osteogenesis imperfecta, Neurologic diseases, Brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, immune disorders, hematopoietic disorders, muscle disorders, inflammation and wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, benign prostatic hypertrophy, arthrogryposis multiplex congenita, osteogenesis imperfecta, keratoconus, scoliosis, duodenal atresia, esophageal atresia, intestinal malrotation, Pancreatitis, Obesity Systemic lupus erythematosus, Autoimmune disease, Emphysema, Scleroderma, allergy, ARDS, Neuroprotection, Fertility Myasthenia gravis, Diabetes, obesity, Growth and reproductive disorders Hemophilia, Hypercoagulation, Idiopathic thrombocytopenic purpura, Immunodeficiencies, Graft vesus

host, Adrenoleukodystrophy, Congenital Adrenal Hyperplasia, Endometriosis, Xerostomia, Ulcers, Cirrhosis, Transplantation, Diverticular disease, Hirschsprung's disease, Appendicitis, Arthritis, Ankylosing spondylitis, Tendinitis, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, erythematosis, Renal tubular acidosis, IgA nephropathy, anorexia, bulimia, psychotic disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease and/or other pathologies and disorders of the like.

The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or a NOVX-specific antibody, or biologically-active derivatives or fragments thereof.

For example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding NOVX may be useful in gene therapy, and NOVX may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

The invention further includes a method for screening for a modulator of disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The method includes contacting a test compound with a NOVX polypeptide and determining if the test compound binds to said NOVX polypeptide. Binding of the test compound to the NOVX polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.

Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes. The test animal expresses a recombinant polypeptide encoded by a NOVX nucleic acid. Expression or activity of NOVX polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly-expresses NOVX polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of NOVX polypeptide in both the test animal and the control animal is compared. A change in the activity of NOVX polypeptide in the test animal relative to the

control animal indicates the test compound is a modulator of latency of the disorder or syndrome.

In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide, a NOVX nucleic acid, or both, in a subject (*e.g.*, a human subject). The method includes measuring the amount of the NOVX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the NOVX polypeptide present in a control sample. An alteration in the level of the NOVX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a NOVX polypeptide, a NOVX nucleic acid, or a NOVX-specific antibody to a subject (*e.g.*, a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

In yet another aspect, the invention can be used in a method to identify the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

NOVX nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVX substances for use in therapeutic or diagnostic methods. These NOVX antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOVX proteins have multiple hydrophilic regions, each of which can be used as an immunogen. These NOVX proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

The NOVX nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not

limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.

5 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references
10 mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

15

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX
20 polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.

TABLE A. Sequences and Corresponding SEQ ID Numbers

NOVX Assignment	Internal Identification	SEQ ID NO (nucleic acid)	SEQ ID NO (polypeptide)	Homology
1a	SC40376139	1	2	Membrane Protein/Neuropilin/Metalloproteinase-like
1b	CG55014-02	3	4	Membrane Protein/Neuropilin/Metalloproteinase-like
2a	GMAC022146_A	5	6	Fibrillin-like
2b	153568997	7	8	Fibrillin-like
2c	CG88987-01	9	10	Fibrillin-like
2d	CG88987-02	11	12	Fibrillin-like
2e	CG88987-03	13	14	Fibrillin-like
2f	CG88987-05	15	16	Fibrillin-like
3	GSAL442663.1_A	17	18	KIAA1589-like
4	GSAL442663.1_B	19	20	WD 40 motif-like
5a	139785504	21	22	Opioid Binding Cell Adhesion molecule-like

5b	139785504_da1	23	24	Opioid Bing Cell Adhesion molecule-like
5c	CG51027-03	25	26	Opioid Bing Cell Adhesion molecule-like
5d	CG51027-05	27	28	Opioid Bing Cell Adhesion molecule-like
6a	SC122982104_A	29	30	Triacylglycerol lipase-like
6b	CG58608-02	31	32	Triacylglycerol lipase-like
7a	SC126624027_A	33	34	IGE Receptor Beta Subunit-like
7b	CG55760-02	35	36	IGE Receptor Beta Subunit-like
8	SC138745558_A	37	38	Munc 18-like
9a	SC138673511_A	39	40	Immunoglobulin-like
9b	CG106625-02	41	42	Immunoglobulin-like
10a	GSAC055715.12_D	43	44	Type II Cytokeratin-like
10b	GSAC055715_C	45	46	Type II Cytokeratin-like
10c	GSAC055715_B	47	48	Type II Cytokeratin-like

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

NOV1 is homologous to a Membrane Protein/ Neuropilin/Metalloproteinase-like family of proteins. Thus, the NOV1 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; cancer, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, Parkinson's disease, Huntington's disease, Cerebral palsy, Multiple sclerosis, hair growth diseases, endocrine disorders and/or other pathologies/disorders.

NOV2 is homologous to a Fibrillin-like family of proteins. Thus NOV2 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; connective tissue disorders, such as severe neonatal Marfan syndrome, Marfan syndrome, inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer, leukemia or pancreatic cancer; Neurologic diseases, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, inflammation, Parkinson's disease, osteoporosis, multiple sclerosis; angina pectoris, myocardial infarction, benign prostatic and/or other pathologies/disorders.

NOV3 is homologous to a family of KIAA1589-like proteins. Thus, the NOV3 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, leukemia or pancreatic cancer.; skin disorders, Neurologic diseases, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, endocrine diseases, muscle disorders, inflammation and wound repair; multiple sclerosis; angina pectoris, myocardial infarction, ulcers, benign prostatic hypertrophy and/or other pathologies/disorders.

NOV4 is homologous to the WD 40 motif-like family of proteins. Thus, NOV4 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated, for example; cancer, Diabetes, Von Hippel-Lindau (VHL) syndrome, Obesity Systemic lupus erythematosus , Autoimmune disease, Asthma, Von Hippel-Lindau (VHL) syndrome , Alzheimer's disease, Stroke, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Neuroprotection Fertility Myasthenia gravis, Neuroprotection Endocrine dysfunctions, obesity, Immunodeficiencies, Graft versus host and/or other pathologies/disorders.

NOV5 is homologous to the Opioid Binding Cell Adhesion Molecule-like protein family. Thus NOV5 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration and/or other pathologies/disorders.

NOV6 is homologous to the Triacylglycerol lipase-like family of proteins. Thus NOV6 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: Diabetes, Von Hippel-Lindau (VHL) syndrome, Obesity, Von Hippel-Lindau (VHL) syndrome, Transplantation, Inflammatory bowel disease, Arthritis, Alzheimer's disease, Stroke, Parkinson's disease, Huntington's disease, Endocrine dysfunctions, Diabetes, Growth and reproductive disorders, Multiple sclerosis, Autoimmune disease, Acne, Hair growth, alopecia, Hypercalcaemia, Lesch-Nyhan syndrome and/or other pathologies/disorders.

NOV7 is homologous to members of the IGE Receptor Beta Subunit-like family of proteins. Thus, the NOV7 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory
5 bowel disease, AIDS; cancers including but not limited to lung cancer, colon cancer, leukemia or pancreatic cancer.; asthma; psoriasis; skin disorders, renal disorders immunological disorders, bone diseases, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, endocrine diseases, muscle disorders, wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), anorexia, bulimia, asthma,
10 osteoporosis, multiple sclerosis; benign prostatic hypertrophy, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease, Gilles de la Tourette syndrome and/or other pathologies/disorders.

NOV8 is homologous to the Munc 18-like family of proteins. Thus, NOV8 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be
15 useful in therapeutic and diagnostic applications implicated in, for example; inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, leukemia or pancreatic cancer.; psoriasis; neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders,
20 endocrine diseases, muscle disorders, wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), Parkinson's disease, acute heart failure, hypotension, hypertension, osteoporosis, multiple sclerosis; angina pectoris, myocardial infarction, psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as
25 Huntington's disease, Gilles de la Tourette syndrome and/or other pathologies/disorders.

NOV9 is homologous to members of the Immunoglobulin-like family of proteins. Thus, the NOV9 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for
30 example; inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, leukemia or pancreatic cancer.; psoriasis; neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, endocrine diseases, muscle disorders, wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), Parkinson's disease, acute

heart failure, hypotension, hypertension, osteoporosis, multiple sclerosis; angina pectoris, myocardial infarction, psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease, Gilles de la Tourette syndrome and/or other pathologies/disorders.

5 NOV10 is homologous to members of the Type II Cytokeratin-like family of proteins. Thus, the NOV10 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; inflammatory and infectious diseases such as AIDS; Neurologic diseases, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, 10 and hematopoietic disorders, endocrine diseases, muscle disorders, wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and Treatment of Albright 15 Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease and/or other pathologies/disorders.

 The NOVX nucleic acids and polypeptides can also be used to screen for molecules, 20 which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, e.g., neurogenesis, cell differentiation, cell proliferation, hematopoiesis, wound healing and angiogenesis.

 Additional utilities for the NOVX nucleic acids and polypeptides according to the 25 invention are disclosed herein.

NOV1

NOV1 includes two novel Membrane protein/neuropilin/metalloproteinase-like proteins disclosed below. The disclosed proteins have been named NOV1a and NOV1b.

NOV1a

30 A disclosed NOV1a nucleic acid of 1668 nucleotides (also referred to as SC40376139) encoding a novel Membrane protein/neuropilin/metalloproteinase-like protein is shown in Table 1A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 7-9 and ending with a TGA codon at nucleotides 1453-1455. Putative

untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 1A, and the start and stop codons are in bold letters.

Table 1A. NOV1a Nucleotide Sequence (SEQ ID NO:1).

GGATCAATGCAAATGGAGAGTTATGATGGAACACTGAGGATTGTGAATGTATCTAGGGAAATGTCAGGAATGTACAGATGT
CAGACCAGCCAATACAATGGATTAACTGTAACCAAGGGAAGCCTTGGTGCAGCTCATCGTTTCAGTATCCCCCTGCAGTG
GAACCAGCATTCTTGGAAATCCGGCAAGGACAGGATCGAAGTGTCACTATGAGTTGCAGAGTACTGAGAGCCTATCCAATA
CGGGTGTGACCTATGAGTGGCGCTTGGGCAATAAATTATTACGGACGGGTCAATTTGACTCTCAGGAATACACAGAGTAC
GCTGTGAAGAGTCTTTCCAATGAAACTATGGGGTTTATACTGTAGCATATAAATGAAGCTGGAGCTGGGAGATGCAGC
TTTCTTGTTCAGGTGGAAAGGCTATGCTCCAGAATTCTATTATGATACCTACAATCCAGTATGGCAGAACAGACCCGT
GTTTATTTCTACAGTCTACAGTGGACACAGATGAATCCTGATGCAGTGGATCGGATTGTTGCATACCGGTTGGGCATCAGG
CAGGCTGGACAGCAGCGCTGGTGGGAGCAGGAGATTAATAAATGAAGTATTCAAAAGGGAGAATTAATTACATATAAC
TTGACAGAGCTAATTAACCAAGAAGCTTATGAAGTCCGACTGACTCCTCTCACCAAATTTGGTGAAGGAGATTCAACAATT
CGTGTGATCAAAATATAGTCTGTAAATCCTCATTGAGTGAATTTTCATTGTGGATTGGAAGATGGTAATATTTGTTGTTC
ACTCAAGATGATACAGATAAATTTGACTGGCAAAAGCAAAGTACAGCAACAAGAAATACAAAATATACTCCTAATACAGGA
CCTAATGCTGACCGTAGTGGCTCCAAGAAGGTTTATATGTACATTGAGACATCAGACCCAGATTGGAAGGCGAAAAG
GCTCGACTTCTCAGCCCTGTTTTTCAGCATAGCTCCAGCCCTGTTTTTCAGCAAGACTTCTCAGCCCTGTTTTTCAGCATAGCT
CCCCAAAACCTTATGGACCCACAAACACTGCATATGTTTCAGCTTCTTTTATCACATGTATGGACAACATATAGGTGTC
TTAAATGTTTATCTACGTTTGAAGGGCAAAACAATAGAGAATCCACTGTGGTCTTCAAGTGGGAATAAAGGACAAAGA
TGGAAATGAGGCTCATGTTAATATATACCAATTACTTTCATTTCAGCTCATTTTTGAAGGTATCCGAGGTCTGGAATAGAA
GGTGACATTGCTATTGATGATGATCAATTGCAGAAGGAGAATGTGCAAAAACAGACCTAGCAACTAAGAATTCGGTTGAT
GGTGTGTTGGGATTTTGGTTTCATATATGGCTTTTCCATTATCGTCCTCATCTCTTAAAGTCTCGAAGGTGACCT
TATCCTGGCAGAGGCTATAAAAGATTCAACAGGCACTGGCATGAAGAAAGAGTCTTTGTAATGGACATTGAACAAACAAA
CTACCAAAGATTCTCCACTGACTACTGACTCAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA
ACATCATGGAAGTATAACTTATTCAGACTAAACATAAAGATAATCTGA

The NOV1a nucleic acid sequence maps to chromosome 14 and has 1030 of 1128 bases (91%) identical to a *Macaca fascicularis* brain mRNA (gb:GENBANK-ID:AB047834|acc:AB047834.1) ($E = 3.2e^{-201}$). Similiarity information was assessed using public nucleotide databases including all GenBank databases and the GeneSeq patent database. Chromosome information was assigned using OMIM and the electronic northern tool from Curatools to derive the the chromosomal mapping of the SeqCalling assemblies, Genomic clones, and/or EST sequences that were included in the invention.

In all BLAST alignments herein, the “E-value” or “Expect” value is a numeric indication of the probability that the aligned sequences could have achieved their similarity to the BLAST query sequence by chance alone, within the database that was searched. For example, the probability that the subject (“Sbjct”) retrieved from the NOV1a BLAST analysis, e.g., *Macaca fascicularis* brain mRNA, matched the Query NOV1a sequence purely by chance is $3.2e^{-201}$. The Expect value (E) is a parameter that describes the number of hits one can "expect" to see just by chance when searching a database of a particular size. It decreases exponentially with the Score (S) that is assigned to a match between two sequences. Essentially, the E value describes the random background noise that exists for matches between sequences.

The Expect value is used as a convenient way to create a significance threshold for reporting results. The default value used for blasting is typically set to 0.0001. In BLAST 2.0, the Expect value is also used instead of the P value (probability) to report the significance of

matches. For example, an E value of one assigned to a hit can be interpreted as meaning that in a database of the current size one might expect to see one match with a similar score simply by chance. An E value of zero means that one would not expect to see any matches with a similar score simply by chance. See, e.g.,

5 <http://www.ncbi.nlm.nih.gov/Education/BLASTinfo/>. Occasionally, a string of X's or N's will result from a BLAST search. This is a result of automatic filtering of the query for low-complexity sequence that is performed to prevent artifactual hits. The filter substitutes any low-complexity sequence that it finds with the letter "N" in nucleotide sequence (e.g., "NNNNNNNN") or the letter "X" in protein sequences (e.g., "XXX"). Low-complexity
10 regions can result in high scores that reflect compositional bias rather than significant position-by-position alignment. Wootton and Federhen, Methods Enzymol 266:554-571, 1996.

The disclosed NOV1a polypeptide (SEQ ID NO:2) encoded by SEQ ID NO:1 has 482 amino acid residues and is presented in Table 1B using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOV1a does not contain a signal peptide and is
15 likely to be localized to the plasma membrane with a certainty of 0.7000.

Table 1B. Encoded NOV1a protein sequence (SEQ ID NO:2).

<p>MQMESYDGTLRIVNVSREMSGMYRCQTSQYNGFNVKPREALVQLIVQYPPAVEPAFLEIRQGQDRSVTMSCRVLRAYPIRV LTYEWRLGNKLLRTGQFDSQEYTEYAVKSLSNENYGVNCSIINEAGAGRCFLVTGGKAYAPEFYDYDYNPWNHRHRY SYSLQWTQMNPDAVDRI VAYRLGIRQAGQQRWWEQEI KINGNIQKGELITYNLTELIKPEAYEVRLTPTKFGEGDSTIRV IKYSPVNPHLSEFHCGFEDGNI CLFTQDDTDNFDWTKQSTATRNTKYTPNTGPNADRSKSGKFYMYIETSRPRLEGEKAR LLSPVFSIAPALFSARLLSPVFSIAPKNPYGPTNTAYCFSFFYHMYGQHIGVLNVYLRLLKGQTTIENPLWSSSGNKQQRWN EAHVNIYPITSFQLIFEGIRGPIEGDIAIDDVSI AEGECAKQDLATKNSVDGAVGILVHIWLFPIIVLISILSPRR</p>

The NOV1a amino acid sequence has 445 of 464 amino acid residues (95%) identical to, and 445 of 464 amino acid residues (95%) similar to, a *Macaca fascicularis* 448 amino acid residue hypothetical 51.2 kda protein (ptnr:TREMBLNEW-ACC:BAB12260) ($E = 1.0e^{-241}$).
20 The NOV1a amino acid sequence also has 71 of 197 amino acid residues (36%) identical to, and 108 of 197 amino acid residues (55%) similar to, a *Xenopus laevis* 928 amino acid residue neuropilin-1 precursor protein (ptnr:SWISSNEW-ACC:P28824) ($E = 1.0e^{-17}$).

NOV1a is predicted to be expressed in brain tissues because of the expression pattern of a closely related *Macaca fascicularis* brain cDNA, clone:QccE-16296 homolog
25 (GENBANK-ID: gb:GENBANK-ID:AB047834|acc:AB047834.1).

NOV1b

A disclosed NOV1b nucleic acid of 1608 nucleotides (also referred to as CG55014-02) encoding a novel Membrane protein/neuropilin/metalloproteinase-like protein is shown in Table 1C. An open reading frame was identified beginning with an ATG initiation codon at
30 nucleotides 6-8 and ending with a TGA codon at nucleotides 1404-1406. Putative

untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 1C, and the start and stop codons are in bold letters.

Table 1C. NOV1b Nucleotide Sequence (SEQ ID NO:3).

GATCAATGCAAAATGGAGAGTTATGATGGAACACTGAGGATTGTGAATGTATCTAGGGAAATGTCAGGAATGTACAGATGTC
AGACCAGCCAATACAATGGATTAAACGTGAAACCAAGGGAAGCCTTGGTGACGCTCATCGTTAGTATCCCCCTGCAGTGG
AACCAGCATTCTTGAAATCCGGCAAGGACAGGATCGAAGTGTCACTATGAGTTGCAGAGTACTGAGAGCCTATCCAATAC
GGGTGCTGACCTATGAGTGGCGCTTGGGCAATAAATTATTACGGACGGGTCAATTGACTCTCAGGAATACACAGAGTACG
CTGTGAAGAGTCTTTCCAATGAAACTATGGGGTTTATAACTGTAGCATCATAAATGAAGCTGGAGCTGGGAGATGCAGCT
TTCTTGTACAGGAAAGGCTATGCTCCAGAATCTATTATGATACCTACAATCCAGTATGGCAGAACAGACACCGTGT
ATTCTTACAGTCTACAGTGGACACAGATGAATCCTGATGCAGTGGATCGGATTGTTGCATACCGGTTGGGCATCAGGCAGG
CTGGACAGCAGCGCTTGGTGGGACAGGAGATTAATAAATAATGGGAATATTCAAAAGGGAGAATTAATTACATATAA
CAGAGCTAATTAACCAAGGCTTATGAAGTCCGACTGACTCCTCTACCAAATTTGGTGAAGGAGATTCAACAATTCGTG
TGATCAATATAGTGCTCCTGTAAATCCTCATTGGAGAGAATTCATTGTGGATTGAAGATGGTAATATTGTTTGTTC
CTCAAGATGATACAGATAATTTTACTGGACAAAGCAAGTACAGCAACAAGAAATACAAATATACTCCTAATACAGGAC
CTAATGCTGACCGTAGTGCTCCAAAGAAGTTTTTATATGTACATTGAGACATCACGACCCAGATTGGAAGGCGAAAAGG
CTCGACTTCTCAGCCCTGTTTTCAGCATAGCTCCCAAAACCCCTTATGGACCCACAAACACTGCATATTGTTTCAGCTTCT
TTTATCATATGATGGACAACATATAGGTGTCTTAAATGTTTATCTACGTTTGAAGGGCAAAACAATAGAGAATCCAC
TGTGGTCTTCAAGTGGGAATAAAGGACAAAGATGGAATGAGGTCATGTTAATATATACCCAATTACTTCATTTAGCTCA
TTTTTGAAGGTATCCGAGGTCTGGAATAGAAGGTGACATTGCTATTGATGATGATCAATTGCAGAAGGAGAATGTGCAA
AACAAGACCTAGCAACTAAGAATTCGTTGATGGTGTGCTGTTGGGATTTGGTTTATATATGGCTTTTCCCATTTATCGTCC
TCACCTCTATCTTAAGTCTCGAAGGTGACCTTATCCTGGCAGAGGCTATAAAGATTACCCAGGCCTGGCATGAAGAAA
GAGTCTTTGTAATGGACATTGAACAAACAACTACCAAGATTCTCCACTGACTACTGACTCAAAATAAAATAATAAA
AACAAATTTTTTAAGCACTGGGGATAAAAGACATCATGGAAGTATACTTATTCAGACTAAACATAA

The NOV1b nucleic acid sequence has 1538 of 1557 bases (98%) identical to a *Macaca fascicularis* brain mRNA (gb:GENBANK-ID:AB047834|acc:AB047834.1) (E = 0.0).

The disclosed NOV1b polypeptide (SEQ ID NO:4) encoded by SEQ ID NO:3 has 466 amino acid residues and is presented in Table 1D using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOV1b does not contain a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.7000.

Table 1D. Encoded NOV1b protein sequence (SEQ ID NO:4).

MQMESYDGLTRIVNVSREMSGMYRCQTSQYNGFNVKPREALVQLIVQYPPAVEPAFLEIRQGQDRSVTMSRCVRLRAYPIRV
LTYEWRLGNKLLRTGQFDSQEYTEYAVKSLSNENYGVNCSINEAGAGRCFLVTGKAYAPEFYDYTNPVWQNRHRVYS
YSLQWTQMNPDVDRIVAYRLGIRQAGQQRWWEQEI KINGNIQKGELITYNLTELIKPEAYEVRLTPLTKFEGEDSTIRVI
KYSAPVNPHLREFHCGFEDGNICLFTQDDTDNFDWTQKSTATRNTKYTPNTGPNADRSKSGKEGFYMIETSRPRLEGEKAR
LLSPVFSIAPKNPYGPTNTAYCFSPFYHMYGQHIGVLNVYLRKQQT IENPLWSSSGNKQQRWNEAHVNIYPTSPQLIF
EGIRGPGIEGDIADDSVIAEGECAKQDLATKNSVDGAVGILVHIWLFPIVLTSILSPRR

The NOV1b amino acid sequence has 446 of 448 amino acid residues (99%) identical to, and 446 of 448 amino acid residues (99%) similar to, a *Macaca fascicularis* 448 amino acid residue hypothetical 51.2 kda protein (ptnr:TREMBLNEW-ACC:BAB12260) (E = 3.1e⁻²⁴⁸).

NOV1b is expressed in at least the following tissues: brain. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources. In addition, NOV1b is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Macaca fascicularis* brain cDNA,

clone:QccE-16296 homolog (GENBANK-ID: gb:GENBANK-
ID:AB047834|acc:AB047834.1):Brain.

Possible small nucleotide polymorphisms (SNPs) found for NOV1b are listed in Tables 1E and 1F. Depth represents the number of clones covering the region of the SNP. The putative allele frequency (PAF) is the fraction of these clones containing the SNP. A dash,
5 when shown, means that a base is not present. The sign ">" means "is changed to."

Table 1E: SNPs			
Consensus Position	Depth	Base Change	PAF
53	16	T > C	N/A
229	27	A > G	N/A

Table 1F: SNPs				
Variant	Nucleotide Position	Base Change	Amino Acid Position	Base Change
13375763	58	A > G	18	Glu > Gly
13375764	87	A > G	28	Ser > Gly
13375765	49	A > G	115	Asn > Ser
13375766	400	G > A	132	Cys > Tyr

10 NOV1a and NOV1b are very closely homologous as is shown in the amino acid alignment in Table 1G.

Table 1G Amino Acid Alignment of NOV1a and NOV1b

	10	20	30	40	50
NOV1a	MQMESYDGTLRIVNVSREMSGMYRCQTSQYNGFNVKPREALVQLIVQYPP				
NOV1b	MQMESYDGTLRIVNVSREMSGMYRCQTSQYNGFNVKPREALVQLIVQYPP				
	60	70	80	90	100
NOV1a	AVEPAFLEIRQGQDRSVTMSCRVLRAYPIRVLTYEWR LGNKLRLTGQFDS				
NOV1b	AVEPAFLEIRQGQDRSVTMSCRVLRAYPIRVLTYEWR LGNKLRLTGQFDS				
	110	120	130	140	150
NOV1a	QEYTEYAVKSLSNENYGVYNCS IINEAGAGRCSFLVTGCKAYAPEFYDDT				
NOV1b	QEYTEYAVKSLSNENYGVYNCS IINEAGAGRCSFLVTGCKAYAPEFYDDT				
	160	170	180	190	200
NOV1a	YNPVWQNRHRVYSYSLQWTQMNPDAVDRI VAYRLGIRQAGQQRWWEQEI K				
NOV1b	YNPVWQNRHRVYSYSLQWTQMNPDAVDRI VAYRLGIRQAGQQRWWEQEI K				
	210	220	230	240	250
NOV1a	INGNIQKGELITYNLTELKPEAYEVRLTPLTKFGE GDS TIRVIKYS -PV				
NOV1b	INGNIQKGELITYNLTELKPEAYEVRLTPLTKFGE GDS TIRVIKYSAPV				
	260	270	280	290	300
NOV1a	NPHLSEFHCGFEDGNICLFTQDDTDNFDWTKQSTATRNTKYTPNTGPNAD				
NOV1b	NPHLSEFHCGFEDGNICLFTQDDTDNFDWTKQSTATRNTKYTPNTGPNAD				

Table 1I. ClustalW Analysis of NOV1a

- 1) Novel NOV1a (SEQ ID NO:2)
- 2) [gi|9967117|dbj|BAB12260.1|](#) (AB047834) hypothetical protein [Macaca fascicularis] (SEQ ID NO:49)
- 3) [gi|7529597|emb|CAB86653.1|](#) (AL049553) dJ402N21.2 (novel protein with MAM domain) [Homo sapiens] (SEQ ID NO:50)
- 4) [gi|12836077|dbj|BAB23491.1|](#) (AK004706) putative [Mus musculus] (SEQ ID NO:51)
- 5) [gi|4929103|gb|AAD33860.1|AF140020_1](#) (AF140020) metalloproteinase 2 [Hydra vulgaris] (SEQ ID NO:52)
- 6) [gi|15929977|gb|AAH15417.1|AAH15417](#) (BC015417) Unknown (protein for MGC:21981) [Homo sapiens] (SEQ ID NO:53)

	10	20	30	40	50
NOV1a	MQMESYDGTLRIVNVSREMSGMYRC	TSQYNSFNMKPREALVQ	IIVQYPP		
gi 9967117	-----MSGMYRC	TSQYNSFNMKPREALVQ	IIVQYPP		
gi 7529597	-----	-----	-----		
gi 12836077	MTKLVLILLSVALCHSFPEEENNDP	GILGSDIILTP	QKSIIEVGGDI		
gi 4929103	-----	-----	-----		
gi 15929977	-----	-----	-----		
	60	70	80	90	100
NOV1a	AVEPAFLEIRCGDRSVTMSCRVL	RAYPIRVLYEWR	LGNKLLRTGQFDS		
gi 9967117	AVEPAFLEIRCGDRSVTMSCRVL	RAYPIRVLYEWR	LGNKLLRTGQFDS		
gi 7529597	-----	-----	-----		
gi 12836077	-----	-----	-----		
gi 4929103	EQAGLLKTERCKRAALSNS	SILWIPNNKIVPW	ITKOLENTAEAFGLM		
gi 15929977	-----	-----	-----		
	110	120	130	140	150
NOV1a	QEYTEYAVKSLSNENYGVYNCST	INEAGRCRCSFLVTGKAYAF	EFYYDT		
gi 9967117	QEYTEYAVKSLSNENYGVYNCST	INEAGRCRCSFLVTGKAYAF	EFYYDT		
gi 7529597	-----	-----	-----		
gi 12836077	-----	-----	-----		
gi 4929103	AFREWEERSCLTFKRRRTDEKDY	IEFFQSGCWSYLGRVGG	LQNISLDDGC		
gi 15929977	-----	-----	-----		
	160	170	180	190	200
NOV1a	YNPVWQNRHRVYSYSLQWTOMN	PDVDRIVAYRLGIRAGG	QRWEQE		
gi 9967117	YNPVWQNRHRVYSYSLQWTOMN	PDVDRIVAYRLGIRAGG	QRWEQE		
gi 7529597	-----	-----	-----		
gi 12836077	-----	-----	-----		
gi 4929103	MGKGTIVHEIGHAMGFGHEONR	PRDOYITIRWENTPESKH	INERLYSNS		
gi 15929977	-----	-----	-----		
	210	220	230	240	250
NOV1a	--IKINGNIQKGLITYNLTETL	KKPEAYEVRLTPLTKFGG			
gi 9967117	--IKINGNIQKGLITYNLTETL	KKPEAYEVRLTPLTKFGG			
gi 7529597	-----	-----	-----		
gi 12836077	-----	-----	-----		
gi 4929103	LVDSINSPDYRSYMOYKTAFG	INISVTHDPKLPGLFQ	LCQRVGFTEHD		
gi 15929977	-----	-----	-----		
	260	270	280	290	300
NOV1a	--STIRVIKYS-PPN-PP	-----LSEFHCCFEDGNICL	FTODD	TDNF	
gi 9967117	--STIRVIKYSADPN-PP	-----LREHHCFFEDGNICL	FTODD	TDNF	
gi 7529597	--MASREIHYEPPINSPN	-----LSBNTCHFEDEKICG	TODL	TDNF	
gi 12836077	--MASREIHYEPPINLPS	-----LSBNTCHFEDEKICG	TODL	TDNF	
gi 4929103	QYQAMQIHYECOGKTRPTT	FFPRYDLKGEVTCDFET	DECCFT	HKITATE	
gi 15929977	--ITIQGSCSSEKLP	-----PPPGECTFEQ-DECT	FTQEKRNRS		
	310	320	330	340	350
NOV1a	DWTRKSTATRNTKYPNTGPN	ADRSCSGEGGYMIETSR	PRLEG	EKARLL	
gi 9967117	DWTRKSTATRNTKYPNTGPN	ADRSCSGEGGYMIETSR	PRLEG	EKARLL	
gi 7529597	DWTRONALTONPKRSPNTG	PPTDISCAPEGGYMIETSR	PREL	CDARLY	
gi 12836077	DWTRONALTONPKRSPNTG	PPTDISCAPEGGYMIETSR	PREL	CDARLY	
gi 4929103	EWQGIY-----GETPSRG	IGPDSHETGR	LCTGYIEASV	QKKNKARLK	

```

gi|15929977| SMHRR---RGETPISYTCPKGDH--RGVSYMYIEAS-HMYGCKARLL
          360      370      380      390      400
NOV1a      SPVFSIAPALFSARLLSPVFSTAPKNPYGPTNTAYCFSEFFVHMYGQHIGV
gi|9967117| S-----PVFSTAPKNPYGPTNTAYCFSEFFVHMYGQHIGV
gi|7529597| S-----PLYNASAK-----FYCVSFFVHMYCKHIGS
gi|12836077| S-----PLYNASAK-----FYCVSFFVHMYCKHIGS
gi|4929103| S-----KWFEKPLS-----AOCFSVFYVMEGRNASM
gi|15929977| SR-----PVRGVSGK-----HCLIFFVHMYCGGTCL

          410      420      430      440      450
NOV1a      LNVY-LRLKGGTTIENPLWSSSGNKGQRMNEAHVNIYEITSFQIIFEGIR
gi|9967117| LNVY-LRLKGGTTIENPLWSSSGNKGQRMNEAHVNIYEITSFQIIFEGIR
gi|7529597| LNL-LRSENKGAETHAWSLSGNKGQRMNEAHVNIYEITSFQIIFEGIR
gi|12836077| LNL-LRSENKGAETHAWSLSGNKGQRMNEAHVNIYEITSFQIIFEGIR
gi|4929103| LNVY-LRSENKGAETHAWSLSGNKGQRMNEAHVNIYEITSFQIIFEGIR
gi|15929977| LNVY-LRSENKGAETHAWSLSGNKGQRMNEAHVNIYEITSFQIIFEGIR

          460      470      480      490      500
NOV1a      GPGIEGDIAIDDVSTAECECAKODLAKNSVDG---AVGILV--HIWLEP
gi|9967117| GPGIEGDIAIDDVSTAECECAKODLAKNSVDG---AVGILV--HIWLEP
gi|7529597| GPGIEGDIAIDDVSTAECECAKODLAKNSVDG---AVGILV--HIWLEP
gi|12836077| GPGIEGDIAIDDVSTAECECAKODLAKNSVDG---AVGILV--HIWLEP
gi|4929103| GPGIEGDIAIDDVSTAECECAKODLAKNSVDG---AVGILV--HIWLEP
gi|15929977| GPGIEGDIAIDDVSTAECECAKODLAKNSVDG---AVGILV--HIWLEP

          510      520
NOV1a      ITVVISLSPRR-----
gi|9967117| ITVVISLSPRR-----
gi|7529597| PMATF-LIALOR-----
gi|12836077| PMATF-LIALOR-----
gi|4929103| QWEQAGYCVSEKTMKLYCRKTCNFC
gi|15929977| QWEQAGYCVSEKTMKLYCRKTCNFC

```

The presence of identifiable domains in NOV1a, as well as all other NOVX proteins, was determined by searches using software algorithms such as PROSITE, DOMAIN, Blocks, Pfam, ProDomain, and Prints, and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro>). DOMAIN results for NOV1a, as disclosed in Tables 1J and 1K, were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST analyses. This BLAST analysis software samples domains found in the Smart and Pfam collections. For

Tables 1J, 1K and all successive DOMAIN sequence alignments, fully conserved single residues are indicated by black shading or by the sign (!) and “strong” semi-conserved residues are indicated by grey shading or by the sign (+). The “strong” group of conserved amino acid residues may be any one of the following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW.

Tables 1J and 1K lists the domain description from DOMAIN analysis results against NOV1a. This indicates that the NOV1a sequence has properties similar to those of other proteins known to contain these domains.

gnl|Smart|smart00137, MAM, Domain in meprin, A5, receptor protein tyrosine phosphatase mu (and others); Likely to have an adhesive function. Mutations in the meprin MAM domain affect noncovalent associations within meprin oligomers. In receptor tyrosine phosphatase mu-like molecules the MAM domain is important for homophilic cell-cell interactions. (SEQ ID NO:54)
Length = 163 residues, 99.4% aligned
Score = 154 bits (390), Expect = 9e-39

Table 1K. Domain Analysis of NOV1a

gnl|Smart|smart00230, CysPc, Calpain-like thiol protease family.;
Calpain-like thiol protease family (peptidase family C2). Calcium
activated neutral protease (large subunit). (SEQ ID NO:55)
Length = 323 residues, 99.1% aligned
Score = 342 bits (877), Expect = 4e-95

NOV1a	258	CGFEDGNICLFTQDDTDNFDWTKQSTATRNTKYPTPNTGPNADRSGSGKEGFYMYIETSRPR	317
		+ ++ + + ++ + + ++	
00230	1	CD FEDGSHCGWSQDSGDDLDWTRVNSATGGS-----TGPRGDHTT-GNGHYMYVDTS-SG	53
NOV1a	318	LEGEKARLLSPVFSIAPALF SARLLSPVFSIAPKNPYGPTNTAYCFSFFYHMYQHIGVL	377
		+ + + + +	
00230	54	QEGQTARLLSPPLP-----PKRSPCLTFWYHYMGSGVGTL	89
NOV1a	378	NVYLRLKGQTTIENPLWSSSGNKGQRWNEAHVNIYPITS-FQLIFE GIRGPGIEGDIAID	436
		+ + + ++ + ++ +	
00230	90	NVYVR-ENGGPSDRLLWSRSGHQGSWLLAEVTLPTSTKPFQVVFEGTRGGSGRGGIALD	148
NOV1a	437	DVSIAEGECAK 447	
		+ ++ +	
00230	149	DISLSEGPCNQ 159	

20

expressed VEGF-R2 and neuropilin-1. The vascular density of fibrovascular tissues evaluated by immunohistochemistry for CD34 was significantly higher in the cases with the expression of VEGF-R2 and neuropilin-1 than in those without their expression ($P < 0.01$), whereas VEGF-R1 expression had no such relationship with the vascular density. The fibrovascular tissues that expressed VEGF165 together with VEGF-R2 and neuropilin-1 were found in significantly younger patients ($P < 0.01$). In situ hybridization and immunohistochemical studies demonstrated that glial cells in the fibrovascular tissues express and produce VEGF. Coexpression of VEGF-R2 and neuropilin-1 is suggested to facilitate fibrovascular proliferation in diabetic retinopathy (Ishida et al., Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. *Invest Ophthalmol Vis Sci* 41(7):1649-56, 2000.)

In the developing nervous system axons navigate with great precision over large distances to reach their target areas. Chemorepulsive signals such as the semaphorins play an essential role in this process. The effects of one of these repulsive cues, semaphorin 3A (Sema3A), are mediated by the membrane protein neuropilin-1 (Npn-1). Recent work has shown that neuropilin-1 is essential but not sufficient to form functional Sema3A receptors and indicates that additional components are required to transduce signals from the cell surface to the cytoskeleton. It was shown that members of the plexin family interact with the neuropilins and act as co-receptors for Sema3A. Neuropilin/plexin interaction restricts the binding specificity of neuropilin-1 and allows the receptor complex to discriminate between two different semaphorins. Deletion of the highly conserved cytoplasmic domain of Plexin-A1 or -A2 creates a dominant negative Sema3A receptor that renders sensory axons resistant to the repulsive effects of Sema3A when expressed in sensory ganglia. These data suggest that functional semaphorin receptors contain plexins as signal-transducing and neuropilins as ligand-binding subunits (Rohm et al., Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A. *Mech Dev* 93(1-2):95-104, 2000).

Mesangial cell proliferation and growth factor over-expression are characteristic features of several glomerular diseases. Vascular endothelial growth factor (VEGF), a potent mitogen, is expressed in podocytes in the glomerulus, and VEGF receptors (flt-1, KDR, and neuropilin-1) are present on endothelial cells and other cell types. In conclusion, flt-1, KDR, and neuropilin-1 are present on cultured HMC, and VEGF(165) induces HMC proliferation. In addition, the flt-1 and KDR receptors are expressed in the mesangium in mesangioproliferative disease (Thomas et al., Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. *J Am Soc Nephrol* 2000 11(7):1236-43, 2000).

Vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, binds to two receptor tyrosine kinases, KDR/Flk-1 and Flt-1. A third VEGF receptor, one that binds VEGF165 but not VEGF121, was cloned and purified from tumor cells. This isoform-specific VEGF receptor (VEGF165R) is identical to human neuropilin-1, a receptor for the
 5 collapsin/semaphorin family that mediates neuronal cell guidance. When coexpressed in cells with KDR, neuropilin-1 enhances the binding of VEGF165 to KDR and VEGF165-mediated chemotaxis. Conversely, inhibition of VEGF165 binding to neuropilin-1 inhibits its binding to KDR and its mitogenic activity for endothelial cells. It is proposed that neuropilin-1 is a novel
 10 VEGF receptor that modulates VEGF binding to KDR and subsequent bioactivity and therefore may regulate VEGF-induced angiogenesis (Soker et al., Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92(6):735-45, 1998).

The above defined information for NOV1 suggests that this Membrane protein/neuropilin/metalloproteinase-like protein may function as a member of the Membrane
 15 protein/neuropilin/metalloproteinase family. Therefore, the NOV1 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV1 compositions of the present invention will have efficacy for treatment of patients suffering from cancer, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections,
 20 Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, Tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, behavioral disorders, addiction, anxiety, pain, psoriasis, actinic keratosis, acne, hair growth diseases, alopecia, pigmentation disorders and endocrine disorders. The NOV1 nucleic acid encoding
 25 Membrane protein/neuropilin/metalloproteinase-like protein, and the Membrane protein/neuropilin/metalloproteinase-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV2

30 NOV2 includes six novel Fibrillin-like proteins disclosed below. The disclosed proteins have been named NOV2a, NOV2b, NOV2c, NOV2d, NOV2e and NOV2f.

NOV2a

A disclosed NOV2a nucleic acid of 9993 nucleotides (also referred to as GMAC022146_A) encoding a novel Fibrillin-like protein is shown in Table 2A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 166-168 and ending with a TGA codon at nucleotides 9151-9153. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 2A. The start and stop codons are in bold letters.

Table 2A. NOV2a nucleotide sequence (SEQ ID NO:5).

CCTCCCATTCCTCTCCTCTCTCTCCCATCTGGACAGCCCCAGCCTTCTGACACCCTGTTTCCCCCCCGGACCTGCTGC
CCTTCCCCACACCACCTAACATGCATTTCTGACCTTGCTCCTCCCACTCAAAGCTTTTCAAGGGCTCTTCATGTCTTGA
CGAATGAGCAAAAGCTGCATGACACTGCTATGCCCACTCCTGCAACGCCTGGCCCCACCTGGCCCCACCTGGCCCTCTCTC
CCCTCCCTTCCACTTCCCACTCCCGTCTTGCTTGGCTGTGCACCTCAGCCCCAAGACCCTTCTTAACATCACACCTCC
TCCAGGAAGCCTCCTCTGACTGTTACCCGCTTCCCGGTTGGGGTGGATGCCCTCCTTCCCTCCCAAGGCCCGGGGCTG
CCCCATTGGCAACCACCTGCCCTCCTCGTTGTTGGGTCCCCATGGCTAGGGTGGGGGGCTCATTAGGGCTGACTC
TGCTTCTCTCCGACGCTCCAGGGGACAGCCATGACTCTGGAGGGTGTGATTGGCAAGGGGCCCCCTGGCCCCGCTC
CTGCTGGCCTGGTGGCCCTGTTGTGCATGGCAGGTGGCCAGGCCGCTGGGACGGGGCCTTGGAGGCTGCAGGTCTTGGG
CGTGTGCGGAGGCGGGGAGCCAGGCATCTTGACGGGGCGAATGTGTGCGGCTCCCGTTCCATGCCTACTGCTGTCCA
GGCTGGAGGACATTCCTTGGCAGGAGCCAGTGTGTGTAACCATCTGTAGGCGCGCTGCGGTGAAGGCTTCTGCTCCAG
CCCAACCTGTGCACCTGTGCGGATGGGACGCTGGCTCCAGCTGCGGGGTGAGCCGAGGGTCAAGGTGCAATGTGAGCTGT
ATGAATGGGGGACCTGCCGGGGGGCGTCTGTCTGTGTGAGAGGGGTACACAGGACCCGTGTGTGGGAGCCCATCTGT
GACCGCGGCTGCCACAATGGGGGTGCTGCAATGGGCCCAACCGCTGCGCTGTGTGTATGGCTTCATGGGACCTCAATGT
GAGAGAGATTACCGGACGGGACCCCTGCTTTGGCCAAGTAGGCCCGAGGGGTGCCAGCATCAGCTGACGGGCTCGTGTGC
ACCAAGGCACCTTTGCTGTGCCACTGTGGGCGGTGCCCTGGGGCCTTCCATGTGAACCTTGGCCCTGCACAGCCACCCCTGC
CGCCGCGGCTTCATCCCAATATCCACAGGGGGCCTGCCAAGATGTGGATGAGTGCCAGGCTGTGCCAGGCTGTGCCAG
GGAGGAGCTGCGCTCAACATGGTGGGCTCCTTCCATTGCCGCTGTCCAGTTGGACACCGGCTCAGTGACAGCAGCGCCGA
TGTGAAGACTACGATGAATGCAGACCAATCTGGAATCTGTGAAGGGGTGAATGTACAACAACAGTCAGCAGTTACTTT
TGCAAAATGTCTCTCTGTTTACACCTCTCCAGATGGTACTTTCATGGACAGTCGCGGGCGGCGCTGCTTCTCAGTG
CTTTTCGGGGGCGCTGTGCTGGAGACCTGCCCGGCCACTACACTGCAGGCAGTGTGCTGTGACAGGGGAGGTGCTGTG
GCAGCTGGCCCGGTCCCTGAGCTGTCTCTCGGGCTCCAATGAATTCAGCAACTGTGCGCCAGCGGCTGCGCTG
CTACCCGGCCACCTGGCTCTTCCCTGGCTCCTGGCTTCCGATCCAATGGCATGGGTCCCCCTCTTGGGCCAGCGCGA
CTCAACCCCATGGCTCTGATGCGCTGGGATCCCCAGCCTGGGCTTGGCAACTCTAATATTGGCACTGCTACCCCTGAAC
CAGACCATGACATCTGCCGACACTTCAACCACTGTGTCTGAATGGCGCTGCCTGCCACGCTTCCAGTACCCTGCG
GAGTGTAAAGTGGGCTACACCCAGGACGTGCGCGGCGAGTGCAATTGATGTAGACGAATGCACAGCAGCCCTGCCACAC
GGTACTGCGTCAACATCCCGGCACCTACCACTGCCGTGTACCCGGCTTCCAGGCCAGCCCAACAGGAGGATGC
GTGGATGTGACGAGTGCAATTGTGAGTGGGCTTTGTCACTGGGCGCTGTGTCAACAGAGGGGAGCTTCCAGTGT
GTCAACGGCGTGTGTCTCAACGAGGATGGGAGCTTCTCTGCTCTGCAAAACCGGCTTCTGCTGGCGCTGGCGGCCAC
TACTGATGACATTGACAGAGTGCCAGACGCGCGGCTGTGCGTGAACGGCCACTGTACCAACACCGAGGGCTCTTCCCG
TGCCAGTGCCTGGGGGGCTGGCGGTAGGCAAGGATGGCGCGGTGTGCTGGACACCCAGTGCGCAGCACTCTGATGGG
GCCATCGAAGAGGCTCCTGTGCCCGCCCTTCCCTGGCACTGTCAACAGTCCGAGTGTCTGTGCAATCCGAGCCAC
GGTTTGGGAGCCCTGCCAGCTTGTCTGCCAAGACTCCGCTGAGTTCAGGCACTGTGCAGCAGTGGGCTTGGCATT
ACCACGATGGTGCAGACATCAACGAGTGTGCTCTGGATCCTGAGGTTTGTGCCAATGGCGTGTGCGAGAACCTTCGGGG
AGTACCGCTGTGTCTGCAACCTGGGTTATGAGGACAGTGCCTCAGGCAAGGACTGCACAGACGTGGATGAGTGTGCCCTC
AACAGCTCCTGTGTGACAACGGGTGGTGCCAGAATAGCCCTGGCAGCTACAGCTGCTCTGCCCGCGGCTTCCACTTC
TGGCAGGACACGGAGATCTGCAAGATGTGACGAATGCCTGTCCAGCCGCTGTGTGAGTGGCGTCTGTGGAACCTGGCC
GGCTCTACACCTGCAATGTGGCCTGGCAGCGGCTGGACCCCTCTGGTACCTTCTGTCTAGACAGACCAAGGGCACC
TGCTGGCTGAAGATCCAGGAGAGCCGCTGTGAGGTGAACCTTCAGGAGAGCCAGCTGCGGTCTGAGTGTGTGCCACCTC
GGGGCAGCCTGGGGGAGCCCTGCGAACGCTGCGAGATCGACCTGCCTGTGCCCGGGCTTGGCCGGATGACGGGTGTG
ACCTGCGATGATGTGAACAGAGTGTGAGTCTTCCCGGAGTCTGTCCCAACGGGCGTTCGCTCAACACTGCTGGGTCTTTC
CGCTGTGAGTGTCCAGAGGCGCTGATGCTGGACGCTCAGGCGGGCTGTGCGTGGATGTGAGATTGGAACCATGTTCTCTG
CGATGGGATGAGGATGAGTGTGGGTACCCCTGCCTGGCAAGTACCGGATGGACGCTGCTGCTGCTCCATCGGGGCGGTG
TGGGAGTTCAGTGCAGGCGCTGCCCGATCCCGAGTCTTGGAGTTCGCGAGCTGTGCCCGGGGGGCTGGGCTTCGCC
AGCCGGGACTTCTGTCTGGCCGACCATTTCTAAGAGTGTGAATGAATGCAAGGTGTTCCCTGGCTTGTGACGCAAGGT
ACCTGCAGAAACACGGTGGGAGCTTCCACTGCGCTGTGCGGGGGCTTCGCCCTGGATGCCAGGAACGGAAGTGCACA
GATATCGACGAGTGTGATCTCTCTGACCTCTGCGGCCAGGGCACCTGTGTCAACAGCCGGGAGCTTGTGAGTGCAG
TGTTTTCCCGGCTACGAGAGTGGCTTCTGCTGATGAAGAACTGCATGGACGTGGACGAGTGTGCAAGGACCCGCTGCTC
TGCCGGGAGGCACTTGCACCAACAGGATGGGAGCTACAAGTGCCAGTGTCCCTGGGCTGAGTGCAGGCGCAAGGGG
ACTGCTGTGAGGACATCGATGAGTGTCTCTGAGTGTGCGCTGTGCTCCCATGGCAGTGTGTCAATGTATCGGTGCC
TTCCAGTGTCTTGCCTGCGGCTTCCAGAGCACCTGACCGCGAGCTACAAGTGCAGTGTGCCGACGGAAGGGCAT
GTGCAGTGTCTTGGGCGTGGGAGCAGTGTGTAAGAGAAACCCCGCTTGTGACCAAGGCCACTGCACCAACATGCCAGGGGTAC
GCTCCCCAGAGCGTGGACGAGTGTGAAGAGAAACCCCGCTTGTGACCAAGGCCACTGCACCAACATGCCAGGGGTAC
CGCTGCTGTGCTATGATGGCTTCTGAGGACAGCATGAGGACATGTGTTGATGTGGATGAGTGTGACCTGAACCTC
CACATCTGCCTCCATGGGACTGCGAGAACAGAGGGTTCCTTGTCTGCCACTGTGAGTGGGCTACATGGTCAGGAAG
GGGGCACAGGCTGCTCTGATGTGGATGAATGCGAGGTTGGAGGACAACTGTGACAGTCAAGCCTCTGCTCAACATC

CCAGGGAGTTTCAGCTGTAGGTGCCCTGCCAGGCTGGGTGGGGGATGGCTTCGAATGTACGACCTGGATGAATGCGTCTCC
CAGGAGCACCGGTGCAGCCCAAGAGGTGACTGTCTCAATGTCCCTGGCTCCTACCGCTGCACCTGCCCGCAGGGCTTTGCC
GGGGATGGCTTCTTCTGCGAAGACAGGGATGAATGTGCCGAGAAGCTGGACCTCTGTGACAAACGGGAGTGCCCTCAATGCG
CCCGCGGGTACCGCTGTGAATGTGAGATGGGCTTTGACCCACCGAGGACCACCGGGCTGCCAGGATGTGGACGAGTGT
GCGCAAGAGAACCTCTGTGCAATTTGGGAGCTGTGAGAACCTGCCCTGGAATGTTCCGCTGCATCTGCAATGGTGGCTACGAA
CTGGACCGAGGGGTGGCAACTGCAACAGACATCAACGAGTGTGACAGCCAGTAAACTGCATCAACGGCGTGTGCAATTAAC
ACCCCGGCGAGCTACCTCTGCAGCTGCCCCAGGATTTTGTAGCTGAACCCAGCGGAGTGGGTGCGTGGACACTCGGGCC
GGGAACTGTTTCTGGAGACGCTGACCGAGGGGACAGTGGCATTTCCTGCAGTGCAGAGATCGGAGTTGGTGTACCCGA
GCTTCTGTCTGTGTCTCCCTGGGCGGGCTTGGGGCAATCCCTGTGAGCTGTGCCCTATGGCCAAACCACTGAGTACAGA
ACCTGTGTCGGGTGGTGGGCTTCCAGCCTAACCGCATCACTGTCTTCTGGAAGACATCGACGAGTGCCAGAGCTG
CCAGGGCTGTGTAGGGGGTGAAGTGTGCGTCAACACGTTTGGCAGTTTCCAGTGTGAGTGCACCTGGCTACCACTCACT
GAGCACACCGCATCTGTGAGGATATTGACGAATGTCCACACACTCCGGCATCTGTGGCCCTGGCACCTGCTACAACACC
CTGGGGAACCTACACCTGTGTCTGCCCTGCAGAGTACCTCCAAGTCAATGGTGGCAACAACCTGCATGGATATGAGGAAGAGT
GTCTGCTTCCGGCACTATAACGGCACATGTCAAAATGAGCTGGCTTCAACGTGACCCGGAATGTTGTTGCTGTCTTAC
AACATTTGGCCAGGCTTGAATAGACCTGTGAGGCTTCCCGCACTCCCATCAGTCTGACTACCAAGATCTGTGTGGAAAT
CAGGCCCCGGGATTTCTACTGACATCCACAGGGGAAGCCCTTGACATTTGATGAGTGTGGGAGATCCCGCCATCTGT
GCCAATGGCATCTGCATAAACAGATCGGGAGTTTCCGTGCGAGTGCCTGCGAGGCTTCAACTACAACAGCATCTGTCTG
GCTTGTGAAGATGTGATGAGTGTGGCAGCAGGGAGAGTCCCTGCCAGCAGAATGCTGACTGCATCAACATCCCGGTGAGC
TACCGCTGCAAGTGCACCCGAGGGTACAACTGTGCGCAGGCGGGCTTGTGTGGACGGAATGAGTGTGGGAGATCCCG
AATGCTGTAGCCATGGTGAAGTGTGCAAGGACAGAGGACGCTACATGTGTCTGTGTACCCTGGATTTCCAGGCTCTGCA
GACCAGACCTGTGCATGGACATTGACGAGTGTGACCGGACGCTTGTGGAAATGGGACCTGCAAGAACATCATTGGCTCC
TACCACTGCTCTGCTTCCCTGGCTTGTGGTGCACACAATGGGGATTGTGTGGATTGATGAGTGTACTACCTGGTGTG
GGCAGGTGTGGGATTTGGCCATTGCTTCAACAGAGGCTTCCCTTCCACTGCTCTGCCAGGATGGCTTGTGAGTGTGCA
GCTGATGGGAAGAACTGTGTGGACCAATGAGTGCCTCAGCCTTGACGAACTGCCTACCCGGCACTTGCCAGAACCTC
GAGGGCTCCTTCCGTGCATCTGTCCCCCTGGCTTCCAGGTGCAGAGTGAACCTGCATTTGATATCCAGAGTGTCTCAGAG
GAGCCCAACCTCTGCCTCTTTGGCACCTGTACCAACAGCCCTGGGAGCTTCCAGTGCCTTGTGCCAAGCTTGTCTCTC
TCTGACAAATGGGACCGTGTGCTTTGACACAGGAGAGTGTCTGCTTCCACCTTTCACCTTGGGAGTGTCTGGTGGCC
AAAGCTTTCAACACCAACAGACCCGCTGTGTGCTGACAGTGAAGAGGCTGGGGAGGGCTGGGGAGACCCCTGCGAATGTGT
CCCCAGGAGGGCAGCGCTGCCTTTTCCAGGAGCTGTGCCCTTTGGCCACGGGGCAGTCCAGGCCCCGATGACTCCCGAGAA
GACGTGAATGAGTGTGACAGAAACCTGGCGTGTGACATACCGGCGTCTGTGTCAACACCGATGGATCTTCCGCTGTGAG
TGTCCCTTTGGCTACAGCCTGGACTTCACTGGCATCACTGTGTGGACACAGACGAGTGTCTGTGCGCCACCCCTGTGGG
CAAGGACATGCACCAATGTCTCGGAGGCTTCAAGTGTGCTGTGCTGACGGCTTTGAGCCTGGCCTCATGATGACCTGC
GAGGAGATCGACGAATGCTCCCTGAAACCCGCTGTCTGTGCGCTTCCGCTGCCACAATACCGAGGGCTTCCACTGTGCA
TGTCCAGCCGCTACACCCCTGCGGGAGGATGGGGCCATGTGTGAAGATGTGGACGAGTGTGCAGATGGTGCAGGAGTGC
CACGCCCCGGGATGAGTGTGCAAGAACCTCATCGGTACCTTCCGCTGCGCTGTGTCCCCAGGATGCGGGCCCTGCTGGC
TCTGGGAGGGCTGCACAGATGACAAATGAATGCCAGCTCAGCCTGACCTCTGTGTCAACGGCCGCTGTGTCAACACCGG
GGCAGCTTCCGGTGCAGTGTGATGAGGGATTCAGCCACGCCCCCTTACCGAGTGCACAGCATCCCGCAGGGGGCCC
TGCTTTGGCAGGTGTGTCAGACCATGTGCCGCTCTGTGCCAGCAGCAGTGAAGGCTGTACACAGGCGCAGTGTCTGT
GGGGTGGGCGGGCTGGGGCCCCGCTGCGAGCTCTGTCCCTGCCCGGACCTCTGCCTACAGGAAGCTGTGCCCCAT
GGCTCAGGCTCAGTGTGAGGGCCAGATGTGATGATGAATGCCATGTGCTGCTCAGCTGTGTGCTCATGGGAGTGCATC
AACAGCCTTGGCTCCTTCCGCTGCCACTGTGAGGCGGGTACACACCGGATGCTACTGCTACTACCTGCCCTGGATATGGAT
GAGTGCAGCCAGGTGCCCAAGCCATGTACCTTCTCTGCAAAAACACGAAGGGCAGTTTCTGTGCAAGTGTCCCCAGGCG
TACCTGTGGAGGAGGATGGCAGGACCTGCAAGACCTGGACGAATGCACCTCCGGCAGCACAACCTGTCAAGTCTCTGT
GTCAACACTGTGGGCGCTTCACTTCCGCTGTCCGCGGGCTTACCCAGCAGCAGCAGGCTGTCTGCAACATGATGAG
TGCTCAGCCAGCCTGGCCATGTGGTGGCCACGGGCACTGCCACAACACCCCGGCGAGCTTCCGCTGTGAATGCCACCAA
GGCTTACCTTGGTCACTCAGGCTATGGCTGTGAAGATGTGAATGAATGTGATGGGCCCCACCGCTGCCAGCATGGCTGT
CAGAACCACTAGGGGGCTACCGCTGCAGCTGCCCGAGGGTTTACCCAGCACTCCAGTGGGCGCAGTGTGTGGATGAG
AATGAGTGTGCCCTGTGCGCCCCACCTGCGGGAGCGCTCTGTGCGCAACACTTGTGTGGCTTCCGCTGCGTGTGCCCC
TCTGGCTTTGACTTTGATCAGGCCCCGCGGGCTGCCAGGAGGTGGATGAGTGCAGCGGACCGGCTGGCCCTGTAGTAC
AGCTGTGCCAACAGCCCTGGTGGCTTCTGTGCGCTGTCTCAAGGCTACTTCCGGGCTGGGCAAGGCACTGTGTCTCC
GGCCTGGGCTTCAAGCCCCGACCCAGGACACCCCGGACAAAGAGGAGTGTCTGTCTGAGGCTGTCTACGAATGCAAG
ATCAATGGCTCTCCCTCGGGACCGGCCACGACGAGTGCACAGGAGCACCAGGTGAACCTGGCCACCTTGAATGCC
GAGGCCCTGTGACCTTGGGCTGAACCTTCAACCTGGGCGGGCCGAGCGCATCTGAGCTCAGGCTCGGGCGGCTGGAG
GGTCTAGAGGGCCGATCCGCTACGTCATCGTCCGCGGAAACGAGCAAGGTTTCTTTGCGATGCATCACTCCGTGGCGTC
AGCTCCCCGAGCTGGGCGGAGGCGGCGGGGCTGGAACCTACCGGCTGGAGGTGGTGAAGCAGATGGCAGGACCCCTGG
GGTGTCCAGCAAGAGGGGCGAGCCAGGGCCATGGGGCCAGGCTTGAAGGTGAAGGTGCAACTGTGAGTGTCTTAGTTGGG
AGGAGCTCAGTGGGCCCCAGCTGTCCAGAGAAGGGGATTTGGAAGTGGGAAGGACTGATCCCGAGAAGCGATGGCTGA
CCAGATTGAACCCGAACTCAGGAAGAGTGAATGCTACACGACAACCTCAGGCAAGCCCGGCTCTGCTGGGCTCTG
TGCCAGCCCCGGGGCCCCCAGTTACTCAGTCTTCTGAGAGACAGCAAGAGCTGCAATGTGCAATCCCCCTGCCCCCA
CAGCCAAGGTGAGGAAGGGCTGTGGTCAACCTGTGCGCAATCTCAGGCTTCACTTCTGTACTGCACTGTGGCTTG
CCCTGGCGGGGGCAGGGGTTGGCAGGACATGGCAATGGGCAACTGGGGTGGGACAGGGCTTATTCCTCGGAGTAGAAG
GGTGTACAGGGGGCCAGACTCCACAGTGAATGCCACATTTGCCCCCCATTTGGAGAATGCTTTTATATCAAAGTGGAG
ACGATAATAAAGTTATTTTGGGTTAAGTCTGCCCTTGGCAAGTCTTGAAGTAAGTAGATGTGCCCTCGGACTGG
GCGAGGCGAGATCTGTGCTGGGGAAGCAGAAGGCTTATGGGCTCCCCAGAATGGTAATAATGGCTCACGCTTCTGACC
ACGTAATAATACAGACACCATTCGATTTTTTTTTTTATTTTTTCTGAGACAGGGTCTGTGCTGTGTGCTAGGTTGGAGT
GCAGTGGCGGATGTGGCTCCCTGTGGTGGCACTTCCCGGCTCGAGCAATCTCCACCTCAGCCTCTCCCAAGTAGC
TGGGACCAAGGTGACGCCACCAACCCAGCTAATTTTTTAAATTTCTTTTCTTTCTTTTCTTTTGGAGACGAGCC
GGCCAACATGACGAACCCCACTCTAATA

The disclosed NOV2a nucleic acid sequence, localized to chromosome 19, has 3196 of 4382 bases (72%) identical to a *Mus musculus* fibrillin 2 (fbn2) mRNA (gb:GENBANK-ID:MUSFBN2|acc:L39790) (E = 0.0).

A NOV2a polypeptide (SEQ ID NO:6) encoded by SEQ ID NO:5 has 2995 amino acid residues and is presented using the one-letter code in Table 2B. Signal P, Psort and/or Hydropathy results predict that NOV2a contains a signal peptide and is likely to be localized to the endoplasmic reticulum membrane with a certainty of 0.5500. The most likely cleavage site for a NOV2a peptide is between amino acids 54 and 55, at: TSS-RK.

Table 2B. Encoded NOV2a protein sequence (SEQ ID NO:6).

```
MSKSCMTLLCPLLQRLAPPGPWPSPSLPLPTPVLPLWLCTLSPKTLLXHHTSSRKPLTVHRFPVAGCLLGLPEAPGLP
HLATTLPPSSLCWVPHGXGGGLIXGLCFLSAASRGHAMTLEGLYLARGPLARLLLAWSALLCMAGGQGRWDGALEAAGPGR
VRRRSGPGLIQQPNVCGSRFHAYCCPGWRTFPGRSQCVPVICRRACGEGFCSQPNLCTCADGTLAPSCGVSRGSGCSVSCM
NGGTGRCASCLCQKGYGTVCQPICDRGCHNGGRCIGPNRCACVYGFMPQCERDYRTGPCFGQVGPEGCQHQLTGLVCT
KALCCATVGRAGLPCLECPAQPHPCRRGFI PNHTGACQDVDECAVPLCQGGSCVNMVGSFHCRCRCPVGHRLSDSSAAC
EDYDECS T I P G I C E G G E C T N T V S S Y F C K C P P G F Y T S P D G T L H G Q S R A G A C F S V L F G G R C A G D L A G H Y T R R Q C C C D R G R C W A
AGPVPELCPRGSGNEFQQLCAQRLPLLPGHPGLFPGLLGFGSNGMGPPLGPARNPHGSDARGI PSLGPGNSIGTATLNQ
T I D I C R H F T N L C L N G R C L P T P S S Y R C E C N V G Y T Q D V R G E C I D V D E C T S S P C H H G D C V N I P G T Y H C R C Y P G F Q A T P T R Q A C V
DVDECI V S G L C H L G R C V N T E G S F Q C V C N A G F E L S P D G K N C V D H N E C A T S T M C V N G V C L N E D G S F S C L C K P G F L L A P G G H
C M D I D E C Q T P G I C V N G H C T N T E G S F R C Q C L G L A V G T D G R V C V D T H V R S T C Y G A I E K G S C A R P F P G T V T K S E C C A N D P H G
F G E P C Q L C P A K D S A E F Q A L C S S G L I T T D G R D I N E C A L D P E V C A N G V C E N L R G S Y R C V C N L G Y E A G A S G K D C T D V D E C A L N
S L L C D N G W C Q N S P G S Y S C S C P P G F H F W Q D T E I C K D V D E C L S S P C V S G V C R N L A G S Y T C K C G P G S R L D P S G T F C L D S T K G T C
C E C P E G L M L D A S G R L C V D V R L E P C F L R W D E D E C G V T L P G K Y R M D V C C S I G A V W G V E C A C P D P E S L E F A S L C P R G L G F A S
R D F L S G R P F Y K D V N E C K V F P G L C T H G T C R N T V G S F H C A C A G G F A L D A Q E R N C T D I D E C R I S P D L C G Q G T C V N T P G S F E C E C
F P G Y E S G F M L M K N C M D V D E C A R D P L L C R G G T C T N T D G S Y K C Q C P P G H E L T A K G T A C E D I D E C S L S D G L C P H G Q C V N V I G A F
Q C S C H A G F Q S T P D R G A T S A S C P T E G H V Q V L G P G E Q M C T G W S I R A K L S T V P N P A P P D V D E C E N P R V C D Q G H C T N M P G H R
C L C Y D G F M A T P D M R T C V D V D E C D L N P H I C L H G D C E N T K G S F V C H C Q L G Y M V R K G A T G C S D V D E C E V G G H N C D S H A S C L N I P
G S F S C R C L P G W V G D G F E C H D L D E C V S Q E H R C S P R G D C L N V P G S Y R C T C R Q G F A G D G F F C E D R D E C A E N V D L C D N G Q C L N A P
G G Y R C E C E M G F D P T E D H R A C Q D V D E C A E N L C A F G S C E N L P G M F R C I C N G G Y E L D R G G G N C T D I N E C A D P V N C I N G V C I N T
P G S Y L C S C P Q D F E L N P S G V G C V D T R A G N C F L E T H D R G D S G I S C S A E I G V G V T R A S C C C S L G R A W G N P C E L C P M A N T T E Y R T
L C P G G E G F Q N R I T V I L E D I D E C Q E L P G L C Q G G D C V N T F G S F Q C E C P P G Y H L S E H T R I C E D I D E C S T H S G I C G P G T C V N T L
G N Y T C V C P A E Y L Q V N G G N N C M D M R K S V C F R H Y N G T C Q N E L A F N V T R K M C C S Y N I G Q A W N R P C E A C P T P I S P D Y Q I L C G N Q
A P G F L T D I H T G K P L D I D E C G E I P A I C A N G I C I N I G S F R C E C P A G F N Y N S I L L A C E D V D E C G S R E S P C Q N A D C I N I P G S Y
R C K C T R G Y K L S P G G A C V G R N E C R E I P N V C S H G D C M D T E G S Y M C L C H R G F Q A S A D Q T L C M D I D E C D R Q P C G N G T C K N I I G S Y
N C L C P P G F V V T H N G D C V D F D E C T T L V G Q V C R F G H C L N T A G S F H C L C Q D G F E L T A D G K N C V D T N E C L S L A G T C L P G T C Q N L
G S F R C I C P P G F Q V Q S D H C I D I D E C S E E P N L C L F G T C T N S P G S F Q C L C P P G F V L S D N G H R C F D T R Q S F C F T R F E A G K C S V P K
A F N T T K T R C C C S K R P G E G W G D P C E L C P Q E G S A A F Q E L C P F G H A V P G P D S R E D V N E A E N P G V C T N G V C V N T D G S F R C E C
P F G Y S L D F T G I N C V D T D E C S V G H P C Q G T C T N V I G G F E C A C A D G F E P G L M M T C E E I D E C S L N P L L C A F R C H N T E G S Y L C T
P A G Y T L R E D G A M C E D V D E C A D Q Q D C H A R G M E C K N I G T F A C V C P P G M R P L P G S G E G C T D D N E C H A Q P D L C V N G R C V N T A G
S F R C D C D E G F Q P S P T L T E C H D I R Q G P C F A E V L Q T M C R S L S S S E A V T R A E C C C G G R G W G P R C E L C P L P G T S A Y R K L C P H G
S G Y T A E G R D V D E C R M L A H L C A H G E C I N S L G S F R C H C Q A G Y T P D A T A T T C L D M D E C S Q V P K P C T F L C K N T K G S F L C S C P R G Y
L L E E D G R T C K D L D E C T S R Q H N C Q F L C V N T V G A F T C R C P P G F T Q H H Q A C F D N D E C S A Q P G P C G A H G H C H N T P G S F R C E C H Q G
F T L V S S G H G C E D V N E C D G P H R C Q H G C Q N Q L G G Y R C S C P Q G F T Q H S Q W A Q C V D E N E C A L S P P T C G S A S C R N T L G G F R C V C P S
G P D F D Q A L G C C Q E V D E C A G R R G P C S Y S C A N T P G G F L C G C P Q G Y F R A G Q G H C V S G L G F S P G P Q D T P D K E E L L S S E A C Y E C K I
N G L S P R D R P R S A H R D H Q V N L A T L D S E A L L T L G L N L S H L G R A E R I L E L R P A L E G L E G R I R Y V I V R G N E Q G F F R M H H L R G V S
S P Q L G R R R P G P G T Y R L E V V S H M A G P W G V Q Q E G Q P G P W Q A L R L K V Q L S V A L V G R S L S G P Q L S R E G G F W N E G L I P R S D G
```

The NOV2a amino acid sequence has 1895 of 2810 amino acid residues (67%) identical to, and 2257 of 2810 amino acid residues (80%) similar to, a *Mus musculus* 2907 amino acid residue fibrillin 2 precursor protein (ptnr:SWISSPROT-ACC:Q61555) (E = 0.0).

The disclosed NOV2a is expressed in at least the following tissues: testes, ovary, lung, liver, B-cells, total-fetus, spleen, Nervous System, Brain, Prosencephalon/Forebrain, Diencephalon, Pituitary Gland, Hematopoietic Tissues, Lymphoid tissue, Lymph node and Whole Organism. This information was derived by determining the tissue sources of the sequences that were included in the invention. In addition, the NOV2a sequence is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Mus musculus* fibrillin 2 (fbn2) gene (GENBANK-ID: gb:GENBANK-

ID:MUSFBN2|acc:L39790): testes, ovary, lung, liver, total-fetus, brain, spleen, Nervous System, Brain, Pituitary Gland; Hematopoietic and Lymphatic System.

NOV2b

A disclosed NOV2b nucleic acid of 9894 nucleotides (also referred to as 153568997) encoding a novel Fibrillin-like protein is shown in Table 2C. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 520-522 and ending with a TGA codon at nucleotides 9052-9054. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 2C, and the start and stop codons are in bold letters.

10

Table 2C. NOV2b nucleotide sequence (SEQ ID NO:7).

<p>CCTCCCATTCCTCTCCTCTCTCTCCCATCTGGACAGCCCCAGCCTTCTGACACCCTGTTTCCCCCCGGGACCTGTGTGC CCTTCCCCACACCACCTAACATGCATTCTGACCTTGTCTCTCCCACTCAAAGCTTTCAAGGGCTCTTCATTGTCTTGA CGAATGAGCAAAAGCTGCATGACACTGTCTATGCCCACTCTGTCAACGCCTGGCCCCACCTGGCCCCACCTGGCCCTCTCTC CCTCCCTTCCACTTCCCACTCCCGTCTTGCCTTGGCTGTGACCCCTCAGCCCCAAGACCCTTCTCTAACATCACACCTCC TCCAGGAAGCCTCTCTGACTGTTTACCGCTTCCCGGTGGGGCTGGATGCCTCCTTGGGCTCCAGAGGCCCGGGGCTG CCCCATTGGCAACCACCTGCCCTCCTCGTTGTGTGGGTCCCCCATGGCTAGGGTGGGGGGCTCATCTAGGGCTGACTC TGCTTCTCTCCGAGCCTCCAGGGGACACGCCATGACTCTGGAGGGTCTGTATTGGCAAGGGGCCCTGGCCCGGCTC CTGTGGCCTGGTGGCCCTGTGTGTCATGGCAGGTGGCCAAGGCCGCTGGGACGGGGCCTTGGAGGCTGCAGGTCTTGGGA CGTGTGCGGAGGCGGGGAGCCAGGCATCTTGAGGGGCGAATGTGTGCGGCTCCCGGTTCATGCCTACTGCTGTCCA GGCTGGAGGACATTCCCTGGCAGGAGCCAGTGTGTGTAACCATCTGTAGGCGCGCCTGCGGTGAAGGCTTCTGCTCCAG CCCAACCTGTGCACCTGTGCGGATGGGACGCTGGCTCCAGCTGCGGGGTGAGCCGAGGGTCAGGTGTCAGTGTGAGCTGT ATGAATGGGGGCACTGCGGGGGGGCGTCTGTCTGTGTGTAAGGGCTACACAGGCACCGGTGTGTGGGAGGCCATCTGT GACCGCGGCTGCCAATGGGGGTGCTGCAATGGGCCAACCGCTGCGCCTGTGTGTATGGCTTCATGGGACCTCAATGT GAGAGAGATTACCGGACGGGATCCTGCTTTGGCCAAAGTAGGCCCCGAGGGGTGCCAGCATCAGCTGACGGGCCCTGTGTGC ACCAAGGCACTTTGCTGTGCCACTGTGGGCGTGCCTGGGGCCTTCCATGTGAACCTTTGCCCTGCACAGCCACACCCCTGC CGCCGCGGCTTATCCCCAATATCCACAGGGGGCCTGCCAAGATGTGGATGAGTGCCAGGCTGTGCCAGGCTGTGCCAG GGAGGACGTGCGTCAACATGGTGGGCTCCTTCCATTGCCGCTGTCCAGTTGGACACCGGCTCAGTGACAGACGCGCGCA TGTGAAGACTACCGGGCCGGCGCCTGCTTCTCAGTGCTTTTCGGGGCCGCTGTGCTGGAGACCTCGCCGGCCACTACACT CGCAGGCACTGCTGTGTGACAGGGGAGGTGCTGGGAGCTGGCCCGGTCCTGAGCTGTGTCTCTCGGGGCTCCAAT GAATTCAGCACTGTGCGCCAGCGGCTGCTGCTGCTACCGGCCACCTGGCCTCTTCCCTGGCCTCTGGGCTTCGGA TCCAATGGCATGGGTCCCCCTTGTGGCCAGCGCACTAACCCCATGGCTCTGATGCGCGTGGGATCCCCAGCCTGGGC CCTGGCACTTAATATTGGCACTGTACCTGAACAGACATTGACATCTGCCGCACTTCACCAACCTGTGTCTGAAT GGCCGCTGCTGCCACGCTTCCAGTACCGCTGCGAGTGTAACTGGGCTACACCGAGCTGCGCGGAGTGCAATT GATGTAGACGAATGCACAGCAGCCCTGCCACCAAGGTGACTGCTCAACATCCCCGGCACCTACCACTGCCGGTGTAC CCGGGCTTCCAGGCCAGCCACAGGCAGGCATGCGTGGATGTGGACGAGTGCAATTGTCACTGGTGGCCTTTGTCACTG GGCCGCTGTGTCAACAGAGGGGAGCTTCCAGTGTGTGTGCAATGCAGGCTTCGAGCTCAGCCCTGACGGCAAGAAGTGT GTGGACCACAAAGTGTGCCACAGCAACCATGTGCGTCAACGGCGTGTGTCTCAACAGGATGGCAGCTTCTCTGGCTC TGCAAAACCGGCTTCTGCTGGCGCTGGCGGCCACTACTGCATGGACATTGACGAGTGCCAGACGCGGCATCTGCGTG AACGGCACTGTACCAACACCGAGGGCTCCTTCCGCTGCCAGTGCTGGGGGGCTGGCGGTAGGCAGGATGGCCGGTGT TGCGTGGACACCCAGTGCGCAGCACCTGCTATGGGGCCATCGAGAAGGGCTCCTGTGCCCGCCCTTCTCTGGCACTGT ACCAAGTCGGAGTGTCTGTGTGCCAATCCGAGCCACGGTTTGGGGAGCCTGCCAGCTTTGTCTGCCAAAACCTCCGCT GAGTTCAGGCACTGTGCAGCAGTGGCTTGGCATTACACGGATGGTTCGAGACATCAACGAGTGTGCTCTGGATCCTGAG GTTTGTGCCAATGGCGTGTGCGAGAACCTTCCGGGACGCTACCGCTGTGTCTGCAACCTGGGTATGAGGACGTGCCTCA GGCAAGGACTGCACAGACGTGGATGAGTGTGCCCTCAACAGCCTCCTGTGTGACAACGGGTGGTGCCAGAATAGCCTTGGC AGCTACAGCTGTCTGCCCCCGGCTTCCACTTCTGGCAGGACAGGAGATCTGCAAGATGTGACGAATGCCTGTCC AGCCCGTGTGTGAGTGGCGTTTGTGGAACTGGCCGGCTCCTACACCTGCAATGTGGCCCTGGCAGCCGGCTGGACCCC TCTGGTACCTTCTGTCTAGACAGCACCAAGGCACTTGTGGCTGAAGATCCAGGAGAGCCGCTGTGAGGTGAACCTTCA GGAGCCAGCCTGGCGTCTGAGTGTGTGCCACCTCGGGGACGCTTGGGGAGGCCCTGCGAACGCTGCGAGATCGACCCT GCCTGTGCCCCGGGCTTTGCCCGGATGACGGGTGTCACTGCCGATGATGTGAACGAGTGTGAGTCTTCCCGGAGTGTGT CCCAACGGGCGTTCGCTCAACTGTGGGTCTTTCCGCTGTGAGTGTCCAGAGGGCTGATGCTGGACGCTCAGGCCG CTGTGCGTGGATGTGAGATTGGAACCATGTTTCTGCGATGGGATGAGGATGAGTGTGGGGTCACTTCCCTGCGCTGTGCGGG CGGATGGACGCTGTGCTGTCTCCATCGGGCGGTGTGGGGAGTTCGAGTGGAGGCTGCCCGGATCCCGAGTCTCTGGAG TTCGCCAGCCTGTGCCCCGGGGGCTGGGCTTCGCCAGCCGGGACTTCTGTCTGGCCGACCACTTATAAAGATGTGAAT GAATGCAAGGTGTTCCCTGGCCTCTGCAAGCAAGGTACCTGCAAGAACAGCGTGGGAGCTTCCACTGCGCCTGTGCGGGG GGCTTCGCCCTGGATGCCAGGAACGGAAGTGCACAGATATCGACGAGTGTGCGATCTCTCCTGACCTCTGCGGCCAGGGC ACCTGTGTCAACACGCCGGGAGCTTTGAGTGCAGTGTGTTTCCCGCTACGAGAGTGGCTTCATGCTGATGAAGAAGTGC ATGGACGTGGAGAGTGTGCAAGGGACCCGCTGCTTCCGGGGAGGCACTTGACCAACAGGATGGGAGCTACAAGTGC CAGTGTCCCCCTGGCATGAGCTGACGGCCAGGGCACTGCTGTGAGGACATCGATGAGTGTCTCCTGAGTGTGGCCTG TGTCCCCATGGCCAGTGTGTCAATGTATCGGTGCCCTTCCAGTGTCTGCTGATGCCGCTTCCAGAGCACCTGACCGC CAGGGCTGCGTGGACATCAACGAATGCCGGTCCAGAATGGTGGGTGTGACGTGCACCGTATTAACACTGAGGGCAGCTAC CGGTGCAGCTGTGGCAGGGCTACTCGTGTATGCCGACGGAAGGGCATGTGCAGACGTGGACGAGTGTGAAGAGAACCC</p>

CGCGTTTGTGACCAAGGCCACTGCACCAACATGCCAGGGGTACCCTGCTGTGCTATGATGGCTTCATGGCCACGCCA
GACATGAGGACATGTGTGTGATGTGGATGAGTGTGACCTGAACCTCACAATCTGCTCCATGGGAGTCCGAGAACCGAAG
GGTTCTTGTCTGCGCACTGTCACTGGGCTACATGGTCAAGGAAGGGGCCACAGGCTGCTCTGATGTGGATGAATGCGAG
GTTGGAGGACACAACGTGACAGTACGCTCCTGTCTCAACATCCCGGGAGTTTCACTGTAGGTGCCTGCCAGGCTGG
GTGGGGGATGGCTTCGAATGTCAACGACCTGGATGAATGCGTCTCCAGGAGCACCGGTGCAGCCCAAGAGGTGACTGTCTC
AATGTCCCTGGCTCCTACCGCTGCACCTGCCCGCAGGGCTTTGCCGGGATGGCTTCTTCTGCGAAGACAGGGATGAATGT
GCCGAGAACGTGACCTCTGTGACAAACGGGCAGTGCCTCAATGCGCCCGCGGGTACCGCTGTGAATGTGAGATGGGCTTT
GACCCACCGAGGACACCGGGCTGCCAGGATGTGGACGAGTGTGCGCAAGAGAACCTCTGTGCATTTGGGAGCTGTGAG
AACCTGCTGGAATGTTCCGCTGCATCTGCAATGGTGGTACGAACTGGACCGAGGGGTGGCAACTGCACAGACATCAAC
GAGTGTGCAGACCCAGTAACTGCATCAACGGCGTGTGCATTAAACCCCGGAGCTACCTCTGCAGCTGCCCCAGGAT
TTTGAGCTGAACCCAGCGAGTGGGCTGCGTGGACACTCGGGCCGGGAATGTTTCTGGAGACGATGACCGAGGGGAC
AGTGGCATTTGCTGCACTGCGAGATCGGAGTTGGTGTCAACCGAGCTTCTGCTGTGTCTCCCTGGCCGGCTTGGGGC
AATCCCTGTGAGTGTGCCCTATGGCCAAACCACTGAGTACAGAACCTGTGCCCGGGTGGTGAAGGCTTCCAGCTAAC
CGCATCACTGTCTTCTGGAAGACATCGACGAGTGCACAGAGCTGCCAGGGCTGTGTGAGGGGGTGAATGCTCAACAG
TTTGGCAGTTTCCAGTGTGAGTGCACCTGGCTACCACTCAGTGAGCACACCCGCTATGTGAGGATATTGACGAATGC
TCCACACACTCCGGCATCTGTGGCCCTGGCACCTGTACAACACCTGGGGAATACACCTGTGTCTGCCCTGCACAGTAC
CTCCAAGTCAATGGTGGCAACAACGTGATGAGGATAGGGAAGAGTGTGTCTTCCGCACTATAACGGCACATGTCAAAAT
GAGCTGGCCTTCAACGTGACCCGGAATGTGTGTGTCTTCTACAACATTTGGCCAGGCTTGAATAGACCTGTGAGGGC
TGCCCCACTCCCATCAGTCTGACTACAGATCCTGTGTGGAATCAGGCCCGGGATTCTCACTGACATCCACAGGGG
AAGCCCTTGACATTTGATGAGTGTGGGAGATCCCCCATCTGTGCCAATGGCATGTGCATAAACAGATCGGAGTTTC
CGCTGCGAGTGGCCCGCAGGCTTCAACTACAACAGCATCTGTGTGGCTTGTGAAGATGTGATGAGTGTGGCAGCAGGGAG
AGTCCCTGCCAGCAGAATGTGACTGCATCAACATCCCCGGTAGCTACCGCTGCAAGTGCACCCGAGGGTACAACTGTGCG
CCAGGCGGGCTTGTGTGGGACGGAATGAGTGTGGGAGATCCCGAATGTCTGTAGCCATGGTGAAGTGCAGACAGAA
GGCAGCTACATGTGTCTGTGTACCGTGGATTCCAGGCTCTGCAGACAGACCTGTGCATGGACATTTGACGAGTGTGAC
CGGACGCTTGTGGAATGGGACCTGCAAGAACATCATTGGCTCCTACAACCTGCTGTCTTCCCTGGCTTTGTGGTGACA
CACAATGGGATTTGTGGATTGTGATGAGTGTACTACCTGGTGGGGCAGGTGTGCCAATTGGCCATTGGCTCAACACA
GCTGGTTCTTCCATGCTCTGCCAGGATGGCTTTGAGCTCACAGCTGATGGGAAGAACTGTGTGGACACCAATCACTGC
CTCAGCTTGCAGAACCTGCTACCCGGCACTTGCAGAACCTCGAGGGCTCCTCCGCTGCATCTGTCCCCCTGGCTTC
CAGGTGCAGAGTGCACCTGCATTGATATCGACGAGTGTCTCAGAGGAGCCCAACCTCTGCTCTTGGCACCTGTACCAAC
AGCCCTGGGAGCTTCCAGTGCCTCTGCCACCTGGCTTTGTCTCTCTGACAAATGGGCACCGTTGCTTTGACACACGGCAG
AGTTTCTGCTTACCCGTTTGGAGCTGGGAAGTGTCTGGTGGCCAAAGCTTTCAACACCAAGACCGCTGCTGCTGC
AGTAAGAGGCTGGGAGGGCTGGGAGACCCCTGCGAAGTGTGTCCCGAGGAGTCCCTCCCCCTCTCCGTCCAGCT
GCCTTTCAAGAGCTCTGCCCTTTGGCCACGGGCGAGTCCAGGCCCGGATGACTCCCGAGAAGACGTGAATGAGTGTGCA
GAGAACCCTGGCGTCTGCACTAACGGCGTCTGTGTCAACACCGATGGATCCTTCCGCTGTGAGTGTCCCTTTGGCTACAGC
CTGGACTTCACTGTCATCAACTGTGAGGACACAGACGAGTGTCTGTGCGCCACCCCTGTGGGCAAGGACATGCACCAAT
GTCATCGGAGGCTTCAATGTGCTGTGTGACGCTTTGAGCCTGGCCTCATGATGACCTGCGAGGACATCGACGAATGC
TCCCTGAACCGCTGCTGTGTGCTTCCGCTGCCACAATACCGAGGGCTCCTACCTGTGCACCTGTCCAGCCGGCTACACC
CTGCGGAGGATGGGGCATGTGTGAGATGTGGACGAGTGTGCAGATGGTGCAGGAGTGCACGCCCCGGGGCATGGAG
TGCAAGAACCTCATCGGTACCTTCCGCTGCGTCTGTCCCCAGGCATGCGGCCCTGCTGGCTCTGGGAGGGCTGCACA
GATGACAATGAATGCGACGCTCAGCCTGACTCTGTGTCAACCGCGCTGTGTCAACACCGGGCAGCTTCCGCTGCGAC
TGTGATGAGGATTTCCAGCCAGCCCAACCTTACCGAGTGCACAGACATCCCGCAGGGGCTGCTTTGCCAGGTTGCTG
CAGACCATGTGCGGCTCTCTGTCCAGCAGAGTGGGCTGTCAACAGGGCGAGTGTCTGTGGGGGTGGCGGGGCTGG
GGCCCGCTGCGAGCTCTGTCCCTTCCCGGCACTCTGCTACAGGAAGCTGTGCCCATGGCTCAGGCTACACTGTCT
GAGGGCCGAGATGTAGATGAATGCCGTATGCTTGTCTCACCTGTGTCTCATGGGAGTGCATCAACAGCCTTGGCTCCTTC
CGCTGCCACTGTCAAGCCGGGTACACCGGATGCTACTGTACTACCTGCCTGGATATGGATGAGTGCAGCCAGGTCCCC
AAGCCATGTACCTTCTCTGCAAAACACGAGGATGCACCTCCCGGAGCACAACTGTCACTTCTCTGTGTCAACACTGTGGGCGCC
GGCAGGACCTGCAAGACCTGGACGAATGCACCTCCCGGAGCACAACTGTCACTTCTCTGTGTCAACACTGTGGGCGCC
TTCACTTCCGCTGTCCACCCGGCTTCAACAGCACCACAGGCTGCTTCGACAATGATGAGTGTCAAGCCAGCCTGGC
CCATGTGGTGGCCACGGGCACTGCCACAACCCCGGCGAGCTTCCGCTGTGAATGCCACCAAGGCTTCAACCTGGTCAGC
TCAGGCCATGCTGTGAAGATGTGAATGAATGTGATGGGCCCCACCGCTGCCAGCATGGCTGTGAGAACCAGTATGGGGC
TACCGCTGCAGCTGCCCCAGGCTTCAACAGCACTCCAGTGGGCGCAGTGTGTGGATGAGAATGAGTGTGCCCTGTG
CCCCCACTGCGGGAGCGCTCCTGTGCGAACACTCTTGGTGGCTTCCGCTGCGCTGCCCCCTCGGCTTTGACTTTGAT
CAGGCCCTGCGGGGCTGCCAGGAGTGGATGAGTGCAGCGGACGGCGTGGCCCTGTAGCTACAGCTGTGCCAACAGCCT
GGTGGCTTCTGTGCGGCTGTCTCAAGGCTACTTCCGGGTGGGCAAGGGCACTGTGTCTCCGGCTGGGCTTCCAGCCCC
GGACCCAGGACACCCCGGACAAAGAGGAGTGTCTCTGTGAGCCTGCTACGAATGCAAGATCAATGGCCTTCTCCCT
CGGACCGGCCACGACGAGTGCACAGGACACCAAGGTGAACCTGGCCACCTTGAATCCGAGGCCCTGTGACCTTTG
GGCTGAACCTCTCACACCTGGGCGGGCCGAGCGCATCTGGAGCTCCGGCCGGCTTGGAGGGTCTAGAGGGCCGGATC
CGCTACGTCTGTCCGCGAAACGAGCAAGGTTTCTTTCGATGCACTACCTCCGTGGCGTCACTCCTGCACTGTGGG
CGGAGGCGGCGGGGCTGGAACCTACCGCTGGAGGTGGAAGTGTCACTGTCACTTGTCTTGTGGGAGGAGCTCAGTGGGCCC
CAGCTGTCCAGAGAAGGGGATTCTGGAATCTGGGAAGGATGATCCCGAGAAGGATGGCTGACAGATGAAACCCGAAA
CTCAGGAAGAGTGAATGTACACGACAACCTCAGGCAAGCCCGGCTCTGCTGGGCTCTGTGCCAGCCCGGGGCC
CCAGTTACTCAGCTTTCTGAGAGACAGCAAGAGCTGCAATGTGCAATCCCTTCCCGCCACAGCCAAGGTGAGGAAG
GGCCTGTGGTCACTGTCTGGCAATCTCAGGCTTCACTTCTGTACTGCACTGTGGCTTCCCTGGCGGGGGCAGG
GGTTGGCAGGACATGGCAATGGGCACTGGGGTGGGCACAGGGCTTATCTCGAGTAGAAGGGTGTACAGGGGGCCAG
ACTCCACAGTGACTTGCACATTTGGCCCCATTTGGAGAATGCTTTATATCAAAAGTGGAGACGATAATAAGTTATTT
TGGGTTAAGTCTGCCCTGGCCTTTGGCAAGTCTTGAAGTAAAGTAGTGTGCCCTCGGACTGGGCGAGGAGATCTGTGTC
CTGGGAAGCAGAAGGCTTATGGGCTCCCGAATGGTAATATGGCTCACGCTTCTGACCACTACTACATACAGAC
ACCATTCGATTTTTTTTTTTTTCTGAGACAGGCTTGTCTGTGTGCTAGGTTGGAGTGCAGTGGCGCGATCTGTG
CTCCCTGTGGTGGCACTTTCCGGGCTCGAGCAATCTCCACCTCAGCCTCTCCCAAGTAGCTGGGACCAAGGTGCAGC
CCACCACCCAGCTAATTTTTTAAATTTCTTTTCTTTCTTTCTTTTGTGAGACAGCCCGGCCAACATGACGAACCC
CCATCTCTAATA

The disclosed NOV2b nucleic acid sequence, localized to chromosome 19, has 3617 of 5008 bases (72%) identical to a *Rattus norvegicus* fibrillin 2 (fbn2) mRNA (gb:GENBANK-ID:AF135060|acc:AF135060.1) (E = 0.0).

A NOV2b polypeptide (SEQ ID NO:8) encoded by SEQ ID NO:7 has 2844 amino acid residues and is presented using the one-letter code in Table 2D. Signal P, Psort and/or Hydropathy results predict that NOV2b contains a signal peptide and is likely to be localized to the nucleus with a certainty of 0.6000. Although PSORT suggests that the Fibrillin-like protein may be localized in the nucleus, the NOV2b protein is similar to the Fibrillin family, some members of which are released extracellularly. Therefore it is likely that NOV2b protein shows a similar localization. The most likely cleavage site for a NOV2b peptide is between amino acids 29 and 30, at: AGG-QG.

Table 2D. Encoded NOV2b protein sequence (SEQ ID NO:8).

```
MTLEGLYLARGPLARLLLAWSALLCMAGGQGRWDGALEAAGPGRVRRRSGSPGILQGPVNCGRFHFAYCCPGWRTFPGRSQC
VVPICRRACGEGFCSQPNLCTCADGTLAPSCGVSRGSGCSVSCMNGGTCRGASCLCQKGYTGTVCGQPICDRGCHNGGRCI
GPNRCACVYGMGPQCDYRTGSCFQGVGPEGQHQLTGLVCTKALCCATVGRWGLPCELCPAQPHPCRRGFIPINIHTG
ACQDVDECAVPGLCQGGSCVMVSGFHCRCVPVGHRLSDSSAACEDYRAGACFSVLFGGRCAGDLAGHYTRRQCCCDRGRC
WAAGPVPELCPPRGSNEFQQLCAQRLPLLPGHPGLFPGLLGFGSNGMGPPLGPARLNPHGSDARGIPSLGPGNSNIGTATL
NQTIDICRHFTNLCLNGRCLPTPSSYRCECNVGYTQDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCPYPGFQATPTRQA
CVDVDECI VSGGLCHLGRVCNTEGSGFQVCNAGFELSPDGKNCVDHNECATSTMVCNVGCLNEDGSFSLCKPGFLLAPGG
HYCMDIDECQTPGICVNGHCTNTEGSRFCQCLGGLAVGTDGRVCDTHVRSTCYGAIEKGSCARFPFGTVTKSECCCANPD
HGFGEPCQLCPAKNSAEFQALCSSLGIITDGRDINECALDPEVCANGVCENLRGSYRCVNLGYEAGASGKDCITDDECA
LNSLLCDNCGWQNSPGSYSCSCP PGHFWQDTEICKDVDECLSSPCVSGVCRNLGASYSYTKCGPGSRDLDPSTGFLDSTKG
TCWLKIQESRCEVNLQGA SLRSECCATLGAAGWSPCERCEIDPACARGFARMTGVTCDVNECESFPGVCPNGRCVNTAGS
FRCECEGLMLDASGRLCVDVRLPCFLRWDEDECGVTLPGKYRMDVCCSIVGAVWGVCEACPDPELSEFASLCPRLGFG
ASRDFLSGRPFYKDVNECKVPFGLCTHGTCTNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLGGQGTCTVNTPGSFEC
ECFPYGESGFMLMKNCMDVDECDARLLCRGGTCTNTDGSYKQCPCPGHELTAKGTACEDIDECSLSDGLCPHQCVNVIG
AFQCSCHAGFQSTPDRQGCVDINECRVQNGGCDVHRI NTGYSYRCSGGQYSLMPDGRACADVDECEENPRVCDQGHCTNM
PGGHRCLCYDGFMATPDMRTCDVDECDLNPICLHGDCEKTSFVCHCQLGYMVRKGTGCSVDVECEVGGHNCDSHAS
CLNIPGSGFSCRLPGWVGDFECHDLDECVS QEHRCSPRGDCLNVPGSYRCTCRQGFAGDGFCEDECAENVDLCDNGQ
CLNAPGGYRCECEMGFDPTEDHRACQDVDECAQENLCAFGSCENLPGMFRCICNGGYELDRGGGNCITDINECAFPVNCING
VCINTPGSYLCSQPD FELNPSGVCVDTRAGNCFLETHDRGDSGISCSAEIGVGVTASCCCSLGRAWNPCBELCPMANT
TEYRTLCPGGEFQPNRIITVILEDIDECQELPGLCQGGDCVNTFGSFQCECPPGYHLSEHTRICEDIDECSTHSGICGPGT
CYNTLGNITCVCPAEYLVQNGNMCMDMRKSVCFRHYNGTCQNELAFNVTRKMCCCSYNIGQAWNRPCEACPTTIPSPDYQI
LCGNQAPGFLTDIHTGKPLDIDECGEIPAICANGICINQIGSFRCCEPAGFNYSILLACEDVDECGSRESPPCQNA DCIN
IPGSYRCKTRGYKLSPGGACVGRNECREIPNVCSHGDCMDTEGSYMCLCHRGFQASADQTLCMDIDECDRQPCGNGTCKN
IGSYNCLCFPGFVVTNHGDCVDFDECTTLVGQVCRFGHCLNTAGSFHCLCQDGFELTADGKNCVDTNECLSLAGTCLPFGT
CQNLGSRFCICPPGFVQSDHCIDIDECSEEPNLCLFGTCTNSPGSFQCLCPPGFVLSDNHRCFDTRQSFCTRFEAGK
CSVPKAFNTTKTRCCSKRPGEGWDPCELCQEDSPPLRPAAPQELCFPHGAVPGPDDSRBDVNECAENPGVCTNGVC
VNTDGSFRCECPFGYSLDFTGINCEDTDECSVGHPCQGTCTNVIGGFECACADGFEPGLMMTCEDIDECSLNPLLCAFR
HNTGSEYLTCTPAGYTLREDGAMCRDVEDACDGGQDCHARGMECKNLIGTFACVCP PGMRLPLPGSGEGCTDDNECHQPD
CVNGRCVNTAGSFRCDCEGFQPSPTLTECHDIRQGPCFAEVLQTMCRSLSSSSEAVTRAECCECGGGRGWGRPCELCPLPG
TSAYRKLCPHSGSYTAEGRDVDECRMLAHLCAHGEICINLSGFRCHCQAGYTPDATATCLDMDECSQVVKPCTFLCKNTK
GSFLCSCPRGYLLEEDGRTCKDLDECTSRQHNCQFLCVNTVGAFTCRCP PGFTQHHQACFDNDECSAQPGPCGAHGHCHNT
PGSFRCECHQGTFLVSSGHGCEDEVNECDGPHRCQHGCNQLGGRYRCSQPAFTQHSQWACQVDENECALSPPTCGSASCRN
TLGGFRVCPSGFDQDQALGGCQEVDEACAGRRGPCSYSCANTPGGFLCGCPQGYFRVGQGHCVSGLGFSFGPQDTPDKEEL
LSSEACYECKINGLSPRDRPRRSARHDHQNLA TL DSEALTLGLNLSHLGRAERILELRPALEGLEGRIYRIVIRGNEQG
FFRMHHLRQSSSLQLGRRRPPGTYRLEVSHMAGPWGVQEGQPGPWGQALRLKVQLSVALVGRSLSGPQLSREGGFWNW
BGLIPRSDG
```

The NOV2b amino acid sequence has 1797 of 2750 amino acid residues (65%) identical to, and 2161 of 2750 amino acid residues (78%) similar to, a *Homo sapiens* 2911 amino acid residue fibrillin 2 precursor protein (ptnr:SWISSNEW-ACC:P35556) (E = 0.0).

NOV2b is expressed in at least the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain - whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney,

lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the NOV2b sequence.

5 NOV2c

A disclosed NOV2c nucleic acid of 9993 nucleotides (also referred to as CG88987-01) encoding a novel Fibrillin-like protein is shown in Table 2E. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 520-522 and ending with a TGA codon at nucleotides 9151-9153. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 2E, and the start and stop codons are in bold letters.

Table 2E. NOV2c nucleotide sequence (SEQ ID NO:9).

CCTCCCATCTCTCTCTCTCTCCCATCTGGACAGCCCCAGCCTTCTGACACCCTGTTTCCCCCCGGGACCCTGCTGC
CCTTCCCCACACCACCTAACATGCATTCTGACCTTGCTCCTCCCACTCAAAGCTTTTCAAGGGCTCTTCATTGTCTTGA
CGAATGAGCAAAAGCTGCATGACACTGCTATGCCCACTCCTGCAACGCCTGGCCCCACCTGGCCCCACCTGGCCCTCTCTC
CCCTCCCTTCCACTTCCCACTCCCGTCTTGCTTGGCTGTGCACCCTCAGCCCCAAGACCCTTCTTAACATCACACCTCC
TCCAGGAAGCCTCCTCTGACTGTTACCGCTTCCCGGTTGGGGCTGGATGCCCTCCTTGGGCTCCAGAGGCCCGGGGCTG
CCCCATTTGGCAACCACCTGCCCTCCTCGTTGTGTGGGTCCCCCATGGCTAGGGTGGGGGGCTCATCTAGGGCTGACTC
TGCTTCCTCTCCGACGCTCCAGGGACACGCCATGACTCTGGAGGGTCTGTATTTGGCAAGGGGCCCTGGCCCGGCTC
CTGCTGGCCCTGTTGGCCCTGTTGTGTCATGGCAGGTGGCCAAAGGCGCTGGGACGGGGCTTGGAGGCTGCAGGCTCTGGA
CGTGTGCGGAGGCGGGGAGCCAGGCATCTGCAAGGGCCGAATGTGTGCGGCTCCCGGTTCCATGCCTACTGCTGTCCA
GGCTGGAGGACATTCCCTGGCAGGAGCCAGTGTGTCGTACCATCTGTAGGCGCGCTGCGGTGAAGGCTTCTGCTCCAG
CCCCACCTGTGCACCTGTGCGGATGGGACGCTGGCTCCAGCTGCGGGGTGAGCCGAGGGTCAGGGTCAGTGTGAGCTGT
ATGAATGGGGGACCTGCCGGGGGCGCTCCTGTCTGTGTGAGAAGGGTACACAGGCACCGTGTGTGGGACGCCATCTGT
GACCGCGCTGCCACAATGGGGGTCGCTGCATTGGGCCAACCGCTGCGCCTGTGTGTATGGCTTCATGGGACCTCAATGT
GAGAGAGATTACCGGACGGGACCTGCTTTGGCCAAAGTAGGCCCGAGGGGTGCCAGCATCAGCTGACGGGCTCGTGTGC
ACCAAGGCACTTTGCTGTGCCACTGTGGCCGTGCTGGGGCCTTCCATGTGAACCTTGCCTGTCAAGCCACACCCCTGC
CGCCCGGGCTTCATCCCCAATATCCACAGGGGGCTGCCAAGATGTGGATGAGTGCCAGGCTGTGCCAGGCTGTGCCAG
GGAGGCAGCTGGTCAACATGGTGGGCTCCTTCCATTGCCGCTGTCCAGTTGGACACCGGCTCAGTGACAGCAGCGCCGA
TGTGAAGACTACGATGAATGCAGCACCATTCTGGAATCTGTGAAGGGGTGAATGTACAAACACAGTCAGCAGTTACTTT
TGCAAAATGTCCTCCTGTTTACACCTCTCCAGATGGTACTCTTCATGGACAGTCGCGGGCCGGCGCTGCTTCTCAGTG
CTTTTCGGGGGCGCTGTGCTGGGACCTCGCCGGCCACTACACTCGCAGGCAGTGTGCTGTGACAGGGGACGGTGTGG
GCAGCTGGCCCGGCTCCCTGAGCTGTGTCTCCTCGGGCTCCAATGAATCCAGCAACTGTGCGCCAGCGGCTGCCGCTG
CTACCGGGCCACCTGGCCTCTTCCCTGGGCTCCTGGGCTTCGATCCAAATGGCATGGGTCCCCCTCTTGGGCGAGCGGA
CTCAACCCCATGGCTCTGATGCGGTGGGATCCCCAGCCTGGGCCCTGGCACTTAATATTGGCACTGTACCTGAAC
CAGACCATTGACATCTGCCGACACTTACCAACCTGTGTCTGAATGGCCGCTCCCTGCCACGCTTCCAGTACCGCTGC
GAGTGTAAAGTGGGCTACACCCAGGAGTGCAGCGCGAGTGCAATTGATGTAGACGAATGCACACGACGCCCTGCCACCAC
GGTGACTGCGTCAACATCCCGGCACCTACCACTGCCGCTGTACCGGGCTTCCAGGCCACGCCACAGGCAGGCATGC
GTGGATGTGGACGAGTGCAATTGTCACTGGTGGCCTTTGTCACTGGGCGCTGTGTCAACACAGAGGGCAGCTTCCAGTGT
GTCTGCAATGCAGGCTTCGAGCTCAGCCCTGACGCAAGAACTGTGTGGACCAACGAGTGTGCCACAGCACCATTGTGC
GTCAACGGCGTGTGTCTCAACGAGGATGGCAGCTTCTCCTGCCTCTGCAAAACCGGCTTCTGCTGGCGCTGGCGGCCAC
TACTGCATGGACATTGACGAGTGCCAGACGCCCGCATCTGCGTGAACGGCCACTGTACCAACACCGAGGGCTCCTTCCGC
TGCCAGTGCCTGGGGGGCTGGCGGTAGGCACGGATGGCCGCTGTGCGTGGACACCCAGTGCAGCAGCTGCTATGGG
GCCATCGAGAAGGGCTCCTGTGCCCGCCCTTCCCTGGCACTGTCAACAGTCCGAGTGTGCTGTGCCAATCCGGACAC
GGTTTTGGGGAGCCCTGCCAGCTTGTCTTCCCAAGACTCCGCTGAGTTCAGGCACTGTGCAGCAGTGGGCTTGGCATT
ACCAAGGATGGTCGAGACATCAACGAGTGTCTCTGGATCCTGAGGTTTGTGCCAATGGCGTGTGCGAGAACCTTCGGGGC
AGCTACCGCTGTGTCTGCAACCTGGGTATGAGGAGGTCCTCAGGCAAGGACTGCACAGACGTGGATGAGTGTGCCCTC
AACAGCCTCCTGTGTGACAACGGGTGGTGCCAGAATAGCCCTGGCAGCTACAGCTGCTCCTGCCCCCGGCTTCCACTTC
TGCGAGGACACGGAGATCTGCAAGATGTGACGAATGCTGTCCAGCCGCTGTGTGAGTGGGCTGTGTCGGAACCTGGCC
GGCTCCTACACCTGCAATGTGGCCCTGGCAGCCGCTGGACCCCTCTGGTACCTTCTGTCTAGACAGCACAAGGGCAC
TGCTGGCTGAAGATCCAGGAGAGCGCTGTGAGGTGAACCTTCAGGGAGCCAGCTGCGGTCTGAGTGTGTGCCACCCTC
GGGGCAGCTGGGGGAGCCCTTGCBAACGCTGCGAGATCGACCTGCCTGTGCGCGGGCTTGGCCCGATGACGGGTGT
ACCTGCGATGATGTGAACGAGTGTGAGTCTTCCCGGAGTCTGTCCCAACGGGCGTGTGCTCAACACTGCTGGGTCTTTC
CGCTGTGAGTGTCCAGAGGGCTGATGTGGACGCTCAGGCCGCTGTGCGTGGATGTGAGATGTGAACCATGTTCTCTG
CGATGGGATGAGATGAGTGTGGGTACCTGTGGCAAGTACCGGATGGACGCTGCTGCTGCTCCATCGGGCCGCTG
TGGGAGTGCAGTGCAGGCGCTGCCCGATCCCGAGTCTCTGGAGTTCGCCAGCTGTGCCCGCGGGGCTGGGCTTCGCC
AGCCGGGACTTCTGTCTGGCCGACCATCTATAAAGATGTGAATGAATGCAAGGTGTTCCCTGGCCTTGCACGACCGGT
ACCTGCAGAAACCGGTGGGAGCTTCACTGCGCTGTGCGGGGGCTTGCCTGGATGCCAGGAACGGAACGCACTGCACA
GATATCGACGAGTGTGCATCTCTCTGACCTTGCGGCCAGGGCACCTGTGTCAACACCGCGGACGCTTGTGAGTGCAG

TGCTTTTCCCGGCTACGAGAGTGGCTTCATGCTGATGAAGAACTGCATGGACGCTGGACAGAGTGTGCAAGGACCCCGTGTCT
TGCCGGGGAGGCACTTGCACCAACACGGATGGGAGCTACAAGTGCCAGTGTCCCCCTGGGATGAGCTGACGGCCAAAGGGC
ACTGCTGCTTGAGACATCGATGAGTGTCTCCCTGAGTGAATGCTGCCCTGTGTCCCCATGGCCAGTGTGTCATGTCACTCGTGCC
TTCAGATGCTCTTCCCATGCGCGCTTCCAGAGACAACCTGACCGCGGGATCAAGAGTGCAGTGTGCCCGACGGAAGGGCAT
GTGCAGGTGCTCTGGGGCTGGGGAGCAGATGTGTACTGGTGGTCTATCAGGGCAAAGCTAAGCACAGTCCCCAACCCCT
GCTCCCCAGACGTGGACAGTGTGAAGAGAACCCCGGCTTTGTGACCAAGGCCACTGACCAACATGCCAGGGGTCA
CGCTGCTCTGTATGATGGCTTCAITGGCCACGCCAGACATGAGACATGTGTGATGTGATGAGTGTGACCTGAACTCC
CACATCTGCTCTGCATGGGACTGCGAGAACAAGGGTTCCTTTGTCTGCCACTGTGAGTGGGTACATGGTCAGGAAG
GGGGCCACAGGCTGCTGTGATGTGGATGAATGCGAGGTTGGAGGACACAACCTGTGACACAGCTCAGCCTCTGTCTCAACAT
CCAGGGAGTTTTCAGTGTAGGTGCTGCGAGCTGGTGGGGATGGCTCGAATGTACAGCATGGATGGATGGAATGGCTCTCC
CAGGAGCACCGGTGACGCCAAGAGGTGACTGTCTCAATGTCCCTGGTCTTACCCTGACCTGCCCGCAGGGCTTTGGC
GGGGATGGCTTCTTCTGCGAAGACAGGGATGAATGTGCCAGAACTGGACCTCTGTGACACCGGCAGTGCCTCAATGCG
CCCGCGAGGTACCGCTGTGAATGTGAGATGGGCTTTGACCCACCGAGGACCCCGGCTGCGAGGATGTGACGAGTGT
CGCGAAGAACTCTGTGCTATTGGGAGCTGTGAGAACTGCTGGAATGTTCCGCTGCACTGTGCAATGGTGGCTACGAG
CTGGACCGAGGGGGTGGCACTGCACAGACATCAACGAGTGTGCAGACCCAGTAACTGCACTCAACGGCGGTGTGCATTAA
ACCCCGCGGACGTACCTCTGCAGTGTCCCCAGGATTTGAGCTGAACCCAGCGGAGTGGCTGCGTGGGACTCGGGC
GGGAATCTGTTTCTGGAGACGATGACCGGAGCAGTGGGATTTCCTGAGTGGCAGATGCGAGATGGGATGGATGTACCCGA
GCTTCTGCTGTTGCTCCCTGGGCGGGCTTGGGGCAATCCTGTGAGCTGTGCCCTATGGCCAAACCACTGAGTACAGA
ACCTGTGTCGGGTGTTGAGGGCTTCCAGCTAACCAGCATCACTGTCAATTGGAAGACATCGACAGTGGCCAAAGAGCT
CCAGGGCTGTGCTCAGGGGTGACTGCGTCAACACGTTTGGCAGTTTCCAGTGTGATGTCACCTGGGTACCACTCAGT
GACACACCCGCATCTGTGGAGATATTGACGAATGCTCCACACTCCGCGATCTGTGGCCCTGGCACCTGCTACACACC
CTGGGGAACATACCTGTGTCTGCCCTGCAGAGTACCTCCAAGTCAATGGTGGCAACAACCTGCATGGATAGGGAAGAGT
GTCTGCTTCCGGCACTAATACCGACATGTCAAAATGAGCTGGCTTCAACGTGACCCGGAAATGTGTGCTCTCTAC
AACATTTGGCCAGGCTGGAATAGACCTGTGAGGCTGCCCACTCCCATCAGTCTGACTACAGATCTGTGTGGAAT
CAGGCCCGGGATTCTCTCACTGACATCCACAGGGGAAGCCCTTGACATTTGATGAGTGTGGGAGATCCCCGCCATCTGT
GCCAATGGCATCTGCATAAACAGCAGTCCGGAGTTTCCTGCGAGTGCCTCCAGGCTTCAACTACAAACAGCATCTGTCT
GCTTGTGAAGATGTGATGACGAGTGTGACAGGAGAGTCTCTGCCAGGAAAGTCTGACTGCATCAACATCCCCGTAGC
TACCGCTGCAAGTGACCGAGGGGTACAACTGTGCGCAGGCGGGCTTGTGTGGACGGAATGAGTGTGCGGAGATCCCG
AATGTCTGTAGCCATGGTGTGACTGTGACATGGAACAGGAGCAGTACATGTGTCTGTGTCACCTGGATTCGAGGATCTGCA
GACACAGACCTGTGTCATGGACATTTGACGAGTGTGACCGGACGCTTGTGGAATGGGACCTGCAAGAACATCATTTGGCTCC
TACAATGCTCTGCTTCCCTGGCTTTGTGGTACACACAATGGGGATTGTGTGGATTTTGATGAGTGTACTACCTGGT
GGGACAGGTGTGCCGATTGTGCCATTGCCCTCAACAGAGTGTGTTCTTCCATGCTCTGCCCAGGATGGCTTTGAGCTACA
GCTGTGAGGGAAGACTGTGTGGACATCCCAATGAGTGCCTCAGCCTTGACGAACTGCTTCAACCGGATCTTCCGTGAC
GAGGGCTCTTCTCCGCTGATCTGTCCCCGTGGCTTCAGGTGAGAGTACACTGCAATGATGACAGAGTGTGTCAGAG
GAGCCCAACCTCTGCTCTTTGGCACCTGTACCAACAGCCCTTGGAGCTTCCAGTGCCTTGCACCACTGGCTTTGTCTCT
TCTGACAATGGGACCGTGTGTTTGACACAGGACAGTTCCTGCTTCAACCCCTTTGAGGCTGGGAAGTGTGCTGGTGCC
AAAGCTTTCAACACCAACGAAGACCTGCTGCTGTGATGAAGAGCTGGGAGGGCTGGGAGAGCCCTGCGAATGTGT
CCCCAGGAAGGCAGCGCTGCCCTTTCAGGAGCTGTGCCCTTTGGCCACGGGCGAGTCCAGGCCCGGATGCTCCCGAGAA
GACGTGAATGAGTGTGCAGAGAACCTTGGCTGTGCACTAACGGGCTCTGTGTCAACACCGATGGATCTTCCGTGTGAG
TGTCCTTTGGCTACAGGCTGACTTCACTGGCATCACTGTGTGAGACAGAGAGTGTCTGTGCGGCACCCCTGTGGG
AAGGAGCATGTCAACATGTCACTCGAGGCTTGAATGTGCTGTGCTGACGGCTTTGAGCTGGCCTCATGATGACCTGC
GAGGACATCGACGAATGCTCCCTGAACCCGCTGCTCTGTGCTTCCGCTGCCAACATACAGGGGCTCTTCACTGTGAC
GTGTCAGCGGCTACACCTGCGGGAGGATGGGCGCATGTGTGTCAGATGTGGACGAGTGTGCAGATGTGACGAGGATGTG
CAGCGCCGGGCGATGGAGTGAAGAACCTCATCGTACTCTGCGCTGCTGTGCTTCCCGCAGGCATGCGGCCCCCTGCTGGC
TCTGGGAGGGCTGCACAGATGACATGAATGCCACGCTCAGCTGACCTCTGTGTCAACGGCCGCTGTGTCAACACCGG
GGCAGTTCGGTGGCATCTGTGATGAGGATTTCCAGCCAGCCACCTTACCGAGTGGCCACGACATCCGCGAGGGCCC
TGCTTTGGCAGGGTGTGACAGCACTGTGCGGCTCTGTGTCAGCAGCATGAGGCTGTCAACGGGCGAGTGTGCTGT
GGGGGTGGCCGGGGCTGGGGGCCCCGCTGCGAGCTCTGTCCCTGCGCGGACCTCTGCTACAGGAAGCTGTGCCCCCAT
GGCTCAGGCTACATCTGTGAGGCGAGATGTAGATGAATCCGATGCTGTCTACCTGTGCTGTGCTCATGGGAGTGCACT
AACAGCTTTGGTCTCTTCCGTGCCACTGTGACGGCGGTACACACCGATGTCTACTGCTACTACTGCTGGATGTGAT
GAGTGCAGCAGGTTCCCAAGCCATGTACCTTCTTGCAAAAACGAAGGGCAGTTTCTGTGACGCTGTCCCCAGGC
TACCTGTGTGAGGAGGATGGCAGGACTGCAAAAGACCTGGACGAATGCATCTCCGCGACACAACTGTGCTCTCTGT
GTCAACACTGTGGGCGCTTCACTGCGCTGTCCACCCGGCTTCAACCGACACACAGGCTGCTGTGCAATGTGAG
TGCTCAGCCAGCTGGCCATGTGTGTGCCACGGGCACTGCCAACACCCCGGCGAGTTCGCTGTGAATGCCACCA
GGCTTCAACCTGTGTCAGCTCAGGCTATGGCTGTGAAGATGTGAATGAATGTGATGGGCCCCAGGCTGCCAGTGGCTGT
CAGAACAGCAGTATGGGGCTACCGCTCAGCTGCGGCTGCCCCAGGCTTCCACACGACTCCAGTGGGCGGATGTGGATGAG
AATGAGTGTGCTCTGTGCGCCCCCATCTGCGGAGCGCTCTGTGCGCAACACTTTGGTGGCTTCCGCTGCGTCTGCCCC
TCCGGCTTTGACTTTGATCAGGCCCTCGGGGGCTGCGAGGAGTGTGATGAGTGGCGGACGCGGTGGCCCGCTGTAGCTAC
AGCTGTGCGCAACACCGCTGTGCTCTCTGTGCGCTCTCTCAAGGCTACTCCGGTTGGGCAAGGCACTGTGCTCTC
GGCTGGGCTTACGCCCGGACCCGAGACACCGGACACCGGACAGGAGTGTCTGCTGAGCGTGTCACTGCAATGTGAG
ATCAATGGCTCTTCCCTCGGGACCGGCCACGACGAGTGGCCACAGGACACCAAGTGAACCTGGCCACCTCTGACTCC
GAGGCTCTGTGACTTGGGCTTGAACCTCTCAACACTGGGCGGGCGAGCGCATCTGGAGCTCGGCGCGGCTGTGCTCC
GGTCTAGAGGCGCGGATCCGCTACGTCATCTGTCGCGGAAACGACGAAGTTCTTTCGATGCATCACTCCGTGGGCTG
AGCTCTGAGCTGAGCTGGGCGAGGCGCGGGCCCTGGAACCTACCGGCTGGAGGTGGTGGAGCCATGGCAGGACCTGG
GGTGTCCAGCAAGAGGGGACGACGGGCCATGGGCGAGGCTTGAAGCTGAAGGTGCAATGCTCAGTGTCTTTAGTTGG
AGGAGCTCTAGTGGGCGGCTGTCCAGAGAAGGGGATCTGGAATGGGAAGGACATGTCCCAAGACGATGGCTTGA
CCAGATTGAACCCCGAACTCAGGAAGAGTGAATGCTACACGACAACCTCAGGCAAGCCCGGCTCTGCTGGGCTCTG
TGCCAGCCCCGGGGCCCCCAGTTACTCAGTCTTTCTGTGGACACGACGAAGCTGCAATGTGCAATCCCCCTGCCCA
CAGCCAAAGTTCAGGAAGAGGCCCTGTGTCACCTGTGGCCAACTCAGGCTTTCACTCTGTACTGCTGCTGCTGCTG
CCCTGGCGGGGGCAGGGGGTTGCGAGACATGGAATGGGCACTGGGTTGGGACAGGGCTATTCTCCGATGAGAA
GGTGTACAGGGGGCCAGACTCCACAGTGACTTGCCACATTTGGCCCCATTGGAGAATGCTTTTATATAAAGTGGAG
ACGATAATAAAGTATTTTTGGTTAAGTCTGCTGCCCTTTGGCAAGTCTTGAAGTAAGTAGATGCTGCCCTCGGACTGG
CGCAGGCGAGATCTTGTGCTGGGAGAGTACGAAGGCTTATGGCTCCCCAGATGTAATGGCTCAGGCTCTCTGACG
ACGTACTACATACGACACCATTCGATTTTTTTTTTTTTTTTCTGAGACAGGCTTTGCTCTGTGCTAGGTGGAGT
CGAGTGGCGCATGTGGCTCCCTGTGTGCGCACTTCCGGGCTCGAGCAATCTTCCACCTCAGGCTCTCCCAAGTAC
TGGGACCAAGGTCGACGCGCACCCAGCAGCTAATTTTTTAAATTTCTTTTCTTCTTCTTTTGGAGACCGCC
GGCAACATGACGAACCCCATCTCTAATA

The disclosed NOV2c nucleic acid sequence, localized to chromosome 19, has 3194 of 4382 bases (72%) identical to a *Mus musculus* fibrillin 2 (fbn2) mRNA (gb:GENBANK-ID:MUSFBN2|acc:L39790.1) (E = 0.0).

A NOV2c polypeptide (SEQ ID NO:10) encoded by SEQ ID NO:9 has 2877 amino acid residues and is presented using the one-letter code in Table 2F. Signal P, Psort and/or Hydropathy results predict that NOV2c contains a signal peptide and is likely to be localized to the nucleus with a certainty of 0.6000. Although PSORT suggests that the Fibrillin-like protein may be localized in the nucleus, the NOV2c protein is similar to the Fibrillin family, some members of which are released extracellularly. Therefore it is likely that NOV2c protein shows a similar localization. The most likely cleavage site for a NOV2c peptide is between amino acids 29 and 30, at: AGG-QG.

Table 2F. Encoded NOV2c protein sequence (SEQ ID NO:10).

```
MTLEGLYLARGPLARLLLAWSALLCMAGGQGRWDGALEAAGPGRVRRRGSPGILQGFNVCGSRFHAYCCPGWRTFPGRSQC
VVPI CRRACGEGFCSQPNLCTCADGTLAPSCGVSRRGSGCSVSCMNGGTCRGASCLCQKGYTGTVCQQPICDRGCHNGGRCI
GNRRCACVYFGMPQCERDYRTGPCFGQVGPEGCQHQLTGLVCTKALCCATVGRAGWLPCELCPAQPHPCRRGFIPNIHTG
ACQDVDECAVPLGCQGGSCVMNVGSHCRCPVGHRLSDSSAACEDYDECSTIPGICEGGECTNTVSSYFCKCPGFTYSP
DGTLLHGQSRAGACFSVLFGRRCAGDLAGHYTRRQCCDRGRCAAGPVPELCPPRGSNEFQQLCAQRLPLLPGLPGLFPGL
LGFGSNGMGPPLGPARLNPHGSDARGIPSLGPGNSNIGTATLNQTDICRHFNTNLCNLRCLPTPSSYRCECNVGYTDQVR
GECIDVDECTSSPCHHGDCVNI PGTYHCRCPYPGFQATPTRQACVDVDECI VSGGLCHLGRVCNTEGSSFCVCNAGFELSPD
GKNCVDHNECATSTMVNGVCLNEDGSFSLCKPGFLLAPGGHYCMDIDEQCTPGICVNGHCTNTEGSRFCQCLGGLAVGT
DGRVCDVTHVRSTCYGAIEKGCARPFPPTVTKSECCANPDHGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECA
LDPEVCANGVCENLRGSYRCVCLNGYEAGASGKDCTDVDECALNSLLCNGWCQNSPGSYSCSCPPGFHFWQDTEICKDVD
ECLSSPCVSGVCNRLAGSYTCKCGPGSRLLDPSTGTFCLDSTKGTCLWKIQESRCEVNLQGASLRSECCATLGAANGSPCERC
EIDPACARGFARMTGVTCDVNECESFPFGVCPNNGRCVNTAGSFRCECPGELMLDASGRLCVDVRLPECFRLWDEDECGVTL
PGKYRMDVCCCSIGAVNGVECEACPDPESELEFASLCPRGLGFASRDFLSGRPFYKDVNECKVFPGLCTHGTCTNTEGSRFC
ACAGGFALDAQERNCTDIDECRISPDLGGQTCVNTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLCRGCTCTNTDG
SYKQCQPPGHELTAKGTACEDI DECSLSDDLCPHGQCVNVI GAFQCSCHAGFQSTPDRGATSASCPTEGHVQVVLGPGEQM
CTGWSIRAKLSVTPNPAPPDVECEENPRVCDQGHCTNMPGGHRLCYDGFMATPDMRTCVDVDECDLNPICLHGDCECT
KGSFVCHCQLGYMVRKATGCSVDVECEVGHNCDSHASCLNIPGSFSCRCPLPGWVGDFECHDLDECVSQRHSCSPRGDC
LNVPGSYRCTCRQGFAGDGFCEBDRDECAENVLDLNDGQCLNAPGGYRCECEMGDFDPTEDHRAQDQVDECAQENLCAFGSC
ENLPGMFRCICNGGYELDRGGGNCCTDINECADPVNCLINGVCINTPGSYLCSQDFELNPSGVGCVDTNAGNCFLETHDRG
DSGISCSAEIGVGVTASCCSLGRAGWNPCELCPMANTTEYRTLCPPGEGFQPNRITVILEDIDEQELPGLCQGGDCVN
TFGSFQCECPGPGYHLSHETRICEDIDECSVTHSGICGPGTCYNTLGNITCVCPAEYLQVNGNCCMDMRKSVCFRHYNGTCQ
NELAFNVTRKMCCCSYNIGQAWNRPCEACPTIPSPDYQILCGNQAPGFLTDIHTGKPLDIDECEGEIPAICANGICINIGS
FRCECPAGFNYSIILLACEDVDECGSRESQCNADCNIPGSYRCKCTRGYKLSPGGACVGRNECREIPNVCSHGDCMDT
EGSYNCLCHRGFQASADQTLMDIDECDRQPCGNGTCKNIIGSYNCLCFPGFVVTNNGDCVDFDECTTLVGQVCRFGHCLN
TAGSFHCLCQDGFELTADGKNCVDTNECLSLAGTCLPGTCQNLGFSFRCICPPGFQVQSDHCIDIDECSSEPNLCLFGTCT
NSPGSFQCLCPGPFVLSDNHRCFDTRQSFCTRFEAGKCSVPKAFNTTKTRCCSKRPGEGWGDPCELCPQEGSAAFQEL
CPFGHGAVPGPDDSDREVDNECAENPGVCTNGVCVNTDGSFRCECPFGYSLDFTGINCVDTDECSVGHPCGQGTCTNVIGGF
ECACADGFEPLMMTCEDI DECSLNPLLCAFRCHNTEGSSYLCTCPAGYTLREDGAMCRDVDECADGQDQCHARGMECKNLI
GTFAVCVCPGMRPLPGSGEGCTDDNECHAQPDLCVNGRCVNTAGSFRCDCEGFPQSPPTLTECHDI RQGPCEAEVLQTMCR
SLSSSSSEAVTRAECCEGGRGWGPRCELCPPLGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGECINSLGSFRCHCQ
AGYTPDATATTCMDMDECSQVPKPCTFLCKNTKGSFLCSCPRGYLLEEDGRCKDLDECTSRQHNCQFLCVNTVGAFTRC
PPGFTQHHQACFDNDECSAQPGPCGAHGHCHNTPGSFRCECHQGFVLVSSGHGCEVDNECDGPHRCQHGCQNLGGYRCSC
PQAFTQHSQWACVDNECALSPPTCGSASCRNTLGGFRVCPSGFDQALGGCQEVDECAGRRGPCSYSCANTPGGFLC
GCPQGYFRVGGHCVSGGLGFSPPQDTPDKEELLSSEACYECKINGLSPDRDRPSSAHRDHQVNLATLDSEALLTLGLNLS
HLGRAERILELRPALEGLEGRIRYVIVRGNEQGFRRMHHLRGVSSQLGRRRRPGPGTYRLEVVSVMAGPWGQVQEGQPGPW
GQALRLKVQLSVALVGRSLSGPQLSREGGFNNWEGLI PRSDG
```

The NOV2c amino acid sequence has 1897 of 2810 amino acid residues (67%) identical to, and 2258 of 2810 amino acid residues (80%) similar to, a *Mus musculus* 2907 amino acid residue fibrillin 2 precursor protein (ptnr:SWISSPROT-ACC:Q61555) (E = 0.0).

NOV2c is expressed in at least the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain -

thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the NOV2c sequence.

NOV2d

A disclosed NOV2d nucleic acid of 9418 nucleotides (also referred to as CG88987-02) encoding a novel Fibrillin-like protein is shown in Table 2G. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 41-43 and ending with a TGA codon at nucleotides 8576-8578. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 2G, and the start and stop codons are in bold letters.

Table 2G. NOV2d nucleotide sequence (SEQ ID NO:11).

CTGACTCTGCTTCTCTCCGACGCTCCAGGGGACACGCCATGACTCTGGAGGGTCTGTATTGGCAAGGGGCCCCCTGGC
CCGGCTCCTGCTGGCCTGGTCCGCCCTGTTGTGCATGGCAGGTGGCCAAGGCCGCTGGGACGGGGCCTTGGAGGCTGCAGG
TCCTGGACGTGTGCGGAGGCGGGCAGCCCCAGGCATCTTGCAGGGGCCGAATGTGTGCGGCTCCCGGTTCCATGCCCTACTG
CTGTCCAGGCTGGAGGACATTCCCTGGCAGGAGCCAGTGTGTGTCATCCCATCTGTAGGCGCGCTGCGGTGAAGGCTTCTG
CTCCAGCCCCAACCTGTGTACCTGTGCGGATGGGACGCTGGCTCCAGCTGCGGGGTGAGCCGAGCCATCTGTGACCGCGG
CTGCCACAATGGGGTGTGTCATTGGGCCCAACCGCTGCGCTGTGTGTATGGCTTCATGGGACCTCAATGTGAGAGAGA
TTACCGGACGGGACCCTGCTTTGGCCAAGTAGGCCCCGAGGGGTGCCAGCATCAGCTGACGGGCCTCGTGTGCCAAGGC
ACTTTGTGTGCCACTGTGGGCGTGTCTGGGGCCTTCCATGTGAACCTTTGCCCTGCACAGCCACACCCCTGCCCGCGG
CTTCATCCCCAATATCCACAGGGGGCTGCCAAGATGTGGATGAGTGCCAGGCTGTGCCAGGCCTGTGCCAGGGAGGCAG
CTGCGTCAACATGGTGGGCTCCTTCCATTGCCGCTGTCCAGTTGGACACCGGCTCAGTGACAGCAGCGCCGATGTGAAGA
CTACGATGAATGCAGCACCATTCTTGAATCTGTGAAGGGGTGAATGTACAAACACAGTCAGCAGTTACTTTTGCAATG
TCCTCTGGTTTTTACACCTCTCCAGATGGTACTCTTCATGGACAGTCGCGGGCCGCGCCTGCTTCTCAGTGTCTTTTCGG
GGGCCGCTGTGCTGGAGACCTCGCCGGCCACTACACTCGCAGGCAGTGTCTGTGACAGGGGAGGTGTGGGCGAGCTGG
CCCGGTCCCTGAGCTGTGTCTCTCGGGCTTCCAAATGAATCCAGCAACTGTGCGCCAGCGGCTGCCGCTGTACCCGG
CCACCTTGGCCTCTTCCCTGGCCTCTGGGCTTCGATCCAAATGGCATGGGTCCCTCTTGGGCCAGCGCACTCAACCC
CCATGGCTCTGATGCGCGTGGGATCCCCAGCCTGGGCCCTGGCAACTCTAATATTGGCACTGCTACCTTGAACCAGACCAT
TGACATCTGCCGACACTTCAACACCTGTGTCTGAATGGCCGCTGCCTGCCACGCTTCCAGCTACCGCTGCGAGTGTA
CGTGGGCTACACCCAGGAGCTGCGCGGCGAGTGCATTGATGTAGACGAATGCACCAGCAGCCCCCTGCCACACCGTGACTG
CGTCAACATCCCCGACCTACCACTGCCGCTGTACCCGGGCTTCCAGGCCACGCCACAGGCAGGCATGCGTGGATGT
GGACGAGTGCATTGTGAGTGGTGGCCTTTGTCACTGGGCGCTGTGTCAACACAGAGGGCAGCTTCCAGTGTGTCTGCAA
TGACGGCTTCAGCTCAGCCCTGACGGCAAGAACTGTGTGGACCAACAGAGTGTGCCACCAGCACCATGTGCGTCAACGG
CGTGTGTCTCAACGAGGATGGCAGCTTCTCTGCTCTGCAAAACCCGGCTTCTGCTGGCGCTTGGCGGCCACTGATCAT
GGACATTGACGAGTGCCAGACGCCCGGCATCTGCGTGAACGGCCACTGTACCAACACCGAGGGCTCCTTCCGCTGCCAGTG
CCTGGGGGGGCTGGCGGTAGGCACGGATGGCCGCTGTGCGTGGACACCCAGCTGCGCAGCAGCTGATGGGGCCATCGA
GAAGGGCTCCTGTGCCCGCCCTTCCCTGGCACTGTACCAAGTCCGAGTGTGTGTGCCAATCCGGACACCGTTTTGG
GGAGCCCTGCCAGCTTTGTCTGCCAAGACTCCGCTGAGTTCCAGGCACTGTGCAGCAGTGGGCTTGGCATTACCACGGA
TGGTCGAGACATCAACGAGTGTGCTCTGGATCCTGAGGTTGTGCCAATGGCGTGTGCGAGAACCTTCGGGGCAGCTACCG
CTGTGTCTGCAACCTGGGTTATGAGGCAAGTGCCTCAGGCAAGGACTGCACAGCAGTGGATGAGTGTGCCCTCAACAGCT
CCTGTGTGCAACCGGGTGGTGCAGAAATAGCCCTGGCAGCTACAGTGTCTTGTGCCCCCGGCTTCCACTTCTGGCAGGA
CACGGAGATCTGCAAGATGTGACGAATGCCTGTCCAGCCGCTGTGTGAGTGGCGTCTGTGCGAACCTTGGCCGCTCCTA
CACCTGCAAAATGTGGCCCTGGCAGCCGCTGGACCCCTCTGGTACCTTCTGTCTAGACAGCAACAGGGCACCTGCTGGT
GAAGATCCAGGAGAGCCGCTGTGAGGTGAACCTTACGGAGCCAGCCTGCGGTCTGAGTGTGTGCCACCTCGGGGACG
CTGGGGAGCCCTGCGAACGCTGCGAGATCGACCTGCTGTGCCCGGGCTTTGCCCGGATGACGGGTGTCACTGCGA
TGATGTGAACGAGTGTGAGTCTTCCCGGAGTCTGTCCCAACGGGCGTTGCGTCAACACTGTGGGTCTTTCCGCTGTGA
GTGTCCAGAGGGCTGATGTGACGCTCAGGCGGCTGTGCGTGGATGTGAGATTGGAACCATGTTTCTGCGATGGGA
TGAGGATGAGTGTGGGTCAACCTGCTGGCAAGTACCGGATGGACGTCTGCTGTGTCTTCCAGGGCGGTGTGGGGAGT
CGAGTGCAGGGCTGCCGGATCCCGAGTCTCTGGAGTTCGCCAGCCTGTGCCCCGGGGGCTGGGCTTCCGACGCGGGA
CTTCTGTCTGCGCGACCATCTATAAAGATGTGAATGAATGAAGGTGTTCCCTGGCCTCTGCACGACCGGTACCTGCAG
AAACACGGTGGCAGCTTCCAATGCGCTGTGCGGGGGCTTCCGCTGGATGCCAGGAACGGAACCTGCACAGATATCGA
CGAGTGTGCGCTCTCTGACCTCTGCGGCCAGGGCACCTGTGTCAACACGCGGGGAGCTTGTGAGTGCAGTGTTCCTC
CGGCTACGAGAGTGGCTTCTATGCTGATGAAGAACTGCATGGACGTGGACAGTGTGCAAGGGACCCGCTGCTTGGCGGG
AGGCACTTGACCAACCGGATGGGAGCTACAAGTGCAGTGTCCCCCTGGGCATGAGCTGACGGCCAAGGGCACTGCGCTG
TGAGGACATCGATGAGTGTCTCCTGAGTGTGTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG
CTCCTGCCATGCCGGCTTCCAGAGCACCTGACCGCGAGCTACAAGTGCCAGTTGCCGACGGAAGGGCATGTGACAGT

CGTCCTGGGGCCTGGGGAGCAGATGTGTA CTGGTGGTCTATCAGGGCAAAGCTAAGCACAGTCCCCAACCTGCTCCCC
AGACCTGGACAGAGTGTGAAGAGAACCCCGCGTTTGTGACCAAGGCCACTGCACCAACATGCCAGGGGTACCCGCTGCTT
GTGCTATGATGGCTTACATGGCCACCGCAGCATGAGGACATGTGTGATGTGGATGAGTGTGACTGAACCTCATCTGCT
CCTCATGGGGACTGCGAAGAACGAGAGGTTCCTTTGTCGCACTGTACAGTGGGTACATGGTCAGGAAGGGGCCAC
AGGCTGCTCTGATGTGGATGAATGCGAGGTTGGAGGACAACTGTGACAGTACAGCCTCTCTGCTCTCAACATCCAGGGAG
TTTCAGTGTAGGTGCTGCCAGCTGGGTGGGGGATGGCTTCGAATGTACAGCACTGGATGAATTCGCTCTCCAGGAGCA
CCGGTGCAGCCCAAGAGTACTGTCTCAATGTCCTGGCTCTACCTGCTCGCAGCTCCGCGCAGGGCTTTGGCGGGGATGG
CTTCTTCTGCGAAGACAGGGATGAATGTGCCGAGAACGTGGACCTCTGTGA CAACGGGCAGTGCTCTCAATGCGCCCGCGG
GTACCGCTGTGAATGTGAGATGGGCTTTGACCCACCGAGGACACCGGGCTGCCAGATGTGGACAGTGTGCGCAGCA
GAACCTTGTGCAATTTGGGAGCTGTGAGAACCTCGCTGGAATTTCCGCTGCATGTGCAATGTGGGTGACAACTGTGACCG
AGGGGTGCGCAACTGCACAGACATCAACAGTGTGCGACCGACATAA CTGCATCAACGGCGTGTGCATTAAACCCCCGG
CAGCTACCTCTGCAGTGCACCCCGAGATTTTGAGCTGAACCCAGCGGAGTGGGTGCGTGGACACTCGGCGCGGGAATCTG
TTTCTGGAGACAGCTGACCGAGGGGACAGTGGCATTTCTCTGCAGTGGCGAGATCGGAGTGGTGTCAACCGAGCTCTCT
CTGTGTGCTCCCTGGGCGGGCTTGGGCAATCCTGTGAGCTGTGCCCTATGGCCAAACCACTAGTAGTACAGAACCTGTG
CCCGGGTGGTGAGGGCTTCCAGCCTAACCGCATCACTGTCA TTTCTGGAAGACATCGACGAGTGCCAAAGAGCTGCCAGGCT
GTGTACAGGGGGTGACTGCGTCAACAGCTTTGGCAGTTTCCAGTGTGAGTGCCCACTGGCTACCACTCACTGAGTACCA
CCGATCTGTGAGGATATGACGAGTGTCCACACTCTCCGATCTGTGCCCTTGGCACTCTGCAACCACTGTGGGAACT
CTACACTTGTGTCTGCCCTGCAAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
CAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
TAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
CAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
TAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
CAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
TAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
CAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
TAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
CAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATGCTGATGATCAACATCTCCCGGTAGTACCGCTG
CAAGTGCACCCGAGGTACAAACTGTGCGCAGGCGGCTTGTGTGGAGCGAATGAGTGTGGGAGATCCGAAATGTCTG
TAGCATGTGTGCTTACCTGACAGTAGTCTTCCAAGTCAATGTGGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAATGAGCTGGCTTTCAACGTGACCCGGAAAAATGTTTGCTGTCTCTACAACATTTGG
CCAGGCTGGAAATGACCTGTGAGGCGTGCCCACTCCCTCACTGAGTCTGACTACCACTCTGTGTGGAAATCAGGCCCC
GGGATTTCTCACTGACATCCACAGCGGGAACCCCTTGACATTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCGCTGCGAGTGGCCCGCAGGCTTCACTACAAAGCATCTGTCTGGCTTGTGA
AGATGTGATGAGTGTGGCAGCAGGAGAGTCTCTGCGACAGAAATG

The disclosed NOV2d nucleic acid sequence, localized to chromosome 19, has 3194 of 4382 bases (72%) identical to a *Mus musculus* fibrillin 2 (fbn2) mRNA (gb:GENBANK- ID:MUSFBN2|acc:L39790.1) (E = 0.0).

A NOV2d polypeptide (SEQ ID NO:12) encoded by SEQ ID NO:11 has 2845 amino acid residues and is presented using the one-letter code in Table 2H. Signal P, Psort and/or Hydropathy results predict that NOV2d contains a signal peptide and is likely to be localized to the nucleus with a certainty of 0.6000. Although PSORT suggests that the Fibrillin-like protein may be localized in the nucleus, the NOV2d protein is similar to the Fibrillin family, some members of which are released extracellularly. Therefore it is likely that NOV2d protein shows a similar localization. The most likely cleavage site for a NOV2d peptide is between amino acids 29 and 30, at: AGG-QG.

Table 2H. Encoded NOV2d protein sequence (SEQ ID NO:12).

MTLEGLYLARGPLARLLALLWSALLCMAGGQGRWDGALEAAGPGRVRRRGSPGILQGPVNCGRSFHAYCCPGWRTFPGRSQC
VVPI CRRACGEFGCSQPNLCTCADGTLAPSCGVSRRAICDRGCHNGGRCIGPNRCACVYGFMGPCQERDYRTGFCFGQVGPE
GCQHQLTGLVCTKALCCATVGRWGLPCELCPAQPHPCRRGFI PNHTGACQDVDECQAVPGLCQGGSCVNMVGSFHCRCRCP
VGHRLSDSSAACEDYDECSTIPGICEGGECTNTVSSYFCKCPCPGFYTSPDGTLLHGQSRAGACFSVLFGGRACAGDLAGHYTR
RQCCCDRGRCAAGVPVPELCPPRGSNEFQQLCAQRLPLLPGHPLPGLPGLLGFSGNGMGPPLGPARLNPHGSDARGIPSLGP
GNSNIGTATLNTQIDICRHFTNLCLNGRCLPTPSSYRCENVGTYQDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCP
GFQATPTTRQACVDVDECI VSGGLCHLGRVCNTEGSGFQVCNAGFELSPDGKNCVDHNECATSTMCVNGVCLNEDGFSCLC
KPGFLLAPGGHYCMDIDECQTPGICVNGHCTNTEGSRFCQCLGGLAVGTDGRVCVDTHVRSTCYGAIEKGCSCARPPPGTVT
KSECCCANPDHGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECALDPEVCANGVCENLRGSYRCVCNLGYEAGASG
KDCTDVDECALMSLLCDNGWCQNSPGSYSCSCPPGFHFWDTEICKDVDECLSSPCVSGVCRNLGASYTCKCGPSRLDPS
GTFCILDSTKGTCLWKIQESRCEVNLQGASLRSECCATLGAANGSPCERCEIDPACARGFARMTGVTCDVNECESFPFGVCP
NGRCVNTAGSFRCCEPGLMLDASGRLCVDVRLPECFRLRWDEDECGVTLPKGYRMDVCCCSIGAVWGVCEACECPDESLEF
ASLCPRGLGFASRDFLSGRPFYKDVNECKVFPGLCTHGTCTRNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLCCGGT
CVNTPGSECECFPGYESGFMLMKNCMDVDECARDPLLCRGGTCTNTDGSYKQCPCPGHELTAKTACEDIDECSLSDGLC
PHGQCVNVI GAFQCSCHAGFQSTPDRGATSASCPTGHEVQVVLGPGEQMTGWSIRAKLSTVNPAPPDVDECEENPRVCD
QGHCTNMPGGHRCCLYDGMATPDMRTCDVDECDLNPICLHGDCECTKGSFVCHCQLGYMVRKATGCSVDVDECEVGGH
NCDSHASCLNIPGSFSCRCLPGWVGDFECHDLDECVSQEHRCSPRGDCLNVPGSYRCTCRQGFAGDGFCEDRDECAENV
DLCDNGQCLNAPGGYRCECEMGFDPTEDHRACQDVDECAQENLCAFGSCENLPGMFRCICNGGYELDRGGGNCCTDINECAD
PVNCGINGVCINTPGSYLCSQPDQFELNPSGVGCVDTFRAGNCFLETHDRGDSGISCSAEIGVGVTASCCSLGRAWGNPCE
LCPMANTTEYRTLCPGGEGFPNRI TVILEDIDECQELPGLCQGGDCVNTFGSFQCECPGPHLSEHTRICEDIDECSTHS
GICGPGTCYNTLGNITCVCPAEYLQVNGGNNCMRKSVCFRHYNGTCQNELAFNVTRKMCCCSYNIGQAWNRPCEACTP
ISPDIQLCGNAPGFLTDIHTGKPLDIDECGEIPAICANGICINIGSFRCCECPAGFNYSILLACEDVDECGSRESPCQ
QNAIDCINIPGSYRCKTRGYKLSPGGACVGRNECREIPNVCSHGDCMDTEGSYMCLCHRGFQASADQTLCMDIDECDRQC
NGTCKNIIGSYNCLCFPGFVTVHNGDCVDFDECTTLVGQVCRFGHCLNTAGSFHCLCQDGFELTADGKNVCVDTNECLSLA
GTCLPGTCQNLGSRFCICPPGFGVQSDHCIDIDECSEEPNLCLFGTCTNSPGSFQCLCPGFLVSDNGHRCFDTRQSPCF
TRFEAGKCSVPKAFNTTKTRCCSKRPGEWGDPCELCPOEGSAAFOELCPFGHGA VPGPDDSDREDVNEAENPGVCTNGV
CVNTDGSFRCECPFGYSLDFTGINCVDTDECSVGHPCQGTCTNVIIGFECACADGFEPGLMTCEDIDECSLNPLLCAFR
CHNTEGSYLCTCPAGYTLREDGAMCRDVDECADGQQDCHARGMECKNLIGTFACVCPGMRPLPGSGEGCTDDNECHAQPD
LCVNGRCVNTAGSFRCDCDEGFQSPPTLTECHDIRQGPCFAEVLQTMCRSLSSSSSEAVTRAECCEGGGRGWGPRCELCLP
GTSAYRKLCPHSGSYTAEGRDVDECRMLAHLCAHGECINSLGSFRCHCQAGYTPDATATTCLDMDECSQVVKPCTFLCKNT
KGSFLCSCPRGYLLEEDGRTCKDLDECTSRQHNCQFLCVNTVGAFTCRCPPGFTQHHQACFDNDECSAQPGPCGAHGHCHN
TPGSFRCECHQFTLVSSGHGCEDEVNECDGPHRCQHGCQNQLGGYRCSQPAFTQHSQWACQVDENECALSPPTCGSASCR
NTLGGFRVCPSGFDQALGGCQEVDECAGRRGPCSYSCANTPGGFLGCGPQGYFRVGGQGHCVSGLGFSFGPQDTPDKKE
LLSSEACYECKINGLSPRDRPRRSARHDQVNLATLDSEALLTLGLNLSHLGRAERILELRPALEGLEGRIRYVIVRGNEQ
GFFRMHHLRGVSSQLQGLRRRPGPGTYRLEVVSVMAGPWGVQEQGPGPWGQALRLKVQLSVALVGRSLSGPQLSREGGFVN
WGLIPRSDG

The NOV2d amino acid sequence has 1836 of 2753 amino acid residues (66%) identical to, and 2187 of 2753 amino acid residues (79%) similar to, a *Mus musculus* 2907 amino acid residue fibrillin 2 precursor protein (ptnr:SWISSPROT-ACC:Q61555) (E = 0.0).

NOV2d is expressed in at least the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain -

thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the NOV2d sequence.

NOV2e

A disclosed NOV2e nucleic acid of 8219 nucleotides (also referred to as CG88987-03) encoding a novel Fibrillin-like protein is shown in Table 2I. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 49-51 and ending with a TGA codon at nucleotides 8134-8136. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 2I, and the start and stop codons are in bold letters.

Table 2I. NOV2e nucleotide sequence (SEQ ID NO:13).

ATCTAGGGCTGACTCTGCTTCTCTCCGACGCTCCAGGGGACACGCCATGACTCTGGAGGGTCTGTATTGGCAAGGGG
CCCCTGCCCCGGCTCTGCTGGCCCTGGTTCGGCCCTGTTGTGCATGGCAGGTGGCCAAAGCCGCTGGGACGGGGCTTGGAG
GCTGCAGGTCTTGGACGTGTGCGGAGGCGGGGACGCCAGGCATCTTGACGGGGCCGAATGTGTGGGGCTCCCGGTTCCAT
GCCTACTGCTGTCCAGGCTGGAGGACATTCCCTGGCAGGAGCCAGTGTGTCGTACCCATCTGTAGGCGCGCCTCGCGTGAA
GGCTTCTGCTCCAGCCCCAAGCTGTGCACCTGTGCGGATGGGACGCTGGCTCCAGCTGCGGGGTGAGCCGAGGGTCAGGG
TGCAGTGTGAGCTGTATGAATGGGGGCACCTGCCGGGGGGCTCCTGTCTGTGTGTCAGAAGGGCTACACAGGCACCGTGTGT
GGGCAGCCCATCTGTGACCGCGGCTGCCAATGGGGGTGCTGCATTGGGCCCAACCGCTGCGCCTGTGTGTATGGCTTC
ATGGGACCTCAATGTGAGAGAGATTACCGGACGGGATCCTGCTTTGGCCAAAGTAGGCCCGGAGGGGTGCCAGCATCAGCTG
ACGGGCTCGTGTGCACCAAGGCATTGTGTGTGCCACTGTGGGCGGTGCTGGGGCCTTCCATGTGAACCTTTGCCCTGCA
CAGCCACACCCCTGCCGCGCGGCTTCATCCCAATATCCACACGGGGGCTGCCAAGATGTGGATGAGTGCCAGGCTGTG
CCAGGCTGTGCCAGGAGGAGCTGCGTCAACATGTTGGGCTCCTTCCATTGCCGCTGTCCAGTTGGACACCGGCTCAGT
GACAGCAGCGCGCATGTGAAGACTACCGGGCCGGCGCTGCTTCTCAGTGCTTTTCGGGGCGCTGTGCTGGAGACCTC
GCCGGCCACTACACTCGCAGGCAGTGTCTGTGTGACAGGGGCGAGTGCTGGGCAGCTGGCCCGGTCCCTGAGCTGTGTCTCT
CCTCGGGCTCCAATGAATTCAGCAACTGTGCGCCAGCGGCTGCGTGTACTCCGGCCACCTGGCCTCTTCCCTGGC
CTCCTGGGCTTCCGATCCAATGGCATGGGTCCCCCTCTTGGGCCAGCGGACTCAACCCCATGGCTCTGATGCGCTGGG
ATCCCCAGCTGGGCCCTGGCAACTCTAATATTGGCACTGTACCCTGAACAGACCATTGACATCTGCCGACACTTCACC
AACCTGTGTCTGAATGGCGCTGCTGCCACGCTTCCAGTACCGCTGCGAGTGTAACTGGGCTACACCCAGGACGTG
CGCGGCGAGTGCAATTGATGTAGACGAATGCACAGCAGCCCCCTGCCACACCGGTGACTGCGTCAACATCCCCGGCACTTAC
CACTGCCGCTGTACTCCGGGCTTCCAGGCCACGCCACAGGCATGCGTGGATGTGGACGAGTGTGTCAGTGTG
GGCCTTTGTCACTGGGCGCTGTGTGTCAACACAGAGGGCAGCTTCCAGTGTGTGTGCAATGCAGGCTTCGAGCTCAGCCCT
GACGGAAGAACTGTGTGGACCAACGAGTGTGCCACAGCACCATGTGCGTCAACGCGCTGTGTCTCAACGAGGATGGC
AGCTTCTCTGCTCTGCAAAACCGGCTTCTGCTGGCGCTGGCGGCCACTACTGCATGGACATTGACGAGTGCCAGACG
CCCCGACTCTGCGTGAACGGCCACTGTACCAACACCGAGGGCTCCTTCCGCTGCCAGTGCCCTGGGGGGGTGGCGGTAGGC
ACGGATGGCGCGCTGTGCGTGGACACCCAGCTGCGCAGCACCTGCTATGGGGCCATCGAGAAGGGTCTCTGTGCCCGCCCC
TTCCCTGGCACTGTCAACAGTCCGAGTGTCTGTGTGCCAATCCGGACACGGTTTGGGGAGCCCTGCCAGCTTTGTCTCT
GCCAAAACCTCCGCTGAGTTCCAGGCATGTGACAGAGTGGGCTTGGCATTACCAAGGATGGTTCGAGACATCAACGAGTGT
GCTCTGGATCCTGAGGTTTGTGCCAATGGCGTGTGCGAGAACCTTGGGGCAGCTACCGCTGTGTCTGCAACCTGGGTAT
GAGGCAGGTGCTCAGGCAAGGACTGCACAGACGTGGATGAGTGTGCCCTCAACAGCCTCTGTGTGACAACGGGTGGTGC
CAGAAATAGCCCTGGCAGTACAGCTGCTCCTGCCCCCCGGCTTCCACTTCTGGCAGGACAGGAGATCTGCAAGATGTCT
GACGAATGCCTGTCCAGCCCCGTGTGTGAGTGGCGTTTGTGGAACCTGGCCGGCTCTACACCTGCAAAATGTGGCCCTGGC
AGCCGCTGGACCCCTCTGGTACCTTCTGTCTAGACAGCACCAAGGGACCTGCTGGCTGAAGATCCAGGAGAGCCGCTGT
GAGGTGAACCTTACGGGAGCCAGCCTGCGGTCTGAGTGTGCGCCACCTCGGGGAGCCCTGGGGAGCCCCCTGCGAACGC
TGCGAGATCTGACCTGCTGTGCCCGGGCTTTGCCGGATGACGGGTGTCACTGCGATGATGTGAACGAGTGTGAGTCC
TTCCCGGAGTCTGTCCCAACGGCGTTCGCTCAACACTGCTGGGTCTTCCGCTGTGAGTGTCCAGAGGCGCTGATGCTG
GACGCTCAGGCCGCTGTGCGTGGATGTGAGATTGGAACCATGTTTCTGCGATGGGATGAGGATGAGTGTGCAAGGGAC
CCGCTGCTGCTGTGGGAGGCACTTGACCAACACGGATGGGAGCTACAAGTGCCAGTGTCCCCCTGGGCATGAGCTGACG
GCACAGGGCACTGCTGTGAGGACATCGATGAGTGTCTCCTGAGTGTGCGCTGTGTCCCCATGGCCAGTGTGTCAATGTC
ATCGGTGCTTCCAGTGTCTGCCATGCGGCTTCCAGAGCACCTGACCGCCAGGGCTGCGTGGACATCAACGAATGC
CGGGTCCAGAAATGGTGGTGTGACGTGCACTGTATTAACACTGAGGGCAGCTACCGGTGACAGTGTGGGAGGGCTACTGCT
CTGATGCCCGACGGAAGGGCATGTGCAGACGTGACAGTGTGAAGAGAACCCCGCGTTTGTGACCAAGGCCACTGCACC
AACATGCCAGGGGTCACCGCTGCTGTGCTATGATGGCTTCATGGCCACGCCAGACATGAGGACATGTGTTGATGTGGAT
GAGTGTGACCTGAACCTCACAATCTGCTCCATGGGAGCTGCGAGAACACGAAGGGTTCCTTTGTCTGCCACTGTCACTG
GGCTACATGGTCAGGAAGGGGCCACAGGCTGCTCTGATGTGGATGAATGCGAGGTGGAGGACACAAGTGTGACAGTCAC
GCCTCCTGTCTCAACATCCCGGGAGTTTCAGTGTAGTGGCTGCCAGGCTGGGTGGGGATGGCTTCAATGTCAACGAC

some members of which are released extracellularly. Therefore it is likely that NOV2e protein shows a similar localization. The most likely cleavage site for a NOV2e peptide is between amino acids 29 and 30, at: AGG-QG.

Table 2J. Encoded NOV2e protein sequence (SEQ ID NO:14).

MTLEGLYLARGPLARLLLAWSALLCMAGGQGRWDGALEAAGPGRVRRRSGSPGILQGPNVCGSRFHAYCCPGWRTFPGRSQC
VVPICRRACGEGFCSQPNLCTCADGTLPSCGVSRGSGCSVSCMNGGTCTRGASCLCQKGYTGTVCGQPIDCRGCHNGGRCI
GPNRCACVYGFMGPPQCDERTYRTGSGCFQGVGPEGQHQHQLTGLVCTKALCCATVGRWGLPCELCPAQPHPCRRGFIPNIHTG
ACQDVDEECQAVPGLCQGGSCVMNVGSHFRCPCVGHRLSDSSAACEDYRAGACFSVLFGGRCAGDLAGHYTRQCCCDRGRG
WAAGPVPELCPGRSNEFQQLCAQRLPLLPGHPLFPGLLGFSGNGMGPPLGPARLNPHGSDARGIPSLGPGNSNIQTATL
NQTIDICRHFTNLCLNGRCLPTPSSYRCECNVGYTQDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCPGQFATPTRQA
CVDVDECI VSGGLCHLGRVCNTEGSPQVCNAGFELS PDGKNCVDHNECATSTMVNGVCLNEDGFSFCLCKPGFLLAPGG
HYCMDIDECQTPGICVNGHCTNTEGSRFCQCLGGLAVGTDGRVCVDTHVRSTCYGAIEKGCARPFPGTVTKSECCCANPD
HGFGEPCQLCPAKNSAEFQALCSSGLGITDGRDINECALDPEVCANGVCENLRGSRVCNLYEAGASGKDCTDVDECA
LNSLLCDNGWCQNSPGSYSCSCPPGFHFQWDTETICKDVDECLSSPCVSGVCRNLGASYTCKCGPGSRLDPSGTFCLDSTKG
TCWLKIQESRCEVNLQGASLRSECCATLGAAWGSPCERCEIDPACARGFARMGTGVTCDVNECESFPGVCPNGRCVNTAGS
FRCECEPEGLMLDASGRCLVDVRLEPCFLRWDEDECARDPLLCWGGTCTNTDGSYKQCPPGHELTAKGTACEDIDECSLSD
GLCPHGQCVNVIGAFQCSCHAGFQSTPDRQGCVDINECRVQNGGCDVHCINTEGSRCSGQGYSLMPDGRACADVDECEE
NPRVCDQGHCTNMPGGHRLCYDGFMATPDMRTCVDVDECDLNPICLHGDCEKTSFVCHCQLGYMVRKGATGCSVDVE
CRVGGHNCDSHASCNTIPGSFSCRLPGWVGDFECHDLDECVSQEHRCSPRGDCLNVPGSYRCTCRQCFACDGFCCSDRD
ECAENVLDLQNGQCLNAPGGYRCECEMGFDPTEDHRAQCMDECAQGNLCAFGSCENLPGMFRCICNGGYELDRGGNCTTD
INECADPVNCCINGVCINTPGSYLCSQPQDFELNPSGVGCVDTFRAGNCFLETHDRGDSGISCSAEIGVGVTRASCCCLSGRA
WGNPCELCPMANTTEYRTLCPGGEGFPQPNRITVILEDIDECQELPGLCQGGDCVNTFGSFQCECPGPGYHLSEHTRICEDID
ECSTHSGICGPGTCYNTLGNVYTCVCPAEYLQVNGGNNCMMRKSVCFRHYNGTCQNELAFNVTRKMCCCSYNIQAWNRPC
EACPTPISPDYQILCGNQAPGFLTDIHTGKPLDIDECGEIPAICANGICINQIGSFRCCECPAGFNYSILLACEDVDECGS
RESPCQGNADCINIPGSYRCKTRGYKLSPGGACVGRNECREIPNVCSHGDCMDTEGSYMCLCHRGFQASADQTLCDMIDE
CDRQPCGNGTKCKNIIGSYNCLCFPGFVVTHNGDCVDFDECTTLVGQVCRFGHCLNTAGSFHCLCQDGFELTADGKNCVDTN
ECLSLAGTCLPGTCQNLGSGFRICPPGFGVQSDHCIDIDECSEEPNCLFLGTCTNSPGSFQCLCPPGFVLSNNGHRCFDT
RQSFCTRFEAGKCSVPKAFNTTKTRCCCSKRPGEWGDPCELCQPEDSPPLRPAAFQELCPFGHGA VPGPDDSDREDVNE
CAENPGVCTNGVCVNTDGSFRCECPFGYSLDFTGINCEDTDECSVGHPCGQGTCTNVIIGFECACADGFEPGLMMTCEDID
ECSLNPILLCAFRCHNTEGSYLCTCPAGYTLREDGAMCRDVEDCADGQDCHARGMECKNLIGTFACVCPPGMRPLPGSGEG
CTDDNECHAQPDLCVNGRCVNTAGSFRCDCEGFPQSPFTLTECHDIRQGPCFAEVLQTMCRSLSSSEAVTRAECCEGGGR
GWGPRCELCPPLPGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGECINSLGSFRCHCQAGYTPDATATTCCLDMDECSQ
VPKPCFLCKNTKGSFLCSCPRGYLLEEDGRTCKDLDECTSRQHNCQFLCVNTVGAFTCRCPPGFTQHHQACFDNDECSAQ
PGPCGAHGCHNTPGSRCECHQGFLLVSSGHGCEVDNECDGPHRCQHGQCNQLGGYRCSQPAFTQHSQWACQVDENECA
LSPTTCGSASCRNTLGGFRVCVPSGFDFDQALGGCQEVDECAGRRGPCSYSCANTPGGFLCGCPQGYFRVGGQHCVSGLGF
SPGPQDTPDKEELLSSSEACYECKINGLSPRDRPRRSABRDHQVNLATLDSEALLTLGLNLSHLGRAERILELRPALEGLEG
RIRYVIVRGNEQGFRRMHHLRGVSSLQLGRRRPGPGTYRLEVVSMMAGPWGVQEGQPGPWGQALRLKVQLSVALVGRSL
GPQLSREGGFWNWEGLIPRSDG

The NOV2e amino acid sequence has 1881 of 2256 amino acid residues (83%) identical to, and 1935 of 2256 amino acid residues (85%) similar to, a *Homo sapiens* 2809 amino acid residue fibrillin 3 protein (ptnr:TREMBLNEW-ACC:BAB47408) (E = 0.0).

NOV2e is expressed in at least the following tissues: lung, colon, bone, trabecular bone cells, placenta, germ cell, melanocyte, heart, uterus, thyroid and brain. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the NOV2e sequence.

NOV2f

A disclosed NOV2f nucleic acid of 9154 nucleotides (also referred to as CG88987-05) encoding a novel Fibrillin-like protein is shown in Table 2K. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 41-43 and ending with a TGA codon at nucleotides 8312-8314. Putative untranslated regions upstream from the

initiation codon and downstream from the termination codon are underlined in Table 2K, and the start and stop codons are in bold letters.

Table 2K. NOV2f nucleotide sequence (SEQ ID NO:15).

CTGACTCTGCTTCTCTCCGACGCTCCAGGGGACACGCCATGACTCTGGAGGGTCTGTATTTGGCAAGGGGCCCCCTGGC
CCGGCTCTGCTGGCCTGGTTCGGCCCTGTTGTGCATGGCAGGTGGCCAAGGCCGCTGGGACGGGGCCTTGGAGGCTGCAGG
TCCTGGACGTGTGCGGAGGCGGGGACGCCAGGCATCTTGCAGGGGCCGAATGTGTGCGGCTCCCGGTTCCATGCCTACTG
CTGTCCAGGTGTGAGGACATTCCCTGGCAGGAGCCAGTGTGTCGTACCCATCTGTAGGCGCGCCTGCGGTGAAGGCTTCTG
CTCCAGCCCAACCTGTGCACCTGTGCGGATGGGACGCTGGCTCCAGCTGCGGGGTGAGCCGAGCCATCTGTGACCGCG
CTGCCAATGGGGTTCGCTGCATTGGGCCCAACCGCTGCGCCTGTGTATGGCTTCATGGGACCTCAATGTGAGAGAGA
TTACCGGACGGGACCTGCTTTGGCCAAGTAGGCCCCGAGGGGTGCCAGCATCAGCTGACGGGCCTCGTGTGCACCAAGGC
ACTTTGCTGTGCCACTGTGGGCGCTGCTGGGGCCTTCCATGTGAACCTTTGCCCTGCACAGCCACACCCCTGCCGCCGCGG
CTTCATCCCAATATCCACACGGGGGCTGCCAAGATGTGGATGAGTGCCAGGCTGTGCCAGGCCTGTGCCAGGGAGGCAG
CTGCGTCAACATGGTGGGCTCCTTCCATTGCCGCTGTCCAGTTGGACACCGGCTCAGTGACAGCAGCGCCGATGTGAAGA
CTACGATGAATGCAGCACCATTCTCTGAATCTGTGAAGGGGTGAATGTACAAACACAGTCAAGCAGTTACTTTTGCAATG
TCCTCTGCTTTTACACCTCTCCAGATGGTACTCTTCATGGACAGTTCGCGGCCGCGCCTGCTTCTCAGTGTCTTTGCGG
GGGCGCTGTGCTGGAGACCTGCGCGGCCACTACACTCGAGGCAGTGTGCTGTGACAGGGGCAAGTGTGGGCACTGG
CCCGGCTCCCTGAGCTGTGCTCCTCCTCGGGCTCCAATGAATTCAGCAACTGTGCGCCAGCGGCTGCCGCTGTACCCGG
CCACCTTGGCCTTCTCCCTGGCCTCCTGGGCTTCGATCCAAATGGATGGGTCCCCCTCTTGGGCCAGCGGACTCAACCC
CCATGGCTCTGATGCGGTGGGATCCCAAGCCTGGGCTGGGCAACTCTAATATTGGCACTGCTACCCCTGAACACAGCCAT
TGACATCTGCCGACACTTACCAACCTGTGTCTGAATGCCGCTGCCCTCCCCACGCTTCCAGCTACCGCTGCGAGTGTAA
CGTGGGCTACACCCAGGACGTGCGCGGCAGTGCATTGATGTAGACGAATGCACCCAGCAGCCCTGCCACACCGGTGACTG
CGTCAACATCCCGGCACCTACACTGCGCGGTCTACCCGGCTTCCAGGCCACGCCACAGGCAGGCTGCGTGGATGT
GGACGAGTGCATTGTGCTGGTGGCTTTGTCACTGGGCGCTGTGTCAACACAGAGGGCAGCTTCCAGTGTGTCTGCAA
TGCAGGCTTCGAGCTCAGCCCTGACGGCAAGAACTGTGTGGACCAACAGAGTGTGCCACAGCACCATGTGCGTCAACGG
CGTGTGTCTCAACGAGGATGGCAGCTTCTCCTGCCTCTGCAAAACCGGCTTCTGCTGGCGCTGGCGGCCACTACTGCAT
GGACATTGACGAGTGCCAGACGCCCGGCATCTGCGTGAACGGCCACTGTACCAACACCGAGGGCTCCTTCGCTGCCAGT
CCTGGGGGGCTGGCGGTAGGCACGATGGCGCGGTGTGCGTGGACACCCAGTGCAGCAGCCTGTATGGGGCCATCGA
GAAGGCTCCTGTGCCCGCCCTTCCCTGGCACTGTACCAAGTCCGAGTGTGCTGTGCCAATCCGACACCGGTTTGG
GGAGCCCTGCGAGCTTGTCTGCAAGACTCCGCTGAGTTCCAGGCAGTGTGCAGCAGTGGGCTTGGCATTACACGGA
TGGTGCAGACATCAACGAGTGTGCTCTGGATCCTGAGGTTTGTGCCAATGGCGTGTGCGAGAACCTTGGGGCAGCTACCG
CTGTGTCTGCAACCTGGGTTATGAGGCAGGTGCCTCAGGCAAGGACTGCACAGACGTGGATGAGTGTGCCCTCAACAGCCT
CCTGTGTGACAACGGGTGGTGCCAGAATAGCCCTGGCAGCTACAGTGTCTCTGCCCGCCGCTTCCACTTCTGGCAGGA
CAGGTGTGCTGCAAAAGATGTGACGAATGCCTGTCCAGCCGTGTGTGAGTGGCGTCTGTGGAACCTGGCCGCTCCTA
CACCTGCAAAATGTGCCCTGGCAGCGGCTGGACCCCTCTGTGACCTTCTGTCTAGACAGCACCAGGGCACCTGTGCT
GAAGATCCAGGAGAGCGCTGTGAGGTGAACCTTCCAGGAGCCAGCCTGCGGTCTGAGTGTGTGCCACCTCGGGGCGC
CTGGGGAGCCCTGCGAACGCTGCGAGATCGACCTGCCTGTGCGCGGGGCTTGGCCGATGACGGGTGTCACTGCGA
TGATGTGAACGAGTGTGAGTCTTCCCGGAGTCTGTCCCAACGGGCGTGTGCTCAACACTGCTGGGTCTTCCGCTGTGA
GTGTCCAGAGGGCTGATGCTGGACGCTCAGGCGGGCTGTGCGTGGATGTGAGATTGGAACCATGTTTCTGCGATGGGA
TGAGGATGAGTGTGGGTACCCTGCCTGGCAAGTACGAGTGGACGTGTGCTGCTGCTCCATCGGGCGGTGTGGGGAGT
CGAGTGCAGGCGCTGCCCGGATCCCGAGTCTCTGGAGTTGCGCAGCCTGTGCCCGGGGGCTGGGCTTCGCCAGCCGGA
CTTCTGTCTGGCGACCATTTATATAAGATGTGAATGAATGCAAGGTGTCCCTGGCCTCTGCACGCAAGGTACCTGCAG
AAACAGGTGGGCGAGCTTCCACTGCGCCTGTGCGGGGGGCTTCGCCCTGGATGCCAGGAACGGAAGTGCACAGATATCGA
CGAGTGTGCTGCTCCTGACCTTCCCGGAGGCACTGTGTCAACAGCGCGGGCAGCTTGTAGTGGAGTGTGTTTCC
CGGCTACGAGAGTGGCTTCTGCTGATGAAGAACTGCATGGACGTGGACGAGTGTGAAGGACCCGCTGCTGCGCGGG
AGGCACCTTGCAACCAACGGAATGGGAGTACAAGTGCCAGTGTCCCTGGGCTGAGCTGACGGCCAAGGGCACTGCGCT
TAGGACATCGATGAGTGTCTCCTGAGTGTGCTGTGTCCTGAGTGGCCAGTGTGTCAATGTCACTGCGCTTCCAGTG
CTCCTGCCATGCCGCTTCCAGAGCACACCTGACCGCGGAGTACAAGTGCCAGTGTGCCGACGGAAGGGCATGTGCAGGT
CGTCTGGGGCTGGGAGCAGATGTGACTGGGTGGTCTATCAGGGCAAAGCTAAGCACAGTCCCAACCTGCTCCCC
GTGCTATGATGGCTTATGGCCACGCCAGACATGAGGACATGTGTTGATGTGGATGAGTGTGACCTGAACCTCACATCTG
CCTCATGGGAGTGCAGAACACGAAGGGTTCCTTTGTCTGCCACTGTGAGTGGGTACATGTCAGGAAGGGGGCCAC
AGGCTGCTCTGATGTGGATGAATGCGAGGTTGGAGGACAACTGTGACAGTCACGCCTCTGTCTCAACATCCAGGGAG
TTTCACTGTAGGTGCTGCCAGGCTGGGTGGGGGATGGCTTCGAATGTACGACCTGGATGAATGCGTCTCCAGGAGCA
CCGGTGCAGCCCAAGAGGTGACTGTCTCAATGTCCCTGGCTCCTACCGTGCACCTGCCCGAGGGCTTTGCCGGGATGG
CTTCTTCTGCGAAGACAGGGATGAATGTGCGGAGAACGTGGACCTGTGACAACGGGCAGTGCCTCAATGCGCCCGCGG
GTACCGCTGTGAATGTGAGATGGCTTTGACCCACCGAGGACACCGGGCTGCCAGGATGTGACGAGTGTGCGCAAGA
GAACCTCTGTGCAATTTGGGAGCTGTGAGAACCTGCCTGGAATGTTCCGCTGCATCTGCAATGGTGGCTACGAACTGGACG
AGGGGTGGCAACTGCACAGACATCAACGAGTGTGCAGACCCAGTAACTGCATCAACGGCGTGTGCATTAACACCCCGG
CAGCTACCTCTGCAGTGCCTCCAGGATTTTGTGCTGAACCCAGCGGAGTGGGCTGCGTGGAAGTGTGCGGCGGAACTG
TTTCTGTGAGACGATGACCGAGGGGACATGGGCTTCTCTGAGTGCAGGATCGGAGTGTGTTGTTGTTGTTGTTGTTG
CTGTTGCTCCCTGGGCGGGCTTGGGGCAATCCCTGTGAGTGTGCCCTATGGCCAAACCACTGAGTACAGAACCCTGTG
CCCGGTGGTGGGCTTCCAGCCTAACCGCATCACTGTCTTCTGGAAGACATCGACGAGTGCCAGAGTGTGCCAGGGCT
GTGTACGGGGGTGACTGCGTCAACAGCTTTGGCAGTTTCCAGTGTGAGTGCACCTGGCTACCACTCAGTGAGCACAC
CCGATCTGTGAGGATATTGACGAATGCTCCACACACTCCGGCATCTGTGGCCTGGCACCTGCTACAACACCTGGGGAA
CTACACCTGTGTCTGCCCTGCAGAGTACCTCCAAGTCAATGTGGCAACAACTGCATGGATATGAGGAAGAGTGTCTGCTT
CCGGCACTATAACGGCACATGTCAAAATGAGCTGGCTTCAACGTGACCCGGAATGTGTTGCTGCTCTACAACTTGG
CCAGGCTTGAATAGACCTGTGAGGCGCTGCCCACTCCCATCAGCTCACTACAGATCCTGTGTGGAATAGGCCCC
GGGATTCCTCACTGACATCCACACGGGAAGCCCTTGCATTTGATGAGTGTGGGAGATCCCGGCATCTGTGCCAATGG
CATCTGCATAAACAGATCGGGAGTTTCCGCTGCGAGTGCCTCCGAGGCTTCAACTACAACAGCATCCTGCTGGCTTGTGA
AGATGTCGATGAGTGTGGCAGCAGGAGAGTCCCTGCCAGCAGAATGCTGACTGCATCAACATCCCGGTAGTACCGCTG
CAAGTGCACCCGAGGATACAACCTGTGCCAGGCGGGCTTGTGTGGACGGAATGAGTGTGGGAGATCCCGAATGTCTG
TAGCCATGTTGACTGCATGGACACAGAAGGCAGCTACATGTCTGTGTACCGTGGATTCCAGGCCTCTGCAGACCAGAC

1001511511301

CCTGTGCATGGACATTGACGAGTGTGACCGGCAGCCTTGTGGAATGGGACCTGCAAGAACATCATTGGCTCCTACAACGT
 CCTCTGCTTCCCTGGCTTTGTGGTGACACACAATGGGGATTGTGTGGATTTGATGAGTGTACTACCTGGTGGGGCAGGT
 GTGCCGATTGGCCATTGCCTCAACACAGCTGGTTCTTCCACTGCCTCTGCCAGGATGGCTTTGAGCTCACAGCTGATGG
 GAAGAACTGTGTGGACACCAATGAGTGCCTCAGCCTTGCAAGAACCTGCCTACCCGGCACTTGCCAGAACCTCGAGGGCTC
 CTTCCGTGCTATGTCCCCCTGGCTTCCAGGTGACAGTGCACCTGATGATCGACGAGTGTCTCAGAGGAGCCCA
 CCTCTGCTTCTTGGCACCTGTACCAACAGCCCTGGGAGCTTCCAGTGCCTCTGCCACCTGGCTTTGTCTCTCTGACAA
 TGGGCACCGTTGCTTTGACACACGGCAGAGTTTCTGCTTACCCGTTTGTAGGCTGGGAAGTGTCTCGGTGCCCAAAGCTTT
 CAACACCACCAAGACCCGCTGCTGCTGCAGTAAGAGGCTGGGGAGGGCTGGGGAGACCCCTGCGAATGTGTCCCCAGGA
 AGGCAGCGCTGCCTTTAGGAGCTCTGCCCTTTGGCCACGGGGCAGTCCAGGCCCGGATGACTCCCGAGAAGACGTGAA
 TGAGTGTGCAGAGAACCTGGCGTCTGCCTAACGGCGTCTGTGTCAACACCGATGGATCCTTCCGTGTGAGTGTCCCTT
 TGGCTACAGCTTGCCTTCACTGGCATCACTGTGAGGACACAGACGAGTGTCTGTGCGGCCACCCCTGTGGGCAAGGGAC
 ATGCACCAATGTCTCGGAGGCTTGAATGTGCTGTGTGACGGCTTGAAGCTGGCTCATGATGACCTGCGAGGACAT
 CGACGAATGTCTCCCTGAACCCGCTGCTGTGTGCTTCCGTGCCACAATACCGAGGGCTCCTACCTGTGCACCTGTCCAGC
 CGGCTACACCTTGGGGAGGACGGGGCCATGTGTGAGATGACAATGAATGCCACGCTCAGCCTGACCTCTGTGTCAACGG
 CCGTGTGTCAACACCGGGGAGCTTCCGTGCGAGTGTGATGAGGGATTCCAGCCCAGCCCCACCTTACCGAGTGCCTG
 CGACATCCGGCAGGGGCCCTGCTTTGGCAGGTGTCTGACAGCATGTGCCGGTCTGTGTCCAGCAGAGTGAAGCTGTCA
 CAGGGCCAGTGTCTGTGGGGGTGGCCGGGGTGGGGGCCCGCTGCGAGCTCTGTCCCTGCCGGCACCTCTGCCTA
 CAGGAAGCTGTGCCCCATGGCTCAGGCTACCTGTGAGGGCCGAGATGTAGATGAATGCCGATGTCTGTCTACCTGTG
 TGCTCATGGGAGTGCATCAACAGCCTTGGCTCCTTCCGTGCCACTGTGAGGCCGGGTACACACCGGATGCTACTGTAC
 TACCTGCCTGGATATGGATGAGTGCAGCCAGGTCCCCAAGCCATGTACCTTCTCTGCAAAAAACGAAGGGCAGTTTCTT
 GTGCAGCTGTCCCGAGGCTACCTGTGAGGAGGATGGCAGGACCTGCAAGACCTGGACGAATGACCTTCCCGGCAGCA
 CAAGTGTCACTTCTGTGTCAACACTGTGGGCGCCTTCACTGCCGTGTCCGCCGGCTTCAACAGCACCACAGGC
 CTGCTTCGATGTGAATGAATGTGATGGGGCCCAACCGCTGCCAGCATGGCTGTGAGAACAGCTAGGGGGCTACCGCTGCAG
 CTGCCCCCAGGGTTTCAACAGCACTCCAGTGGGCCAGTGTGTGGATGAGAATGAGTGTGCCCTGTGCCCCCACCTG
 CGGGAGCGCTCTGTGCAACACTTGTGGTGGCTTCCGTGCGTGTGCCCTGTGGCTTTGACTTTGATCAGGCCCTCGG
 GGGCTGCCAGGAGTGGATGAGTGCAGCGGACCGGCTGGCCCTGTAGCTACAGCTGTGCCAACACGCTTGTGCTTCTT
 GTCCGCTGTCTTCAAGCTACTTCCCGCTCCGCAAGGCCACTGTCTCTCCGCTTCCGCTTCAACCCCCGACCCAGCA
 CACCCCGGACAAAGAGGAGCTGCTCTGCTGAGGCTGCTACGAATGCAAGATCAATGGCCTTCTCCCTCGGAGCCGGCC
 ACGACGAGTGCACAGGACCAACAGGTGAACCTGGCCACCTTGAATCCGAGGCCCTGCTGACCTTGGGCCCTGAACCT
 CTCACACCTGGGCGGGCCGAGCGCATCCTGGAGCTCCGGCCGGCCCTGAGGGGTCTAGAGGGCCGGATCCGCTACGTAT
 CGTCCCGGAAACAGCAAGGTTTCTTTCGATGCATCACTCCGTGGCGTCACTCCCTGCAGCTGGGGCGGAGCGGCC
 GGGGCTGGAACCTACCGGCTGGAGTGGTGAGCCATGGCAGGACCTGGGGTGTCCAGCAAGAGGGGCAGCCAGGGCC
 ATGGGGCCAGGCTTGAAGCTGAAGGTGCAACTGTCACTTGTCTTGTAGTGGGAGGAGCTCAGTGGGGCCAGCTGTCCAG
 AGAAGGGGATTCTGGAATGGAAGGAGTATCCCCAGAAGCGATGGCTGACCAGATTGAACCCGAACTCAGGAAGAG
 TGAATGTCTACAGCAACCTCAGGCAAGCCCGGCTCTGCTGGGCTCTGTGCCAGCCCCGGGGGGCCCCAGTTACTC
 AGTCTTTCTGGAGACAGCAAGAGCTGCAATGTGCAATCCCTTGCCTCCACAGCCAGGTGAGGAAGAGGCCCTGTGGT
 CACCGTGTCTGGCAATCTCAGGCTTCACTTCTGTACTGCACTGTGGCTTGGCTTGGCGGGGGCAGGGGGTTGGCAGGA
 CATGGCAATGGGCAACTGGGTGGGCAAGGGCTTATTCCTCGGAGTAGAAGGGTGTACAGGGGGCCAGACTCCACAGTG
 ACTTGCCACATTTGCCCCCATTTGGAGAATGCTTTTATATCAAAAGTGGAGACGATAATAAAGTTATTTTGGGTAAAGTC
 TGCCCTGCCCTTTGGCAAGTTCTTGAAGTAAGTAGATGCTGCCCTCGGACTGGGCGAGGAGATCTTGTGCTTGGGGAAGCA
 GAAGGCTTATGGGCTCCCCAGAATGGTAATAATGGCTCACGCTTCTGACCAGTACTACATACAGACACCATTCGATT
 TTTTCTTATTTTCTGAGACAGGGTCTTGTCTGTGTGCTAGGTTGGAGTGCAGTGGCGGATCGTGGCTCCCTGTGGT
 CGCCACTTTCCGGGCTCGAGCAATCTCCACCTCAGCCTTCCCAAGTAGCTGGGACCAAGGTGACCGCCACCAAGCC
 AGCTAATTTTTTAAATTTCTTTTCTTTCTTTTCTTTTGTAGACCAGCCCGGCCAATGACGAAACCCCATCTCTAAT
 A

The disclosed NOV2f nucleic acid sequence, localized to chromosome 19, has 3401 of 3689 bases (92%) identical to a *Homo sapiens* KIAA1776 protein (fibrillin3) mRNA (gb:GENBANK-ID:AB053450|acc:AB053450.2) (E = 0.0).

- 5 A NOV2f polypeptide (SEQ ID NO:16) encoded by SEQ ID NO:15 has 2757 amino acid residues and is presented using the one-letter code in Table 2L. Signal P, Psort and/or Hydropathy results predict that NOV2f contains a signal peptide and is likely to be localized to the nucleus with a certainty of 0.6000. Although PSORT suggests that the Fibrillin-like protein may be localized in the nucleus, the NOV2f protein is similar to the Fibrillin family, some
- 10 members of which are released extracellularly. Therefore it is likely that NOV2f protein shows a similar localization. The most likely cleavage site for a NOV2f peptide is between amino acids 29 and 30, at: AGG-QG.

Table 2L. Encoded NOV2f protein sequence (SEQ ID NO:16).

MTLEGLYLARGPLARLLLAWSALLCMAGGQGRWDGALEAAGPGRVRRRSGSPGILQGPNVCGSRFHAYCCPGWRTFPGRSQC
VVPICRRACGEGFCSQPNLCTCADGTLAPSCGVSRACIDRGCHNGGRCIGPNRCACVYGFMPQGERDYRTGPCFGQVGPE
GCQHQLTGLVCTKALCCATVGRRAWGLPCELCPAQPHPCRRGFIPNIHTGACQDVDECQAVPGLCQGGSCVNMVGSFHCRC
VGHRLLSDSSAACEDYDECSTIPGICEGGECTNTVSSYFCCKPPGFYTS PDGTLHGQSRAGACFSVLFGGRACAGDLAGHYTR
RQCCCDRGRCAWAGVPVPELCPGRSNEFQQLCAQRLPLLPHPGLFPGLLGFSGNSGMGPPLPARLNPHGSDARGIPSLGP
GNSNIGTATLNQTDICRHFNTLCLNGRCLPTPSSYRCECNVGYTQDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCP
GFQATPTRQACVDVDECIVSGGLCHLGRVCNTEGSFQVCNAGFELSPDGKNCVDHNECATSTMVNGVCLNEDGSFSCLC
KPGFLLAPGGHYCMDIDECQTPGICVNGHCTNTEGSFRCQCLGGLAVGTDGRVVDTHVRSTCYGAIEKGS CARPPGTVT
KSECCCANPDHGFGEPCQLCPAKDSAEFQALCSSLGITTDGRDINECALDPEVCANGVCENLRGSYRCVNCNLGYEAGASG
KDCTDVDECALNSLLCDNGWCQNSPGSYSCSCPPGFHFQDTEICKDVDECLSSPCVSGVCRNLAGSYTKCGPGSRLDPS
GTFCLDSTKGTCLWKIQESRCEVNLOQASLRSECCATLGAANGSPCERCEIDPACARGFARMGTGVTCDVNECESFPGVCP
NGRCVNTAGSFRCCEPGLMLDASGRCLCDVRLPECFLRWDEDECGVTLPKGYRMDVCCCSIGAVWGVECEACPDPESELEF
ASLCPRGLGFASRDFLSGRPFYKDVNECKVFPGLCTHGTCTCRNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLCGQGT
CVNTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLCRGGTCTNTDGSYKQCPCPPGHELTAKGTACEDIDECSLSDGLC
PHGQCVNVI GAFQCSCHAGFQSTPDRGATSASCPTEGHVQVVLGPGEQMC TGWSIRAKLSTVPNPAPPDVDECEENPRVCD
QGHCTNMPGGHRCCLCYDGFMATPDMRTCDVDVDECDLNPHICLHGDCENTKGSFVCHCQLGYMVRKGATGCSDDVDECEVGGH
NCDSHASCLNIPGSFSCRCLPGWVGDFGECHDLDECVSQEHRCSPRGDCLNVPGSYRCTCRQGFAGDGFCEDRDECAENV
DLCDNGQCLNAPGGYRCECEMGFDPTEDHRACQDVDECAQENLCAFGSCENLPGMFRCICNGGYELDRGGGNCITDINECAD
PVNCTINGVCINTPGSYLCSQDFELNPSGVGCVDTRAGNCFLETHDRGDSGISCSAEIGVGVTASCCCSLGRAGNPNCE
LCPMANTTEYRTLCPPGEGFQPNRI TVILEDIDECQELPGLCQGGDCVNTFGSFQCECPGYYHLSEHTRICEDIDECSTHS
GICGPGTCYNTLGNITCVCBAEYLQVNGGNNCMMDMRKSVCFRHYNGTCQNELAFNVTRKMCCCSYNIQAWNRPEACPTP
ISPDYQILCGNQAPGFLTDIHTGKPLDIDECGEIPAICANGICINQIGSFRCCECPAGFNYSILLACEDVDECGSRESPOC
QANADINIPGSYRCKTRGYKLSPGGACVGRNECREIPNVCSHGDCMDTEGSYMCLCHRGFQASADQTLCDMDIDECDRQPC
CNCTCKNICSYNCLCFPCFVVTNHCDCVDFDECTTLVQVCRFGHICLNTAGSFHICLCQDGFELTADGKNCVDTNECLSLA
GTCLPGTCQNLGFSFRICIPPGFQVQSDHCDIDECSEEPNLCLFGTCTNSPGSFQCLCPPGFVLSDNHRCFTTRQSFCE
TRFEAGKCSVPKAFNTTKTRCCSKRPFGEWGDPCELCPQEGSAAFQELCPFGHGA VPGPDDSDREDVNECAENPGVCTNGV
CVNTDGSFRCECFPGYSLDFTGINCEDTDECSVGHPCQGGTCTNVI GGFECACADGFEPGLMMTCEDIDECSLNPLLCAPR
CHNTEGSYLCTCPAGYTLREDGAMCRDDNECHAQPDLCVNGRCVNTAGSFRCDCDEGFQPSPTLTETCRDIRQGPCFAEVLQ
TMCRLSSSSSEAVTRAECCECGGGRGWGRPCELPLPGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGEICINSLGSFR
CHCQAGYTPDATATTCLDMDECSQVFKPCTFLCKNTKGSFLCSCPRGYLLEEDGRTCKDLDECTSRQHNCQFLCVNTVGAF
TCRCPPPGFTQHHQACFDVNECDGPHRCQHGCQNQLGGYRCSCPQGFQHSQWACQVDENECALSPPTCGSASCRNTLGGFR
CVCPSGGFDQALGGCQEVDECAGRGPGCSYSCANTPGGFLCGCPQGYFRAGQGHCVSGLGFSPPGQDTPDKEELLSEAC
YECKINGLSPDRPRRAHRDHQVNLATLDSEALLTLGLNLSHLGRAERILELRPALEGLEGRIYVIVRGNEQGFRRMH
LRGVSSLQLGRRRPPGPGTYRLEVVSVMAGPWGVQEQGPQGPWGQALRLKVQLSVALVGRSLSGPQLSREGGFWNWEGLI PR
SDG

The NOV2f amino acid sequence has 2176 of 2568 amino acid residues (84%) identical to, and 2245 of 2568 amino acid residues (87%) similar to, a *Homo sapiens* 2809 amino acid residue fibrillin 3 protein (ptrn:TREMBLNEW-ACC:BAB47408) (E = 0.0).

NOV2f is expressed in at least the following tissues: Mammalian Tissue, Brain and Lung. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the NOV2f sequence.

In addition, NOV2f is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Homo sapiens* mRNA homolog for KIAA1776 protein (fibrillin3) (gb:GENBANK-ID:AB053450|acc:AB053450.2): adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus.

Possible small nucleotide polymorphisms (SNPs) found for NOV2a are listed in Table 2M.

Table 2M: SNPs

Variant	Neucleotide Position	Base Change	Amino Acid Position	Base Change
13375333	4160	A > G	1214	Gln > Arg
13375332	4244	A > G	1242	Asn > Ser

NOV2a – NOV2f are very closely homologous as is shown in the amino acid alignment in Table 2N.

Table 2N Amino Acid Alignment of NOV2a - NOV2f

	10	20	30	40	50
NOV2a	MSKSCMTLLCPLLQRLAPP	GPTWPSLPSLPLPTPVLPWLCTLS	PKTKLLXH		
NOV2b	-----	-----	-----	-----	-----
NOV2c	-----	-----	-----	-----	-----
NOV2d	-----	-----	-----	-----	-----
NOV2e	-----	-----	-----	-----	-----
NOV2f	-----	-----	-----	-----	-----
	60	70	80	90	100
NOV2a	HTSSRKPLTVHRFPV	GAGCLLGLPEAPGLPHL	ATTLPSSSLCVPHGXGG		
NOV2b	-----	-----	-----	-----	-----
NOV2c	-----	-----	-----	-----	-----
NOV2d	-----	-----	-----	-----	-----
NOV2e	-----	-----	-----	-----	-----
NOV2f	-----	-----	-----	-----	-----
	110	120	130	140	150
NOV2a	GLIXGLCFLSAASRGHAM	MTLEGLYLARGPLARLL	LAWSALLCMAGGQGR		
NOV2b	-----	MTLEGLYLARGPLARLL	LAWSALLCMAGGQGR		
NOV2c	-----	MTLEGLYLARGPLARLL	LAWSALLCMAGGQGR		
NOV2d	-----	MTLEGLYLARGPLARLL	LAWSALLCMAGGQGR		
NOV2e	-----	MTLEGLYLARGPLARLL	LAWSALLCMAGGQGR		
NOV2f	-----	MTLEGLYLARGPLARLL	LAWSALLCMAGGQGR		
	160	170	180	190	200
NOV2a	WDGALEAAGPGRVRRRGSPGILQGP	NVCGSRFHAYCCPGWRTFPGRSQCV			
NOV2b	WDGALEAAGPGRVRRRGSPGILQGP	NVCGSRFHAYCCPGWRTFPGRSQCV			
NOV2c	WDGALEAAGPGRVRRRGSPGILQGP	NVCGSRFHAYCCPGWRTFPGRSQCV			
NOV2d	WDGALEAAGPGRVRRRGSPGILQGP	NVCGSRFHAYCCPGWRTFPGRSQCV			
NOV2e	WDGALEAAGPGRVRRRGSPGILQGP	NVCGSRFHAYCCPGWRTFPGRSQCV			
NOV2f	WDGALEAAGPGRVRRRGSPGILQGP	NVCGSRFHAYCCPGWRTFPGRSQCV			
	210	220	230	240	250
NOV2a	VPICRRACGEGFCSQPNLCTCADGTLAP	SCGVS	RGSGCSVSCMNGGTCRG		
NOV2b	VPICRRACGEGFCSQPNLCTCADGTLAP	SCGVS	RGSGCSVSCMNGGTCRG		
NOV2c	VPICRRACGEGFCSQPNLCTCADGTLAP	SCGVS	RGSGCSVSCMNGGTCRG		
NOV2d	VPICRRACGEGFCSQPNLCTCADGTLAP	SCGVS	RGSGCSVSCMNGGTCRG		
NOV2e	VPICRRACGEGFCSQPNLCTCADGTLAP	SCGVS	RGSGCSVSCMNGGTCRG		
NOV2f	VPICRRACGEGFCSQPNLCTCADGTLAP	SCGVS	RGSGCSVSCMNGGTCRG		
	260	270	280	290	300
NOV2a	ASCLCQKGYGTGTCGQPICDRGCHNGGRCIGPNRCACVYGF	FMGPQCERD			
NOV2b	ASCLCQKGYGTGTCGQPICDRGCHNGGRCIGPNRCACVYGF	FMGPQCERD			
NOV2c	ASCLCQKGYGTGTCGQPICDRGCHNGGRCIGPNRCACVYGF	FMGPQCERD			
NOV2d	-----	AICDRGCHNGGRCIGPNRCACVYGF	FMGPQCERD		
NOV2e	ASCLCQKGYGTGTCGQPICDRGCHNGGRCIGPNRCACVYGF	FMGPQCERD			
NOV2f	-----	AICDRGCHNGGRCIGPNRCACVYGF	FMGPQCERD		
	310	320	330	340	350
NOV2a	RTGPCFGQVGP	PEGCQHQLTGLVCTKALCCATV	GRAWGLPCELCPAQPHPC		
NOV2b	RTGSCFGQVGP	PEGCQHQLTGLVCTKALCCATV	GRAWGLPCELCPAQPHPC		
NOV2c	RTGPCFGQVGP	PEGCQHQLTGLVCTKALCCATV	GRAWGLPCELCPAQPHPC		
NOV2d	RTGPCFGQVGP	PEGCQHQLTGLVCTKALCCATV	GRAWGLPCELCPAQPHPC		

NOV2e	RTGSCFGQVGPPEGCGHQLTGLVCTKALCCATVGRAWGLPCELCPAQPHPC
NOV2f	RTGPCFGQVGPPEGCGHQLTGLVCTKALCCATVGRAWGLPCELCPAQPHPC
	360 370 380 390 400
NOV2a	RRGFI PNIIHTGACQDVDECQAVPGLCQGGSCVNMVGSFHCRCVPVGHRLSD
NOV2b	RRGFI PNIIHTGACQDVDECQAVPGLCQGGSCVNMVGSFHCRCVPVGHRLSD
NOV2c	RRGFI PNIIHTGACQDVDECQAVPGLCQGGSCVNMVGSFHCRCVPVGHRLSD
NOV2d	RRGFI PNIIHTGACQDVDECQAVPGLCQGGSCVNMVGSFHCRCVPVGHRLSD
NOV2e	RRGFI PNIIHTGACQDVDECQAVPGLCQGGSCVNMVGSFHCRCVPVGHRLSD
NOV2f	RRGFI PNIIHTGACQDVDECQAVPGLCQGGSCVNMVGSFHCRCVPVGHRLSD
	410 420 430 440 450
NOV2a	SSAACEDYDECSTIPGICEGGECTNTVSSYFCKCPPGFYTPDGTLHGQS
NOV2b	SSAACEDY-----
NOV2c	SSAACEDYDECSTIPGICEGGECTNTVSSYFCKCPPGFYTPDGTLHGQS
NOV2d	SSAACEDYDECSTIPGICEGGECTNTVSSYFCKCPPGFYTPDGTLHGQS
NOV2e	SSAACEDY-----
NOV2f	SSAACEDYDECSTIPGICEGGECTNTVSSYFCKCPPGFYTPDGTLHGQS
	460 470 480 490 500
NOV2a	RAGACFSVLFGGRCAGDLAGHYTRRQCCDRGRCAAGVPVELCPPRGSN
NOV2b	RAGACFSVLFGGRCAGDLAGHYTRRQCCDRGRCAAGVPVELCPPRGSN
NOV2c	RAGACFSVLFGGRCAGDLAGHYTRRQCCDRGRCAAGVPVELCPPRGSN
NOV2d	RAGACFSVLFGGRCAGDLAGHYTRRQCCDRGRCAAGVPVELCPPRGSN
NOV2e	RAGACFSVLFGGRCAGDLAGHYTRRQCCDRGRCAAGVPVELCPPRGSN
NOV2f	RAGACFSVLFGGRCAGDLAGHYTRRQCCDRGRCAAGVPVELCPPRGSN
	510 520 530 540 550
NOV2a	EFQQLCAQRLPLLPGHPGLFPGLLGFGSNGMGPPLGPARLNPHGSDARGI
NOV2b	EFQQLCAQRLPLLPGHPGLFPGLLGFGSNGMGPPLGPARLNPHGSDARGI
NOV2c	EFQQLCAQRLPLLPGHPGLFPGLLGFGSNGMGPPLGPARLNPHGSDARGI
NOV2d	EFQQLCAQRLPLLPGHPGLFPGLLGFGSNGMGPPLGPARLNPHGSDARGI
NOV2e	EFQQLCAQRLPLLPGHPGLFPGLLGFGSNGMGPPLGPARLNPHGSDARGI
NOV2f	EFQQLCAQRLPLLPGHPGLFPGLLGFGSNGMGPPLGPARLNPHGSDARGI
	560 570 580 590 600
NOV2a	PSLGPGNSNIGTATLNQTIIDICRHFTNLCLNGRCLPTPSSYRCECNVGYT
NOV2b	PSLGPGNSNIGTATLNQTIIDICRHFTNLCLNGRCLPTPSSYRCECNVGYT
NOV2c	PSLGPGNSNIGTATLNQTIIDICRHFTNLCLNGRCLPTPSSYRCECNVGYT
NOV2d	PSLGPGNSNIGTATLNQTIIDICRHFTNLCLNGRCLPTPSSYRCECNVGYT
NOV2e	PSLGPGNSNIGTATLNQTIIDICRHFTNLCLNGRCLPTPSSYRCECNVGYT
NOV2f	PSLGPGNSNIGTATLNQTIIDICRHFTNLCLNGRCLPTPSSYRCECNVGYT
	610 620 630 640 650
NOV2a	QDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCYPGFQATPTRQACVDV
NOV2b	QDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCYPGFQATPTRQACVDV
NOV2c	QDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCYPGFQATPTRQACVDV
NOV2d	QDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCYPGFQATPTRQACVDV
NOV2e	QDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCYPGFQATPTRQACVDV
NOV2f	QDVRGECIDVDECTSSPCHHGDCVNI PGTYHCRCYPGFQATPTRQACVDV
	660 670 680 690 700
NOV2a	DECI VSGGLCHLGRVCNTEGSFQVCNAGFELSPDGKNCVDHNECATSTM
NOV2b	DECI VSGGLCHLGRVCNTEGSFQVCNAGFELSPDGKNCVDHNECATSTM
NOV2c	DECI VSGGLCHLGRVCNTEGSFQVCNAGFELSPDGKNCVDHNECATSTM
NOV2d	DECI VSGGLCHLGRVCNTEGSFQVCNAGFELSPDGKNCVDHNECATSTM
NOV2e	DECI VSGGLCHLGRVCNTEGSFQVCNAGFELSPDGKNCVDHNECATSTM
NOV2f	DECI VSGGLCHLGRVCNTEGSFQVCNAGFELSPDGKNCVDHNECATSTM
	710 720 730 740 750
NOV2a	CVNGVCLNEDGSFSLCKPGFLLAPGGHYCMDI DECQTPGICVNGHCTNT
NOV2b	CVNGVCLNEDGSFSLCKPGFLLAPGGHYCMDI DECQTPGICVNGHCTNT
NOV2c	CVNGVCLNEDGSFSLCKPGFLLAPGGHYCMDI DECQTPGICVNGHCTNT
NOV2d	CVNGVCLNEDGSFSLCKPGFLLAPGGHYCMDI DECQTPGICVNGHCTNT
NOV2e	CVNGVCLNEDGSFSLCKPGFLLAPGGHYCMDI DECQTPGICVNGHCTNT
NOV2f	CVNGVCLNEDGSFSLCKPGFLLAPGGHYCMDI DECQTPGICVNGHCTNT
	760 770 780 790 800
NOV2a	EGSFRQCQLGGLAVGTDGRVCVDTHVRSTCYGAI EKGSCARPPFGTVTKS
NOV2b	EGSFRQCQLGGLAVGTDGRVCVDTHVRSTCYGAI EKGSCARPPFGTVTKS

NOV2c	EGSFRCQCLGGLAVGTDGRVCVDTHVRSTCYGAIEKGSCARPPFGTVTKS
NOV2d	EGSFRCQCLGGLAVGTDGRVCVDTHVRSTCYGAIEKGSCARPPFGTVTKS
NOV2e	EGSFRCQCLGGLAVGTDGRVCVDTHVRSTCYGAIEKGSCARPPFGTVTKS
NOV2f	EGSFRCQCLGGLAVGTDGRVCVDTHVRSTCYGAIEKGSCARPPFGTVTKS
810.....820.....830.....840.....850
NOV2a	ECCCANPDHGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECALDP
NOV2b	ECCCANPDHGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECALDP
NOV2c	ECCCANPDHGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECALDP
NOV2d	ECCCANPDHGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECALDP
NOV2e	ECCCANPDHGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECALDP
NOV2f	ECCCANPDHGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECALDP
860.....870.....880.....890.....900
NOV2a	EVCANGVCENLRGSYRCVCNLGYEAGASGKCTDVDECALNSLLCDNGWC
NOV2b	EVCANGVCENLRGSYRCVCNLGYEAGASGKCTDVDECALNSLLCDNGWC
NOV2c	EVCANGVCENLRGSYRCVCNLGYEAGASGKCTDVDECALNSLLCDNGWC
NOV2d	EVCANGVCENLRGSYRCVCNLGYEAGASGKCTDVDECALNSLLCDNGWC
NOV2e	EVCANGVCENLRGSYRCVCNLGYEAGASGKCTDVDECALNSLLCDNGWC
NOV2f	EVCANGVCENLRGSYRCVCNLGYEAGASGKCTDVDECALNSLLCDNGWC
910.....920.....930.....940.....950
NOV2a	QNSPGSYSCSCPPGFHFWQDTEICKDVDECLSSPCVSGVCRNLAGSYTCK
NOV2b	QNSPGSYSCSCPPGFHFWQDTEICKDVDECLSSPCVSGVCRNLAGSYTCK
NOV2c	QNSPGSYSCSCPPGFHFWQDTEICKDVDECLSSPCVSGVCRNLAGSYTCK
NOV2d	QNSPGSYSCSCPPGFHFWQDTEICKDVDECLSSPCVSGVCRNLAGSYTCK
NOV2e	QNSPGSYSCSCPPGFHFWQDTEICKDVDECLSSPCVSGVCRNLAGSYTCK
NOV2f	QNSPGSYSCSCPPGFHFWQDTEICKDVDECLSSPCVSGVCRNLAGSYTCK
960.....970.....980.....990.....1000
NOV2a	CGPGSRLDPSGTFCLDSTKGTCLWKIQESRCEVNLQGASLRSECCATLGA
NOV2b	CGPGSRLDPSGTFCLDSTKGTCLWKIQESRCEVNLQGASLRSECCATLGA
NOV2c	CGPGSRLDPSGTFCLDSTKGTCLWKIQESRCEVNLQGASLRSECCATLGA
NOV2d	CGPGSRLDPSGTFCLDSTKGTCLWKIQESRCEVNLQGASLRSECCATLGA
NOV2e	CGPGSRLDPSGTFCLDSTKGTCLWKIQESRCEVNLQGASLRSECCATLGA
NOV2f	CGPGSRLDPSGTFCLDSTKGTCLWKIQESRCEVNLQGASLRSECCATLGA
1010.....1020.....1030.....1040.....1050
NOV2a	AWGSPCERCEIDPACARGFARMTGVTCTDDVNECESFPGVCPNGRCVNTAG
NOV2b	AWGSPCERCEIDPACARGFARMTGVTCTDDVNECESFPGVCPNGRCVNTAG
NOV2c	AWGSPCERCEIDPACARGFARMTGVTCTDDVNECESFPGVCPNGRCVNTAG
NOV2d	AWGSPCERCEIDPACARGFARMTGVTCTDDVNECESFPGVCPNGRCVNTAG
NOV2e	AWGSPCERCEIDPACARGFARMTGVTCTDDVNECESFPGVCPNGRCVNTAG
NOV2f	AWGSPCERCEIDPACARGFARMTGVTCTDDVNECESFPGVCPNGRCVNTAG
1060.....1070.....1080.....1090.....1100
NOV2a	SFRCECPEGLMLDASGRLCVDVRLEPCFLRWDEDECGVTLPGKYRMDVCC
NOV2b	SFRCECPEGLMLDASGRLCVDVRLEPCFLRWDEDECGVTLPGKYRMDVCC
NOV2c	SFRCECPEGLMLDASGRLCVDVRLEPCFLRWDEDECGVTLPGKYRMDVCC
NOV2d	SFRCECPEGLMLDASGRLCVDVRLEPCFLRWDEDECGVTLPGKYRMDVCC
NOV2e	SFRCECPEGLMLDASGRLCVDVRLEPCFLRWDEDECGVTLPGKYRMDVCC
NOV2f	SFRCECPEGLMLDASGRLCVDVRLEPCFLRWDEDECGVTLPGKYRMDVCC
1110.....1120.....1130.....1140.....1150
NOV2a	CSIGAVWGVECEACPDPESELEFASLCPRGLGFASRDFLSGRPFYKDVNEC
NOV2b	CSIGAVWGVECEACPDPESELEFASLCPRGLGFASRDFLSGRPFYKDVNEC
NOV2c	CSIGAVWGVECEACPDPESELEFASLCPRGLGFASRDFLSGRPFYKDVNEC
NOV2d	CSIGAVWGVECEACPDPESELEFASLCPRGLGFASRDFLSGRPFYKDVNEC
NOV2e	CSIGAVWGVECEACPDPESELEFASLCPRGLGFASRDFLSGRPFYKDVNEC
NOV2f	CSIGAVWGVECEACPDPESELEFASLCPRGLGFASRDFLSGRPFYKDVNEC
1160.....1170.....1180.....1190.....1200
NOV2a	KVFPGLCTHGTTCRNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLCG
NOV2b	KVFPGLCTHGTTCRNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLCG
NOV2c	KVFPGLCTHGTTCRNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLCG
NOV2d	KVFPGLCTHGTTCRNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLCG
NOV2e	KVFPGLCTHGTTCRNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLCG
NOV2f	KVFPGLCTHGTTCRNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLCG
1210.....1220.....1230.....1240.....1250

NOV2a	QGTVCNTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLCRGGTCTNT
NOV2b	QGTVCNTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLCRGGTCTNT
NOV2c	QGTVCNTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLCRGGTCTNT
NOV2d	QGTVCNTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLCRGGTCTNT
NOV2e	QGTVCNTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLQWGGTCTNT
NOV2f	QGTVCNTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLCRGGTCTNT
	1260 1270 1280 1290 1300
NOV2a	DGSYKQCQPPGHELTAKGTACEDIDECSLSDGLCPHGQCQVNVIGAFQCSC
NOV2b	DGSYKQCQPPGHELTAKGTACEDIDECSLSDGLCPHGQCQVNVIGAFQCSC
NOV2c	DGSYKQCQPPGHELTAKGTACEDIDECSLSDGLCPHGQCQVNVIGAFQCSC
NOV2d	DGSYKQCQPPGHELTAKGTACEDIDECSLSDGLCPHGQCQVNVIGAFQCSC
NOV2e	DGSYKQCQPPGHELTAKGTACEDIDECSLSDGLCPHGQCQVNVIGAFQCSC
NOV2f	DGSYKQCQPPGHELTAKGTACEDIDECSLSDGLCPHGQCQVNVIGAFQCSC
	1310 1320 1330 1340 1350
NOV2a	HAGFQSTPDRG--ATSASCPTEGHVQVVLGPGEQMCTGWSIRAKLSTVPN
NOV2b	HAGFQSTPDRGCGVDINECRVQNGGCDVHRINTEGSYRCSCGQGYSLMPD
NOV2c	HAGFQSTPDRG--ATSASCPTEGHVQVVLGPGEQMCTGWSIRAKLSTVPN
NOV2d	HAGFQSTPDRG--ATSASCPTEGHVQVVLGPGEQMCTGWSIRAKLSTVPN
NOV2e	HAGFQSTPDRGCGVDINECRVQNGGCDVHCINTEGSYRCSCGQGYSLMPD
NOV2f	HAGFQSTPDRG--ATSASCPTEGHVQVVLGPGEQMCTGWSIRAKLSTVPN
	1360 1370 1380 1390 1400
NOV2a	-PAPPDVDECEENPRVCDQGHCTNMPGGHRCLCYDGFMATPDMRTCVDVD
NOV2b	GRACADVDECEENPRVCDQGHCTNMPGGHRCLCYDGFMATPDMRTCVDVD
NOV2c	-PAPPDVDECEENPRVCDQGHCTNMPGGHRCLCYDGFMATPDMRTCVDVD
NOV2d	-PAPPDVDECEENPRVCDQGHCTNMPGGHRCLCYDGFMATPDMRTCVDVD
NOV2e	GRACADVDECEENPRVCDQGHCTNMPGGHRCLCYDGFMATPDMRTCVDVD
NOV2f	-PAPPDVDECEENPRVCDQGHCTNMPGGHRCLCYDGFMATPDMRTCVDVD
	1410 1420 1430 1440 1450
NOV2a	ECDLNPHICLHGDCEENTKGSFVCHCQLGYMVRKGATGCSDDVDECEVGGHN
NOV2b	ECDLNPHICLHGDCEENTKGSFVCHCQLGYMVRKGATGCSDDVDECEVGGHN
NOV2c	ECDLNPHICLHGDCEENTKGSFVCHCQLGYMVRKGATGCSDDVDECEVGGHN
NOV2d	ECDLNPHICLHGDCEENTKGSFVCHCQLGYMVRKGATGCSDDVDECEVGGHN
NOV2e	ECDLNPHICLHGDCEENTKGSFVCHCQLGYMVRKGATGCSDDVDECEVGGHN
NOV2f	ECDLNPHICLHGDCEENTKGSFVCHCQLGYMVRKGATGCSDDVDECEVGGHN
	1460 1470 1480 1490 1500
NOV2a	CDSHASCLNIPGSFSCRCLPGWVGDFECHDLDECVSQEHRCSPRGDCLN
NOV2b	CDSHASCLNIPGSFSCRCLPGWVGDFECHDLDECVSQEHRCSPRGDCLN
NOV2c	CDSHASCLNIPGSFSCRCLPGWVGDFECHDLDECVSQEHRCSPRGDCLN
NOV2d	CDSHASCLNIPGSFSCRCLPGWVGDFECHDLDECVSQEHRCSPRGDCLN
NOV2e	CDSHASCLNIPGSFSCRCLPGWVGDFECHDLDECVSQEHRCSPRGDCLN
NOV2f	CDSHASCLNIPGSFSCRCLPGWVGDFECHDLDECVSQEHRCSPRGDCLN
	1510 1520 1530 1540 1550
NOV2a	VPGSYRCTCRQGFAGDGFCEDRDECAENVDLCDNGQCLNAPGGYRCECE
NOV2b	VPGSYRCTCRQGFAGDGFCEDRDECAENVDLCDNGQCLNAPGGYRCECE
NOV2c	VPGSYRCTCRQGFAGDGFCEDRDECAENVDLCDNGQCLNAPGGYRCECE
NOV2d	VPGSYRCTCRQGFAGDGFCEDRDECAENVDLCDNGQCLNAPGGYRCECE
NOV2e	VPGSYRCTCRQGFAGDGFCEDRDECAENVDLCDNGQCLNAPGGYRCECE
NOV2f	VPGSYRCTCRQGFAGDGFCEDRDECAENVDLCDNGQCLNAPGGYRCECE
	1560 1570 1580 1590 1600
NOV2a	MGFDPTEDHRACQDVDECAQENLCAFGSCENLPGMFRCICNGGYELDRGG
NOV2b	MGFDPTEDHRACQDVDECAQENLCAFGSCENLPGMFRCICNGGYELDRGG
NOV2c	MGFDPTEDHRACQDVDECAQENLCAFGSCENLPGMFRCICNGGYELDRGG
NOV2d	MGFDPTEDHRACQDVDECAQENLCAFGSCENLPGMFRCICNGGYELDRGG
NOV2e	MGFDPTEDHRACQDVDECAQENLCAFGSCENLPGMFRCICNGGYELDRGG
NOV2f	MGFDPTEDHRACQDVDECAQENLCAFGSCENLPGMFRCICNGGYELDRGG
	1610 1620 1630 1640 1650
NOV2a	GNCT-DINECADPVNCINGVCINTPGSYLCSCPQDFELNPSGVGCVDTTRA
NOV2b	GNCT-DINECADPVNCINGVCINTPGSYLCSCPQDFELNPSGVGCVDTTRA
NOV2c	GNCT-DINECADPVNCINGVCINTPGSYLCSCPQDFELNPSGVGCVDTTRA
NOV2d	GNCT-DINECADPVNCINGVCINTPGSYLCSCPQDFELNPSGVGCVDTTRA
NOV2e	GNCT-DINECADPVNCINGVCINTPGSYLCSCPQDFELNPSGVGCVDTTRA
NOV2f	GNCT-DINECADPVNCINGVCINTPGSYLCSCPQDFELNPSGVGCVDTTRA

	1660	1670	1680	1690	1700
NOV2a	GNC	FLE	THDR	GD	SGISCSAEIGVG
NOV2b	GNC	FLE	THDR	GD	SGISCSAEIGVG
NOV2c	GNC	FLE	THDR	GD	SGISCSAEIGVG
NOV2d	GNC	FLE	THDR	GD	SGISCSAEIGVG
NOV2e	GNC	FLE	THDR	GD	SGISCSAEIGVG
NOV2f	GNC	FLE	THDR	GD	SGISCSAEIGVG

	1710	1720	1730	1740	1750
NOV2a	TEY	RTL	CPGG	EGFQPNRIT	VI
NOV2b	TEY	RTL	CPGG	EGFQPNRIT	VI
NOV2c	TEY	RTL	CPGG	EGFQPNRIT	VI
NOV2d	TEY	RTL	CPGG	EGFQPNRIT	VI
NOV2e	TEY	RTL	CPGG	EGFQPNRIT	VI
NOV2f	TEY	RTL	CPGG	EGFQPNRIT	VI

	1760	1770	1780	1790	1800
NOV2a	CPP	G	YHLS	EH	TRICEDIDEC
NOV2b	CPP	G	YHLS	EH	TRICEDIDEC
NOV2c	CPP	G	YHLS	EH	TRICEDIDEC
NOV2d	CPP	G	YHLS	EH	TRICEDIDEC
NOV2e	CPP	G	YHLS	EH	TRICEDIDEC
NOV2f	CPP	G	YHLS	EH	TRICEDIDEC

	1810	1820	1830	1840	1850
NOV2a	NGG	NNC	MDMR	KSVCFR	HYNGTCQNEL
NOV2b	NGG	NNC	MDMR	KSVCFR	HYNGTCQNEL
NOV2c	NGG	NNC	MDMR	KSVCFR	HYNGTCQNEL
NOV2d	NGG	NNC	MDMR	KSVCFR	HYNGTCQNEL
NOV2e	NGG	NNC	MDMR	KSVCFR	HYNGTCQNEL
NOV2f	NGG	NNC	MDMR	KSVCFR	HYNGTCQNEL

	1860	1870	1880	1890	1900
NOV2a	AC	PTPI	SPDY	QILCG	NQAPGFLTDI
NOV2b	AC	PTPI	SPDY	QILCG	NQAPGFLTDI
NOV2c	AC	PTPI	SPDY	QILCG	NQAPGFLTDI
NOV2d	AC	PTPI	SPDY	QILCG	NQAPGFLTDI
NOV2e	AC	PTPI	SPDY	QILCG	NQAPGFLTDI
NOV2f	AC	PTPI	SPDY	QILCG	NQAPGFLTDI

	1910	1920	1930	1940	1950
NOV2a	QIG	S	FRCE	CPAG	FNYSILL
NOV2b	QIG	S	FRCE	CPAG	FNYSILL
NOV2c	QIG	S	FRCE	CPAG	FNYSILL
NOV2d	QIG	S	FRCE	CPAG	FNYSILL
NOV2e	QIG	S	FRCE	CPAG	FNYSILL
NOV2f	QIG	S	FRCE	CPAG	FNYSILL

	1960	1970	1980	1990	2000
NOV2a	KCT	R	G	YKLS	PGGACVGR
NOV2b	KCT	R	G	YKLS	PGGACVGR
NOV2c	KCT	R	G	YKLS	PGGACVGR
NOV2d	KCT	R	G	YKLS	PGGACVGR
NOV2e	KCT	R	G	YKLS	PGGACVGR
NOV2f	KCT	R	G	YKLS	PGGACVGR

	2010	2020	2030	2040	2050
NOV2a	AD	Q	T	L	C
NOV2b	AD	Q	T	L	C
NOV2c	AD	Q	T	L	C
NOV2d	AD	Q	T	L	C
NOV2e	AD	Q	T	L	C
NOV2f	AD	Q	T	L	C

	2060	2070	2080	2090	2100
NOV2a	CT	T	L	V	G
NOV2b	CT	T	L	V	G
NOV2c	CT	T	L	V	G
NOV2d	CT	T	L	V	G
NOV2e	CT	T	L	V	G
NOV2f	CT	T	L	V	G

NOV2f	CTTLVGQVCRFGHCLNTAGSFHCLCQDGFELTADGKNCVDNECLSLAGT
2110.....2120.....2130.....2140.....2150.....
NOV2a	CLPGTCQNLEGSFRICPPGFQVQSDHCIDIDECSEEPNLCLFGTCTNSP
NOV2b	CLPGTCQNLEGSFRICPPGFQVQSDHCIDIDECSEEPNLCLFGTCTNSP
NOV2c	CLPGTCQNLEGSFRICPPGFQVQSDHCIDIDECSEEPNLCLFGTCTNSP
NOV2d	CLPGTCQNLEGSFRICPPGFQVQSDHCIDIDECSEEPNLCLFGTCTNSP
NOV2e	CLPGTCQNLEGSFRICPPGFQVQSDHCIDIDECSEEPNLCLFGTCTNSP
NOV2f	CLPGTCQNLEGSFRICPPGFQVQSDHCIDIDECSEEPNLCLFGTCTNSP
2160.....2170.....2180.....2190.....2200.....
NOV2a	GSFQCLCPPGFVLSDNHRCFDTRQSFCTRFEAGKCSVPKAFNTTKTRC
NOV2b	GSFQCLCPPGFVLSDNHRCFDTRQSFCTRFEAGKCSVPKAFNTTKTRC
NOV2c	GSFQCLCPPGFVLSDNHRCFDTRQSFCTRFEAGKCSVPKAFNTTKTRC
NOV2d	GSFQCLCPPGFVLSDNHRCFDTRQSFCTRFEAGKCSVPKAFNTTKTRC
NOV2e	GSFQCLCPPGFVLSDNHRCFDTRQSFCTRFEAGKCSVPKAFNTTKTRC
NOV2f	GSFQCLCPPGFVLSDNHRCFDTRQSFCTRFEAGKCSVPKAFNTTKTRC
2210.....2220.....2230.....2240.....2250.....
NOV2a	CCSKRPGEGWGDPCELCPQEGS-----AAFQELCPFGHGAVPGPDDRSRE
NOV2b	CCSKRPGEGWGDPCELCPQEGSPPPLRPAAFQELCPFGHGAVPGPDDRSRE
NOV2c	CCSKRPGEGWGDPCELCPQEGS-----AAFQELCPFGHGAVPGPDDRSRE
NOV2d	CCSKRPGEGWGDPCELCPQEGS-----AAFQELCPFGHGAVPGPDDRSRE
NOV2e	CCSKRPGEGWGDPCELCPQEGSPPPLRPAAFQELCPFGHGAVPGPDDRSRE
NOV2f	CCSKRPGEGWGDPCELCPQEGS-----AAFQELCPFGHGAVPGPDDRSRE
2260.....2270.....2280.....2290.....2300.....
NOV2a	DVNECAENPGVCTNGVCVNTDGSFRCECPFGYSLDFTGINCVDTDECSVG
NOV2b	DVNECAENPGVCTNGVCVNTDGSFRCECPFGYSLDFTGINCEDTDECSVG
NOV2c	DVNECAENPGVCTNGVCVNTDGSFRCECPFGYSLDFTGINCVDTDECSVG
NOV2d	DVNECAENPGVCTNGVCVNTDGSFRCECPFGYSLDFTGINCVDTDECSVG
NOV2e	DVNECAENPGVCTNGVCVNTDGSFRCECPFGYSLDFTGINCEDTDECSVG
NOV2f	DVNECAENPGVCTNGVCVNTDGSFRCECPFGYSLDFTGINCEDTDECSVG
2310.....2320.....2330.....2340.....2350.....
NOV2a	HPCGQGTCTNVIGGFECACADGFEPGLMMTCEDIDECSLNPLLCFAFRCHN
NOV2b	HPCGQGTCTNVIGGFECACADGFEPGLMMTCEDIDECSLNPLLCFAFRCHN
NOV2c	HPCGQGTCTNVIGGFECACADGFEPGLMMTCEDIDECSLNPLLCFAFRCHN
NOV2d	HPCGQGTCTNVIGGFECACADGFEPGLMMTCEDIDECSLNPLLCFAFRCHN
NOV2e	HPCGQGTCTNVIGGFECACADGFEPGLMMTCEDIDECSLNPLLCFAFRCHN
NOV2f	HPCGQGTCTNVIGGFECACADGFEPGLMMTCEDIDECSLNPLLCFAFRCHN
2360.....2370.....2380.....2390.....2400.....
NOV2a	TEGSYLCTCPAGYTLREDGAMCRDVDECADGQQDCHARGMECKNLIGTFA
NOV2b	TEGSYLCTCPAGYTLREDGAMCRDVDECADGQQDCHARGMECKNLIGTFA
NOV2c	TEGSYLCTCPAGYTLREDGAMCRDVDECADGQQDCHARGMECKNLIGTFA
NOV2d	TEGSYLCTCPAGYTLREDGAMCRDVDECADGQQDCHARGMECKNLIGTFA
NOV2e	TEGSYLCTCPAGYTLREDGAMCRDVDECADGQQDCHARGMECKNLIGTFA
NOV2f	TEGSYLCTCPAGYTLREDGAMCR-----
2410.....2420.....2430.....2440.....2450.....
NOV2a	CVCPPGMRPLPGSGEGCTDDNECHAQPDLCVNGRCVNTAGSFRCDCEGFF
NOV2b	CVCPPGMRPLPGSGEGCTDDNECHAQPDLCVNGRCVNTAGSFRCDCEGFF
NOV2c	CVCPPGMRPLPGSGEGCTDDNECHAQPDLCVNGRCVNTAGSFRCDCEGFF
NOV2d	CVCPPGMRPLPGSGEGCTDDNECHAQPDLCVNGRCVNTAGSFRCDCEGFF
NOV2e	CVCPPGMRPLPGSGEGCTDDNECHAQPDLCVNGRCVNTAGSFRCDCEGFF
NOV2f	-----DDNECHAQPDLCVNGRCVNTAGSFRCDCEGFF
2460.....2470.....2480.....2490.....2500.....
NOV2a	QPSPTLTECHDIRQGPCFAEVLQTMCRSLSSSSSEAVTRAECCECGGGRGWG
NOV2b	QPSPTLTECHDIRQGPCFAEVLQTMCRSLSSSSSEAVTRAECCECGGGRGWG
NOV2c	QPSPTLTECHDIRQGPCFAEVLQTMCRSLSSSSSEAVTRAECCECGGGRGWG
NOV2d	QPSPTLTECHDIRQGPCFAEVLQTMCRSLSSSSSEAVTRAECCECGGGRGWG
NOV2e	QPSPTLTECHDIRQGPCFAEVLQTMCRSLSSSSSEAVTRAECCECGGGRGWG
NOV2f	QPSPTLTECHDIRQGPCFAEVLQTMCRSLSSSSSEAVTRAECCECGGGRGWG
2510.....2520.....2530.....2540.....2550.....
NOV2a	PRCELCPPLPGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGECINSI
NOV2b	PRCELCPPLPGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGECINSI
NOV2c	PRCELCPPLPGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGECINSI

```
PRCELCPPLPGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGECINSL
PRCELCPPLPGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGECINSL
PRCELCPPLPGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGECINSL
```

[illegible]

2610 2620 2630 2640 2650

G Y L L E E D G R T C K D L D E C T S R Q H N C F L C V N T V G A F T C R C P P G F T Q H H Q A C
G Y L L E E D G R T C K D L D E C T S R Q H N C F L C V N T V G A F T C R C P P G F T Q H H Q A C
G Y L L E E D G R T C K D L D E C T S R Q H N C F L C V N T V G A F T C R C P P G F T Q H H Q A C
G Y L L E E D G R T C K D L D E C T S R Q H N C F L C V N T V G A F T C R C P P G F T Q H H Q A C
G Y L L E E D G R T C K D L D E C T S R Q H N C F L C V N T V G A F T C R C P P G F T Q H H Q A C
G Y L L E E D G R T C K D L D E C T S R Q H N C F I C V N T V G A F T C R C P P G F T Q H H Q A C

[illegible]

2710 2720 2730 2740 2750

GPHRCQHGCQNQLGGYRCSGPCPQFTQHSQWAQCVDENECALSPPTCGSAS
GPHRCQHGCQNQLGGYRCSPCPAQFTQHSQWAQCVDENECALSPPTCGSAS
GPHRCQHGCQNQLGGYRCSGPCPQFTQHSQWAQCVDENECALSPPTCGSAS
GPHRCQHGCQNQLGGYRCSPCPAQFTQHSQWAQCVDENECALSPPTCGSAS
GPHRCQHGCQNQLGGYRCSGPCPQFTQHSQWAQCVDENECALSPPTCGSAS
GPHRCQHGCQNQLGGYRCSPCPAQFTQHSQWAQCVDENECALSPPTCGSAS
GPHRCQHGCQNQLGGYRCSGPCPQFTQHSQWAQCVDENECALSPPTCGSAS

[illegible][illegible][illegible][illegible]

2960 2970 2980 2990 3000

 PWGVOOEGOPGPWGOALRLKVLVSVALVGRSLSGPOLSRREGGFWNWEGLI

NOV2b
 NOV2c
 NOV2d
 NOV2e
 NOV2f

. . . . |
 PRSDG
 PRSDG
 PRSDG
 PRSDG
 PRSDG
 PRSDG

Homologies to any of the above NOV2 proteins will be shared by the other NOV2 proteins insofar as they are homologous to each other as shown above. Any reference to NOV2 is assumed to refer to both of the NOV2 proteins in general, unless otherwise noted.

- 5 NOV2a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 2O.

Table 2O. BLAST results for NOV2a					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 1335064 emb CAA45118.1 (X63556)	fibrillin [Homo sapiens]	3002	1723/2862 (60%)	2149/2862 (74%)	0.0
gi 4557591 ref NP_00129.1 (NM_000138)	fibrillin 1; Fibrillin-1 [Homo sapiens]	2871	1723/2848 (60%)	2147/2848 (74%)	0.0
gi 663111 gb AAA62177.1 (U20217)	fibrillin-2 [Mus musculus]	1062	720/1067 (67%)	865/1067 (80%)	0.0
gi 1706768 sp P98133 FBN1_BOVIN	FIBRILLIN 1 PRECURSOR (MP340) (Bos taurus)	2871	1725/2851 (60%)	2139/2851 (74%)	0.0
gi 13929180 ref NP_114014.1 (NM_031826)	fibrillin-2 [Rattus norvegicus]	2906	1884/2821 (66%)	2243/2821 (78%)	0.0

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 2P.

Table 2P. ClustalW Analysis of NOV2a

- 1) NOV2a (SEQ ID NO:6)
- 2) gi|1335064|emb|CAA45118.1|(X63556) fibrillin [Homo sapiens] (SEQ ID NO:56)
- 3) gi|4557591|ref|NP_000129.1|(NM_000138) fibrillin 1; Fibrillin-1 [Homo sapiens] (SEQ ID NO:57)
- 3) gi|663111|gb|AAA62177.1|(U20217) fibrillin-2 [Mus musculus] (SEQ ID NO:58)
- 4) gi|1706768|sp|P98133|FBN1_BOVIN FIBRILLIN 1 PRECURSOR (MP340) (Bos taurus) (SEQ ID NO:59)
- 5) gi|13929180|ref|NP_114014.1|(NM_031826) fibrillin-2 [Rattus norvegicus] (SEQ ID NO:60)

10 20 30 40 50
 | | | | | |
 NOV2a MSKSCMTLLCPLLQRLAPPGPTWPSLPSLPLPTPVLPWLC
 gi|1335064| YFSREKPLRGYLRWGKEGAAGAAETVGATSGQEPQLGQLRAEPSSGC
 gi|4557591|
 gi|663111|
 gi|1706768|

2013

```

gi|663111|      -----
gi|1706768|      FYTSPDGRCIDVRPSCYCYTALANGRCNQIPQITKMQCCCDAGRCWSP
gi|13929180|      FVTSFDGSRCIDORTCTCFSCLVNGRCAQEPGRMAKAQCCCEPGRCWGI

          510      520      530      540      550
NOV2a      GP-VPEDCPGRSNEFQOLCAQRLPL--PCHPGLFPCLLGFSGNGMGP
gi|1335064|      GVTVAPEMCHIRATEDENKLCVPMVIT--P-GRPEYPPPLCPIPPVLPV
gi|4557591|      GVTVAPEMCHIRATEDENKLCVPMVIT--P-GRPEYPPPLCPIPPVLPV
gi|663111|      GVTVAPEMCHIRATEDENKLCVPMVIT--P-ERPGYPPPLCPVPPVQPV
gi|1706768|      GT--TPACEVRGSEEMRRLCLDGLPMGGITPSSVSRPGSGSNSNGMGP
gi|13929180|      GT--TPACEVRGSEEMRRLCLDGLPMGGITPSSVSRPGSGSNSNGMGP

          560      570      580      590      600
NOV2a      -----PFGPARINPHGSDARCTPSLGPNSNIGTATLNQIDICRHHTN
gi|1335064|      PPG--FPPGPQIPVPRPPVEYLYPSREPVRVLP-----VNVTDYCOLVRY
gi|4557591|      PPG--FPPGPQIPVPRPPVEYLYPSREPVRVLP-----VNVTDYCOLVRY
gi|663111|      PPG--FPPGPQIMIPRPPVEYLYPSREPVRVLP-----VNVTDYCOLVRY
gi|1706768|      PPG--FPPGPQIMIPRPPVEYLYPSREPVRVLP-----VNVTDYCOLVRY
gi|13929180|      GGTGFLPFGNGFSPGVGAGVAGGQSPPIITLTILNQTIDICKHAN

          610      620      630      640      650
NOV2a      LCLNGRCPTPSSYRCECNMGYTODVRGECIDVDECTSSPCHHGDCVNI
gi|1335064|      LCLNGRCPTPSSYRCECNMGYTODVRGECIDVDECEKNPCAGGECINNO
gi|4557591|      LCLNGRCPTPSSYRCECNMGYTODVRGECIDVDECEKNPCAGGECINNO
gi|663111|      LCLNGRCPTPSSYRCECNMGYTODVRGECIDVDECEKNPCAGGECINTO
gi|1706768|      LCLNGRCPTPSSYRCECNMGYTODVRGECIDVDECEKNPCAGGECINTO
gi|13929180|      LCLNGRCPTPSSYRCECNMGYTODVRGECIDVDECEKNPCAGGECINTO

          660      670      680      690      700
NOV2a      GSYTCRCRAGMOSITLRTTECRDDEDECLONGRCINNGRCINTEGSHFCVCN
gi|1335064|      GSYTCRCRAGMOSITLRTTECRDDEDECLONGRCINNGRCINTEGSHFCVCN
gi|4557591|      GSYTCRCRAGMOSITLRTTECRDDEDECLONGRCINNGRCINTEGSHFCVCN
gi|663111|      GSYTCRCRAGMOSITLRTTECRDDEDECLONGRCINNGRCINTEGSHFCVCN
gi|1706768|      GSYTCRCRAGMOSITLRTTECRDDEDECLONGRCINNGRCINTEGSHFCVCN
gi|13929180|      GSYTCRCRAGMOSITLRTTECRDDEDECLONGRCINNGRCINTEGSHFCVCN

          710      720      730      740      750
NOV2a      AGFELSPDGKNCVDHNECATSTMCVNGVCTNEDGSRFCCKPGFQLASDG
gi|1335064|      AGFELSPDGKNCVDHNECATSTMCVNGVCTNEDGSRFCCKPGFQLASDG
gi|4557591|      AGFELSPDGKNCVDHNECATSTMCVNGVCTNEDGSRFCCKPGFQLASDG
gi|663111|      AGFELSPDGKNCVDHNECATSTMCVNGVCTNEDGSRFCCKPGFQLASDG
gi|1706768|      AGFELSPDGKNCVDHNECATSTMCVNGVCTNEDGSRFCCKPGFQLASDG
gi|13929180|      AGFELSPDGKNCVDHNECATSTMCVNGVCTNEDGSRFCCKPGFQLASDG

          760      770      780      790      800
NOV2a      HYQMDIECQTPGICNGHCINTEGSRFCCLGLAVGTDGRVCVDTHMR
gi|1335064|      RYCKDINECETPGICNGRCVNTGSGSRFCCLGLAVGLDGRVCVDTHMR
gi|4557591|      RYCKDINECETPGICNGRCVNTGSGSRFCCLGLAVGLDGRVCVDTHMR
gi|663111|      RYCKDINECETPGICNGRCVNTGSGSRFCCLGLAVGLDGRVCVDTHMR
gi|1706768|      RYCKDINECETPGICNGRCVNTGSGSRFCCLGLAVGLDGRVCVDTHMR
gi|13929180|      RYCKDINECETPGICNGRCVNTGSGSRFCCLGLAVGLDGRVCVDTHMR

          810      820      830      840      850
NOV2a      STCYGALFKGSCARPPFGTVTKSECCCANPDGFGPEPCPCPAKNSAEFQ
gi|1335064|      STCYGALFKGSCARPPFGTVTKSECCCANPDGFGPEPCPCPAKNSAEFQ
gi|4557591|      STCYGALFKGSCARPPFGTVTKSECCCANPDGFGPEPCPCPAKNSAEFQ
gi|663111|      STCYGALFKGSCARPPFGTVTKSECCCANPDGFGPEPCPCPAKNSAEFQ
gi|1706768|      STCYGALFKGSCARPPFGTVTKSECCCANPDGFGPEPCPCPAKNSAEFQ
gi|13929180|      STCYGALFKGSCARPPFGTVTKSECCCANPDGFGPEPCPCPAKNSAEFQ

          860      870      880      890      900
NOV2a      ALCSSGPGITVDGRDINECALDPPVPCANGVCENLRGYSYRCVNLGYBAGA
gi|1335064|      ALCSSGPGITVDGRDINECALDPPVPCANGVCENLRGYSYRCVNLGYBAGA
gi|4557591|      ALCSSGPGITVDGRDINECALDPPVPCANGVCENLRGYSYRCVNLGYBAGA
gi|663111|      ALCSSGPGITVDGRDINECALDPPVPCANGVCENLRGYSYRCVNLGYBAGA
gi|1706768|      ALCSSGPGITVDGRDINECALDPPVPCANGVCENLRGYSYRCVNLGYBAGA
gi|13929180|      ALCSSGPGITVDGRDINECALDPPVPCANGVCENLRGYSYRCVNLGYBAGA

          910      920      930      940      950
NOV2a      SGKECTDMDICALNSLLCNGMCONSPGSYSCTPPGFHFWDTHICKDV

```

```

gi|1335064|TGKNCVDINECVLNSLLCDNGOCRNTPGSEVCHCPKGFIMKPOLKTCBDI
gi|4557591|TGKNCVDINECVLNSLLCDNGOCRNTPGSEVCHCPKGFIMKPOLKTCBDI
gi|663111|-----
gi|1706768|TGKNCVDINECVLNSLLCDNGOCRNTPGSEVCHCPKGFIMKPOLKTCBDI
gi|13929180|SGRNCIDIDECLVNRLLCDNGLCRNTPGSSYSCPCPPGVVETETETCBDV

          960          970          980          990          1000
NOV2a      .....|.....|.....|.....|.....|
gi|1335064|DECLSSPCVSGVCRNLGASYTCKCGPGSRLLDPSCITFCMDSTKGTGWLKIC
gi|4557591|DECESSPCDNGVCKNSPGSEIICCSSESTLDPKKTICIELIKGTCWQTVI
gi|663111|DECESSPCDNGVCKNSPGSEIICCSSESTLDPKKTICIELIKGTCWQTVI
gi|1706768|DECESSPCDNGVCKNSPGSEIICCSSESTLDPKKTICIELIKGTCWQTVI
gi|13929180|NECBSNPCVNGACRNNLGSEHCECSPGSKLSSGLICIGSLKGTCWNLIO

          1010         1020         1030         1040         1050
NOV2a      .....|.....|.....|.....|.....|
gi|1335064|ESRCEVNNGAHLKSGCCSSLGAAWGSPCTLCQVDFICGKGYSRFKGTQC
gi|4557591|ESRCEVNNGAHLKSGCCSSLGAAWGSPCTLCQVDFICGKGYSRFKGTQC
gi|663111|ESRCEVNNGAHLKSGCCSSLGAAWGSPCTLCQVDFICGKGYSRFKGTQC
gi|1706768|ESRCEVNNGAHLKSGCCSSLGAAWGSPCTLCQVDFICGKGYSRFKGTQC
gi|13929180|ENRCEVNNGAHLKSGCCATLGTAWGSPCERCELDACPRGFARFKGVTC

          1060         1070         1080         1090         1100
NOV2a      .....|.....|.....|.....|.....|
gi|1335064|EDVNECEVFPGVCPNGRCVNTAGSFRCECEPEGLMLDASGRICVDVRLBPC
gi|4557591|EDVNECEVFPGVCKNGLCVNTRGSFKCCCFSSMTLDAIGRICTDIRLETG
gi|663111|EDVNECEVFPGVCKNGLCVNTRGSFKCCCFSSMTLDAIGRICTDIRLETG
gi|1706768|EDVNECEVFPGVCKNGLCVNTRGSFKCCCFSSMTLDAIGRICTDIRLETG
gi|13929180|EDVNECEVFPGVCPNGRCVNNKGSFHCCECEPEGLTLDCTGRVCLDVRMHC

          1110         1120         1130         1140         1150
NOV2a      .....|.....|.....|.....|.....|
gi|1335064|FLRWDEDECGVTLPGSKYRMDVCCCSLGAVWG-VBCEACPOPESLBPSLCL
gi|4557591|FLRWDEDECTEPTIACGRHMDACCCSYGAAWGTBCEBECFMRNTPEYELCL
gi|663111|FLRWDEDECTEPTIACGRHMDACCCSYGAAWGTBCEBECFMRNTPEYELCL
gi|1706768|FLRWDEDECTEPTIACGRHMDACCCSYGAAWGTBCEBECFMRNTPEYELCL
gi|13929180|FLRWDEDECVHPPKCFRMDACCCSYGAAWG-TECEBECPPGTHKEYETLC

          1160         1170         1180         1190         1200
NOV2a      .....|.....|.....|.....|.....|
gi|1335064|PRGPGFARK-EITNGKRFKDKINECKMIPSLCTHGKCRNTGSGFKRCRDS
gi|4557591|PRGPGFARK-EITNGKRFKDKINECKMIPSLCTHGKCRNTGSGFKRCRDS
gi|663111|PRGPGFARK-EITNGKRFKDKINECKMIPSLCTHGKCRNTGSGFKRCRDS
gi|1706768|PRGPGFARK-EITNGKRFKDKINECKMIPNLCTHGKCRNTGSGFKRCRDS
gi|13929180|PRGPGFARK-EILTGRPFKDKINECKALPCYCTHGKCRNTGSGFKRCRNS

          1210         1220         1230         1240         1250
NOV2a      .....|.....|.....|.....|.....|
gi|1335064|GFALDSEERNCTDIDECRISPDLCGRGOCVNTPGSFECECFEGYBSGFMM
gi|4557591|GFALDSEERNCTDIDECRISPDLCGRGOCVNTPGDFECKODEGYBSGFMM
gi|663111|GFALDSEERNCTDIDECRISPDLCGRGOCVNTPGDFECKODEGYBSGFMM
gi|1706768|GFALDSEERNCTDIDECRISPDLCGRGOCVNTPGDFECKODEGYBSGFMM
gi|13929180|GFALDSEERNCTDIDECRISPDLCGRGICVNTPGSFECECFEGYBSGFMM

          1260         1270         1280         1290         1300
NOV2a      .....|.....|.....|.....|.....|
gi|1335064|MKNCMDYDECARDPLLCRGGTCVNTGSGYKCCPPPGHELAKGTACEDID
gi|4557591|MKNCMDYDECARDPLLCRGGVCHNTGSGYKCCPPPGHELSPNISACIDIN
gi|663111|MKNCMDYDECARDPLLCRGGVCHNTGSGYKCCPPPGHELSPNISACIDIN
gi|1706768|MKNCMDYDECARDPLLCRGGVCLNTGSGYKCCPPPGHELAPNISACIDIN
gi|13929180|MKNCMDYDECERNPLLCRGGTCVNTGSGYKCCDFLGHELSPREDIDIN

          1310         1320         1330         1340         1350
NOV2a      .....|.....|.....|.....|.....|
gi|1335064|ECSLSDGLCPHGKCVNMIGASQCSCHACFQSTPDRG--ATSASCPTEGHV
gi|4557591|ECLSAHLCPNGKCVNLIKQKQCHNPGMHSTPDRLFVCDIDECSIMNGG
gi|663111|ECLSAHLCPNGKCVNLIKQKQCHNPGMHSTPDRLFVCDIDECSIMNGG
gi|1706768|ECLSAHLCPHGKCVNLIKQKQCHNPGMHSTPDRLFVCDIDECSIMNGG
gi|13929180|ECSLSDNLCRNGKCVNMIGTQCSCHACFQSTPDRGQCSIDIDECSIMNGG

          1360         1370         1380         1390         1400

```

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1410 1420 1430 1440 1450

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1460 1470 1480 1490 1500

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1510 1520 1530 1540 1550

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1560 1570 1580 1590 1600

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1610 1620 1630 1640 1650

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1660 1670 1680 1690 1700

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1710 1720 1730 1740 1750

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1760 1770 1780 1790 1800

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1810 1820 1830 1840 1850

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1860 1870 1880 1890 1900

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1910 1920 1930 1940 1950

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

1960 1970 1980 1990 2000

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

2010 2020 2030 2040 2050

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

2060 2070 2080 2090 2100

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

2110 2120 2130 2140 2150

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

2160 2170 2180 2190 2200

NOV2a
gi|1335064|
gi|4557591|
gi|663111|
gi|1706768|
gi|13929180|

2210 2220 2230 2240 2250

NOV2a
gi|1335064|
gi|4557591|
gi|663111|

```

gi|1706768| DLRMSYCYAKFFGGKCSSPKSRNHSKQKCCCKLK-GEGWGDPCCLCPTEP
gi|13929180| DTRQSFCTNFENGKCSVPKAFNTTKKCCCSKMPGEGWGDPCCLCPKDD

      2260      2270      2280      2290      2300
NOV2a      S-----AAFOELCPYGHGAVPGPDDSDREDVNECAENPGVCTNGVCVNTD
gi|1335064| D-----BAFROICPYGSGIIVGPDSDAVDMDECKE-PDVCKHGCCINTD
gi|4557591| D-----BAFROICPYGSGIIVGPDSDAVDMDECKE-PDVCKHGCCINTD
gi|663111|  B-----VAFOELCPYGHGIVPSLHDTREDVNECLSPGHC-SNGCCINTD
gi|1706768| D-----BAFROICPYGSGIIVGPDSDAVDMDECKE-PDVCKHGCCINTD
gi|13929180| E-----VAFOELCPYGHGIVPSLHDTREDVNECLSPGHC-SNGCCINTD

      2310      2320      2330      2340      2350
NOV2a      GSFRCECPFGYSLDETGINCVDTDECSVGHPCGQGTCTNVIGGFECACAD
gi|1335064| GSYRCECPFGYILA--GNECVDTDECSVGNPCNGTCKNVIGGFECTCEE
gi|4557591| GSYRCECPFGYILA--GNECVDTDECSVGNPCNGTCKNVIGGFECTCEE
gi|663111|  GSFRCECPFGYLLDHTGVRVDTDECSHGNPCNGTCTNVIGSFECTCNE
gi|1706768| GSYRCECPFGYILQ--GNECVDTDECSVGNPCNGTCKNVIGGFECTCEE
gi|13929180| GSFRCECPFGYNLLSGVRVDTDECSHGNPCNGTCAENVIGSFECONE

      2360      2370      2380      2390      2400
NOV2a      GFEPGPMMTCEEIDECSLNPLLCAFRONTGSGYLCTCPAGYTLREDGAM
gi|1335064| GFEPGPMMTCEDINECAONPLLCAFRONTYGSYECKCPFGYVLRREDRRM
gi|4557591| GFEPGPMMTCEDINECAONPLLCAFRONTYGSYECKCPFGYVLRREDRRM
gi|663111|  GFEPGPMMTCEDINECAONPLLCAFRONTYGSYECKCPFGYVLRREDRRM
gi|1706768| GFEPGPMMTCEDINECAONPLLCAFRONTYGSYECKCPAGYVLRREDRRM
gi|13929180| GFEPGPMMTCEDINECAONPLFCAFRONTFGSYECTCEPVGYALREDQKM

      2410      2420      2430      2440      2450
NOV2a      CEDVDECAEGGODCHARGMECKNLIGTFACVCPPGMRPLPGSGEGCTDEN
gi|1335064| CKDEDECEEGKHDCETEKQMECKNLIGTFMCHCPCPGYQRRP-DGEGCVDEN
gi|4557591| CKDEDECEEGKHDCETEKQMECKNLIGTFMCHCPCPGYQRRP-DGEGCVDEN
gi|663111|  CKDVECAEGLHDCESRGMCKNLIGTFMCHCPCPGMARRP-DGEGCVDEN
gi|1706768| CKDEDECEEGKHDCAEKQMECKNLIGTYLCHCPCPGYQRRP-DGEGCVDEN
gi|13929180| CKDEDECAEGLHDCESRGMCKNLIGTFMCHCPCPGMARRP-DGEGCVDEN

      2460      2470      2480      2490      2500
NOV2a      ECHAEDEECVNGRCVNTAGSRRCCEEGFQPSFHLTECHDIRQGPCFAEV
gi|1335064| ECQTKPGICENGRCNTRGSGYTCECNDGFTASFNQDECLDNREGYCFTEV
gi|4557591| ECQTKPGICENGRCNTRGSGYTCECNDGFTASFNQDECLDNREGYCFTEV
gi|663111|  ECRTK-----
gi|1706768| ECQTKPGICENGRCNTRGSGYTCECNDGFTASFNQDECLDNREGYCFTEV
gi|13929180| ECRTKPGICENGRCVNIIGSYRCECNEGFQSSSSGTECLDNROGLCFAEV

      2510      2520      2530      2540      2550
NOV2a      LQTMCSLSSSSSEAVTRAECCCGGGRGWGPRCELCPPLPGTSAYRKLCPHG
gi|1335064| LQNMCIIGSSNRNPVTKECCCDGGRGWGPHCEICPFQGTVAERKLCPHG
gi|4557591| LQNMCIIGSSNRNPVTKECCCDGGRGWGPHCEICPFQGTVAERKLCPHG
gi|663111|  LQNMCIIGSSNRNPVTKECCCDGGRGWGPHCEICPFQGTVAERKLCPHG
gi|1706768| LQNMCIIGSSNRNPVTKECCCDGGRGWGPHCEICPFQGTVAERKLCPHG
gi|13929180| LQTMCMASSSRNLPVTKECCCDGGRGWGPRCELCPPLPGTAQYRKLCPHG

      2560      2570      2580      2590      2600
NOV2a      SGYTAEGRDIDECKMPSLCTNGLCNMNGSFRCFCKVGYTDISCTACV
gi|1335064| RCEMTNGADIDECKMPSLCTNGLCNMNGSFRCFCKVGYTDISCTACV
gi|4557591| RCEMTNGADIDECKMPSLCTNGLCNMNGSFRCFCKVGYTDISCTACV
gi|663111|  RCEMTNGADIDECKMPSLCTNGLCNMNGSFRCFCKVGYTDISCTACV
gi|1706768| RCEMTNGADIDECKMPSLCTNGLCNMNGSFRCFCKVGYTDISCTACV
gi|13929180| PGYATGRDIDECKMPSLCTNGLCNMNGSFRCFCKVGYTDISCTACV

      2610      2620      2630      2640      2650
NOV2a      DYDECSQVPKPCFHCNKNTGSGMOCSCPRGYLLEDGRSCKDLDECAIKQ
gi|1335064| DYDECSQVPKPCFHCNKNTGSGMOCSCPRGYLLEDGRSCKDLDECAIKQ
gi|4557591| DYDECSQVPKPCFHCNKNTGSGMOCSCPRGYLLEDGRSCKDLDECAIKQ
gi|663111|  DYDECSQVPKPCFHCNKNTGSGMOCSCPRGYLLEDGRSCKDLDECAIKQ
gi|1706768| DYDECSQVPKPCFHCNKNTGSGMOCSCPRGYLLEDGRSCKDLDECAIKQ
gi|13929180| DYDECSQVPKPCFHCNKNTGSGMOCSCPRGYLLEDGRSCKDLDECAIKQ

      2660      2670      2680      2690      2700
NOV2a      HNCQFLCVNTIGGFTCCPPPGFTQHHQACFDNDECSAQPGPCGAGHCHN
gi|1335064| HNCQFLCVNTIGGFTCCPPPGFTQHHQACFDNDECSAQPGPCGAGHCHN

```

gi|4557591| HNCQFLCVNTIGGFTCKCPPPGFTQHHHTACIDNNECTSDINLCCSKGICQN
gi|663111| HNCQFLCVNTIGGFTCKCPPPGFTQHHHTACIDNNECTSDINLCCSKGICQN
gi|1706768| HNCQFLCVNTIGGFTCKCPPPGFTQHHHTACIDNNECTSDINLCCSKGICQN
gi|13929180| HNCQFLCVNTIGGFTCKCPPPGFTQHHHTACIDNNECTSDINLCCSKGICQN

2710 2720 2730 2740 2750

NOV2a
gi|1335064| TPGSFRCCECHQGFTLVSSGHGCEDEVNECDGPHRCQHGGCONLGGYRCSCEP
gi|4557591| TPGSFRCCECHQGFTLVSSGHGCEDEVNECDGPHRCQHGGCONLGGYRCSCEP
gi|663111| TPGSFRCCECHQGFTLVSSGHGCEDEVNECDGPHRCQHGGCONLGGYRCSCEP
gi|1706768| TPGSFRCCECHQGFTLVSSGHGCEDEVNECDGPHRCQHGGCONLGGYRCSCEP
gi|13929180| TPGSFRCCECHQGFTLVSSGHGCEDEVNECDGPHRCQHGGCONLGGYRCSCEP

2760 2770 2780 2790 2800

NOV2a
gi|1335064| QGHTORSHQWACQVDENECLSLPTCGSASGRNTLGGFRCVCPSGDFDQAF
gi|4557591| QGHTORSHQWACQVDENECLSLPTCGSASGRNTLGGFRCVCPSGDFDQAF
gi|663111| QGHTORSHQWACQVDENECLSLPTCGSASGRNTLGGFRCVCPSGDFDQAF
gi|1706768| QGHTORSHQWACQVDENECLSLPTCGSASGRNTLGGFRCVCPSGDFDQAF
gi|13929180| QGHTORSHQWACQVDENECLSLPTCGSASGRNTLGGFRCVCPSGDFDQAF

2810 2820 2830 2840 2850

NOV2a
gi|1335064| LGGCOEVEECAGRCPCPSYSCANTPGEELCGCPGCGYFRAGQGHCVSGYGF
gi|4557591| LGGCOEVEECAGRCPCPSYSCANTPGEELCGCPGCGYFRAGQGHCVSGYGF
gi|663111| LGGCOEVEECAGRCPCPSYSCANTPGEELCGCPGCGYFRAGQGHCVSGYGF
gi|1706768| LGGCOEVEECAGRCPCPSYSCANTPGEELCGCPGCGYFRAGQGHCVSGYGF
gi|13929180| LGGCOEVEECAGRCPCPSYSCANTPGEELCGCPGCGYFRAGQGHCVSGYGF

2860 2870 2880 2890 2900

NOV2a
gi|1335064| GRGN-PEPPVSGEMDENSELSPEACEYCKINGYPKRGRKRSTNETDASNI
gi|4557591| GRGN-PEPPVSGEMDENSELSPEACEYCKINGYPKRGRKRSTNETDASNI
gi|663111| GRGN-PEPPVSGEMDENSELSPEACEYCKINGYPKRGRKRSTNETDASNI
gi|1706768| GRGN-PEPPVSGEMDENSELSPEACEYCKINGYPKRGRKRSTNETDASNI
gi|13929180| GRGN-PEPPVSGEMDENSELSPEACEYCKINGYPKRGRKRSTNETDASNI

2910 2920 2930 2940 2950

NOV2a
gi|1335064| EDQSETEANVSLASWVEKTAIFAFNISHVSNKVRILELLPALTTLTNNH
gi|4557591| EDQSETEANVSLASWVEKTAIFAFNISHVSNKVRILELLPALTTLTNNH
gi|663111| EDQSETEANVSLASWVEKTAIFAFNISHVSNKVRILELLPALTTLTNNH
gi|1706768| EDQSETEANVSLASWVEKTAIFAFNISHVSNKVRILELLPALTTLTNNH
gi|13929180| EDQSETEANVSLASWVEKTAIFAFNISHVSNKVRILELLPALTTLTNNH

2960 2970 2980 2990 3000

NOV2a
gi|1335064| RYVIVSGNEGGFFKKNQKECHSYLHFTKKKPVAGTYSLSSTPL--YKK
gi|4557591| RYVIVSGNEGGFFKKNQKECHSYLHFTKKKPVAGTYSLSSTPL--YKK
gi|663111| RYVIVSGNEGGFFKKNQKECHSYLHFTKKKPVAGTYSLSSTPL--YKK
gi|1706768| RYVIVSGNEGGFFKKNQKECHSYLHFTKKKPVAGTYSLSSTPL--YKK
gi|13929180| RYVIVSGNEGGFFKKNQKECHSYLHFTKKKPVAGTYSLSSTPL--YKK

3010 3020 3030 3040 3050

NOV2a
gi|1335064| QEGCPGPGWGSALRIKVLQVSLVGRSLSGPQLSREGGFNNWEGLI PRSD
gi|4557591| QEGCPGPGWGSALRIKVLQVSLVGRSLSGPQLSREGGFNNWEGLI PRSD
gi|663111| QEGCPGPGWGSALRIKVLQVSLVGRSLSGPQLSREGGFNNWEGLI PRSD
gi|1706768| QEGCPGPGWGSALRIKVLQVSLVGRSLSGPQLSREGGFNNWEGLI PRSD
gi|13929180| QEGCPGPGWGSALRIKVLQVSLVGRSLSGPQLSREGGFNNWEGLI PRSD

NOV2a
gi|1335064| G
gi|4557591| -
gi|663111| -
gi|1706768| -
gi|13929180| -

Tables 2Q - 2X list the domain description from DOMAIN analysis results against NOV2a. This indicates that the NOV2a sequence has properties similar to those of other proteins known to contain these domains.

Table 2Q Domain Analysis of NOV2a

gnl|Pfam|pfam00683, TB, TB domain. This domain is also known as the 8 cysteine domain. This family includes the hybrid domains. This cysteine rich repeat is found in TGF binding protein and fibrillin. (SEQ ID NO:61)
Length = 42 residues, 95.2% aligned
Score = 50.1 bits (118), Expect = 2e-06

NOV2a	1663	CSAEIGVGVTTRASCCSLGRAWGNPCELCPMANTTEYRTL	1702
		+ ++ + +	
00683	3	CSNPLPGRVTKSECCSLGRAWGTPCEPCVPVPGTAHEYKTL	42

5

Table 2R Domain Analysis of NOV2a

gnl|Pfam|pfam00683, TB, TB domain. (SEQ ID NO:62)
Length = 42 residues, 100.0% aligned
Score = 46.2 bits (108), Expect = 3e-05

NOV2a	2181	GKCSVPKAFNTTKTRCCSKRPGEGWGDPCELCPQEGSAAFQEL	2224
		+ + + +	
00683	1	GRCSNPLPGRVTKSECCS--LGRAWGTPCEPCVPVPGTAHEYKTL	42

Table 2S Domain Analysis of NOV2a

gnl|Pfam|pfam00683, TB, TB domain. (SEQ ID NO:63)
Length = 42 residues, 100.0% aligned
Score = 43.9 bits (102), Expect = 1e-04

NOV2a	1816	GTCQNELAFNVTRKMCCCSYNIGQAWNRPCEACPTPISPDYQIL	1859
		+ + + + +	
00683	1	GRCSNPLPGRVTKSECCSL--GRAWGTPCEPCVPVPGTAHEYKTL	42

Table 2T Domain Analysis of NOV2a

gnl|Pfam|pfam00683, TB, TB domain. (SEQ ID NO:64)
Length = 42 residues, 95.2% aligned
Score = 43.5 bits (101), Expect = 2e-04

NOV2a	314	CQHQLTGLVCTKALCCATVGRAWGLPCELCPAQPHPCRRGF	354
		+ + ++ +	
00683	3	CSNPLPGRV-TKSECCSLGRAWGTPCEPCVPVPGTAHEYKTL	42

Table 2U Domain Analysis of NOV2a

gnl|Pfam|pfam00683, TB, TB domain. (SEQ ID NO:65)
Length = 42 residues, 100.0% aligned
Score = 43.1 bits (100), Expect = 2e-04

NOV2a	787	GSCARPPPGTVTKSECCCANPDHGFGEPCQLCPAKDSAEFQAL	829
		+ + + + + ++	
00683	1	GRCSNPLPGRVTKSECCSLGR-AWGTPEPCVPVPGTAHEYKTL	42

Table 2V Domain Analysis of NOV2a

gnl|Pfam|pfam00683, TB, TB domain. (SEQ ID NO:66)
Length = 42 residues, 95.2% aligned
Score = 42.7 bits (99), Expect = 3e-04

NOV2a	979	SRCEVNLQGASLRSECCATLGAAWGSPCERCEIDPACARG	1018
		+ + + +	
00683	1	GRCSNPLPGRVTKSECCSLGRAWGTPCEPCVPVPGTAEYK	40

Table 2W Domain Analysis of NOV2a

gnl|Pfam|pfam00683, TB, TB domain. (SEQ ID NO:67)
Length = 42 residues, 100.0% aligned
Score = 39.3 bits (90), Expect = 0.003

NOV2a	462	GRCAGDLAGHYTRRQCCDRGRCWAAGPVPELCPPRGSNEFQQL	505
		+ + + ++	
00683	1	GRCSNPLPGRVTKSECCSLGRAW--GTPCEPCVPVPGTAEYKTL	42

Table 2X Domain Analysis of NOV2a

gnl|Pfam|pfam00683, TB, TB domain. (SEQ ID NO:68)
Length = 42 residues, 97.6% aligned
Score = 38.5 bits (88), Expect = 0.006

NOV2a	1085	ECGVTLPGKYRMDVCCSIGAVWGVCEACPDPESLEFASL	1125
		+ + + + +	
00683	2	RCSNPLPGRVTKSECCSLGRAWGTPCEPCVPVPGTAEYKTL	42

Fibrillins 1 and 2 are the main constituents of the extracellular microfibrils responsible for the biomechanical properties of most tissues and organs. They are cysteine-rich glycoproteins predominantly made of multiple repeats homologous to the calcium-binding epidermal growth factor module, and are translated as precursor proteins cleaved by furine/PACE-like activities. Fibrillins polymerize extracellularly as parallel bundles of head-to-tail monomers. Binding to calcium rigidifies the structure of the monomers and the supramolecular organization of the macroaggregates. Elastic fibers form a network that contributes to the elasticity and resilience of tissues such as the skin. Histopathologic and ultrastructural abnormalities in the elastic fibers have been observed in several diseases of the skin and other tissues. Recent cloning of several genes involved in elastic fiber architecture has lead to the approach of the study of elastic fiber genodermatoses through molecular analysis. In recent years, mutations in several of the genes encoding elastic fiber proteins have been demonstrated in other diseases. Fibrillin-1 mutations result in the pleiotropic manifestations of Marfan syndrome, and fibrillin-2 alterations cause the overlapping phenotype of congenital contractural arachnodactyly, and, most recently, demonstration of abnormalities in the Menkes syndrome gene in X-linked cutis laxa. The first disorders to involve mutations in the elastin gene itself are, surprisingly, cardiovascular and

neurobehavioral disorders, such as supraaortic stenosis and Williams syndrome. It is hypothesized that fibrillin-2 guides elastogenesis, whereas fibrillin-1 provides force-bearing structural support (PMID: 10216958, PMID: 7963685).

The above defined information for NOV2 suggests that the NOV2 protein may function as a member of a family of novel Fibrillin-like proteins. Therefore, the NOV2 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV2 compositions of the present invention will have efficacy for treatment of patients suffering from connective tissue disorders, such as severe neonatal Marfan syndrome, dominant ectopia lentis, familial ascending aortic aneurysm, isolated skeletal features of Marfan syndrome, and Shprintzen-Goldberg syndrome, genodermatoses, contractural arachnodactyly, inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, leukemia or pancreatic cancer.; blood disorders; asthma; psoriasis; vascular disorders, hypertension, skin disorders, renal disorders including Alport syndrome, immunological disorders, tissue injury, fibrosis disorders, bone diseases, Ehlers-Danlos syndrome type VI, VII, type IV, S-linked cutis laxa and Ehlers-Danlos syndrome type V, osteogenesis imperfecta, Neurologic diseases, Brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, endocrine diseases, muscle disorders, inflammation and wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, benign prostatic hypertrophy, contractural arachnodactyly/CCA, arthrogryposis multiplex congenita, osteogenesis imperfecta, keratoconus, scoliosis, duodenal atresia, esophageal atresia and intestinal malrotation. The NOV2 nucleic acid encoding Fibrillin-like proteins, and the Fibrillin-like proteins of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV3

A disclosed NOV3 nucleic acid of 2713 nucleotides (also referred to as GSAL442663.1_A) encoding a novel KIAA1589-like protein is shown in Table 3A. An open

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 3D.

Table 3D. ClustalW Analysis of NOV3

- 1) NOV3 (SEQ ID NO:18)
- 2) [gi|14749609|ref|XP_027303.1|](#) (XM_027303) hypothetical protein XP_027303 [Homo sapiens] (SEQ ID NO:69)
- 2) [gi|14042048|dbj|BAB55085.1|](#) (AK027399) unnamed protein product [Homo sapiens] (SEQ ID NO:70)
- 3) [gi|10047253|dbj|BAB13415.1|](#) (AB046809) KIAA1589 protein [Homo sapiens] (SEQ ID NO:71)
- 4) [gi|14749607|ref|XP_027304.1|](#) (XM_027304) zinc finger protein, subfamily 2A (FYVE domain containing) , 1 [Homo sapiens] (SEQ ID NO:72)
- 5) [gi|13958036|gb|AAK50771.1|AF361055_1](#) (AF361055) FYVE-finger protein EIP1 [Homo sapiens] (SEQ ID NO:73)

	10	20	30	40	50
NOV3				
gi 14749609	MGRARWVTSVIPALWEAKCGPHSKSDFPNAQKMAMLSPTQTFEFRNKIELI				
gi 14042048	-----				
gi 10047253	-----				
gi 14749607	-----				
gi 13958036	-----				
	60	70	80	90	100
NOV3				
gi 14749609	SEALPEDQERTFQDLQEPELSHTPNVQNPVEVSCSLQTQIFVFTPGASS				
gi 14042048	-----				
gi 10047253	-----SVQNPVEVSCSLQTQIFVFTPGASS				
gi 14749607	-----				
gi 13958036	-----				
	110	120	130	140	150
NOV3				
gi 14749609	VTIIWWVCFLTSMMSAQTSPAEGKGLNPGLMCQESYACSGTDEAIFECDE				
gi 14042048	-----MSAQTSPAEGKGLNPGLMCQESYACSGTDEAIFECDE				
gi 10047253	-----MSAQTSPAEGKGLNPGLMCQESYACSGTDEAIFECDE				
gi 14749607	VTIIWWVCFLTSMMSAQTSPAEGKGLNPGLMCQESYACSGTDEAIFECDE				
gi 13958036	-----				
	160	170	180	190	200
NOV3				
gi 14749609	CCSLQCLRCHEELHRQERLRNHERIRLKPGHVPHYCDLCKGLSGHLPGVRC				
gi 14042048	CCSLQCLRCHEELHRQERLRNHERIRLKPGHVPHYCDLCKGLSGHLPGVRC				
gi 10047253	CCSLQCLRCHEELHRQERLRNHERIRLKPGHVPHYCDLCKGLSGHLPGVRC				
gi 14749607	CCSLQCLRCHEELHRQERLRNHERIRLKPGHVPHYCDLCKGLSGHLPGVRC				
gi 13958036	-----				
	210	220	230	240	250
NOV3				
gi 14749609	RAIVRCQTCKINLCLCQKRTSHSGGNKRRHPVTYVNVSNLQESLEAEEMD				
gi 14042048	RAIVRCQTCKINLCLCQKRTSHSGGNKRRHPVTYVNVSNLQESLEAEEMD				
gi 10047253	RAIVRCQTCKINLCLCQKRTSHSGGNKRRHPVTYVNVSNLQESLEAEEMD				
gi 14749607	RAIVRCQTCKINLCLCQKRTSHSGGNKRRHPVTYVNVSNLQESLEAEEMD				
gi 13958036	-----				
	260	270	280	290	300
NOV3				
gi 14749609	EETKRKKMTEKVVSFLLVDENEEIQVTNEEDFIRKLDCKPDQHLKVVSI				
gi 14042048	EETKRKKMTEKVVSFLLVDENEEIQVTNEEDFIRKLDCKPDQHLKVVSI				
gi 10047253	EETKRKKMTEKVVSFLLVDENEEIQVTNEEDFIRKLDCKPDQHLKVVSI				
gi 14749607	EETKRKKMTEKVVSFLLVDENEEIQVTNEEDFIRKLDCKPDQHLKVVSI				
gi 13958036	-----MMEERANLHMMLKLSIKVLLQSALSL				
	310	320	330	340	350
NOV3				

S **O** **B** **E** **R** **T**

		760	770	780	790	800
NOV3		KTRPVPERGWGAPVRVCDNCYEARNVQLAVTEAQVDDDEGGTLIARKVGE				
gi 14749609		KTRPVPERGWGAPVRVCDNCYEARNVQLAVTEAQVDDDEGGTLIARKVGE				
gi 14042048		KTRPVPERGWGAPVRVCDNCYEARNVQLAVTEAQVDDDEGGTLIARKVGE				
gi 10047253		KTRPVPERGWGAPVRVCDNCYEARNVQLAVTEAQVDDDEGGTLIARKVGE				
gi 14749607		KTRPVPERGWGAPVRVCDNCYEARNVQLAVTEAQVDDDEGGTLIARKVGE				
gi 13958036		RQLQRQLQHEKDTSSRLRMELOQVEGLKKELRLEQDEKAEKQKICEQE				
		810	820	830	840	850
NOV3		AVQNTLGAVVTAIDIPGLVKDAARPAY---WVPDHEILHCHNCRKEFSI				
gi 14749609		AVQNTLGAVVTAIDIPGLVKDAARPAY---WVPDHEILHCHNCRKEFSI				
gi 14042048		AVQNTLGAVVTAIDIPGLVKDAARPAY---WVPDHEILHCHNCRKEFSI				
gi 10047253		AVQNTLGAVVTAIDIPGLVKDAARPAY---WVPDHEILHCHNCRKEFSI				
gi 14749607		AVQNTLGAVVTAIDIPGLVKDAARPAY---WVPDHEILHCHNCRKEFSI				
gi 13958036		QALQEMQLHLSQSKKMEDEKEVNQALKGHAWIKDDEATHCROCEKEFSI				
		860	870	880	890	900
NOV3		KLSKHHCRACGQGFCDCESHDRAVPSRGWDHPVRVCFNCNKKPGDL---				
gi 14749609		KLSKHHCRACGQGFCDCESHDRAVPSRGWDHPVRVCFNCNKKPGDL---				
gi 14042048		KLSKHHCRACGQGFCDCESHDRAVPSRGWDHPVRVCFNCNKKPGDL---				
gi 10047253		KLSKHHCRACGQGFCDCESHDRAVPSRGWDHPVRVCFNCNKKPGDL---				
gi 14749607		KLSKHHCRACGQGFCDCESHDRAVPSRGWDHPVRVCFNCNKKPGDL---				
gi 13958036		SRRKHHCRCNCGHIFCNTCSNELAAPS--YPKPVRVCDSCHTLLQRCSS				
NOV3		...				
gi 14749609		---				
gi 14042048		---				
gi 10047253		---				
gi 14749607		---				
gi 13958036	TAS					

Tables 3E – 3H list the domain description from DOMAIN analysis results against NOV3. This indicates that the NOV3 sequence has properties similar to those of other proteins known to contain these domains.

Table 3E Domain Analysis of NOV3

gnl|Smart|smart00064, FYVE, Protein present in Fab1, YOTB, Vac1, and EEA1; Zinc-binding domain, possibly involved in endosomal targetting. Recent data indicates that these domains bind PtdIns(3)P. (SEQ ID NO:74)
Length = 69 residues, 92.8% aligned
Score = 70.9 bits (172), Expect = 3e-13

NOV3	822	RPAYWVPDHEILHCHNCRKEFSIKLSKHHCRACGQGFCDCESHDRAVPSRGWDHPVRVC	881
		+ + + ++ + + + +	
00064	2	VRPHWIPDVEASNCMGCGEFNLTKRHHCRNCGRIFCSKCSSKAPLPKLGNEPVRVC	61
NOV3	882	FNCN	885
		+	
00064	62	DDCY	65

Table 3F Domain Analysis of NOV3

gnl|Smart|smart00064, FYVE. (SEQ ID NO:75)
Length = 69 residues, 89.9% aligned
Score = 62.8 bits (151), Expect = 8e-11

NOV3	708	YWRPNSQILSCNKCATSFKDNDTKHHCRACGEGFCDSCSSKTRPVPERGWGAPVRVCDN	767
		+ + + + + + +	
00064	5	HWIPDVEASNCMGCGEFNLTKRHHCRNCGRIFCSKCSSKAPLPKLGNEPVRVCD	63
NOV3	768	CYE	770

Table 3G Domain Analysis of NOV3

gnl|Pfam|pfam01363, FYVE, FYVE zinc finger. The FYVE zinc finger is named after four proteins that it has been found in: Fab1, YOTB/ZK632.12, Vac1, and EEA1. The FYVE finger has been shown to bind two Zn⁺⁺ ions. The FYVE finger has eight potential zinc coordinating cysteine positions. Many members of this family also include two histidines in a motif R+HHC+XCG, where + represents a charged residue and X any residue. We have included members which do not conserve these histidine residues but are clearly related. (SEQ ID NO:76)
 Length = 66 residues, 92.4% aligned
 Score = 67.4 bits (163), Expect = 3e-12

```
NOV3      824  AYWVPDHEILHCHNCRKEFSIKLSKHHCRACGQGFCDECSHDDRAVPSRGWDHPVRVCFN  883
          +||| |+ +|  |  |++  +||| |+  ||  |  +|  | + ||| | +
01363     1   PHWVPDEEVSNCMRGKPFLLTKRRHHCACGRIFCSCSSKTVPLPPMG-ERPVRVCD  59

NOV3      884  CN  885
          |
01363     60  CY  61
```

5

Table 3H Domain Analysis of NOV3

gnl|Pfam|pfam01363, FYVE, FYVE zinc finger. (SEQ ID NO:77)
 Length = 66 residues, 98.5% aligned
 Score = 64.7 bits (156), Expect = 2e-11

```
NOV3      707  AYWRPNSQILSCNKCATSFKDNDTKHHCRACGEGFCDCSSKTRPVPERGWGPAPVRVCD  766
          +| |+ ++ +| +|  |  +||| |  || | | | | | +|  |  ||| | |
01363     1   PHWVPDEEVSNCMRGKPFLLTKRRHHCACGRIFCSCSSKTVPLPPM--GERPVRVCD  58

NOV3      767  NCYEARN  773
          +||+ |
01363     59  SCYDLLN  65
```

The above defined information for NOV3 suggests that this NOV3 protein may function as a member of a KIAA1589 protein family. Therefore, the NOV3 nucleic acids and proteins of the invention are useful in potential therapeutic and diagnostic applications. For example, a cDNA encoding the NOV3 protein may be useful in gene therapy, and the NOV3 protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, leukemia or pancreatic cancer.; blood disorders; asthma; psoriasis; vascular disorders, hypertension, skin disorders, renal disorders including Alport syndrome, immunological disorders, tissue injury, fibrosis disorders, bone diseases, Ehlers-Danlos syndrome type VI, VII, type IV, S-linked cutis laxa and Ehlers-Danlos syndrome type V, osteogenesis imperfecta, Neurologic diseases, Brain and/or autoimmune disorders like

encephalomyelitis, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, endocrine diseases, muscle disorders, inflammation and wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis; multiple sclerosis; and Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers and benign prostatic hypertrophy. The NOV3 nucleic acid encoding KIAA1589-like protein, and the KIAA1589-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV4

A disclosed NOV4 nucleic acid of 1761 nucleotides (designated CuraGen Acc. No. GSAL442663.1_B) encoding a novel WD40-motif protein-like protein is shown in Table 4A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 48-50 and ending with a TAA codon at nucleotides 1536-1538. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 4A, and the start and stop codons are in bold letters.

Table 4A. NOV4 Nucleotide Sequence (SEQ ID NO:19)

AGCTGAGCCGGAGGGAATCCGGAAGGACACGCTGAACAGGAACAGAAATGAATAAAAGTCGCTGGCAGAGTAGAAGACG
ACATGGGAGAAGAAGCCACAGCAGAACCCCTTGGTTCAGACTCCGTGATTCTGAAGACAGGTCTGACTCCCGGGCAGCA
CAGCCCGCTCAGGATTCGGGCCACGGTGATGACGAGTCTCCGTCAACCTCGTCTGGCACAGCTGGGACCTCCTCTGTGC
CAGAGCTACCTGGGTTTACTTTGACCTGAAAAGAAACGCTACTTCCGCTTGCTCCCTGGACATAACAACTGCAACCC
CCTGACGAAAGAGAGCATCCGGCAGAAGGAGATGGAGAGCAAGAGACTGCGGCTGCTCCAGGAAGAAGACAGACGGAAA
AAGATTGCCAGGATGGGATTAAATGCATCTTCCATGCTACGAAAAGCCAGCTGGGTTTCTCAACGTCACCAATTACT
GCCATTTAGCCCCAGAGCTGCGTCTCAGCTGCATGGAGAGGAAAAAGTCCAGATTGCAAGCATGAGGGATCCCTCCGC
CTTGGCAAGCGACCGATTTAACCTCATACTGGCAGATACCAACAGTGACCGGCTCTTCACAGTGAACGATGTAAAGTT
GGAGGCTCCAAGTATGGTATCATCAACCTGCAAAGTCTGAAGACCCCTACGCTCAAGGTGTTTCATGCACGAAAACCTCT
ACTTCACCAACCGGAAGGTGAATTTCGGTGTGCTGGGCTCGCTGAATCACTGGATTCCACATTCTGCTATGCCTCAT
GGGACTCGCAGAGACTCCAGGCTGTGCCACCTGCTCCAGCATCACTGTTTCGTCATAGTCAACCCAGGAATAGACCGG
CCTGGCATGCTCTGCAGTTTCCGGATCCCTGGTGCTGGTCCCTGATATCCAAGCAAATAACTGCT
TCAGTACAGGCTTGTCTCGGCGGTCTGTTGACCAACGTGGTGACGGGACACCGGCAGTCCTTTGGGACCAACAGTGA
TGTCTTGGCCAGCAGTTTGTCTCATGGCTCCTGCTGTTTAAATGGCTGCCGCTCTGGGAAATCTTTGCCATTGAT
CTGCGTTTGGAATCAAGGCAAGGGATGGAAGGCCACCGCCTGTTTCATGATTACAGCAGTGACCTCTGTGCGGATCC
TCCAAGATGAGCAATACCTGATGGCTTCAGACATGGCTGGAAAGATCAAGCTGTGGGACCTGAGGACCACGAAGTCCGT
AAGGCAGTACGAAGGCCAGTGAATGAGTACGCCTACCTGCCCTGCATGTGCACGAGGAAGAAGGAATCCTGGTGGCA
GTGGGCCAGGACTGTACACGAGAATCTGGAGCCTCCACGATGCCCGCTACTGAGAACCATAACCTCCCCGTACCTG
CCTCCAAGGCCGACATTCACAGTGTGGCCTTCTCGTCGCGGCTGGGGGCTCCCGGGCGCGCGGGGCTGCTCATGGC
TGTCGGGCAGGACCTTACTGTTACTCCTACAGCTAATTCTGCAGGGCACAGCCCAGAGCCATGTGGATTGACTTACG
GGAGTAAAGCGTAACCTTTTACTGCATCTAATGAGGGTGTTTAAGTGACACTCAGTGTACACAGATCCCATCCTCTGG
CTGCTAGGAGAGAAGTGCTGAATGTTCCGTGTGGAGATGCTCAGGAAGTTATTTGAGTTAAATTGCTGGCTGAGAGAG
CTTGAAGTCTTTTCATAAAAG

The nucleic acid sequence of NOV4 maps to chromosome 14 and has 1282 of 1287 bases (99%) identical to a *Homo sapiens* DKFZp434K114 mRNA (gb:GENBANK-ID:HSM800674|acc:AL080157.1) ($E = 2.6e^{-282}$).

A NOV4 polypeptide (SEQ ID NO:20) encoded by SEQ ID NO:19 is 496 amino acid residues and is presented using the one letter code in Table 4B. Signal P, Psort and/or Hydropathy results predict that NOV4 does not contain a signal peptide and is likely to be localized to the nucleus with a certainty of 0.9600.

Table 4B. NOV4 protein sequence (SEQ ID NO:20)	
MNKSRWQSRRRHGRSHQONPWFLRDSRSDSRAAQAHDSGHGDDSPSTSSGTAGTSSVPELPGFYFDPEKKRYFRLLP GHNNCNPLTKESIRQKEMESKRLRLQLQEDRRKKIARMGFNASSMLRKSQGLNVTNYCHLAHELRLSCMERKKVQIRSMRD PSALASDRFNLIILADTNSDRLFTVNDVKVGGSKYGIINLQSLKPTLKVFMHENLYFTNRKVNVCWASLNHLDLHLLCLMG LAETPGCATLLPASLFVNSHPGIDRPGMLCSFRIPGAWSCAWSLNIQANNCFTGLSRRVLLTNVVTGHRQSFGTNSDVLAAQQ FALMAPLLFNGCRSGEIPAIIDLRCGNQKGWKATRLFHDSAVTSVRILQDEQYLMASDMAGKIKLWDLRTTKCVRQYEGHVNE YAYLPLHVHEEGILVAVGQDCYTRIWSLHDARLLRTIPSPYPASKADIPSVAFSSRLGGSRGAPGLLMAVGQDLYCYSYS	

The NOV4 amino acid sequence has 425 of 428 amino acid residues (99%) identical to, and 425 of 428 amino acid residues (99%) similar to, a *Homo Sapiens* 430 amino acid residue hypothetical 48.5 kDa protein (ptnr:SPTREMBL-ACC:Q9Y4P5) ($E = 1.0e^{-232}$).

NOV4 is expressed in at least the following tissues: cancer tissue, pancreas, fetal lung NbHL19W, testis NHT, B-cell and brain. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Genomic Clone sources, Literature sources, and/or RACE sources. In addition, NOV4 is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Homo sapiens* DKFZp434K114 mRNA homolog (GENBANK-ID: gb:GENBANK-ID: HSM800674 |acc:AL080157.1): Rhabdomyosarcoma, neuroepithelium, pancreas, fetal lung, NbHL19W, testis NHT, B-cell and brain.

NOV4 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 4C.

Table 4C. BLAST results for NOV4					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 14749605 ref XP_027300.1 (XM 027300)	hypothetical protein XP_027300 [Homo sapiens]	489	487/497 (97%)	487/497 (97%)	0.0
gi 14042651 dbj BAB55337.1 (AK027745)	unnamed protein product [Homo sapiens]	489	485/497 (97%)	487/497 (97%)	0.0
gi 7512629 pir T12541	hypothetical protein DKFZp434K114.1 - (fragment) [Homo sapiens]	430	425/428 (99%)	425/428 (99%)	0.0
gi 13096981 gb AAH03284.1 AAH03284 (BC003284)	Unknown (protein for MGC:7874) [Mus musculus]	519	400/498 (80%)	446/498 (89%)	0.0
gi 14749602 ref XP_027301.1 (XM 027301)	DKFZP434K114 protein [Homo sapiens]	333	331/332 (99%)	331/332 (99%)	0.0

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 4D.

Table 4D ClustalW Analysis of NOV4

- 1) NOV4 (SEQ ID NO:20)
- 2) [gi|14749605|ref|XP_027300.1|](#) (XM_027300) hypothetical protein XP_027300 [Homo sapiens] (SEQ ID NO:78)
- 3) [gi|14042651|dbj|BAB55337.1|](#) (AK027745) unnamed protein product [Homo sapiens] (SEQ ID NO:79)
- 4) [gi|7512629|pir|T12541](#) hypothetical protein DKFZp434K114.1 -(fragment) [Homo sapiens] (SEQ ID NO:80)
- 5) [gi|13096981|gb|AAH03284.1|AAH03284](#) (BC003284) Unknown (protein for MGC:7874) [Mus musculus] (SEQ ID NO:81)
- 6) [gi|14749602|ref|XP_027301.1|](#) (XM_027301) DKFZP434K114 protein [Homo sapiens] (SEQ ID NO:82)

		10	20	30	40	50
NOV4		MNKSRWQSRRRHGRRSHQONPWFLRDSEDRSDSRAAQPAHDSGHGDDDES				
gi 14749605		MNKSRWQSRRRHGRRSHQONPWFLRDSEDRSDSRAAQPAHDSGHGDDDES				
gi 14042651		MNKSRWQSRRRHGRRSHQONPWFLRDSEDRSDSRAAQPAHDSGHGDDDES				
gi 7512629		---GRWQSRRRHGRRSHQONPWFLRDSEDRSDSRAAQPAHDSGHGDDDES				
gi 13096981		MDRNLWQSRRRHGRRSHQONPWFLRDSEDRSDSRAAQPAHDSGHGDDDES				
gi 14749602		MNKSRWQSRRRHGRRSHQONPWFLRDSEDRSDSRAAQPAHDSGHGDDDES				
		60	70	80	90	100
NOV4		PSTSSGTAGTSSVPELPGFYFDPEKKRYFRLLPGHNNCNPLTKESI RQKE				
gi 14749605		PSTSSGTAGTSSVPELPGFYFDPEKKRYFRLLPGHNNCNPLTKESI RQKE				
gi 14042651		PSTSSGTAGTSSVPELPGFYFDPEKKRYFRLLPGHNNCNPLTKESI RQKE				
gi 7512629		PSTSSGTAGTSSVPELPGFYFDPEKKRYFRLLPGHNNCNPLTKESI RQKE				
gi 13096981		PSTSSRTCESSVPELPGFYFDPEKKRYFRLLPGHNNCNPLTKESI RQKE				
gi 14749602		PSTSSGTAGTSSVPELPGFYFDPEKKRYFRLLPGHNNCNPLTKESI RQKE				
		110	120	130	140	150
NOV4		MESKRLRLQEEEDR-RKKIARMGFNASSMLRKSQGLFNLVNTNYCHLAHEL				
gi 14749605		MESKRLRLQEEEDR-RKKIARMGFNASSMLRKSQGLFNLVNTNYCHLAHEL				
gi 14042651		MESKRLRLQEEEDR-RKKIARMGFNASSMLRKSQGLFNLVNTNYCHLAHEL				
gi 7512629		MESKRLRLQEEEDR-RKKIARMGFNASSMLRKSQGLFNLVNTNYCHLAHEL				
gi 13096981		MESKRLRLQEEEDR-RKKIARMGFNASSMLRKSQGLFNLVNTNYCHLAHEL				
gi 14749602		MESKRLRLQEEEDR-RKKIARMGFNASSMLRKSQGLFNLVNTNYCHLAHEL				
		160	170	180	190	200
NOV4		RLSCMERKKVQIRSM-DPSALASDRFNLI LADTNSDRLFTVNDVKVGGSK				
gi 14749605		RLSCMERKKVQIRSM-DPSALASDRFNLI LADTNSDRLFTVNDVKVGGSK				
gi 14042651		RLSCMERKKVQIRSM-DPSALASDRFNLI LADTNSDRLFTVNDVKVGGSK				
gi 7512629		RLSCMERKKVQIRSM-DPSALASDRFNLI LADTNSDRLFTVNDVKVGGSK				
gi 13096981		RLSCMERKKVQIRSM-DPSALASDRFNLI LADTNSDRLFTVNDVKVGGSK				
gi 14749602		RLSCMERKKVQIRSM-DPSALASDRFNLI LADTNSDRLFTVNDVKVGGSK				
		210	220	230	240	250
NOV4		YGIINLQSLKTPTLKVFHMHENLYFTNRKVN SVCWASLNHLD SHI LLCLMG				
gi 14749605		YGIINLQSLKTPTLKVFHMHENLYFTNRKVN SVCWASLNHLD SHI LLCLMG				
gi 14042651		YGIINLQSLKTPTLKVFHMHENLYFTNRKVN SVCWASLNHLD SHI LLCLMG				
gi 7512629		YGIINLQSLKTPTLKVFHMHENLYFTNRKVN SVCWASLNHLD SHI LLCLMG				
gi 13096981		YGIINLQSLKTPTLKVFHMHENLYFTNRKVN SVCWASLNHLD SHI LLCLMG				
gi 14749602		YGIINLQSLKTPTLKVFHMHENLYFTNRKVN SVCWASLNHLD SHI LLCLMG				
		260	270	280	290	300
NOV4		LAETPGCATLLPASLFVNSHEG-IDRPGMLCSFRI PGAWSCAWSLNIQAN				
gi 14749605		LAETPGCATLLPASLFVNSHEG-IDRPGMLCSFRI PGAWSCAWSLNIQAN				
gi 14042651		LAETPGCATLLPASLFVNSHEG-IDRPGMLCSFRI PGAWSCAWSLNIQAN				
gi 7512629		LAETPGCATLLPASLFVNSHEG-IDRPGMLCSFRI PGAWSCAWSLNIQAN				
gi 13096981		LAETPGCATLLPASLFVNSHEG-IDRPGMLCSFRI PGAWSCAWSLNIQAN				
gi 14749602		LAETPGCATLLPASLFVNSHEG-IDRPGMLCSFRI PGAWSCAWSLNIQAN				
		310	320	330	340	350
NOV4		NCFSTGLSRRVLLTNVVTGHRQSFGTNSDVLAAQQFALMAPLLFNGCRSGE				

```

gi|14749605| NCFSTGLSRRVLLTNVVTGHRQSFGTNSDVL-----PLLFNGCRSGE
gi|14042651| NCFSTGLSRRVLLTNVVTGHRQSFGTNSDVL-----PLLFNGCRSGE
gi|7512629| NCFSTGLSRRVLLTNVVTGHRQSFGTNSDVLAAQQAFMAPLLFNGCRSGE
gi|13096981| NCFSTGLSRRVLLTNVVTGHRQSFGTNSDVLAAQQFAVKTPLLFNGCRSGE
gi|14749602| NCFSTGLSRRVLLTNVVTGHRQSFGTNSDVLAAQQFALMAPLLFNGCRSGE

          360      370      380      390      400
NOV4      IFAIDLRCGNQKGWKATRLFHDSAVTSVRILQDEQYLMASDMAGKIKLW
gi|14749605| IFAIDLRCGNQKGWKATRLFHDSAVTSVRILQDEQYLMASDMAGKIKLW
gi|14042651| IFAIDLRCGNQKGWKATRLFHDSAVTSVRILQDEQYLMASDMAGKIKLW
gi|7512629| IFAIDLRCGNQKGWKATRLFHDSAVTSVRILQDEQYLMASDMAGKIKLW
gi|13096981| IFAIDLRCGNQKGWKATRLFHDSAVTSVRILQDEQYLMASDMAGKIKLW
gi|14749602| IFAIDLRCGNQKGWKATRLFHDSAVTSVRILQDEQYLMASDMAGKIKLW

          410      420      430      440      450
NOV4      DLRTTKCVRQYEGHVNEYAYLPLHVHEEEGILVAVGQDCYTRIWSLHDAR
gi|14749605| DLRTTKCVRQYEGHVNEYAYLPLHVHEEEGILVAVGQDCYTRIWSLHDAR
gi|14042651| DLRTTKCVRQYEGHVNEYAYLPLHVHEEEGILVAVGQDCYTRIWSLHDAR
gi|7512629| DLRTTKCVRQYEGHVNEYAYLPLHVHEEEGILVAGT-----
gi|13096981| DLRTTKCVRQYEGHVNEYAYLPLHVHEEEGILVAVGQDCYTRIWSLHDAR
gi|14749602| DLRTTKCVRQYEGHVNEYAYLPLHVHEEEGILVAGT-----

          460      470      480      490      500
NOV4      LLRTIPSPYPASKADIPSVAFSSRLGGSRGAPGLLMAVGQDLYCYSYS--
gi|14749605| LLRTIPSPYPASKADIPSVAFSSRLGGSRGAPGLLMAVGQDLYCYSYS--
gi|14042651| LLRTIPSPYPASKADIPSVAFSSRLGGSRGAPGLLMAVGQDLYCYSYS--
gi|7512629| LLRTIPSPYPASKADIPSVAFSSRLGGSRGAPGLLMAVGQDLYCYSYS--
gi|13096981| LLRTIPSPYPASKADIPSVAFSSRLGGSRGAPGLLMAVGQDLYCYSYS--
gi|14749602| LLRTIPSPYPASKADIPSVAFSSRLGGSRGAPGLLMAVGQDLYCYSYS--

          510      520
NOV4      -----
gi|14749605| -----
gi|14042651| -----
gi|7512629| -----
gi|13096981| CPDSQEGRWELPSVSNEDIL
gi|14749602| -----

```

Recent studies have demonstrated the importance of F-box/WD40 proteins in the regulation of developmental processes, by a mechanism of specific ubiquitination and subsequent proteolysis of target proteins belonging to the Wnt, Hh and NF-kappaB signaling pathways. A new human gene, Dactylin, encoding a novel member of the F-box/WD40 protein family was recently cloned and characterized. The Dactylin gene comprises nine exons distributed in more than 85 kb of genomic DNA and encoding a protein with four WD40 repeats and an F-box motif. The chromosomal location of Dactylin and its putative function as an F-box/WD40 repeat protein, likely to be involved in key signaling pathways crucial for normal limb development, make it a promising candidate gene for SHFM3 (Ianakiev et al., A novel human gene encoding an F-box/WD40 containing protein maps in the SHFM3 critical region on 10q24. Biochem Biophys Res Commun 261(1):64-70, 1999).

Several other proteins have been identified as containing WD40 repeat domains including the COP1 (constitutively photomorphogenic 1) protein in Arabidopsis which is a repressor of light-regulated development and its mammalian homologue which acts within the nucleus to repress photomorphogenic development (Wang et al., Evidence for functional conservation of a mammalian homologue of the light-responsive plant protein COP1. Curr

Biol 9(13):711-4, 1999). Another protein which contains the WD40 repeat domain is the Schizosaccharomyces pombe 72 kDa TFIID subunit. This protein contains several significant highly conserved regions including the WD40 repeats, that are indispensable for the viability (Yamamoto et al., Molecular genetic elucidation of the tripartite structure of the Schizosaccharomyces pombe 72 kDa TFIID subunit which contains a WD40 structural motif. Genes Cells 2(4):245-54, 1997).

The above defined information for NOV4 suggests that this NOV4 protein may function as a member of a WD40-motif protein-like protein family. Therefore, the NOV4 nucleic acids and proteins of the invention are useful in potential therapeutic and diagnostic applications. For example, a cDNA encoding the NOV4 protein may be useful in gene therapy, and the NOV4 protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from cancer, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections Diabetes, Von Hippel-Lindau (VHL) syndrome , Pancreatitis, Obesity Systemic lupus erythematosus , Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, ARDS, Von Hippel-Lindau (VHL) syndrome , Alzheimer's disease, Stroke, Tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, Behavioral disorders, Addiction, Anxiety, Pain, Neuroprotection Fertility Myasthenia gravis, Leukodystrophies, Pain, Neuroprotection Endocrine dysfunctions, Diabetes, obesity, Growth and reproductive disorders Hemophilia, Hypercoagulation, Idiopathic thrombocytopenic purpura , Immunodeficiencies and Graft versus host. The NOV4 nucleic acid encoding WD40-motif protein-like protein, and the WD40-motif protein-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV5

NOV5 includes four novel Opioid Binding Cell Adhesion Molecule-like proteins disclosed below. The disclosed proteins have been named NOV5a, NOV5b, NOV5c and NOV5d.

NOV5a

A disclosed NOV5a nucleic acid of 1018 nucleotides (also referred to as 139785504) encoding a novel Opioid Binding Cell Adhesion Molecule-like protein is shown in Table 5A.

An open reading frame lacking a signal peptide was identified beginning with an CTG at nucleotides 1-3 and ending with a TAG codon at nucleotides 958-960. A putative untranslated region downstream from the termination codon are underlined in Table 5A, and the start and stop codons are in bold letters.

Table 5A. NOV5a Nucleotide Sequence (SEQ ID NO:21)

CTGGCCGGCTTGGCCGTCATCAGCCGAGGGCTGCTCTCCAGAGCCTGGAGTTCAACTCTCCTGCCGACAACTACACAGTGT
GTGAAGGTGACAAACGCCACCTCAGCTGCTTATCGACGAGCAGTGACCCGCGTGGCTTGGCTGAACCGCTCCAACATCCT
GTATGCCGGCAATGACCGCTGGACCGACGCCGCGGTGCGGCTGCTCATCAACACCCCGAGGAGTTCTCCATCCTCATC
ACCGAGGTGGGGCTCGGCGACGAGGGCTCTACACCTGCTCTTCCAGACCCGCCACCGGTACACCACTCAGGTCTACC
TCATTGTCCACGTCCCTGCCCGCATTGTGAACATCTCGTCCGCTGTGACGGTGAATGAGGGGGCAATGTGAACCTGCTTGG
CCTGGCCGTGGGGCGGCCAGAGCCACGGTCACCTGGAGACAGCTCCGAGACGGCTTCACTCGGAGGGAGAGATCCTGGAG
ATCTCTGACATCCAGCGGGGCCAGGCCGGGGAGTATGAGTGGTGAATCACAACGGGGTTAACTCGGCGCCGACAGCCGCC
GCGTGTGCTGTCACAGTCAACTATCCTCCGACCATCACGGACGTGACAGCGCCCGACCGCGCTGGGCCGGACCGCCCTCCT
GCGCTGCGAAGCCATGGCGGTTCCCCCGCGGATTTCAGTGGTACAAGGATGACAGACTGCTGAGCAGCGGCACGGCCGAA
GGCCTGAAGGTGCAGACGGAGCGCACCCGCTCGATGCTTCTCTTGGCAAAGTGAAGCGCCCGCATTACGGCAACTATAGT
GTCGCGCCGCAATCGACTGGGAGCGTCCAGCGCTCCATGCGGCTCCTGCGCCAGGATCCCTGGAGAACTCAGCCCCGAG
GCCCCAGGGCTCCTGGCCCTCCTCTCCGCTGGCTGGTGTGGTGGAGAATG**TAG**CGCAACCCAGTCCAGTCCACCTC
CCCCGAGGGGCCCTCAAACCAAGAGTGAGAGA

5

The NOV5a nucleic acid was identified on chromosome 7 and has 260 of 389 bases (66%) identical to a *Homo sapiens* (clone pHOM) opioid-binding cell adhesion molecule mRNA (gb:GENBANK-ID:HUMOBCAM|acc:L34774.1) ($E = 3.4e^{-50}$).

A disclosed NOV5a polypeptide (SEQ ID NO:22) encoded by SEQ ID NO:21 is 319 amino acid residues and is presented using the one-letter code in Table 5B. Signal P, Psort and/or Hydropathy results predict that NOV5a does not contain a signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.4686 and the cytoplasm with a certainty of 0.4500.

Although SignalP, Psort and/or hydropathy suggest that NOV5a protein may be localized in the mitochondrial matrix space and cytoplasm, the protein predicted here is similar to the Opioid Binding Cell Adhesion Molecule family, some members of which are released extracellularly. The closest homolog SWISSPROT-ACC:Q14982 opioid binding protein/cell adhesion molecule is a type Ia membrane protein that is localized to the plasma membrane extracellularly. This indicates that the signal peptide of the mature protein is cleaved. Therefore it is likely that NOV5a protein is available at the same sub-cellular localization and hence accessible to a diagnostic probe and for various therapeutic applications. It also indicates that the use of a heterologous signal peptide to target the novel protein to the appropriate location, i.e. extracellularly, is appropriate.

Table 5B. Encoded NOV5a protein sequence (SEQ ID NO:22)

LAGLAVISRGLLSQSLEFNSPADNYTVCEGDNATLSCFIDEHVTRVAWLNRSNILYAGNDRWTS DPRVLLINTPEEFSIL
ITEVGLGDEGLYTCSEFQTRHQPYTTQVYLIVHVPARIVNISSPVTVNEGGVNLCLAVGRPEPTVTRQLRDGFTSEGEI
LEISDIQRGQAGEYECVTHNGVNSAPDSRRVLVTVNYPPITDVTSTARTALGRTALLRCEAMAVPPADPQWYKDRLLSSG
TAEGLKVQTERTRSMLLFANVSARHYGNYTCRAANRLGASSASMRLLRPGSLNSAPRPPGLLALLSALGWLWWRM

The NOV5a amino acid sequence has 162 of 300 amino acid residues (54%) identical to, and 213 of 300 amino acid residues (71%) similar to, a *Homo Sapiens* 345 amino acid residue opioid binding protein/cell adhesion molecule precursor (OBCAM) / opioid-binding cell adhesion molecule (OPCML) protein (ptnr:SWISSPROT-ACC:Q14982) ($E = 3.1 \times 10^{-80}$).

NOV5a is expressed in at least the following tissues: Brain and Fetal brain. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, genomic clone sources, literature sources, and/or RACE sources. In addition, NOV5a is predicted to be expressed in brain tissues because of the expression pattern of a closely related Human (clone pHOM) opioid-binding cell adhesion molecule mRNA homolog (gb:GENBANK-ID:HUMOBCAM|acc:L34774.1).

NOV5b

A disclosed NOV5b nucleic acid of 1017 nucleotides (also referred to as 139785504_da1) encoding a novel Opioid Binding Cell Adhesion Molecule-like protein is shown in Table 5C. An open reading frame lacking the signal peptide was identified beginning with an GCC at nucleotides 3-5 and ending with a TAG codon at nucleotides 958-960. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 5C, and the start and stop codons are in bold letters.

Table 5C. NOV5b Nucleotide Sequence (SEQ ID NO:23)

CTGGCCGGCTGGCCGTCATCAGCCGAGGGCTGCTCTCCAGAGCCTGGAGTTCAACTCTCCTGCCGACAACTACACAG
TGTGTAAGGTGACAACGCCACCCTCAGCTGCTTCATCGACGAGCACGTGACCCGCGTGGCCTGGCTGAACCGCTCCAA
CATCCTGTATGCCGGCAATGACCGCTGGACCAGCGACCCGCGGTGCGGCTGCTCATCAACACCCCGAGGAGTTCTCC
ATCCTCATCACCGAGGTGGGGCTCGGCGACGAGGGCTCTACACCTGCTCCTTCCAGACCCGCCACGACCGGTACACCA
CTCAGGTCACCTCATTGTCCACGTCCCTGCCCGCATTTGTGAACATCTCGTCGCTGTGACGGTGAATGAGGGGGCAA
TGTGAACCTGCTTTGCCTGGCCGTGGGGCGGCCAGAGCCACGGTCACCTGGAGACAGCTCCGAGACGGCTTCACTCG
GAGGGAGAGATCCTGGAGATCTCTGACATCCAGCGGGGCCAGGCCGGGGAGTATGAGTGCCTGACTCACAACGGGGTTA
ACTCGGCGCCCGACAGCCGCCGCGTCTGGTCAAGTCAACTATCCTCCGACCATCAGGACGTGACCGCGCCGAC
CGCGCTGGGGCGGGCCGCCCTCCTGCGCTGCGAAGCCATGGCGGTTCCCCCGCGGATTTCCAGTGGTACAAGGATGAC
AGACTGCTGAGCAGCGGACGGCCGAAGGCTGAAGGTGCAGACGAGCGCACCCGCTCGATGCTTCTTTGCCAAGC
TGAGCGCCCGGATTACGGCAACTATACGTGTCGCGCGCCCAACCGACTGGGAGCGTCCAGCGCCTCCATGCGGCTCCT
GCGCCAGGATCCCTGGAGAACTCAGCCCCGAGGCCCGCAGGGCTCCTGGCCCTCCTCTCCGCCCTGGGCTGGCTGTGG
TGGAGAATGTAGGCCAACCCAGTCCAGCTCACCTCCCCCTGCAGGGGGCTCAAACCAAGAGTGAGAGA

The NOV5b nucleic acid was identified on chromosome 7 and has 261 of 389 bases (67%) identical to a *Homo sapiens* (clone pHOM) opioid-binding cell adhesion molecule mRNA (gb:GENBANK-ID:HUMOBCAM|acc:L34774.1) ($E = 1.3 \times 10^{-50}$).

A disclosed NOV5b polypeptide (SEQ ID NO:24) encoded by SEQ ID NO:23 is 319 amino acid residues and is presented using the one-letter code in Table 5D. Signal P, Psort and/or Hydropathy results predict that NOV5b does not contain a signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.4686 and the cytoplasm with a certainty of 0.4500.

Although SignalP, Psort and/or hydropathy suggest that NOV5b protein may be localized in the mitochondrial matrix space and cytoplasm, the protein predicted here is similar to the Opioid Binding Cell Adhesion Molecule family, some members of which are released extracellularly. The closest homolog SWISSPROT-ACC:Q14982 opioid binding protein/cell adhesion molecule is a type Ia membrane protein that is localized to the plasma membrane extracellularly. This indicates that the signal peptide of the mature protein is cleaved. Therefore it is likely that NOV5b protein is available at the same sub-cellular localization and hence accessible to a diagnostic probe and for various therapeutic applications. It also indicates that the use of a heterologous signal peptide to target the novel protein to the appropriate location, i.e. extracellularly, is appropriate.

Table 5D. Encoded NOV5b protein sequence (SEQ ID NO:24).

LAGLAVISRGLLSQSLEFNSPADNYTVCEGDNATLSCFIDEHVTRVAWLNRSNILYAGNDRWTS DPRVRLINTPEEFSILITEV
GLGDEGLYTCSTFQTRHQPYYTQVYLIVHVPARIVNISSPVTVNEGNNVLLCLAVGRPEPTVTWRQLRDGFTSEGEILEISDIQR
GQAGEYECVTHNGVNSAPDSRRVLVTVNYPPTITDVT SARTALGRAALLRCEAMAVPPAD FQWKDDRLSSGTAEG LKVQ TERT
RSM L LFANVSARHYGNYTCRAANRLGASSASMRLLRPGSLENSAPRPPGLLALLSALGWLWWRM

The NOV5b amino acid sequence has 164 of 300 amino acid residues (54%) identical to, and 213 of 300 amino acid residues (71%) similar to, a *Bos taurus* 345 amino acid residue opioid binding protein/cell adhesion molecule precursor (OBCAM) / opioid-binding cell adhesion molecule (OPCML) protein (ptnr:SWISSPROT-ACC:P11834) ($E = 1.7e^{-80}$).

NOV5b is expressed in at least the following tissues: Brain and Fetal brain. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, genomic clone sources, literature sources, and/or RACE sources. In addition, NOV5b is predicted to be expressed in brain tissues because of the expression pattern of a closely related *Homo sapiens* (clone pHOM) opioid-binding cell adhesion molecule mRNA homolog (gb:GENBANK-ID:HUMOBCAM|acc:L34774.1).

NOV5c

A disclosed NOV5c nucleic acid of 1136 nucleotides (also referred to as CG51027-03) encoding a novel Opioid Binding Cell Adhesion Molecule-like protein is shown in Table 5E. An open reading frame lacking a signal peptide was identified beginning with an TCC at nucleotides 2-4 and ending with a TAG codon at nucleotides 923-925. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 5E, and the start and stop codons are in bold letters.

Table 5E. NOV5c Nucleotide Sequence (SEQ ID NO:25)

CTCCAGAGCCTGGAGTTCAACTCTCCTGCCGCAACTACACAGTGTGTGAAGGTGACAAACGCCACCTCAGCTGCTTCATC
GACGAGCAGTGACCCGCGTGGCCTGGCTGAACCGTCCAACATCCTGTATGCCGGCAATGACCGCTGGACCAGCGACCCGC
GGTGTGGCTGCTCATCAACACCCCGAGGAGTTCTCCATCCTCATCACCGAGGTGGGGCTCGGCGACGAGGGCCTCTACAC
CTGCTCCTTCCAGACCCGCCACAGCGGTACACCACTCAGGTCTACCTATTGTCCACGTCCCTGCCCGCATTGTGAACATC
TCGTGCGCTGTGATGGTGAATGAGGGGGCAATGTGAACCTGCTTTGCTGCGCGTGGGGCGGCCAGAGCCACCGTCACCT
GGAGACAGTCCGAGACGGCTTACCTCGGAGGAGAGATCTGAGATCTCTGACATCCAGCGGGGCCAGGCCGGGAGTA
TGAGTGGCTGACTCAACCGGGTTAACTCGGCGCCGACAGCGCGCGTGTGGTCAAGTCAACTATCTCCGACCATC
ACGACGTGACGAGCGCCCGCACCGCGTGGGCGGGCGCCCTCCTGCGCTGCGAAGCCATGGCGGTTCCCCCGCGGATT
TCCAGTGGTATAAGGATGACAGACTGCTGAGCAGCGGCACGGCCGAAGGCCTGAAGGTGCAGATGGAGCGCACCCGCTCGAT
GCTTCTCTTTGCCAACGTGAGCGCCCGCATTAACGCAACTATACGTGTGCGCGCCCAACCGACTGGGAGCGTCCAGCGCC
TCCATGCGGCTCCTGCGCCAGGATCCTGGAGAACTCAGCCCCGAGGCCCCAGGGCTCCTGGCCCTCCTCTCCGCCCTGG
GCTGGCTGTGGTGGAGAATGTAGGCGCAACCCAGTGGAGCTCACCCTCCCCCTGCAGGGGGCCTCAGGCCAAGAGTGAGAGAA
ACGGGGGAGCAAGAGCCGTGGGTCTCGTGGGGGAGAAGAGCTCTCGGCCACCAAGGAAGAAGAGAGGAGAAGAGGAGGA
GGCAGAGGAAGAAAGATCTTCAGAGAACCCATCACTGTGAGGGATAACGCAAAATTATGCATCTTTCTAC

The NOV5c nucleic acid was identified on chromosome 7 and has 274 of 389 bases (70%) identical to a *Bos taurus* opioid binding protein/cell adhesion molecule (OBCAM) mRNA (gb:GENBANK-ID:BTB0CAM|acc:X12672.1) ($E = 1.3e^{-56}$).

5 A disclosed NOV5c polypeptide (SEQ ID NO:26) encoded by SEQ ID NO:25 is 307 amino acid residues and is presented using the one-letter code in Table 5F. Signal P, Psort and/or Hydropathy results predict that NOV5c does not contain a signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.4686 and the cytoplasm with a certainty of 0.4500.

10 Although SignalP, Psort and/or hydropathy suggest that NOV5c protein may be localized in the mitochondrial matrix space and cytoplasm, the protein predicted here is similar to the Opioid Binding Cell Adhesion Molecule family, some members of which are released extracellularly. The closest homolog SWISSPROT-ACC:Q14982 opioid binding protein/cell adhesion molecule is a type Ia membrane protein that is localized to the plasma
15 membrane extracellularly. This indicates that the signal peptide of the mature protein is cleaved. Therefore it is likely that NOV5c protein is available at the same sub-cellular localization and hence accessible to a diagnostic probe and for various therapeutic applications. It also indicates that the use of a heterologous signal peptide to target the novel protein to the appropriate location, i.e. extracellularly, is appropriate.

Table 5F. Encoded NOV5c protein sequence (SEQ ID NO:26)

SQSLEFNSPADNYTVCEGDNATLSCFIDEHVTRVAWLNRSNILYAGNDRWTS DPRVWLLINTPEEFSILITEVGLGDEGLY
TCSFQTRHQPYTTQVYLIVHVPARIVNISSPVMVNEGGNVNLLCLAVGRPEPTVTWRQLRDGFTSEGEILEISDIQRGQAG
EYECVTHNGVNSAPDSRRVLVTVNPPTITDVTARTALGRAALLRCEAMAVPPADFWQYKDRLLSSGTAEGLVKQVMERT
RSMLLFANVSARHYGNYTCRAANRLGASSAMRLLRPGLENSAPRPPGLLALLSALGWLWWRM

20 The NOV5c amino acid sequence has 163 of 300 amino acid residues (54%) identical to, and 212 of 300 amino acid residues (70%) similar to, a *Homo Sapiens* 345 amino acid residue opioid binding protein/cell adhesion molecule precursor (OBCAM) / opioid-binding cell adhesion molecule (OPCML) protein (ptnr:SWISSPROT-ACC:Q14982) ($E = 1.2e^{-79}$).

NOV5c is expressed in at least the following tissues: Brain and Fetal brain. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, genomic clone sources, literature sources, and/or RACE sources.

5 **NOV5d**

A disclosed NOV5d nucleic acid of 1169 nucleotides (also referred to as CG51027-05) encoding a novel Opioid Binding Cell Adhesion Molecule-like protein is shown in Table 5G. An open reading frame was identified beginning with an ATG codon at nucleotides 71-73 and ending with a TAG codon at nucleotides 1079-1081. Putative untranslated regions upstream
10 from the initiation codon and downstream from the termination codon are underlined in Table 5G, and the start and stop codons are in bold letters.

Table 5G. NOV5d Nucleotide Sequence (SEQ ID NO:27)
<u>CTCCAACAAGCATAGCGCGCCCGGACCGGCCCCCTTTCCCTCCCTCCCGTGCCGCTCTGCCGCGATG</u> CCCCCGCTGCGCCCGGGCCCGGCTCCGGCTTCTCGCCGCCCGCCCTGGCCGGCTTGCCCGTCATCAGCC GGGGGCTGCTCTCCAGAGGCTGGAGTTCAACTCTCTGCCGACAACACACAGTGTGTGAAGGTGACAACGC CACCTCAGCTGCTTATGACGAGCATGTGACCGCGTGGCTGGCTGAACCGCTCCAACATCTGTACGCC GGCAACGACCGCAGGACCGAGGACCGCGGGTGGCGCTGCTCATCAACACCCCGAGGAGTTCTCCATCCTCG TCACCGAGGTGGGGCTCGGCGACGAGGCGCTTACACCTGCTCTTCCAGACCCGCCACCGCCGTACACCAC TCAGTCTACCTCATTGTCCAGTCCCTGCCCGGTTGTGAACATCTCGTCGCTGTGATGGTGAATGAGGA GGTAATGTGAACCTGCTTTGCTTGGCGTGGGCGGCCAGAGCCACCGTCACCTGGAGACAGCTCCGAGACG GCTTACCTCGGAGGAGAGATCCTGGAGATCTTGACATCTCGGGGCCAGGCCGGGAGTATGAGTGGT GACTCACAACGGGGTTAACTCGGCGCCGACAGCCGCGCGTGTGGTCAAGTCAACTATCTCTCGACCATC ACGGACGTGACCAGCGCCCGCACCGCGCTGGGGCCGGGCCCTACTGCGTGGCAAGCCATGGCGGTTTCCC CCGCGGATTTCCAGTGGTATAAGGATGACAGACTACTGAGCAGCGGCCAGGCCGAGGGCTGAAGGTGCAGAT GGAGCGCACTCGCTCGATGCTTCTTTGCCAACATGAGCGCCCGGCATTACGGCAACTATACGTGTGCGCC GCCAACCGGCTGGGAGCGTCCAGCGCTCCATGCGGCTCCTGTGCCAGGATCCCTGGAGAACTCAGCCCCGA GGCCCCAGGGCCCTGGCCCTCTCTCCGCTGGGCTGGTGTGGTGGAGAATGTAGGCGCAACCCAGTGG AGCTCGCTCCCTCCCTGACGGGGCCCTCAGGCCAAGAGTGAGAGAAAAGGGGAGCAAGAGCCCTGGGTCTCGT G

The NOV5d nucleic acid was identified on chromosome 7 and has 257 of 389 bases (66%) identical to a *Homo sapiens* (clone pHOM) opioid-binding cell adhesion molecule
15 mRNA (gb:GENBANK-ID:HUMOBCAM|acc:L34774.1) ($E = 2.0e^{-46}$).

A disclosed NOV5d polypeptide (SEQ ID NO:28) encoded by SEQ ID NO:27 is 336 amino acid residues and is presented using the one-letter code in Table 5H. Signal P, Psort and/or Hydropathy results predict that NOV5d contains a signal peptide and is likely to be localized extracellularly with a certainty of 0.6329. The most likely cleavage site for a NOV5d
20 peptide is between amino acids 30 and 31, at: LLS-QR.

Table 5H. Encoded NOV5d protein sequence (SEQ ID NO:28)
MPPAAPGARLRLAAALAGLAVISRGLLSQRLEFNSPADNYTVEGDNATLSCFMDEHVTRVAWLNRSNIL YAGNDRRTRDPRVRLINTPEEFSILVTEVGLGDEGLYTCFQTRHQPYYTQVYLIVHVPARVVNISSPVMV NEGGNVNLLCLAVGRPEPTVTWRQLRDGFTSEGEILEISDILRGQAGEYECVTHNGVNSAPDSRRVLVTVNY PPTITDVTARSALTGPGRLLRCEAMAVSPADFQWKDDRLSSGTAEGLKVMERTRSMLLFANMSARHYGN YTCCAANRLGASSAMRLLCPGSLNSAPRPPGPLALLSALGWLWWRM

The NOV5d amino acid sequence has 160 of 327 amino acid residues (48%) identical to, and 218 of 327 amino acid residues (66%) similar to, a *Bos taurus* 345 amino acid residue opioid binding protein/cell adhesion molecule precursor (OBCAM) / opioid-binding cell adhesion molecule (OPCML) protein (ptnr:SWISSNEW-ACC:P11834) ($E = 1.5e^{-75}$).

- 5 NOV5d is expressed in at least the following tissues: Brain and Fetal brain. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, genomic clone sources, literature sources, and/or RACE sources. In addition, NOV5d is predicted to be expressed in occipital cortex tissues because of the expression pattern of a closely related
- 10 *Homo sapiens* (clone pHOM) opioid-binding cell adhesion molecule mRNA homolog (GENBANK-ID: gb:GENBANK-ID:HUMOBCAM|acc:L34774.1).

Possible small nucleotide polymorphisms (SNPs) found for NOV5c are listed in Table 5I.

Table 5I: SNPs			
Consensus Position	Depth	Base Change	PAF
141	25	C > T	0.080
190	32	A > G	0.062
205	38	C > T	0.053
246	84	G > A	0.429
280	88	T > C	0.023
335	94	C > G	0.043
360	94	A > G	0.255
385	94	C > T	0.277
398	100	G > A	0.270
401	100	C > T	0.270
433	99	G > A	0.020
463	100	T > C	0.020
514	100	A > T	0.300
575	94	C > T	0.043
619	62	G > T	0.032
620	62	A > C	0.032
665	58	G > A	0.190
670	58	A > C	0.362
695	57	C > T	0.368
719	55	T > C	0.400
734	55	G > A	0.400
755	47	A > G	0.234
772	43	C > T	0.302
782	41	C > T	0.293
807	35	G > A	0.286
840	24	C > T	0.167
854	20	A > G	0.150
888	19	C > T	0.158

NOV5a - NOV5d are very closely homologous as is shown in the amino acid alignment in Table 5J.

Table 5J Amino Acid Alignment of NOV5a and NOV5b

	10	20	30	40	50
NOV5a
NOV5b
NOV5c
NOV5d
	60	70	80	90	100
NOV5a
NOV5b
NOV5c
NOV5d
	110	120	130	140	150
NOV5a
NOV5b
NOV5c
NOV5d
	160	170	180	190	200
NOV5a
NOV5b
NOV5c
NOV5d
	210	220	230	240	250
NOV5a
NOV5b
NOV5c
NOV5d
	260	270	280	290	300
NOV5a
NOV5b
NOV5c
NOV5d
	310	320	330		
NOV5a		
NOV5b		
NOV5c		
NOV5d		

- 5 Homologies to any of the above NOV5 proteins will be shared by the other NOV5 proteins insofar as they are homologous to each other as shown above. Any reference to NOV5 is assumed to refer to both of the NOV5 proteins in general, unless otherwise noted.

NOV5a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 5K.

Table 5K. BLAST results for NOV5a

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect

gi 129173 sp P11834 OPCM_BOVIN	opioid binding protein/cell adhesion molecule precursor (OBCAM) (opioid-binding cell adhesion molecule) (OPCML) [Bos taurus]	345	164/302 (54%)	213/302 (70%)	3e-86
gi 4505505 ref NP_02536.1 (NM_002545)	opioid-binding cell adhesion molecule precursor; opiate binding-cell adhesion molecule [Homo sapiens]	345	162/302 (53%)	213/302 (69%)	2e-85
gi 1352640 sp P32736 OPCM_RAT	opioid binding protein/cell adhesion molecule precursor (OBCAM) (opioid-binding cell adhesion molecule) (OPCML) [Rattus norvegicus]	345	163/306 (53%)	213/306 (69%)	8e-85
gi 112102 pir JC1238	opioid-binding protein (clone DUZ1) [Rattus norvegicus]	338	163/306 (53%)	213/306 (69%)	1e-84
gi 3298456 dbj BAA31514.1 (AB011810)	CEPU-1 [Gallus gallus]	344	155/283 (54%)	199/283 (69%)	7e-81

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 5L.

Table 5L Clustal W Sequence Alignment

- 1) NOV5a (SEQ ID NO:22)
- 2) gi|129173|sp|P11834|OPCM_BOVIN opioid binding protein/cell adhesion molecule precursor (OBCAM) (opioid-binding cell adhesion molecule) (OPCML) [Bos taurus] (SEQ ID NO:83)
- 3) gi|4505505|ref|NP_002536.1|(NM_002545) opioid-binding cell adhesion molecule precursor; opiate binding-cell adhesion molecule [Homo sapiens] (SEQ ID NO:84)
- 4) gi|1352640|sp|P32736|OPCM_RAT opioid binding protein/cell adhesion molecule precursor (OBCAM) (opioid-binding cell adhesion molecule) (OPCML) [Rattus norvegicus] (SEQ ID NO:85)
- 5) gi|112102|pir|JC1238 opioid-binding protein (clone DUZ1) [Rattus norvegicus] (SEQ ID NO:86)
- 6) gi|3298456|dbj|BAA31514.1|(AB011810) CEPU-1 [Gallus gallus] (SEQ ID NO:87)

	10	20	30	40	50
NOV5a	LAGLAVTSRGELSS	..LENSPADNYTVCEG		
gi 129173	MGVCGSLFQPWKC	VVVSRLRLFLVPTGVPVRS	GDATFPKAMDNVTVRQG		
gi 4505505	MGVCGYFLFPWKCE	VVVSRLRLFLVPTGVPVRS	GDATFPKAMDNVTVRQG		
gi 1352640	MGVCGYFLFPWKCE	VVVSRLRLFLVPTGVPVRS	GDATFPKAMDNVTVRQG		
gi 112102	-----MYHPAYW	VFSATTALLFTF	GVPRVSGDATFPKAMDNVTVRQG		
gi 3298456	MGVGGCLALPWRC	VVLCRLRLFLVPTGVPVRS	GDATFPKAMDNVTVRQG		
	60	70	80	90	100
NOV5a	ESATLRCTIDRVTRVAWLNR	STILYAGNDKWSIDPRVRL	LNTPETQYSI		
gi 129173	ESATLRCTIDRVTRVAWLNR	STILYAGNDKWSIDPRVRL	LNTPETQYSI		
gi 4505505	ESATLRCTIDRVTRVAWLNR	STILYAGNDKWSIDPRVRL	LNTPETQYSI		
gi 1352640	ESATLRCTIDRVTRVAWLNR	STILYAGNDKWSIDPRVRL	LNTPETQYSI		
gi 112102	ESATLRCTIDRVTRVAWLNR	STILYAGNDKWSIDPRVRL	LNTPETQYSI		
gi 3298456	ESATLRCTIDRVTRVAWLNR	STILYAGNDKWSIDPRVRL	LNTPETQYSI		
	110	120	130	140	150
NOV5a	LTTEVGGGDEGLYTCS	FQTRHQPYPYTCVYLIV	HVEARLVNISSPVTVNEG		

gi 129173	MIQNVDVYDEGPYTCSVQTDNHPKTSRVHLIVQVPPQIMNISSDVTVNEG
gi 4505505	MIQNVDVYDEGPYTCSVQTDNHPKTSRVHLIVQVPPQIMNISSDITVNEG
gi 1352640	MIQNVDVYDEGPYTCSVQTDNHPKTSRVHLIVQVPPQIMNISSDITVNEI
gi 112102	MIQNVDVYDEGPYTCSVQTDNHPKTSRVHLIVQVPPQIMNISSDITVNEI
gi 3298456	QIHQVDVYDEGPYTCSVQTDNHPKTSRVHLIVQVSPKITEISSDITVNEG
	160 170 180 190 200
NOV5a	GVNLLCLAVGRPEPTVTWRQLR---DGFSTSEGEILEISDIQRGAGEY
gi 129173	SSVTLCLAVGRPEPTVTWRHLSVKEGQGFVSEDEYLEISDIKRDSGEY
gi 4505505	SSVTLCLAVGRPEPTVTWRHLSVKEGQGFVSEDEYLEISDIKRDSGEY
gi 1352640	SSVTLCLAVGRPEPTVTWRHLSVKEGQGFVSEDEYLEISDIKRDSGEY
gi 112102	SSVTLCLAVGRPEPTVTWRHLSVKEGQGFVSEDEYLEISDIKRDSGEY
gi 3298456	GVNSTCTATGRPEPTVTWRHLSVKEGQGFVSEDEYLEISDIKRDSGEY
	210 220 230 240 250
NOV5a	ECVTHNGVNSAPDSRRVLVTVNYPPYITDVTSEARTALGRTALLRCEAMAV
gi 129173	ECSALNDV-AAPDVRRVKITVNYPPYISKAKNTGVSVGQKGLSCEASAV
gi 4505505	ECSALNDV-AAPDVRRVKITVNYPPYISKAKNTGVSVGQKGLSCEASAV
gi 1352640	ECSALNDV-AAPDVRRVKITVNYPPYISKAKNTGVSVGQKGLSCEASAV
gi 112102	ECSALNDV-AAPDVRRVKITVNYPPYISKAKNTGVSVGQKGLSCEASAV
gi 3298456	ECSASNDV-AAPVVRRVKITVNYPPYISDAKSTGVVPGQKGLMCEASAV
	260 270 280 290 300
NOV5a	EPAEFQWYKEDRLSSCTAEGCLKVQTERTRSMLLFANVSARHYGNYTCRA
gi 129173	PMAEFQWYKEDTRLATG-LDGVRLENKGHISTLTFFNVSEKDYGNYTCA
gi 4505505	PMAEFQWYKEDTRLATG-LDGVRLENKGRMSTLTFFNVSEKDYGNYTCA
gi 1352640	PMAEFQWYKEDTRLATG-LDGVRLENKGRISTLTFFNVSEKDYGNYTCA
gi 112102	PMAEFQWYKEDTRLATG-LDGVRLENKGRISTLTFFNVSEKDYGNYTCA
gi 3298456	PSAEFQWYKEDKRLAEG-QKCLKVENKAFFSRILTFFNVSEKDYGNYTCA
	310 320 330 340
NOV5a	ANRLGASSASMYRLRPGSLLEN---SAPRPPGLALLS-ALGWLWWRM
gi 129173	TNKLGINASITLYGPGCAVIDGVNSASRALACWLSGTLFAHFFIKF
gi 4505505	TNKLGINASITLYGPGCAVIDGVNSASRALACWLSGTLFAHFFIKF
gi 1352640	TNKLGINASITLYGPGCAVIDGVNSASRALACWLSGTFFAHFFIKF
gi 112102	TNKLGINASITLYGPGCAVIDGVNSASRALACWLSGTFFAHFFIKF
gi 3298456	SNLGINASITLYGPGCAVHDGNSCAWRRGSCAWLLALPLAQLARQF

Tables 5M – 5R list the domain description from DOMAIN analysis results against NOV5a. This indicates that the NOV5a sequence has properties similar to those of other proteins known to contain these domains.

Table 5M Domain Analysis of NOV5a

gnl|Smart|smart00409, IG, Immunoglobulin (SEQ ID NO:88)
Length = 86 residues, 100.0% aligned
Score = 53.1 bits (126), Expect = 2e-08

5

NOV5a	122	SSPVTVNEG	GVNLLCLAVGRPEPTVTWRQ-----LRDGFSTSEGE-----ILEISDIQR	170
			+ + + ++	
00409	1	PPSVTVKEGESVTL	SCEASGNPPPTVTWYKQGGKLLAESGRFVSRSRGGNSTLTISNVTP	60
NOV5a	171	GQAGEYECVTHNGVNSAPDSRRVLVT	196	
			+ +	
00409	61	EDSGTYTCAATN	SSGSASSGTTTLTVL	86

Table 5N Domain Analysis of NOV5a

gnl|Smart|smart00409, IG, Immunoglobulin (SEQ ID NO:89)
Length = 86 residues, 87.2% aligned
Score = 49.3 bits (116), Expect = 3e-07

NOV5a	214	GRTALLRCEAMAVPPAD	FQWYKDDRLSSCTAEGCLKVQTERTRSMLLFANVSARHYGNYT	273
			+ + + + +	

00409 9 GESVTLSCESAGNPPPTVTWYKQGGKLLAES-GRFSVSRSGNSTLTISNVTPEDSGTYT 67
 NOV5a 274 CRAANRLGASSASMRL 289
 | | | | ++ | + |
 00409 68 CAATNSSGSASSGTTL 8

Table 5O Domain Analysis of NOV5a

gnl|Smart|smart00409, IG, Immunoglobulin (SEQ ID NO:90)
 Length = 86 residues, 97.7% aligned
 Score = 43.9 bits (102), Expect = 1e-05

NOV5a 24 NYTVCEGDNATLSCFIDEHVT-RVAWLNRNRSNILEYAGNDRWTS DPRVRL LINTPEEFSILI 82
 + | | | ++ | | | + | | + | ++ + ++ |
 00409 3 SVTVKEGESVTLSCESAGNPPPTVTWYKQGGKLLAESGRFSVS-----RSGNSTLTI 55
 NOV5a 83 TEVGLGDEGLYTCSFQTRHQPYTTQVYLIVH 113
 + | | | | ++ + + | |
 00409 56 SNVTPEDSGTYTCAATNSSGSASSGTTLTVL 86

5

Table 5P Domain Analysis of NOV5a

gnl|Smart|smart00408, IGc2, Immunoglobulin C-2 Type (SEQ ID NO:91)
 Length = 63 residues, 100.0% aligned
 Score = 51.6 bits (122), Expect = 7e-08

NOV5a 128 NEGGNVNLLCLAVGRPEPTVTWR----QLRDG-FTSEGEILEISDIQRGQAGEYECVTHN 182
 | | + | | | | | | + | | + + | | | ++ + | | | |
 00408 1 LEGESVTLTCLPASGDPVPNITWLKDGKPLPESRVVASGSTLTIKNVSLEDSGLYTCVARN 60
 NOV5a 183 GVN 185
 |
 00408 61 SVG 63

Table 5Q Domain Analysis of NOV5a

gnl|Smart|smart00408, IGc2, Immunoglobulin C-2 Type (SEQ ID NO:92)
 Length = 63 residues, 96.8% aligned
 Score = 50.8 bits (120), Expect = 1e-07

NOV5a 214 GRTALLRCEAMAVPPADFWYKDDRLLSSGTAEGLKVQTERTRSMLLFANVSARHYGNYT 273
 | + | | | | + | | + | + + | | | | | |
 00408 3 GESVTLTCLPASGDPVPNITWLKDGKPLPES-----RVVASGSTLTIKNVSLEDSGLYT 55
 NOV5a 274 CRAANRLG 281
 | | | + |
 00408 56 CVARN SVG 63

10

Table 5R Domain Analysis of NOV5a

gnl|Pfam|pfam00047, ig, Immunoglobulin domain. Members of the immunoglobulin superfamily are found in hundreds of proteins of different functions. Examples include antibodies, the giant muscle kinase titin and receptor tyrosine kinases. Immunoglobulin-like domains may be involved in protein-protein and protein-ligand interactions. The Pfam alignments do not include the first and last strand of the immunoglobulin-like domain. (SEQ ID NO:93)
 Length = 68 residues, 100.0% aligned
 Score = 35.0 bits (79), Expect = 0.007

NOV5a	214	GRTALLRCEAMAVPP-ADFQWKDDRLSSGTAEGLKVQTERTRSM----	LLFANVSARH	268
		+ + + + + + + ++ +		
00407	1	GESVTLTCSVSGYPDPPTVTWLRDGKEIELLGSSESERVSSGGRFSISSLSLTISSVTPED		60
NOV5a	269	YGNITCRA	276	
00407	61	SGTYTCVV	68	

Opioid-binding cell adhesion molecule (OBCAM), a neuron-specific protein, consists of three immunoglobulin (Ig)-like domains anchored to the membrane through a glycosylphosphatidylinositol (GPI)-tail. OBCAM has been presumed to play a role as a cell adhesion/recognition molecule, but its function has not been fully elucidated and may also play a role in early neuronal development (Hachisuka et al., Developmental expression of opioid-binding cell adhesion molecule (OBCAM) in rat brain. *J Brain Res Dev Brain Res* 122(2):183-91, 2000).

It has been previously reported that transfection of antisense OBCAM cDNA into NG108-15 neuroblastoma x glioma hybrid cells, which contain delta-opioid receptors, results in greatly reduced opioid binding (Ann et al., *J. Biol. Chem.* 267, 7921-7926, 1992) and more recently it has been reported that these cells show altered coupling between opioid receptors and G-proteins (Govitrapong et al., Transfection of NG108-15 cells with antisense opioid-binding cell adhesion molecule cDNA alters opioid receptor-G-protein interaction. *J Biol Chem* 268(24):18280-5, 1993).

Despite the recent cloning of mu, delta and kappa opioid receptors, a role in opioid receptor function for OBCAM is supported by several lines of evidence, including inhibition of opioid binding by opioid binding cell adhesion molecule antibodies, down-regulation of opioid binding cell adhesion molecule by chronic opioid agonist treatment of cultured NG108-15 cells, and reduction of opioid binding in NG108-15 cells by transfection of opioid binding cell adhesion molecule antisense cDNA (Kalyuzhny et al., An opioid binding protein is specifically down-regulated by chronic morphine treatment in dorsal root and trigeminal ganglia. *Neuroscience* 66(4):943-9, 1995).

The tissue distribution and brain localization of OBCAM was investigated in the adult rats. OBCAM was preferentially expressed in the central nervous system (CNS) and at a very low level in the spleen. Within the brain, OBCAM was distributed in almost all the gray matter, but little or no immunoreactive OBCAM was found in the white matter. Morphologically, the distribution pattern of OBCAM immunoreactivity was very similar to that of synaptophysin, suggesting a role in the synaptic machinery (Hachisuka et al., Localization of opioid-binding cell adhesion molecule (OBCAM) in adult rat brain. *J Neurosci* 19(2):842(2):482-6, 1999). Another study investigated the expression of two immunoglobulin

superfamily (IgSF) proteins, Kilon and OBCAM. This study demonstrated the specific expression of Kilon and OBCAM in the hypothalamic magnocellular neurons, particularly in dendrites, suggesting that they confer on magnocellular neurons the ability to rearrange dendritic connectivity (Miyata et al., Expression of the IgLON cell adhesion molecules Kilon and OBCAM in hypothalamic magnocellular neurons. 424(1):74-85, 2000).

The above defined information for NOV5 suggests that this NOV5 protein may function as a member of a Opioid Binding Cell Adhesion Molecule-like protein family. Therefore, the NOV5 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV5 compositions of the present invention will have efficacy for treatment of patients suffering from Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration. The NOV5 nucleic acid encoding Opioid Binding Cell Adhesion Molecule-like protein, and the Opioid Binding Cell Adhesion Molecule-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV6

NOV6 includes two novel triacylglycerol lipase-like proteins disclosed below. The disclosed proteins have been named NOV6a and NOV6b.

NOV6a

A disclosed NOV6a nucleic acid of 1377 nucleotides (also referred to as SC122982104_A) encoding a novel triacylglycerol lipase-like protein is shown in Table 6A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 91-93 and ending with a TAA codon at nucleotides 1243-1245. Putative untranslated regions upstream from the start codon and downstream from the termination codon are underlined in Table 6A, and the start and stop codons are in bold letters.

Table 6A. NOV6a Nucleotide Sequence (SEQ ID NO:29)

<p>CAGTTTATAAATGGTATTATTGCTGCAATTTAACTGTATAAACATCTCCCTTTATATATAGGTCCCAATGTGGTATC TTTTCACAATGATGTATTTATCCGAATTCCTGGAATTACTCATGGTGTCTTTCAAAATTATAGATCTGTGAAACCTGAAGC AGATATGAATATTAGCCAGATTATTCCTACTGGGGCTACCTGATGAAGAATATGATATTGTAACCGAAGATGGTTATATC CTTGGCCTTTATAGAATTCCTTATTGGAGGACAGACAATAATAAAAAATCTAGGTAATTCAGCTCAGAGGGTTGTGTATACT TGCAACATGGTTTGCTTACATCTGCCAGCAGCTGGATTTCGAATCTTCCCAACAATAGTCTGGGCTTCATTCTGGCAGATGC TGGTTATGATGTGTGGATGGGAAATAGCAGAGGAAATACCTGGTCCAGGAAACACTTGTACCTAGAAACGAGTCCAAAGAA TTCTGGGCTTTCAGGTACGCTCAAGGAGGCCTGCCTGCCTCTGTAGACTGCATCTTGGTGAAGAAGAGAGAGAGAAAAATA TATATCATTATATCTTTCATTCCCAAGTACATAGCCAGGGAACCTTAGGTTTCATAACATTTTCTACTATATCAAAGATAGC TGAAAGAATCAAAATATTTTGGCTTTAGCACCCCTCATCTCAGTCAAATATACCAAGTCAATTATTCTTAACTTACATAC</p>

AAATGGAAGTCAATAGGCAACAAAGACTTCTTGCCTAAAACCTCATTTAAAAAATTCATTGGTTCAAAGCTGTGTCCACTAC
 AGATTTTTTGATAAGATTTGCCTCAATATCTTGTATTATGATGTTTGGATATGACCCAAAAACTTAAATATGAGTCGTTTGA
 TGTGTATTTTTACACAACCCAGCAGGAACATCTGTTCAAAATATGCTTCATTGGAGTCAGGCTTATGACTGGGGCAGTCCT
 GATCTGAACCTTGGTTTATTATAATCAGACAACGCTCTCCATTATACAACATGACAAACATGAATGTGGCAACTGCAATTTGGA
 ATGGTAAAAGTGACTTGTGGCTGACCTGAAGACGTTAACATTTTACATTCTGAAATCACAACACATTATTATAAAAC
 TATTTCTTACTACAATCATATAGACTCTTGTGGATTAGATGTCTATGATCAAGTTTACCATGAAATCATGATATTATC
 CAAGACAATCTATAAAGAACCATGGCGCTGTGTGTTAAAGATCTACATCATTCCTAATGAAATCCAATTCCTATTTTTTT
 TACCTGTGTATGTTCTTTCATTTTAAAACTAAATATGTAGTTTCTCTATATTCTCATTGA

The NOV6a nucleic acid was identified on chromosome 10 and has 367 of 543 bases (67%) identical to a rabbit gastric lipase precursor coding sequence mRNA (gb:GENBANK-ID:A26689|acc:A26689.1) ($E = 9.1e^{-81}$).

- 5 A disclosed NOV6a polypeptide (SEQ ID NO:30) encoded by SEQ ID NO:29 is 390 amino acid residues and is presented using the one-letter code in Table 6B. Signal P, Psort and/or Hydropathy results predict that NOV6a contains a signal peptide and is likely to be localized in the microbody (peroxisome) with a certainty of 0.7480. The most likely cleavage site for a NOV6a peptide is between amino acids 19 and 20, at: THG-VF.

Table 6B. Encoded NOV6a protein sequence (SEQ ID NO:30)

MWYLFMMYFIRILGITHGVFQNYRSVKPEADMNISQII SYWGYDDEYDIVTEDGYILGLYRIPYWRDNNKLNLSAQR
 VVVYLQHGLLTSASSWISNLPNNSLGFIADAGYDVMGNSRGNTWSRKHLYLETSSKEFWAFRYAQGLPASVDCILVKK
 RGEKNIYHYIFHSQVHSQGTIGFITFSTISKIAERIKIFFALAPSSSVKYTKSII LKLTYSKWSIGNKDFLPKTSFKKFIG
 SKLCLPLQIFDKICLNILFMMFGYDPKNLNMRLDVYFSHNPAGTSVQNMHLWSQAYDWGSPDLNLVHYNQTTSPLYNMTNM
 NVATAIWNKSDLLADPEDVNILHSEITNHIYYKTISSYNHIDSLFGLDVYDQVYHEIIDIIQDNL

- 10 The NOV6a amino acid sequence has 218 of 396 amino acid residues (55%) identical to, and 288 of 396 amino acid residues (72%) similar to, a *Homo sapiens* 398 amino acid residue (triacylglycerol lipase, gastric precursor (ec 3.1.1.3) (gastric lipase) protein (ptnr:SWISSPROT-ACC:P07098) ($E = 8.0^{-114}$).

- 15 NOV6a is expressed in at least the following tissues: Whole Organism , fetal lung. This information was derived by determining the tissue sources of the sequences that were included in the invention. SeqCalling sources: Whole Organism, PublicEST sources: fetal lung NbHL19W, testis NHT, and B-cell, pooled germ cell. In addition, NOV6a is predicted to be expressed in the following tissues because of the expression pattern of a closely related precursor of rabbit gastric lipase coding sequence homolog in species synthetic construct (gb:GENBANK-ID:A26689|acc:A26689.1): lung, testis, tumors .
- 20

NOV6b

- A disclosed NOV6b nucleic acid of 1260 nucleotides (also referred to as CG58608-02) encoding a novel triacylglycerol lipase-like protein is shown in Table 6C. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 31-33 and ending with a TAA codon at nucleotides 1234-1236. Putative untranslated regions upstream from the
- 25

start codon and downstream from the termination codon are underlined in Table 6C, and the start and stop codons are in bold letters.

Table 6C. NOV6b Nucleotide Sequence (SEQ ID NO:31)

ATTAAATTTCTTTCCTAGGCAGATCCCAAATGTGGCAGCTTTTAGCAGCAGCATGCTGGATGCTTCTTCTGGATCTA
TGTATGGTTATGACAAGAAAGGAAACAATGCAACCCCTGAAGCTAATATGAATATTAGCCAGATTATTTCTACTGGGG
CTACCCTGATGAAGAATATGATATTGTAACCGAAGATGGTTATATCCTTGGCCTTTATAGAATTCCTTATGGAGGACA
GACAATAATAAAAAATCTAGGTAATTCAGCTCAGAGGGTTGTTGTATACTTGCAACATGGTTTGCTTACATCTGCCAGCA
GCTGGATTCCCAATCTTCCCAACAATAGTCTGGGCTTCATTCTGGCAGATGCTGGTTATGATGTGTGGATGGGAAATAG
CAGAGGAAATACCTGGTCCAGGAAACACTTGTACCTAGAACGAGTTCCAAAGAATTCCTGGGCTTCAGTTTGTATGAG
ATGGCAAAATATGACCTTCCAGCCTCTATTGATTCACTGTGAAGCAAACAGACAAGAGGAAATATTTATGTAGGCC
ATTACAGGGTACTACTATTGGTTTCATAACATTTTCTACTATATCAAAGATAGCTGAAAGAATCAAATATTTTGTGC
TTTAGCACCAGTTTTCACAAAGTACTTAAAGTCCCTTAATTAGAATGACATACAAATGGAAGTCAATAGTCATG
GCTTTTTCAGGCAACAAAGACTTCTTGCCTAAACCTCATTAAAAAATTCATTGGTTCAAAGCTGTGTCCACTACAGA
TTTTTGATAAGATTGCTCAATATCTTGTATGATGTTGGATATGACCCAAAAAATTAATATGAGTCGTTTGGGA
TGTGTATTTTTCACAAACCCAGCAGGAACATCTGTTCAAATATGCTTCATTGGAGTCAGCTTTAAATCTACTCAT
TTGAAAGCTTATGACTGGGGCAGTCTGATCTGAACCTGGTTTATTATAATCAGACAACGCTCCATTATACAACATGA
CAACATGAATGTGGCAACTGCAATTTGGAATGGTAAAGTGACTTGTGGCTGACCCTGAAGACGTTAATCATTTTACA
TTCTGAAATCACAACCAATTTATTATAAACTATTCTTACTACAATCATATAGACTCTTTGTTGGATTAGATGTC
TATGATCAAGTTTACCATGAAATCATTGATATTATCAAGACAATCTATAAAGAACCATTGGCGCTGTGTGTTAA

The NOV6b nucleic acid was identified on chromosome 1 and has 711 of 997 bases
(71%) identical to a *Homo sapiens* gastric lipase mRNA (gb:GENBANK-
ID:A01046|acc:A01046.1) ($E = 1.3e^{-117}$)

A disclosed NOV6b polypeptide (SEQ ID NO:32) encoded by SEQ ID NO:31 is 401
amino acid residues and is presented using the one-letter code in Table 6D. Signal P, Psort
and/or Hydropathy results predict that NOV6b contains a signal peptide and is likely to be
localized in the lysosome (lumen) with a certainty of 0.5078. The most likely cleavage site for
a NOV6b peptide is between amino acids 19 and 20, at: MYG-YD.

Table 6D. Encoded NOV6b protein sequence (SEQ ID NO:32).

MWQLLAACWMLLLGSMYGYDKKGNANPEANMNISQIISYWGYPDEEYDIVTEDGYILGLYRIPYWRDNNKNLGNLSAQRVVVY
LQHGLLTSSASSWISNLPNNSLGFIADAGYDVWGMNSRGNTWSRKHLYLETSSKEFWAFSFDMAKYDLPASIDFTVKQTRQEEI
FYVGHSGQTTIGFITFSTISKIAERIKIFFALAPVFSTKYLSPLIRMTYKWKSI VMAFSGNKDFLPKTSFKKFIGSKLCPQLIF
DKICLNILFMMFGYDPKNLNMRLDVYFSHNPAGTSVQNMLHWSQLLNSTHLKAYDWGSPDLNLVHYNQTTSPLYNMNTNMNVATA
IWNKSDLLADPEDVNILHSEITNHIYYKTISYNNHIDSLFGLDVYDQVYHEIIDIQDNL

The NOV6b amino acid sequence has 224 of 400 amino acid residues (56%) identical
to, and 298 of 400 amino acid residues (74%) similar to, a *Homo sapiens* 398 amino acid
residue (triacylglycerol lipase, gastric precursor (EC 3.1.1.3) (gastric lipase) protein
(ptnr:SWISSPROT-ACC:P07098) ($E = 3.5e^{-124}$).

NOV6b is expressed in at least the following tissues: Mammalian Tissue. This
information was derived by determining the tissue sources of the sequences that were included
in the invention including but not limited to SeqCalling sources, Public EST sources,
Literature sources, and/or RACE sources.

Possible small nucleotide polymorphisms (SNPs) found for NOV6a are listed in Table
6E.

Table 6E: SNPs

Variant	Neucleotide Position	Base Change	Amino Acid Position	Base Change
13375771	629	T > C	186	Ile > Tyr

NOV6a and NOV6b are very closely homologous as is shown in the amino acid alignment in Table 6F.

Table 6F Amino Acid Alignment of NOV6a and NOV6b

	10	20	30	40	50
NOV6a	MWYLF	TMMYF	IRRLG	ITIGV	FONYR
NOV6b	MWQLL	AAACW	MLLGL	SMYGY	DKGNNA
	60	70	80	90	100
NOV6a	IVTEDG	YILGL	YRIPY	WRDNN	KNLGN
NOV6b	IVTEDG	YILGL	YRIPY	WRDNN	KNLGN
	110	120	130	140	150
NOV6a	LPNNSL	GFILAD	AGYDV	WMGNS	RGNTWS
NOV6b	LPNNSL	GFILAD	AGYDV	WMGNS	RGNTWS
	160	170	180	190	200
NOV6a	QGGLPA	SVVDC	IVKKR	CEKNY	IHYHIF
NOV6b	XYDLPAS	IDEFTV	KKTRCE	EE-----	IFVVG-
	210	220	230	240	250
NOV6a	RIKIFF	FALAP	SSSVK	YTKSI	MLKTY
NOV6b	RIKIFF	FALAP	SSSVK	YTKSI	MLKTY
	260	270	280	290	300
NOV6a	IGSKLC	PQLQI	FDKIC	LNILF	MMFGY
NOV6b	IGSKLC	PQLQI	FDKIC	LNILF	MMFGY
	310	320	330	340	350
NOV6a	MLHWSQ	-----	AYDWG	SPDLN	LVHYN
NOV6b	MLHWSQ	LLNSTH	LKAYD	WGSPDL	NLVHYN
	360	370	380	390	400
NOV6a	KSDLLA	DPEDVN	ILHSEI	TNHIY	YKTI
NOV6b	KSDLLA	DPEDVN	ILHSEI	TNHIY	YKTI
	410	420	430	440	450
NOV6a	DI IQDN	L-----			
NOV6b	DI IQDN	L-----			

- 5 Homologies to any of the above NOV6 proteins will be shared by the other NOV6 proteins insofar as they are homologous to each other as shown above. Any reference to NOV6 is assumed to refer to both of the NOV6 proteins in general, unless otherwise noted.

NOV6a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 6G.

Table 6G. BLAST results for NOV6a

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 4758676 ref NP_04181.1 (NM_004190)	lipase, gastric [Homo sapiens]	398	218/405 (53%)	288/405 (70%)	1e-117
gi 758064 emb CAA29414.1 (X05997)	gastric lipase precursor [Homo sapiens]	392	214/399 (53%)	284/399 (70%)	1e-114
gi 3041702 sp P80035 LIPG CANFA	triacylglycerol lipase, gastric precursor (gastric lipase) (GL) [Canis familiaris]	398	216/402 (53%)	285/402 (70%)	1e-113
gi 7546565 pdb 1HLG A	Chain A, Crystal Structure Of Human Gastric Lipase	371	/377 (54%)	274/377 (72%)	1e-109
gi 8394193 ref NP_059037.1 (NM_017341)	lingual lipase [Rattus norvegicus]	395	203/405 (50%)	290/405 (71%)	1e-107

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 6H.

Table 6H Information for the ClustalW proteins

- 1) NOV6a (SEQ ID NO:30)
- 2) gi|4758676|ref|NP_004181.1| (NM_004190) lipase, gastric [Homo sapiens] (SEQ ID NO:94)
- 3) gi|758064|emb|CAA29414.1| (X05997) gastric lipase precursor [Homo sapiens] (SEQ ID NO:95)
- 4) gi|3041702|sp|P80035|LIPG CANFA triacylglycerol lipase, gastric precursor (gastric lipase) (GL) [Canis familiaris] (SEQ ID NO:96)
- 5) gi|7546565|pdb|1HLG|A Chain A, Crystal Structure Of Human Gastric Lipase (SEQ ID NO:97)
- 6) gi|8394193|ref|NP_059037.1| (NM_017341) lingual lipase [Rattus norvegicus] (SEQ ID NO:98)

	10	20	30	40	50
NOV6a
gi 4758676	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE
gi 758064	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE
gi 3041702	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE
gi 7546565	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE
gi 8394193	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE	MWVLFPTMMYFIRILGITHGVFQNYRSVKPEADMNISQHLISYWGYPPEEYE
	60	70	80	90	100
NOV6a
gi 4758676	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN
gi 758064	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN
gi 3041702	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN
gi 7546565	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN
gi 8394193	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN	VVTEDGYILGVRIPIYGRDNNKNGNSAQFVVVYLOHGLLTSASSWISN
	110	120	130	140	150
NOV6a
gi 4758676	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA
gi 758064	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA
gi 3041702	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA
gi 7546565	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA
gi 8394193	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA	LPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMA
	160	170	180	190	200
NOV6a
gi 4758676	QGGLPASVDCIVKKRGKKNIIHYHIFHSQVHSQC-TEGFIIFSTISKMAE	QGGLPASVDCIVKKRGKKNIIHYHIFHSQVHSQC-TEGFIIFSTISKMAE	QGGLPASVDCIVKKRGKKNIIHYHIFHSQVHSQC-TEGFIIFSTISKMAE	QGGLPASVDCIVKKRGKKNIIHYHIFHSQVHSQC-TEGFIIFSTISKMAE	QGGLPASVDCIVKKRGKKNIIHYHIFHSQVHSQC-TEGFIIFSTISKMAE
gi 758064	KYDLPATIDFIVKKTGOKO-----HYVGH-SQGTITGFIASFSTNPSLAK	KYDLPATIDFIVKKTGOKO-----HYVGH-SQGTITGFIASFSTNPSLAK	KYDLPATIDFIVKKTGOKO-----HYVGH-SQGTITGFIASFSTNPSLAK	KYDLPATIDFIVKKTGOKO-----HYVGH-SQGTITGFIASFSTNPSLAK	KYDLPATIDFIVKKTGOKO-----HYVGH-SQGTITGFIASFSTNPSLAK

```

gi|3041702| KYDLPATIDFIIKKTGDK-----LHYVG-HSQGTTIGFIAFSTNPKLAK
gi|7546565| KYDLPATIDFIVKKTGQKQ-----LHYVG-HSQGTTIGFIAFSTNPSLAK
gi|8394193| KYDLPATINFIIVKKTGQEK-----LHYVG-HSQGTTIGFIAFSTNPTLAK

      210      220      230      240      250
NOV6a      RIKTFYALAPSSSVKYTKSITLKLTVKWKST-----CNKDFLEKTSFKKRF
gi|4758676| RIKTFYALAPVATVKYTKSLINKLREVPSLKFETFGDKIIFYPHNEFDQF
gi|758064|  RIKTFYALAPVATVKYTKSLINKLREVPSLKFETFGDKIIFYPHNEFDQF
gi|3041702| RIKTFYALAPVATVKYTEILINKLMLVPSLFLKLFQNKIIFYPHNEFDQF
gi|7546565| RIKTFYALAPVATVKYTKSLINKLREVPSLKFETFGDKIIFYPHNEFDQF
gi|8394193| RIKTFYALAPVATVKYTSPLKKTSTETFTFLFKLMFGKKMLPHTYFDQF

      260      270      280      290      300
NOV6a      LGSKLCPLDIFDKICLNILFMMFCGYDPKNNMSRLDVYFSHNPAGTSVQN
gi|4758676| LATEVCSREMLLLCSNALFIICGFDSKNPNTSRLDVYLSHNPAGTSVQN
gi|758064|  LATEVCSREMLLLCSNALFIICGFDSKNPNTSRLDVYLSHNPAGTSVQN
gi|3041702| LATEVCSREITVLLCSNALFIICGFDTMNNMSRLDVYLSHNPAGTSVQN
gi|7546565| LATEVCSREMLLLCSNALFIICGFDSKNPNTSRLDVYLSHNPAGTSVQN
gi|8394193| LATEVCSREMLLLCSNLTFLICGFDSKNPNTSRLDVYLSHNPAGTSVQN

      310      320      330      340      350
NOV6a      MLHWSQ-----AYDWGSPDLNLVHYNORTSFLYNYTMMNVATAIHWNG
gi|4758676| MFHWTCQAVKSGKFQAYDWGSPVQNRMHYDOSQPPYYNYTMMNVPIAVWNG
gi|758064|  MFHWTCQAVKSGKFQAYDWGSPVQNRMHYDOSQPPYYNYTMMNVPIAVWNG
gi|3041702| MLHWSQAVKSGKFQAYDWGSPVQNMHYHOSMPYYNYTDMVPIAVWNG
gi|7546565| MFHWTCQAVKSGKFQAYDWGSPVQNRMHYDOSQPPYYNYTMMNVPIAVWNG
gi|8394193| FLHWACLVRSKGKFOAENWGSESONMEHYNOKTPPEYDVSAMTVPIAVWNG

      360      370      380      390      400
NOV6a      KSDLLADPQDVNLLHSEITNHIYKRTISVYNHIDSEKGLDYDQVYHEIT
gi|4758676| GKOLLADPQDVGLLIPKLENLIYHKETIPYNHLDFIWAMDAPOEVYNDIV
gi|758064|  GKOLLADPQDVGLLIPKLENLIYHKETIPYNHLDFIWAMDAPOEVYNDIV
gi|3041702| GNDLLADPHVDVLLSKLENLIYHKKETIPPYNHLDFIWAMDAPOAVYNBIV
gi|7546565| GKOLLADPQDVGLLIPKLENLIYHKETIPYNHLDFIWAMDAPOEVYNDIV
gi|8394193| GNDLLADPQDVAMLLIPKLENLIYHKKETILAYNHLDFIWAMDAPOEVYNEMH

      . . . . .
NOV6a      DFIQDNL-
gi|4758676| SMISEDKK
gi|758064|  SMISEDKK
gi|3041702| SMIGTDNK
gi|7546565| SMISEDKK
gi|8394193| SMIAED--

```

The hydrolysis of triglycerides under influence of lipoprotein lipase is among the first recognised and well defined processes in postprandial lipid metabolism. More recently, also hepatic lipase has been implicated in the clearing of postprandial lipoproteins. Lipoprotein lipase as well as hepatic lipase are also involved in the metabolism of several other lipoproteins. However, their capacity is limited. This may lead to interaction of different metabolic processes and competition for the available lipase by different lipoproteins. Indeed, it is generally accepted that the exaggerated postprandial response in subjects with hypertriglyceridemia is at least partially due to competition between endogenous (VLDL) and exogenous (chylomicrons) lipoproteins. Similar mechanisms may also take place in the liver where hepatic lipase plays a role in the metabolism of several lipoproteins (Jansen et al., Role of lipoprotein lipases in postprandial lipid metabolism. *Atherosclerosis* 141 Suppl 1:S31-4, 1998).

Hepatic lipase (HL) is an enzyme that is made primarily by hepatocytes (and also found in adrenal gland and ovary) and hydrolyzes phospholipids and triglycerides of plasma lipoproteins. It is secreted and bound to the hepatocyte surface and readily released by heparin. It is a member of the lipase superfamily and is homologous to lipoprotein lipase and pancreatic lipase. The enzyme can be divided into an NH₂-terminal domain containing the catalytic site joined by a short spanning region to a smaller COOH-terminal domain. The NH₂-terminal portion contains an active site serine in a pentapeptide consensus sequence, Gly-Xaa-Ser-Xaa-Gly, as part of a classic Ser-Asp-His catalytic triad, and a putative hinged loop structure covering the active site. The COOH-terminal domain contains a putative lipoprotein-binding site. The heparin-binding sites may be distributed throughout the molecule, with the characteristic elution pattern from heparin-sepharose determined by the COOH-terminal domain. Of the three N-linked glycosylation sites, Asn-56 is required for efficient secretion and enzymatic activity. HL is hypothesized to directly couple HDL lipid metabolism to tissue/cellular lipid metabolism. The potential significance of the HL pathway is that it provides the hepatocyte with a mechanism for the uptake of a subset of phospholipids enriched in unsaturated fatty acids and may allow the uptake of cholesteryl ester, free cholesterol, and phospholipid without catabolism of HDL apolipoproteins. HL can hydrolyze triglyceride and phospholipid in all lipoproteins, but is predominant in the conversion of intermediate density lipoproteins to LDL and the conversion of post-prandial triglyceride-rich HDL into the postabsorptive triglyceride-poor HDL. HL plays a secondary role in the clearance of chylomicron remnants by the liver. A rare family with HL deficiency has been described. Affected patients are compound heterozygotes for a mutation of Ser267 to Phe that results in an inactive enzyme and a mutation of Thr383 to Met that results in impaired secretion and reduced specific activity. Human HL deficiency in the context of a second factor causing hyperlipidemia is strongly associated with premature coronary artery disease (Connelly and Hegele, Hepatic lipase deficiency. Crit Rev Clin Lab Sci 35(6):547-72, 1998).

The above defined information for NOV6 suggests that NOV6 may function as a member of a triacylglycerol lipase family. Therefore, the NOV6 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV6 compositions of the present invention will have efficacy for treatment of patients suffering from Adrenoleukodystrophy, Congenital Adrenal Hyperplasia, Diabetes, Von Hippel-Lindau (VHL) syndrome, Pancreatitis, Obesity, Endometriosis, Xerostomia, Scleroderma, Hypercalcaemia, Ulcers Von Hippel-Lindau (VHL) syndrome, Cirrhosis, Transplantation, Inflammatory bowel

disease, Diverticular disease, Hirschsprung's disease , Crohn's Disease, Appendicitis, Hypercalcaemia, Arthritis, Ankylosing spondylitis, Arthritis, Tendinitis on Hippel-Lindau (VHL) syndrome , Alzheimer's disease, Stroke, Tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Endocrine dysfunctions, Diabetes, Growth and reproductive disorders, Multiple sclerosis, Leukodystrophies, Pain, Myasthenia gravis, Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, ARDS, Psoriasis, Actinic keratosis ,Tuberous sclerosis, Acne, Hair growth, alopecia, pigmentation disorders, endocrine disorders Diabetes, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, erythematosis, Renal tubular acidosis, IgA nephropathy, Hypercalcaemia, Lesch-Nyhan syndrome. The NOV6 nucleic acid encoding triacylglycerol lipase-like protein, and the triacylglycerol lipase-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV7

NOV7 includes two novel IGE receptor beta subunit-like proteins disclosed below. The disclosed proteins have been named NOV7a and NOV7b.

NOV7a

A disclosed NOV7a nucleic acid of 691 nucleotides (also referred to SC126624027_A) encoding a novel IGE receptor beta subunit-like protein is shown in Table 7A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 52-54 and ending with a TGA codon at nucleotides 652-654. Putative untranslated regions are found upstream from the initiation codon and downstream from the termination codon in Table 7A, and the start and stop codons are in bold letters.

Table 7A. NOV7a Nucleotide Sequence (SEQ ID NO:33)	
GACTGAAGTACCAACTAAGTCATCTCCTTTCAAATTATCACCGACACCATCAT	TGGATTCAAGCACCGCACACAGTCCGGT
GTTTCTGGTATTTCTCCAGAAATCACTGCTTCAGAATATGAGTCCACAGAACTTTCAGCCACGACCTTTTCAACTCAAA	
GCCCCTTGCAAAAATTATTTGCTAGAAAAATGAAAATCTTAGGGACTATCCAGATCCTGTTTGGAAATTATGACCTTTTCT	
TTTGAGTATATCTTCTTTTCACTTTGTGTTAAACCATATCCAAGGTTCCCTTTATATTTCTTTTCAGGATATCCATTCTG	
GGGCTCTGTTTGTTCATTAATTCTGGAGCCTTCTAATTCAGTGAAAAGAAAAACACAGAACTCTGATAAATATTGA	
GCCGAATAATGAATTTTCTTAGTGCCCTGGGAGCAATAGCTGGAATCATTTCTCCTCACATTGGTTTCATCCTAGATCAA	
AACTACATTGTGGTTATTCTACCAAAATAGTCAGTGTAAGGCTGTTACTGTCCTGTTCTTGGGAATTTTGATTACATT	
GATGACTTTCAGCATTATTGAATTATTCATTTCTCTGCCTTTCTCAATTTTGGGGTGCCACTCAGAGGATTGTGATTGTG	
AACAATGTTGT GACTAGCACTGTGAGAATAAAGATGTGTTAAATAAAAA	

The disclosed NOV7a nucleic acid sequence, localized to chromosome 15, has 325 of 560 bases (58%) identical to a *Mus musculus* mast cell high affinity IgE receptor (Fc-epsilon-RI) beta subunit mRNA (gb:GENBANK-ID:MUSFCERB|acc:J05019.1) ($E = 2.2e^{-05}$).

A disclosed NOV7a polypeptide (SEQ ID NO:34) encoded by SEQ ID NO:33 is 200 amino acid residues and is presented using the one-letter amino acid code in Table 7B. Signal P, Psort and/or Hydropathy results predict that NOV7a contains a signal peptide and is likely to be localized in the plasma membrane with a certainty of 0.6000. The most likely cleavage site for a NOV7a peptide is between amino acids 20 and 21, at: ITA-SE.

Table 7B. Encoded NOV7a protein sequence (SEQ ID NO:34).

MDSSTAHSPPVFLVFPPEITASEYESTELSATTFTSQSPLQKLFARKMKILGTIQILFGIMTFSGVIFLFTLLKPYPRFP
FIPLSGYPFWGSVLFINSAGFLIAVKRKTETLIILSRIMNFLSALGAIAIGIILLTFGFILDQNYICGYSHQNSQCKAVT
VLFLGILITLMTFSIIELFISLPFSILGCHSEDCDCQECC

The NOV7a amino acid sequence has 52 of 184 amino acid residues (28%) identical to, and 88 of 184 amino acid residues (47%) similar to the *Homo Sapiens* 214 amino acid residue IGE receptor beta subunit protein (ptnr:REMTREMBI.-ACC:AAA62319) (E = 2.9e⁻¹³).

NOV7a is expressed in at least the following tissues: Testis Whole Organism Male Reproductive System; SeqCalling_celltypes: testis liver spleen parathyroid_tumor. This information was derived by determining the tissue sources of the sequences that were included in the invention. SeqCalling sources: Testis Whole Organism Male Reproductive System, PublicEST sources: testis liver spleen parathyroid_tumor. In addition, NOV7a is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Mus musculus* mast cell high affinity IgE receptor (Fc-epsilon-RI) beta subunit homolog mRNA (GENBANK-ID: gb:GENBANK-ID:MUSFCERB |acc:J05019.1): Whole Organism Male Reproductive System.

NOV7b

A disclosed NOV7b nucleic acid of 500 nucleotides (also referred to CG55760-02) encoding a novel IGE receptor beta subunit-like protein is shown in Table 7C. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 26-28 and ending with a TGA codon at nucleotides 473-475. Putative untranslated regions are found upstream from the initiation codon and downstream from the termination codon in Table 7C, and the start and stop codons are in bold letters.

Table 7C. NOV7b Nucleotide Sequence (SEQ ID NO:35)

CTTTCAAATTATCACCACACCATCATGGATTCAAGCACCCGACACAGTCCGGTGTCTGGTATTTCTCCAGAAATCA
CTGCTTCAGAAATATGAGTCCACAGAACTTTCAGCCACGACCTTTCAACTCAAAGCCCCTGCAAAAATTATTGCTAGA
AAAATGAAATCTTAGGGACTATCCAGATCCTGTTTGAATTATGACCTTTCTTTGGAGTTATCTTCCTTTTCACCTT
GTTAAACCATATCCAAGGTTCCCTTTATATTCTTTCAGGATATCCATTCTGGGGCTCTGTTTGTTCATTAATCTG
GAGCCTTCCTAATGTCAGTGAAGAAAAACACAGAACTCTGGGAATTTGATTACATTGATGACTTTCAGCATTATT
GAATTATTCAATTTCTGTCTTTCTCAATTTTGGGGTGCCACTCAGAGGATTGTGATTGTGAACAATGTTGTGACTAGC
ACTGTGAGAATAAAGATGTG

100151520

The disclosed NOV7b nucleic acid sequence, localized to chromosome 15, has 167 of 269 bases (62%) identical to a *Mus musculus* mast cell high affinity IgE receptor (Fc-epsilon-RI) beta subunit mRNA (gb:GENBANK-ID:MUSFCERB|acc:J05019.1) (E = 0.0023).

A disclosed NOV7b polypeptide (SEQ ID NO:36) encoded by SEQ ID NO:35 is 149 amino acid residues and is presented using the one-letter amino acid code in Table 7D. Signal P, Psort and/or Hydropathy results predict that NOV7b contains a signal peptide and is likely to be localized in the plasma membrane with a certainty of 0.6000. The most likely cleavage site for a NOV7b peptide is between amino acids 20 and 21, at: ITA-SE.

Table 7D. Encoded NOV7b protein sequence (SEQ ID NO:36).	
MDSSTAHS	PVFLVFPPEITASEYESTELSATTFTSQSPLQKLFARKMKILGTIQILFGIMTFSFGVIFLFTLLKPYPRFP
FIFLSGY	PFWGSVLFINSGAFLIAVKRKTETELGILITLMTFSIIELFISLSFSILGCHSEDCDCEQCC

The NOV7b amino acid sequence has 117 of 122 amino acid residues (95%) identical to, and 118 of 122 amino acid residues (96%) similar to the *Homo Sapiens* 200 amino acid residue MS4A5 protein (ptrn:TREMBLNEW-ACC:BAB18739) (E = 5.7e⁻⁵⁷).

NOV7b is expressed in at least the following tissues: testis. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.

Possible small nucleotide polymorphisms (SNPs) found for NOV7a are listed in Table 7E.

Table 7E: SNPs				
Variant	Nucleotide Position	Base Change	Amino Acid Position	Base Change
13374029	162	C > T	N/A	Silent
13374028	468	C > T	N/A	Silent

NOV7a and NOV7b are very closely homologous as is shown in the amino acid alignment in Table 7F.

Table 7F Amino Acid Alignment of NOV7a and NOV7b

	10	20	30	40	50
NOV7a	MDSSTAHS	PVFLVFPPEITASEYESTELSATTFTSQSPLQKLFARKMKIL		
NOV7b	MDSSTAHS	PVFLVFPPEITASEYESTELSATTFTSQSPLQKLFARKMKIL		
	60	70	80	90	100
NOV7a	GTIQILFGIMTFSFGVIFLFTLLKPYPRFPFIFLSGY	PFWGSVLFINS		
NOV7b	GTIQILFGIMTFSFGVIFLFTLLKPYPRFPFIFLSGY	PFWGSVLFINS		
	110	120	130	140	150
				

NOV7a
NOV7b

FLIAVKRKTETLIILSRIMNFLSALGAIAGIILLTFGFILDQNYICGYS
FLIAVKRKTET-----

160 170 180 190 200

NOV7a
NOV7b

HQNSQCKAVTVLFLGILITLMTFSIIELFISLPFSILGCHSEDCDCCEQCC
-----LGILITLMTFSIIELFISLSFSILGCHSEDCDCCEQCC

Homologies to any of the above NOV7 proteins will be shared by the other NOV7 proteins insofar as they are homologous to each other as shown above. Any reference to NOV7 is assumed to refer to both of the NOV7 proteins in general, unless otherwise noted.

- 5 NOV7a also has homology to the amino acid sequence shown in the BLASTP data listed in Table 7G.

Table 7G. BLAST results for NOV7a					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 13647408 ref XP_015541.1 (XM_015541)	hypothetical protein XP_015541 [Homo sapiens]	200	200/200 (100%)	200/200 (100%)	3e-92
gi 12965205 ref NP_076434.1 (NM_023945)	testis-expressed transmembrane-4 protein [Homo sapiens]	200	199/200 (99%)	199/200 (99%)	4e-92
gi 16184634 ref XP_043510.2 (XM_043510)	hypothetical protein XP_043510 [Homo sapiens]	239	47/152 (30%)	77/152 (49%)	9e-13
gi 14517598 dbj BAB61018.1 (AB022821)	similar to Fc epsilon receptor beta subunit [Homo sapiens]	239	47/152 (30%)	77/152 (49%)	1e-12
gi 16184624 ref XP_015539.3 (XM_015539)	hypothetical protein XP_015539 [Homo sapiens]	220	47/152 (30%)	77/152 (49%)	1e-12

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 7H.

Table 7H. Information for the ClustalW proteins

- 1) NOV7a (SEQ ID NO:34)
- 2) gi|13647408|ref|XP_015541.1| (XM_015541) hypothetical protein XP_015541 [Homo sapiens] (SEQ ID NO:99)
- 3) gi|12965205|ref|NP_076434.1| (NM_023945) testis-expressed transmembrane-4 protein [Homo sapiens] (SEQ ID NO:100)
- 4) gi|16184634|ref|XP_043510.2| (XM_043510) hypothetical protein XP_043510 [Homo sapiens] (SEQ ID NO:101)
- 5) gi|14517598|dbj|BAB61018.1| (AB022821) similar to Fc epsilon receptor beta subunit [Homo sapiens] (SEQ ID NO:102)
- 6) gi|16184624|ref|XP_015539.3| (XM_015539) hypothetical protein XP_015539 [Homo sapiens] (SEQ ID NO:103)

10 20 30 40 50

NOV7a
gi|13647408|
gi|12965205|
gi|16184634|
gi|14517598|

-----MDSSTAHSVPVFLVFPPEITASEYESTELSATTFS
-----MDSSTAHSVPVFLVFPPEITASEYESTELSATTFS
-----MDSSTAHSVPVFLVFPPEITASEYESTELSATTFS
MHQTYSRHCRPEESTFSAAMITMQCMEQAMPGAGPGVPQLGNMAVIHSHL
MHQTYSRHCRPEESTFSAAMITMQCMEQAMPGAGPGVPQLGNMAVIHSHL

```

gi|16184624| -----M1TMQGM2EQAMP3GAGPGVPQLGNMAVIH4SHL
          60       70       80       90      100
NOV7a      TQSPLOKLFARKMKILGTIQILFGIMTFSFGVIFLFTLLKPYRPFPIFL
gi|13647408| TQSPLOKLFARKMKILGTIQILFGIMTFSFGVIFLFTLLKPYRPFPIFL
gi|12965205| TQSPLOKLFARKMKILGTIQILFGIMTFSFGVIFLFTLLKPYRPFPIFL
gi|16184634| WKGLQEKFLKGE5PKVLGVVQILTA6MSLSMGIT7TMMCMASNTYGSNEISVY
gi|14517598| WKGLQEKFLKGE5PKVLGVVQILTA6MSLSMGIT7TMMCMASNTYGSNEISVY
gi|16184624| WKGLQEKFLKGE5PKVLGVVQILTA6MSLSMGIT7TMMCMASNTYGSNEISVY

          110      120      130      140      150
NOV7a      SGYPFWGSVLFINS8GAF9LI10AVKRKT11TETL12ILSRIMN13FLSALGATAGI14IL
gi|13647408| SGYPFWGSVLFINS8GAF9LI10AVKRKT11TETL12ILSRIMN13FLSALGATAGI14IL
gi|12965205| SGYPFWGSVLFINS8GAF9LI10AVKRKT11TETL12ILSRIMN13FLSALGATAGI14IL
gi|16184634| IGYTIWGSV15VFIT16SGSL17SLIAAGIR18TTKGL19MRGSLGMNITSSVLAASGILI20
gi|14517598| IGYTIWGSV15VFIT16SGSL17SLIAAGIR18TTKGL19MRGSLGMNITSSVLAASGILI20
gi|16184624| IGYTIWGSV15VFIT16SGSL17SLIAAGIR18TTKGL19MRGSLGMNITSSVLAASGILI20

          160      170      180      190      200
NOV7a      LTFGFILD--QNYICG21YSHONS22OCKAVTV23FLGILITLMTFSI24IELFISL
gi|13647408| LTFGFILD--QNYICG21YSHONS22OCKAVTV23FLGILITLMTFSI24IELFISL
gi|12965205| LTFGFILD--QNYICG21YSHONS22OCKAVTV23FLGILITLMTFSI24IELFISL
gi|16184634| NTFSLAFYSFHH25PYCN26YGN27SNNCHGTMS28ILM29CHDGMVLLSVLEFRI30AV
gi|14517598| NTFSLAFYSFHH25PYCN26YGN27SNNCHGTMS28ILM29CHDGMVLLSVLEFRI30AV
gi|16184624| NTFSLAFYSFHH25PYCN26YGN27SNNCHGTMS28ILM29CHDGMVLLSVLEFRI30AV

          210      220      230
NOV7a      PFSILGCHSEDCDCEQCC-----
gi|13647408| PFSILGCHSEDCDCEQCC-----
gi|12965205| PFSILGCHSEDCDCEQCC-----
gi|16184634| SL31SAFGCKVLCCT32PGGVVLI33LPSHSHMAETASPTPLNEV
gi|14517598| SL31SAFGCKVLCCT32PGGVVLI33LPSHSHMAETASPTPLNEV
gi|16184624| SL31SAFGCKVLCCT32PGGVVLI33LPSHSHMAETASPTPLNEV

```

The IgE receptor plays a central role in allergic disease, coupling allergen and mast cell to initiate the inflammatory and immediate hypersensitivity responses that are characteristic of disorders such as hay fever and asthma. The allergic response occurs when 2 or more high-affinity IgE receptors are crosslinked via IgE molecules that in turn are bound to an allergen (antigen) molecule. A perturbation occurs that brings about the release of histamine and proteases from the granules in the cytoplasm of the mast cell and leads to the synthesis of prostaglandins and leukotrienes--potent effectors of the hypersensitivity response. The IgE receptor consists of 3 subunits: alpha, beta (147138), and gamma (147139); only the alpha subunit is glycosylated. Shimizu et al. (1988) cloned and sequenced cDNAs for the rat and human alpha subunits of high-affinity IgE receptor. Both encode an NH2-terminal signal peptide, 2 immunoglobulin-like extracellular domains (encoded by discrete exons), a hydrophobic transmembrane region, and a positively charged cytoplasmic tail. The human and rat alpha subunits share similarities with each other and with the immunoglobulin gene family, suggesting origin from a common ancestral gene, and share structural homology with their ligands. Liu et al. (1988) used a synthetic oligonucleotide homologous to the amino-terminal sequence of the alpha subunit to screen a cDNA library from a rat basophilic leukemia cell line. Nucleotide sequencing demonstrated 4 distinct varieties of cloned cDNAs, differing at the 5-prime ends and within the region encoding the second extracellular domain, suggesting

the existence of at least 4 distinct protein products of the gene. By study of somatic cell hybrid DNA and in situ hybridization, Tepler et al. (1989) assigned the alpha chain of the Fc IgE receptor to human 1q21-q23. Seldin (1989) assigned the homologous mouse gene to chromosome 1. By in situ hybridization, Le Coniat et al. (1990) assigned genes for both the alpha and the gamma subunits to 1q23. Garman et al. (1998) determined the x-ray crystal structure of the antibody-binding domains of the human IgE receptor alpha subunit at 2.4-angstrom resolution. The structure revealed a highly bent arrangement of immunoglobulin domains that form an extended convex surface of interaction with IgE. A prominent loop that confers specificity for IgE molecules extends from the receptor surface near an unusual arrangement of 4 exposed tryptophans. The crystal structure of the IgE receptor provides a foundation for the development of new therapeutic approaches to allergy treatment. Garman et al. (2000) solved the crystal structure of the human IgE-Fc-FCER1A complex to 3.5-angstrom resolution. The crystal structure revealed that 1 receptor binds 1 dimeric IgE-Fc molecule asymmetrically to interactions at 2 sites, each involving 1 C-epsilon-3 domain of the IgE-Fc. The interaction of 1 receptor with the IgE-Fc blocks the binding of a second receptor, and features of this interaction are conserved in other members of the Fc receptor family. (Garman et al., Crystal structure of the human high-affinity IgE receptor. *Cell* 95: 951-961, 1998; Garman et al., Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc-epsilon-RI-alpha. *Nature* 406: 259-266, 2000; Le Coniat et al., The human genes for the alpha and gamma subunits of the mast cell receptor for immunoglobulin E are located on human chromosome band 1q23. *Immunogenetics* 32: 183-186, 1990; Liu et al., cDNA heterogeneity suggests structural variants related to the high-affinity IgE receptor. *Proc. Nat. Acad. Sci.* 85: 5639-5643, 1988; Shimizu et al., Human and rat mast cell high-affinity immunoglobulin E receptors: characterization of putative alpha-chain gene products. *Proc. Nat. Acad. Sci.* 85: 1907-1911, 1988; Tepler et al., The gene for the human mast cell high-affinity IgE receptor alpha chain: chromosomal localization to 1q21-q23 and RFLP analysis. *Am. J. Hum. Genet.* 45: 761-765, 1989).

The above defined information for NOV7 suggests that this NOV7 protein may function as a member of a IGE receptor beta subunit protein family. Therefore, the NOV7 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV7 compositions of the present invention will have efficacy for treatment of patients suffering from inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers

including but not limited to lung cancer, colon cancer, leukemia or pancreatic cancer.; blood disorders; asthma; psoriasis; inflammatory skin disorders; vascular disorders, hypertension, skin disorders, renal disorders including Alport syndrome, immunological disorders, inflammation including irritable bowel disease, and tissue injury, cancers, fibrosis disorders, bone diseases, Ehlers-Danlos syndrome type VI, VII, type IV, S-linked cutis laxa and Ehlers-Danlos syndrome type V, osteogenesis imperfecta. Immuno therapy of inflammatory and infectious diseases such as AIDS, cancer therapy, treatment of Neurologic diseases, Brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, endocrine diseases, muscle disorders, wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome. The NOV8 nucleic acid encoding IGE receptor beta subunit-like protein, and the IGE receptor beta subunit-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV8

A disclosed NOV8 nucleic acid of 1386 nucleotides (also referred to SC138745558_A) encoding a novel Munc18-like protein is shown in Table 8A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 36-38 and ending with a TGA codon at nucleotides 1350-1352. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 8A, and the start and stop codons are in bold letters.

Table 8A. NOV8 Nucleotide Sequence (SEQ ID NO:37)
<p>CACTCTGGCCGTGGCCGACGTTGCTCCTCCGAAGCATGGCGCCGGCGGAGTTGTAACCCGGGCTGTCCGGAGCGGGGAG CTGCCCCCTACAAGCATGGCGTCAGCTGAAAATGAAGCCTGTGCTGTGCGGAGCGTCGCCTGCCCTCACAAGCATGGCG TCTGCAGAAAGTGCTGTGCGGCCGTGCGGGGCGGCCAGCTGCCCTTCACAAACATGGCGGCCGAGGGGTGCGGGGAGTG GCGGGGTAAGGATGGGAAGCCGAGCAGACGGCCCCAGAACAAAGCGGTGATGTGACTGGGAAGATGGCCGTCTTTCCTTGG CACTCCAGGAATAGGAAGTACAAAGCTGAATTGCAATCATGCCGACTGGAGGCTGTACCATGGAGTTTGGGACTATCA CCCTCTGAAACCCATAACTGTCAAGAGTCAAGACAAAGAAAGTGAACCGGAAAGGAAGCACTTCTTCCACGTCCTCCT CCTCCTCAGCTCCGTGGTGGACCCGCTGAGCAGCGTCCTCGATGGGACTGACCCCTCTCCATGTTTGCAGCCACTGCT</p>

GACCCCGCAGCCTTGGCAGCTGCCATGGACAGCTCCAGAAGGAAACGTGATAGAGATGATAACTCCGTTGTAGGATCGGA
 TTTTGAGCCTTGGACCAACAAACGGGGAGAAATCCTTGCCCGGTACACCCTACCGAAAAGCTGTCTATTAATCTGTTTA
 TGGGATCTGAAAAAGGCAAGCTGGGACTGCCACATTGGCAATGTCAGAGAAGGTGCGGACCCGGCTGGAGGAGCTGGAT
 GACTTTGAGGAGGGTTCCAAAAGGAGCTGTGAACCTGACTCAGCAGGATTACGTGAACCGCATAGAGGAGCTCAACCA
 ATCGCTGAAGGATGCCCTGGGCTCAGACCAGAAAGTGAAGGCTCTAAAAATAGTCATCCAGTGTTCAAAGCTCTTTTCAG
 ACACCAGTGTTATTAGTTCTACCCAAAGCAAATTTGTCTTATCACCACATCTTGATACATTTGAAAGCTCGTGTAC
 GAGCGCATCTTTTCCATGTGTGTGGATAGCCGAGCGTCTTACCAGATCACTTTTCTCCAGAGAATGCAATGACACGGC
 CAAGGAAACATGCCTAAATTTGGTTTTCAAGATTGCCTCCATCAGGGAACCTATCCAAAGATTTTACGTGGAGGCATCCA
 TCCTGAAATGTAAACAATTCCTCTCCAAAACGGGAATTCAGAGTGCCTGCCCGGTTGACATGCATGATCAGAGGGATC
 GGAGACCCACTAGTGTGCGTGTATGCCCGTGCCTACCTGTGCCCGGTAGGCCATGCGAGTCACTGCCCTTGACGGGACCG
 CTGCCACCCGTCTCCTGAATGTTC

The disclosed NOV8 nucleic acid sequence is localized to chromosome 16.

A disclosed NOV8 polypeptide (SEQ ID NO:38) encoded by SEQ ID NO:37 is 438 amino acid residues and is presented using the one-letter amino acid code in Table 8B. Signal P, Psort and/or Hydropathy results predict that NOV8 does not contain a signal peptide and is likely to be localized to the mitochondrial matrix space with a certainty of 0.4363.

Table 8B. Encoded NOV8 protein sequence (SEQ ID NO:38).

MAPAGVVTRAVRSGELPLTSMASAEACAVRSVACPSQAWRLQKVLGRCGAASCPSQWPRGAGSGGVRMGSRADGP
 RTSGHVTGKMAVFPWHSRNRNYKAEFASCRLEAVPLEFGDYHPLKPI TVTESKTKKVNKRGSTSTSSSSSSSVVDPLSS
 VLDGTDPLSMFAATADPAALAAAMDSSRRKDRDDNSVVGSDFEFPTNKRGEILARYTTTEKLSINLFMGSEKKGAGTAT
 LAMSEKVRTRLEELDDFEESQKELNLTQQDYVNRIEELNQLKDAWASDQKVKALKIIVICSKLSDTSVIQFYPSKF
 VLI TDILDTFGKLVYERIFSMCVDSRSLPDHFS PENANDTAKETCLNWF FKIASIRELIPRFYVEASILKCNKFLSKTG
 ISECLPRLTCMIRGIDPLVSVYARAYLCRVGHASHCP

The NOV8 amino acid sequence has 204 of 204 amino acid residues (100%) identical to, and 204 of 204 amino acid residues (100%) similar to, a *Homo sapiens* 824 amino acid residue FLJ21040 FIS, CLONE CAE10642 protein (ptnr:TREMBLNEW-ACC:BAB14965)(E = 1.9e⁻¹⁰⁵).

NOV8a is expressed in at least the following tissues: Adrenal Gland/Suprarenal gland, Amygdala, Cervix, Pituitary Gland, Thymus, Tonsils, Whole Organism, SeqCalling_celltypes: liver, spleen, testis, tumor. This information was derived by determining the tissue sources of the sequences that were included in the invention. SeqCalling sources: Adrenal Gland/Suprarenal gland, Amygdala, Cervix, Pituitary Gland, Thymus, Tonsils, Whole Organism; PublicEST sources: liver, spleen, testis, tumor.

The disclosed NOV8 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 8C.

Table 8C. BLAST results for NOV8

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 12858347 dbj BAB 31285.1 (AK018573)	putative [Mus musculus]	434	317/343 (92%)	324/343 (94%)	1e-178
gi 14777378 ref XP 040052.1 (XM_040052)	hypothetical protein XP_040052 [Homo sapiens]	824	204/204 (100%)	204/204 (100%)	1e-120
gi 12847855 dbj BAB 27735.1 (AK011615)	putative [Mus musculus]	241	213/244 (87%)	222/244 (90%)	1e-108

gi 15292597 gb AAK93567.1 (AY052143)	SD1031lp [Drosophila melanogaster]	942	146/303 (48%)	199/303 (65%)	9e-69
gi 7299081 gb AAF54281.1 (AE003680)	CG8202 gene product [Drosophila melanogaster]	979	134/303 (44%)	182/303 (59%)	1e-56

The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 8D.

Table 8D. ClustalW Analysis of NOV8

- 1) Novel NOV8 (SEQ ID NO:38)
- 2) [gi|12858347|dbj|BAB31285.1|](#) (AK018573) putative [Mus musculus] (SEQ ID NO:104)
- 3) [gi|14777378|ref|XP_040052.1|](#) (XM_040052) hypothetical protein XP_040052 [Homo sapiens] (SEQ ID NO:105)
- 4) [gi|12847855|dbj|BAB27735.1|](#) (AK011615) putative [Mus musculus] (SEQ ID NO:106)
- 5) [gi|15292597|gb|AAK93567.1|](#) (AY052143) SD1031 lp [Drosophila melanogaster] (SEQ ID NO:107)
- 6) [gi|7299081|gb|AAF54281.1|](#) (AE003680) CG8202 gene product [Drosophila melanogaster] (SEQ ID NO:108)

	10	20	30	40	50	
NOV8	MAPAGVV	TRAVRSGEL	PLTSMASAE	NEACAVRSV	ACPSQAWRLQKVL	CGR
gi 12858347	-----	-----	-----	-----	-----	-----
gi 14777378	-----	-----	-----	-----	-----	-----
gi 12847855	-----	-----	-----	-----	-----	-----
gi 15292597	-----	-----	-----	-----	-----	-----
gi 7299081	-----	-----	-----	-----	-----	-----
	60	70	80	90	100	
NOV8	CGAASCP	SQTWRPRG	AGSGGVR	MGSRADG	PRTSGHV	TGKMAVFPWHSRNR
gi 12858347	-----	-----	-----	-----	-----	MAVFPWHSRNR
gi 14777378	-----	-----	-----	-----	-----	MAVFPWHSRNR
gi 12847855	-----	-----	-----	-----	-----	MAVFPWN
gi 15292597	-----	-----	-----	-----	-----	MAVFPWN
gi 7299081	-----	-----	-----	-----	-----	MSCHQAAVRNA
	110	120	130	140	150	
NOV8	NYKAEF	ASCRLEAV	PLPFGDY	HPLKPITV	TESKTKK	VNRKGSTSTSSSS
gi 12858347	NYKAEF	ASCRLEAV	PLPFGDY	HPLKPITV	TESKTKK	VNRKGSTSTSSSS
gi 14777378	NYKAEF	ASCRLEAV	PLPFGDY	HPLKPITV	TESKTKK	VNRKGSTSTSSSS
gi 12847855	NYKAEF	ASCRLEAV	PLPFGDY	HPLKPITV	TESKTKK	VNRKGSTSTSSSS
gi 15292597	NYKAEF	ASCRLEAV	PLPFGDY	HPLKPITV	TESKTKK	VNRKGSTSTSSSS
gi 7299081	NYKAEF	ASCRLEAV	PLPFGDY	HPLKPITV	TESKTKK	VNRKGSTSTSSSS
	160	170	180	190	200	
NOV8	SSSVVD	PLSSVLE	GGTDPLS	MFAAT	ADPAAL	AAAMDSSRKRD
gi 12858347	SSSVVD	PLSSVLE	GGTDPLS	MFAAT	ADPAAL	AAAMDSSRKRD
gi 14777378	SSSVVD	PLSSVLE	GGTDPLS	MFAAT	ADPAAL	AAAMDSSRKRD
gi 12847855	SSSVVD	PLSSVLE	GGTDPLS	MFAAT	ADPAAL	AAAMDSSRKRD
gi 15292597	SSSVVD	PLSSVLE	GGTDPLS	MFAAT	ADPAAL	AAAMDSSRKRD
gi 7299081	SSSVVD	PLSSVLE	GGTDPLS	MFAAT	ADPAAL	AAAMDSSRKRD
	210	220	230	240	250	
NOV8	SVVGS	DFEPWTK	RGEILAR	YTTTEKLS	EN	LFMGSEKGRAG
gi 12858347	SVVGS	DFEPWTK	RGEILAR	YTTTEKLS	EN	LFMGSEKGRAG
gi 14777378	SVVGS	DFEPWTK	RGEILAR	YTTTEKLS	EN	LFMGSEKGRAG
gi 12847855	SVVGS	DFEPWTK	RGEILAR	YTTTEKLS	EN	LFMGSEKGRAG
gi 15292597	SVVGS	DFEPWTK	RGEILAR	YTTTEKLS	EN	LFMGSEKGRAG
gi 7299081	SVVGS	DFEPWTK	RGEILAR	YTTTEKLS	EN	LFMGSEKGRAG
	260	270	280	290	300	
NOV8	LAMSEK	VRTRLE	ELDDFE	GSQKEL	LNLTQ	QDYVNRIEELNQSLKDAWAS

```

gi|12858347|SAMSEKVRTRLEELDDFEEGSQKELLNLTQQDYVNRIEELNQLKDAWAS
gi|14777378|LAMSEKVRTRLEELDDFEEGSQKELLNLTQQDYVNRIEELNQLKDAWAS
gi|12847855|SAMSEKVRTRLEELDDFEEGSQKELLNLTQQDYVNRIEELNQLKDAWAS
gi|15292597|TVVADKTKFRLEQLDHFDDGSMRHMMDLTQQDYTORFEQLKQELIQSWHN
gi|7299081|TVVADKTKFRLEQLDHFDDGSMRHMMDLTQQDYTORFEQLKQELIQSWHN

      310      320      330      340      350
NOV8
gi|12858347|DQKVKALKIVIQCSKLLSDTSVIQFYPSKFVLITDILDFTGKLVYERIFS
gi|14777378|DQKVKALKIVIQCSKLLSDTSVIQFYPSKFVLITDILDFTGKLVYERIFS
gi|12847855|DQKVKALKIVIQCSKLLSDTSVIQFYPSKFVLITDILDFTGKLVYERIFS
gi|15292597|DQKVKALKIVIQCSKLLSDTSVIQFYPSKFVLITDILDFTGKLVYERIFS
gi|7299081|DQKVKALKIVIQCSKLLSDTSVIQFYPSKFVLITDILDFTGKLVYERIFS

      360      370      380      390      400
NOV8
gi|12858347|MCVDSRSVLPDHFSPENANETAKETCLNWFVKIASIRELPRFYVEASIL
gi|14777378|MCVDSRSVLPDHFSPENANETAKETCLNWFVKIASIRELPRFYVEASIL
gi|12847855|MCVDSRSVLPDHFSPENANETAKETCLNWFVKIASIRELPRFYVEASIL
gi|15292597|KASGDPAAASAATLERE--REAARDTCQNWFKIASIRELPRFYVELSIF
gi|7299081|KASGDPAAASAATLERE--REAARDTCQNWFKIASIRELPRFYVELSIF

      410      420      430      440      450
NOV8
gi|12858347|CKNKFLSKIG--ISECLPRLTCMIRGIGDPLVSVYARAYLCRVG
gi|14777378|CKNKFLSKIG--ISECLPRLTCMIRGIGDPLVSVYARAYLCRVG
gi|12847855|CKNKFLSKIG--ISECLPRLTCMIRGIGDPLVSVYARAYLCRVG
gi|15292597|KCYEFLSSSREEYERITLRLTHQIRGIADPLVSSYARCYLVRMGVTTSS
gi|7299081|KCYEFLSSSREEYERITLRLTHQIRGIADPLVSSYARCYLVRMGVTTSS

      460      470      480      490      500
NOV8
gi|12858347|LRESINKNEFDFLITEK-----QIHGDTVQNOQVA
gi|14777378|LRESINKNEFDFLITEK-----QIHGDTVQNOQVV
gi|12847855|LRESINKNEFDFLITEK-----QIHGDTVQNOQVV
gi|15292597|KTYERENFADFLIMP-----QIFRFVARFNHP
gi|7299081|KTYERENFADFLIMP-----QIFRFVARFNHP

      510      520      530      540      550
NOV8
gi|12858347|QGVELLSYLPLYSFAMGNTFOCVSYHAPCALSSIPSLSELRGLSHWR
gi|14777378|QGVELPSYLPLYPAMDWIFOCVSYHAPALLTEMERCKKLGNNALLN
gi|12847855|QGVELPSYLPLYPAMDWIFOCVSYHAPALLTEMERCKKLGNNALLN
gi|15292597|EIVTASSYLQLYAPAFDYMLLCL-VHKSLEHTQDILNECKQLKNNGATLM
gi|7299081|EIVTASSYLQLYAPAFDYMLLCL-VHKSLEHTQDILNECKQLKNNGATLM

      560      570      580      590      600
NOV8
gi|12858347|CAEAV-----
gi|14777378|SVMSAFRAEFIATRSMDFIGMIKECDESGFPKHLFRSLGLNLALADPPE
gi|12847855|SVMSAFRAEFIATRSMDFIGMIKECDESGFPKHLFRSLGLNLALADPPE
gi|15292597|SVLSSFNSEFIATNALEFIALINASETPGISKSQLLRSLGSCVSSCPPLQ
gi|7299081|SVLSSFNSEFIATNALEFIALINASETPGISKSQLLRSLGSCVSSCPPLQ

      610      620      630      640      650
NOV8
gi|12858347|SDRLQILNEAWKVITKLNPQDYINCAEVWVEYTCKHFT-----
gi|14777378|SDRLQILNEAWKVITKLNPQDYINCAEVWVEYTCKHFT-----
gi|12847855|SDRLQILNEAWKVITKLNPQDYINCAEVWVEYTCKHFT-----
gi|15292597|EQRVTFKAAAFETINKLTDPNIEYINCVETWAVFVSQYFT-----
gi|7299081|EQRVTFKAAAFETINKLTDPNIEYINCVETWAVFVSQYFTVVSFKSISKILS

      660      670      680      690      700
NOV8
gi|12858347|-----KREVNTVLADVIKHMTDPDRAFEDSYPLQLLIKKVIAHFHDF
gi|14777378|-----KREVNTVLADVIKHMTDPDRAFEDSYPLQLLIKKVIAHFHDF
gi|12847855|-----KREVNTVLADVIKHMTDPDRAFEDSYPLQLLIKKVIAHFHDF
gi|15292597|IHEVNRLLGELNTRMCLGKAYEKHYSQQLNLTTRIMQNYRSI
gi|7299081|MMLKSFYQIHEVNRLLGELNTRMCLGKAYEKHYSQQLNLTTRIMQNYRSI

      710      720      730      740      750

```

NOV8
gi 12858347	-----
gi 14777378	SVLFSVEKFLPFLDMFQKESVRVEVCKCIMDAFIKHQQEPTKDPVILNAL
gi 12847855	-----
gi 15292597	ELLLIQPNFLPYLDLFQKESVRVEVCKNILSFYKQNSDEYTCDAVVTNAL
gi 7299081	ELLLIQPNFLPYLDLFQKESVRVEVCKNILSFYKQNSDEYTCDAVVTNAL
	760 770 780 790 800
NOV8
gi 12858347	-----
gi 14777378	LHVCKTMHDSVNALTLEDEKRMLSYLINGFIKMVSFGRDFEQQLSFYVES
gi 12847855	-----
gi 15292597	MYLGKILNDSVNALSVDERRQIAQLINVFHKKVHFGNDLEQQLSFYVEA
gi 7299081	MYLGKILNDSVNALSVDERRQIAQLINVFHKKVHFGNDLEQQLSFYVEA
	810 820 830 840 850
NOV8
gi 12858347	-----
gi 14777378	RSMFCNLEPVLVQLIHSVNRLAMETRKVMKGNHSRKTAAFVRACVAYCFI
gi 12847855	-----
gi 15292597	RGTFSNLDAVYVTLVHAACKLATRNRSKSTG-----FVKACIAYCFI
gi 7299081	RGTFSNLDAVYVTLVHAACKLATRNRSKSTG-----FVKACIAYCFI
	860 870 880 890 900
NOV8
gi 12858347	-----
gi 14777378	TIPSLAGIFTRLNLYLHSGQVALANQCLSQADAFFKAAISLVPEVPMK-I
gi 12847855	-----
gi 15292597	TIPSEIAVQQQMNLVLLCGQLALQHLCLGQADACFEAALQLVNELPAATV
gi 7299081	TIPSEIAVQQQMNLVLLCGQLALQHLS---DACFEAALQLVNELPAATV
	910 920 930 940 950
NOV8
gi 12858347	-----
gi 14777378	NIDGKMRPSESFLLEFLCNFFSTLLIIPDHPEHGVLFLVRELLNVIQDYT
gi 12847855	-----
gi 15292597	DFDGKPRSLEPFLVSYMCNIIATLIVVPDSPEQGVLYFLRLLLEVVGGRHK
gi 7299081	DFDGKPRSLEPFLVSYMCNIIATLIVVPDSPEQGVLYFLRLLLEVVGGRHK
	960 970 980 990 1000
NOV8
gi 12858347	-----
gi 14777378	WEDNSDEKIRIYTCVLHLLSAMSQETYLYHIDKVDNSDSLYGGDSKFLAE
gi 12847855	-----
gi 15292597	FKVDSSAPSI IYLHSLDMLYVQSLERFPYHIKGVVSNDLYGHDPKFLQE
gi 7299081	FKVDSSAPSI IYLHSLDMLYVQSLERFPYHIKGVVSNDLYGHDPKFLQE
	1010 1020 1030 1040 1050
NOV8
gi 12858347	-----
gi 14777378	NNKLCETVMAQILEHLKTLAKDEALKRQSSLGLSFFNSILAHGDLRNNKL
gi 12847855	-----
gi 15292597	VNNMCAQVVDAILLQLKSLGVAQQQRSQAELALELFLRIVKYADLERETI
gi 7299081	VNNMCAQVVDAILLQLKSLGVAQQQRSQAELALELFLRIVKYADLERETI
	1060 1070 1080 1090 1100
NOV8
gi 12858347	-----
gi 14777378	NQLSVNLWHLA-QRHGCADTRTMVKTLEYIKKQSKQPDMTHTLALRLP
gi 12847855	-----
gi 15292597	AQLAVNLWLLANKAQSQQLDVKTLPQTLRSVEI IYKQIKDASPIRAQTIK
gi 7299081	AQLAVNLWLLANKAQSQQLDVKTLPQTLRSVEI IYKQIKDASPIRAQTIK

NOV8	-----
gi 12858347	-----
gi 14777378	LQTRT---
gi 12847855	-----
gi 15292597	LLLRVRSS
gi 7299081	LLLRVRSS

The Sec1-related proteins bind to syntaxin family t-SNAREs with high affinity, thus controlling the interaction of syntaxins with their cognate SNARE partners. Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane. Mutational studies implied that Munc18-2 function in apical membrane trafficking involves aspects independent of the syntaxin 3 interaction (Riento et al., Munc18-2, a functional partner of syntaxin 3, controls apical membrane trafficking in epithelial cells. *J Biol Chem* 275(18):13476-83, 2000).

The Q-SNARE syntaxin 1 is a central component of the synaptic membrane fusion machinery. Syntaxin probably interacts with multiple proteins during synaptic vesicle exocytosis. In vitro, the tightest binding partners for syntaxin 1 are other SNAREs (synaptobrevin/VAMP and SNAP-25) and munc18-1 (also known as rbsec1/nsec1) (Matos et al., The relation of protein binding to function: what is the significance of munc18 and synaptotagmin binding to syntaxin 1, and where are the corresponding binding sites? *Eur J Cell Biol* 79(6):377-82, 2000).

Mint1 (X11/human Lin-10) and Mint2 are neuronal adaptor proteins that bind to Munc18-1 (n/rb-sec1), a protein essential for synaptic vesicle exocytosis. Mint1 has previously been characterized in a complex with CASK, another adaptor protein that in turn interacts with neurexins. Neurexins are neuron-specific cell surface proteins that act as receptors for the excitatory neurotoxin -latrotoxin. Hence, one possible function for Mint1 is to mediate the recruitment of Munc18 to neurexins. In agreement with this hypothesis, it was shown that the cytoplasmic tail of neurexins captures Munc18 via a multiprotein complex that involves Mint1. Furthermore, it was demonstrated that both Mint1 and Mint2 can directly bind to neurexins in a PDZ-domain mediated interaction. Various Mint and/or CASK containing complexes can be assembled on neurexins, and we demonstrate that Mint1 can bind to Munc18 and CASK simultaneously. These data support a model whereby one of the functions of Mints is to localize the vesicle fusion protein Munc18 to those sites at the plasma membrane that are defined by neurexins, presumably in the vicinity of points of exocytosis (Biederer and Sudhof, Mints as adaptors. Direct binding to neurexins and recruitment of munc18. *J Biol Chem* 275(51):39803-6, 2000).

The above defined information for NOV8 suggests that NOV8 may function as a member of a Munc18 protein family. Therefore, the NOV8 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV8 compositions of the present invention will have efficacy for treatment of patients suffering from inflammatory

disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, leukemia or pancreatic cancer.; blood disorders; asthma; psoriasis; inflammatory skin disorders; vascular disorders, hypertension, skin disorders, renal disorders including Alport syndrome, immunological disorders, tissue injury, cancers, fibrosis disorders, bone diseases, Ehlers-Danlos syndrome type VI, VII, type IV, S-linked cutis laxa and Ehlers-Danlos syndrome type V, osteogenesis imperfecta, Immuno therapy of inflammatory and infectious diseases such as AIDS, treatment of Neurologic diseases, Brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, endocrine diseases, muscle disorders, wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, multiple sclerosis; and Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome. The NOV8 nucleic acid encoding Munc18-like protein, and the Munc18-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV9

NOV9 includes two novel Immunoglobulin-like proteins disclosed below. The disclosed proteins have been named NOV9a and NOV9b.

NOV9a

A disclosed NOV9a nucleic acid of 1514 nucleotides (also referred to SC138673511_A) encoding a novel Immunoglobulin-like protein is shown in Table 9A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 29-31 and ending with a TGA codon at nucleotides 1319-1321. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon is underlined in Table 9A, and the start and stop codons are in bold letters.

Table 9A. NOV9a Nucleotide Sequence (SEQ ID NO:39)

CTCTGTAAAGGCCAGAAGTGAGGCAGGGATGGGGGTGTTGGATGCCTGGATGGGCCAGAGGTC TGGGTCCCCAGGGGG
CAGGGGCCAAAGGTCCAGACCCCCAAGTCCAGTGAGGGCAGTAGGGAATGGGTGGGGGAAGATAACTGGGGGAAGAGCC
AGGGCCCGGCGCTTCAGTGGCCGCTGCTGCTGCTGTGGGCGCGCGCGGGGCCAGGAGCAGGAGGATACAGAC
AGAGAAAGTGACAGTGGCTGAGGTGGGTGGCTGAGATCACTTCGCGTGTGCACAGGATGATGGGTCATAGTTGTCA
TCCAGAAACCCAGCCGGCGAGACCCCTCTTCTTCAA7TGGCACCCGTGCCTTGAAGGATGAGCGTTTCCAGCTTGAGGAGTTC
TCCCCACGCCGGGTGCGGATCCGGCTCTCAGATGACCGCTGGAGGACAGGGGGGGCTATT7TCCGACGCT7TACACAGA
AGACACCCACAGCAGGAT7GCCAGCTCAAGGTCAGCTAGTGGGCCACAGAAATCCTTGCTGGAGTCCGGGAGCAGGGCG
TAGAGGCGCGCAGGTTGAGACTCAGCTGCCTCGTTCCGCGGTCCGCTCCGCGTGCACCTGCGCTGGTAACGGGACGCG
AAGGAGCTGAAAGGAGTGAGCAGCAGCCAGGAAATGGCAAGGTCGGAGCGTGGCAAGCAAGTACGGTTTCGTGTGGA
CCGTAAAGGACGACGCTGGTATCATCATCTGTGTGAGGCGAGCAACAGGCGCTGCCCTCCGGACAGCAAGCAAGCAGCAT
ACGTGCTGTGATGTGCAGTATCTCCCCACGCGCCGGATTATGCCTCCAAGTCTGTGGTGAGGAGGGAGACAGCTGTGTG
TGAGCTGTGCTGTCAACGGGAAACCCAGGCCAAACAGATCCGCTGGAACCGCGGGAATGAGTCTT7GCCGGAGAGGGC
GGAGGCCGTGGGAGAGACGCTACGCTGCCGGTCTGGTATCCGCGGATAACGGCAGCTACACT7GCGAGCGCT7CCAATA
AGCAGCGGCATCGCAGGCGCTCTACGACTCTGTGTTCTACGACCTGGTGCGGTGAGTACAGGCTCAGACGCTCGGTTCCC
TATGCCATTGTGGCGGACCTCTGCGCTGCTGTTTCTGATCATATGTGTGCTAGTGGCATGTTCTGGTGTCTCGGT
ACGGCAGTAAGGGTTCTCATCTGACCCACGAAGCCAGTGGCTTGGATGAACAGGGAGAAGCAAGAGAAGCCTTCTCAATG
GCAGCGACGGAACAAGAGGAAAGGAAATCTTCATCTGACCCATCTCCCAAGCCAGCCTAGGCTGGGCTGGGCTGGG
GTCCGCCCACTGCCAGCTGCAAGGAACCAAGACATTTACCAGATCTGGGATGGTGGGCTTCTCCCCCAACCACT
AACACCTTCAGACGCTTGGCGAGGATGGGGGTGTTGGATGCTGGATCTCTGTAAGGCCAGAAGTGAGGGCC

The disclosed NOV9a nucleic acid sequence, maps to chromosome 19, has 510 of 852 bases (59%) identical to a *Mus musculus* immunosuperfamily protein BI2 mRNA from (gb:GENBANK-ID:AF061260|acc:AF061260) ($E = 7.6e^{-21}$).

A disclosed NOV9a polypeptide (SEQ ID NO:40) encoded by SEQ ID NO:39 is 430 amino acid residues and is presented using the one-letter amino acid code in Table 9B. Signal P, Psort and/or Hydropathy results predict that NOV9a contains a signal peptide and is likely to be localized in the plasma membrane with a certainty of 0.7300. The most likely cleavage site for a NOV9a peptide is between amino acids 66 and 67, at: GAG-QE.

Table 9B. Encoded NOV9a protein sequence (SEQ ID NO:40).

MGVLDAWMGPEVWVPQAGAGKGPDPSPVRAVIGLGEDNWGKARARRFQWPLLLLWAAAGPGAGQEVQTNENVTVAEGG
VAEITCRHLHQYDGSIVVTQNPARTLFLFNGTRALKDERQLEEPSRRVIRLSDARLEDEGGYFCLQYETDTHHQIATL
TVLTPAENPENVREQAEGVEGVELSLCLVPSRPAATLRWYDRKLEKGVSSQKGVWVASTVFRFRVDRKDDGGI I I
CEAQNQALPSGHSKQTQYVLVDQYSPTARIHASQAVVREGDTLVLTCAVTGNPRPNQIRWNWRGNSLPERAEAVGETLTL
PGLVSADNGTYTECASNKHGARALYLVVYDPAVVEAQTSPYPAIVGGILALLVFL I ICVLVGMVWCVSVRQKGSYLTH
FASGI.DEQGEAREAFLNGSDGHRKEEFFI

The NOV9a amino acid sequence has 366 of 381 amino acid residues (96%) identical to, and 366 of 381 amino acid residues (96%) similar to, the *Homo sapiens* 381 amino acid residue F22162_1 protein (ptnr:SPTREMBL-ACC:Q9Y4A4) ($E = 2.8e^{-191}$).

NOV9a is expressed in at least the following tissues: Amygdala, Brain, Coronary Artery, Heart, Hippocampus, Hypothalamus, Kidney, Lung, Pituitary Gland, Spinal Chord, Substantia Nigra, Thalamus, Whole Organism, SeqCalling_celltypes: glioblastoma total_fetus schizo brain brain oligodendrogloma Fetal brain. This information was derived by determining the tissue sources of the sequences that were included in the invention.

SeqCalling sources: Amygdala, Brain, Coronary Artery, Heart, Hippocampus, Hypothalamus, Kidney, Lung, Pituitary Gland, Spinal Chord, Substantia Nigra, Thalamus, Whole Organism, PublicEST sources: glioblastoma total_fetus schizo brain brain oligodendrogloma Fetal brain.

In addition, NOV9a is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Mus musculus* immunosuperfamily protein B12 mRNA (GENBANK-ID: gb:GENBANK-ID:AF061260|acc:AF061260): glioblastoma total_fetus schizo brain brain oligodendrogloma Fetal brain.

5 **NOV9b**

A disclosed NOV9b nucleic acid of 1161 nucleotides (also referred to CG106625-02) encoding a novel Immunoglobulin-like protein is shown in Table 9C. An open reading frame lacking the signal peptide was identified beginning with an GCC codon at nucleotides 2-4 and ending with a TGA codon at nucleotides 1157-1159. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon is underlined in Table 9C, and the start and stop codons are in bold letters.

Table 9C. NOV9b Nucleotide Sequence (SEQ ID NO:41)
<u>GGCCCGGCGCTTCCAGTGGCCGCTGCTGCTGCTGTGGGCGGCCGCGCGGGGCCAGGGGCAGGACAGGAAGTACAGACAG</u> AGAACGTGACAGTGGCTGAGGGTGGGGTGGCTGAGATCACCTGCCGTCTGCACCAAGTATGATGGGTCCATAGTTGTCTATC CAGAACCCAGCCCGGCAGACCTCTTCTTCAATGGCACCCGTGCCCTTGAAGGATGAGCGTTTCCAGCTTGAGGAGTTCTC CCCACGCCGGGTGCGGATCCGGCTCTCAGATGCCCGCTGGAGGACGAGGGGGGCTATTTCTGCCAGCTCTACACAGAAG ACACCCACCACAGATTGCCACGCTCACGGTACTAGTGGCCCCAGAGAATCCTGTGGTGGAGGTCCGGGAGCAGGCGGTA GAGGGCGGCGAGGTGGAGCTCAGCTGCCTCGTTCCGCGTCCCGTCCGCTGCCACCTGCCGTGGTACCGGGACCGCAA GGAGCTGAAAGGAGTGAGCAGCAGCCAGGAAATGGCAAGTCTGGAGCGTGGCAAGCACAGTACGGTTTCGTGTGGACC GTAAGGACGACGGTGGTATCATCATCTGTGAGGCGCAGAACAGGCGCTGCCCTCCGGACACAGCAAGCAGACCGCAGTAC GTGCTGGATGTGCAGTACTCCCCACGGCCCGGATTATGCCTCCCAAGCTGTGGTGGAGGGAGACACGCTGGTGT GACGTGTGCTGTACCGGGGAACCCAGGCCAAACAGATCCGCTGGAACCGCGGGAATGAGTCTTTGCCGAGAGGGCGG AGGCCGTGGAGAGACGCTCACGCTGCCGGTCTGGTATCCGCGGATAACGGCACCTACACTTGCAGGCGCTCCAATAAG CACGGCCATGCGAGGGCGCTCTACGTACTTGTGGTCTACGACCTGGTGGTGGTAGAGGCTCAGACGTCGGTCCCTA TGCCATTGTGGGCGGCATCCTGCGCTGCTGGTGTCTGTATCATATGTGTGCTAGTGGGCATGGTCTGGTGTCTCGGTAC GGCAGAAGGGTTCTATCTGACCCAGCAAGCCAGTGGCTTGGATGAACAGGAGAAGCAAGAGAAGCCTTCTCAATGGC AGCGACGGACACAAGAGGAAAGAGGAATTCTTCACTGACC

The disclosed NOV9b nucleic acid sequence, maps to chromosome 19, has 557 of 931 bases (59%) identical to a *Mus musculus* sgisf mRNA for spermatogenic immunoglobulin superfamily protein (gb:GENBANK-ID:AB052293|acc:AB052293.1) ($E = 2.1e^{-26}$).

A disclosed NOV9b polypeptide (SEQ ID NO:42) encoded by SEQ ID NO:41 is 385 amino acid residues and is presented using the one-letter amino acid code in Table 9D. Signal P, Psort and/or Hydropathy results predict that NOV9b contains a signal peptide and is likely to be localized in the plasma membrane with a certainty of 0.4600. The most likely cleavage site for a NOV9b peptide is between amino acids 21 and 22, at: GAG-QE.

Table 9D. Encoded NOV9b protein sequence (SEQ ID NO:42).
ARRFQWPLLLWAAAAGPGAGQEVQTEENVTVAEAGVAEITCRLHQYDGSIVVIQNPARTLFFNGTRALKDERFQLEEFSS PRRVRIRLSNDARLEDEGGYFCQLYTETHHQIATLTVLVAPENPVVEVREQAVEGGEVELSCLVPRSRPAATLRWYDRK ELKGVSSSQENGKVWSVASTVRFVRDRKDDGGIIICEAQNALPSGHSKQTQYVLDVQYSPTARIHASQAVVREGDTLVL TCAVTGNPRPNQIRWNRGNESLPERAEAVGETLTLPLGLVSADNGTYTCEASNKHGHARALYLVVVYDPGAVVEAQTSPVY AIVGGILALLVFLIICVLVGMVWCSVRQKGSYLTHEASGLDEQGEAREFLNGSDGHRKKEEFFI

The NOV9b amino acid sequence has 366 of 381 amino acid residues (96%) identical to, and 366 of 381 amino acid residues (96%) similar to, the *Homo sapiens* 381 amino acid residue F22162_1 protein (ptnr:SPTREMBL-ACC:Q9Y4A4) ($E = 3.7e^{-191}$).

NOV9b is expressed in at least the following tissues: Amygdala, Brain, Coronary Artery, Heart, Hippocampus, Hypothalamus, Kidney, Lung, Pituitary Gland, Spinal Chord, Substantia Nigra, Thalamus, Whole Organism. This information was derived by determining the tissue sources of the sequences that were included in the invention. SeqCalling sources: Amygdala, Brain, Coronary Artery, Heart, Hippocampus, Hypothalamus, Kidney, Lung, Pituitary Gland, Spinal Chord, Substantia Nigra, Thalamus, Whole Organism, PublicEST sources: glioblastoma total_fetus schizo brain brain oligodendroglioma Fetal brain. In addition, NOV9b is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Mus musculus* sgigsf mRNA for spermatogenic immunoglobulin superfamily protein (gb:GENBANK-ID:AB052293|acc:AB052293.1): Fetal brain.

NOV9a and NOV9b are very closely homologous as is shown in the amino acid alignment in Table 9E.

Table 9E Amino Acid Alignment of NOV9a and NOV9b

	10	20	30	40	50
NOV9a
NOV9b	MGVLD	AWMGPEV	WVPQ	GAGAKG	PDPPSPVRAVGIGLGEDN
	ARRFQ
	ARRFQ
	60	70	80	90	100
NOV9a
NOV9b	WPLLLL	WAAAAGPG	AGQEVQ	TENVTV	AEAGGVAEIT

	110	120	130	140	150
NOV9a
NOV9b	PARQTL	FFNGTR	ALKDER	FQLEEF	SPRRVRIRLS

	160	170	180	190	200
NOV9a
NOV9b	EDTHHQ	IATLTV	LVAPE	NPVVEV	REQAVEG

	210	220	230	240	250
NOV9a
NOV9b	YRDRKE	LKGVSS	SQENGK	VWSV	ASTVRF

	260	270	280	290	300
NOV9a
NOV9b	GHSKQT	QYVLDV	QYSPT	ARIHAS	QAVVREG

	310	320	330	340	350
NOV9a
NOV9b	NRGNES	LPERAE	AVGETL	TLPLGL	VSADNG

	360	370	380	390	400
NOV9a
NOV9b	YDPGAV	VEAQT	SVPYA	IVGGI	LALLV

	410	420	430
NOV9a
NOV9b	EASGLDEQGEAREAFNGSDGHKRKEEFFI	EASGLDEQGEAREAFNGSDGHKRKEEFFI	EASGLDEQGEAREAFNGSDGHKRKEEFFI

Homologies to any of the above NOV9 proteins will be shared by the other NOV9 proteins insofar as they are homologous to each other as shown above. Any reference to NOV9 is assumed to refer to both of the NOV9 proteins in general, unless otherwise noted.

- 5 NOV9a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 9F.

Table 9F. BLAST results for NOV9a					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 3451335 gb AAC32740.1 (AC005525)	F22162_1 [Homo sapiens]	381	366/381 (96%)	366/381 (96%)	0.0
gi 7767239 gb AAF69029.1 AF132811_1 (AF132811)	nectin-like protein 2 [Homo sapiens]	442	159/416 (38%)	242/416 (57%)	1e-68
gi 7657226 ref NP_055148.1 (NM_014333)	immunoglobulin superfamily, member 4 [Homo sapiens]	442	158/416 (37%)	242/416 (57%)	2e-68
gi 14328885 dbj BAB60686.1 (AB052293)	spermatogenic immunoglobulin superfamily protein [Mus musculus]	445	160/420 (38%)	243/420 (57%)	1e-66
gi 12851464 dbj BAB29050.1 (AK013911)	putative [Mus musculus]	494	160/431 (37%)	246/431 (56%)	5e-63

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 9G.

Table 9G Information for the ClustalW proteins

- 1) NOV9a (SEQ ID NO:40)
- 2) gi|3451335|gb|AAC32740.1| (AC005525) F22162_1 [Homo sapiens] (SEQ ID NO:109)
- 3) gi|7767239|gb|AAF69029.1|AF132811_1 (AF132811) nectin-like protein 2 [Homo sapiens] (SEQ ID NO:110)
- 4) gi|7657226|ref|NP_055148.1| (NM_014333) immunoglobulin superfamily, member 4 [Homo sapiens] (SEQ ID NO:111)
- 5) gi|14328885|dbj|BAB60686.1| (AB052293) spermatogenic immunoglobulin superfamily protein [Mus musculus] (SEQ ID NO:112)
- 6) gi|12851464|dbj|BAB29050.1| (AK013911) putative [Mus musculus] (SEQ ID NO:113)

	10	20	30	40	50
NOV9a
gi 3451335	-----MGVLD	AWMGPEVW	YPOCSG	-----AKGPD	PPSPVR
gi 7767239	-----	MASVVI	PSCS	-----	QCAAAA
gi 7657226	-----	MASVVI	PSCS	-----	QCAAAA
gi 14328885	-----	MASAVI	PSCS	-----	QCAAAA
gi 12851464	CHDWS	LLTPPPAHL	ISISLA	VRSC	GGSHRRQSEAGARHGEC
	60	70	80	90	100
NOV9a	-----	LGEDN	WGKARAR	RFQWPL	LLLWAAAAGP
gi 3451335	-----	AGCE	NOTEN	NTVA	EGGV
gi 7767239	-----	AAAAP	PGLRL	LLLL	FSAAALIFT
gi 7657226	-----	AAAAP	PGLRL	LLLL	FSAAALIFT

```

gi|14328885|-----AAAAAPPGLRLRLRLRLLSAAALIPETGQGNLFTKDVTVIEGEV
gi|12851464|CGGTAVAAAAAPPGLRLRLRLRLLSAAALIPETGQGNLFTKDVTVIEGEV

      110      120      130      140      150
NOV9a      AEITRLHQYDGSIVVTQNPARTLRFNGTRALKDERFQLEEFSPRRVRI
gi|3451335|AEITRLHQYDGSIVVTQNPARTLRFNGTRALKDERFQLEEFSPRRVRI
gi|7767239|ATISQVNVKSDDSVITQLNPNRQTLYFRDFRPLKDSRFQLLNFSSSELKV
gi|7657226|ATISQVNVKSDDSVITQLNPNRQTLYFRDFRPLKDSRFQLLNFSSSELKV
gi|14328885|ATISQVNVKSDDSVITQLNPNRQTLYFRDFRPLKDSRFQLLNFSSSELKV
gi|12851464|ATISQVNVKSDDSVITQLNPNRQTLYFRDFRPLKDSRFQLLNFSSSELKV

      160      170      180      190      200
NOV9a      RLSDARIEDEGGYFCQLYTEDTHHQIATITVLVAPENPVVEVR-EOAVEG
gi|3451335|RLSDARIEDEGGYFCQLYTEDTHHQIATITVLVAPENPVVEVR-EOAVEG
gi|7767239|SLTNVSTISDEGRYFCQLYTDPQESYTTITVLVPPRNLMDIQKDTAVEG
gi|7657226|SLTNVSTISDEGRYFCQLYTDPQESYTTITVLVPPRNLMDIQKDTAVEG
gi|14328885|SLTNVSTISDEGRYFCQLYTDPQESYTTITVLVPPRNLMDIQKDTAVEG
gi|12851464|SLTNVSTISDEGRYFCQLYTDPQESYTTITVLVPPRNLMDIQKDTAVEG

      210      220      230      240      250
NOV9a      GEVELSCLVPRSIRPAATIRWYDRKELKGVSSSQENGKQVWSVASTVRFV
gi|3451335|GEVELSCLVPRSIRPAATIRWYDRKELKGVSSSQENGKQVWSVASTVRFV
gi|7767239|EEIEVNTAMASKPATTIRWFKGNTELKCKSEVEEWSDMYTVTSQMLKV
gi|7657226|EEIEVNTAMASKPATTIRWFKGNTELKCKSEVEEWSDMYTVTSQMLKV
gi|14328885|EEIEVNTAMASKPATTIRWFKGNTELKCKSEVEEWSDMYTVTSQMLKV
gi|12851464|EEIEVNTAMASKPATTIRWFKGNTELKCKSEVEEWSDMYTVTSQMLKV

      260      270      280      290      300
NOV9a      DRKDDGGIITICEAONQALPSGHSKQTYVLDVQYSEPTARIHAS---QAVV
gi|3451335|DRKDDGGIITICEAONQALPSGHSKQTYVLDVQYSEPTARIHAS---QAVV
gi|7767239|HKEDDGVPIICQVEHPAVTG--NLQTORYLEVQYKQVHIQMTYPLOGIT
gi|7657226|HKEDDGVPIICQVEHPAVTG--NLQTORYLEVQYKQVHIQMTYPLOGIT
gi|14328885|HKEDDGVPIICQVEHPAVTG--NLQTORYLEVQYKQVHIQMTYPLOGIT
gi|12851464|HKEDDGVPIICQVEHPAVTG--NLQTORYLEVQYKQVHIQMTYPLOGIT

      310      320      330      340      350
NOV9a      REGDTLVLTCAVTGNPRPNQIRWNRGNESLPERAEAVGETLTLPGLVSAD
gi|3451335|REGDTLVLTCAVTGNPRPNQIRWNRGNESLPERAEAVGETLTLPGLVSAD
gi|7767239|REGDALELTCEAIGKPPVMTWVRVDDDEMPQHAVLSGPNLFINNLNKTD
gi|7657226|REGDALELTCEAIGKPPVMTWVRVDDDEMPQHAVLSGPNLFINNLNKTD
gi|14328885|REGDAFELTCEAIGKPPVMTWVRVDDDEMPQHAVLSGPNLFINNLNKTD
gi|12851464|REGDAFELTCEAIGKPPVMTWVRVDDDEMPQHAVLSGPNLFINNLNKTD

      360      370      380      390      400
NOV9a      NGTYRCEASNIVCKAHSYDLYVVDPPPTIPPPTTTTTTTTTTTTTTTI
gi|3451335|NGTYRCEASNIVCKAHSYDLYVVDPPPTIPPPTTTTTTTTTTTTTTTI
gi|7767239|NGTYRCEASNIVCKAHSYDLYVVDPPPTIPPPTTTTTTTTTTTTTTTI
gi|7657226|NGTYRCEASNIVCKAHSYDLYVVDPPPTIPPPTTTTTTTTTTTTTTTI
gi|14328885|NGTYRCEASNIVCKAHSYDLYVVDPPPTIPPPTTTTTTTTTTTTTTTI
gi|12851464|NGTYRCEASNIVCKAHSYDLYVVDPPPTIPPPTTTTTTTTTTTTTTTI

      410      420      430      440      450
NOV9a      QTS-----VPYATVGCILALLVFLITCYLVGMV
gi|3451335|QTS-----VPYATVGCILALLVFLITCYLVGMV
gi|7767239|ITD-----SRAGEEGSIRAVDHAVIGGVAVVVFAMLCILLIG
gi|7657226|ITD-----SRAGEEGSIRAVDHAVIGGVAVVVFAMLCILLIG
gi|14328885|ITD-----SRAGEEGTIGAVDHAVIGGVAVVVFAMLCILLIG
gi|12851464|ITDTATTEPAVHDSRAGEEGTIGAVDHAVIGGVAVVVFAMLCILLIG

      460      470      480      490
NOV9a      WCSVRQKGSYLTAEASGLDEQGEAREAFINGSDGHRK---KEEFPI
gi|3451335|WCSVRQKGSYLTAEASGLDEQGEAREAFINGSDGHRK---KEEFPI
gi|7767239|RYFARHKGYFTHEAKCADAAADATTAIINAEGGQNNSEBKKEFI
gi|7657226|RYFARHKGYFTHEAKCADAAADATTAIINAEGGQNNSEBKKEFI
gi|14328885|RYFARHKGYFTHEAKCADAAADATTAIINAEGGQNNSEBKKEFI
gi|12851464|RYFARHKGYFTHEAKCADAAADATTAIINAEGGQNNSEBKKEFI

```

Tables 9H – 9P list the domain description from DOMAIN analysis results against NOV9. This indicates that the NOV9 sequence has properties similar to those of other proteins known to contain these domains.

Table 9H. Domain Analysis of NOV9a

gnl|Smart|smart00408, IGc2, Immunoglobulin C-2 Type (SEQ ID NO:114)
Length = 63 residues, 100.0% aligned
Score = 63.2 bits (152), Expect = 3e-11

5

NOV9a	278	REGDTLVLTCAVTGNPRPNQIRWNRGNESLPE-RAEAVGETLTLPLGLVSADNGTYTCEAS	336
		+++ + + + + + + +	
00408	1	LEGESVTLTCPASGDPVPN-ITWLKDGKPLPESRVVASGSTLTIKNVSLEDSGLYTCVAR	59
NOV9a	337	NKHG 340	
00408	60	NSVG 63	

Table 9I. Domain Analysis of NOV9a

gnl|Smart|smart00408, IGc2, Immunoglobulin C-2 Type (SEQ ID NO:115)
Length = 63 residues, 96.8% aligned
Score = 40.4 bits (93), Expect = 2e-04

NOV9a	179	EGGEVELSCLVPRSRPAATLRWYDRKELKGVSSSQENGKVWSVASTVRFVRVDRKDDGGI	238
		+ + + + + + +	
00408	2	EGESVTLTCPA-SGDPVPNITWLKDGKPLPESRVVASG-----STLTIKNVSLEDSGL	53
NOV9a	239	IICEAQNQA 247	
		+	
00408	54	YTCVARNV 62	

Table 9J. Domain Analysis of NOV9a

gnl|Smart|smart00409, IG, Immunoglobulin (SEQ ID NO:116)
Length = 86 residues, 98.8% aligned
Score = 60.5 bits (145), Expect = 2e-10

10

NOV9a	273	SQAVVREGDTLVLTCAVTGNPRPNQIRWNRGNESL---PERAEAVGE---TLTLPLGLVS	325
		+ +++ + + + + + +	
00409	2	PSVTVKEGESVTLSCASGNPPP-TVTWYKQGGKLLAESGRFSVSRSGGNSTLTISNVTP	60
NOV9a	326	ADNGTYTCEASNKHGHARALYVLVY 351	
		+ + +	
00409	61	EDSGTYTCAATNSSGSASSGTTTLTVL 86	

Table 9K. Domain Analysis of NOV9a

gnl|Smart|smart00409, IG, Immunoglobulin (SEQ ID NO:117)
Length = 86 residues, 98.8% aligned
Score = 44.7 bits (104), Expect = 1e-05

NOV9a	72	ENVTVAEAGVAEITCRHLHQYDGSIVVIQNPARTLFFNGTRALKDERFQLEEFSPRRVRI	131
		+ ++ + + + +	
00409	2	PSVTVKEGESVTLSCASGNPPPTVTWYKQGGKLLAESG-----RFSVSR-SGGNSTL	53
NOV9a	132	RLSDARLEDEGGYFCQLYTED-THHQIATLTVL 163	
		+ + + +	
00409	54	TISNVTPEDSGTYTCAATNSSGSASSGTTTLTVL 86	

gnl|Smart|smart00409, IG, Immunoglobulin (SEQ ID NO:118)
Length = 86 residues, 77.9% aligned
Score = 36.6 bits (83), Expect = 0.003

Table 9M. Domain Analysis of NOV9a

Table 9N. Domain Analysis of NOV9a

Table 9O. Domain Analysis of NOV9a

NOV9a	386	MVWCSVRQKGSYLT	THEASG	404
			+	
00294	1	MYRYKHRDEGSYHT	THEPKG	19

Table 9P. Domain Analysis of NOV9a

gnl|Smart|smart00406, IGv, Immunoglobulin V-Type (SEQ ID NO:122)
Length = 80 residues, 97.5% aligned
Score = 37.0 bits (84), Expect = 0.002

NOV9a	82	AEITCRLHQYDGSIVVI-----QNPARTLFF-----NGTRALKDERFQL-EEFSPRRV	129
		++ + + + + + + + + ++	
00406	2	VTLSCKASGFTFSSYYVSWVRQPPGKLEWLG YIGSDVSYSEASYKGRVTISKDNSKNDV	61
NOV9a	130	RIRLS DARLEDEGGYFCQ	147
		+ + + + +	
00406	62	SLTISNLRVEDTGTYICA	79

The effect of rIL-4 on the expression of low affinity receptor for the Fc part of IgE (Fc epsilon R2/CD23) and class II MHC antigens on Burkitt's lymphoma (BL) cell lines was investigated. Some of the BL lines contained low percentages of CD23 and HLA-DQ-positive cells, but virtually all cells expressed HLA-DR. IL-4 induced CD23 and class II MHC Ag expression on 7 of 9 BL. Optimal CD23 and class II MHC expression was observed after 48-72 h of incubation. Induction of CD23 and class II MHC Ag in the BL cell line BL2 by IL-4 was confirmed at the specific mRNA level. Significant activation of HLA-DQ mRNA was obtained after 6 h of incubation with IL-4 and gradually increased during prolonged incubation. Maximal induction of mRNA transcription occurred after 48 to 72 h. Optimal induction of HLA-DR and CD23 transcription in BL2 was also observed after 48 to 72 h. The induction of CD23 and class II MHC Ag seems to be specific for IL-4, because rIL-1, rIL-2, rIFN-gamma, recombinant granulocyte-macrophage-CSF, and a commercial source of low m.w. B cell growth factor were ineffective. In addition, the expression of class I MHC Ag, the transferrin receptor, CD38, CD25, CD10, CD20, and CD21 were not affected by IL-4. Interestingly, IFN-gamma and PGE2 suppressed the IL-4-induced membrane expression of CD23 and class II MHC Ag in a dose-dependent way. IFN-gamma also blocked IL-4-induced CD23 mRNA transcription in BL2 completely, whereas PGE2 (10⁻⁷ M) was partially inhibitory. The induction of CD23 and class II MHC Ag by IL-4 required intact protein synthesis as shown by its inhibition by cycloheximide. These results indicate that the induction of CD23 and class II MHC Ag by IL-4 is regulated in a coordinated way (Rousset et al., Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-gamma. J Immunol 140(8):2625-32, 1988).

The B cell surface trigger(s) and the molecular mechanism(s) of somatic hypermutation remain unknown, partly because of the lack of amendable in vitro models. Recently, however, it was reported that upon B cell receptor cross-linking and coculture with activated T cells, the Burkitt's lymphoma cell line BL2 introduces mutations in its IgVH gene in vitro. The relevance of a culture model is confirmed by establishing that the entire spectrum

of somatic mutations observed in vivo, including insertions and deletions, could be found in the DNA of BL2 cells. Additionally, it was showed that among four human B cell lines, only two with a centroblast-like phenotype can be induced to mutate. Triggering of somatic mutations in BL2 cells requires intimate T-B cell contacts and is independent of CD40-CD40-ligand (CD40L) interactions as shown by 1) the lack of effect of anti-CD40 and/or anti-CD40L blocking Abs on somatic mutation and 2) the ability of a CD40L-deficient T cell clone (isolated from an X-linked hyper-IgM syndrome patient) to induce somatic mutation in B cell receptor-engaged BL2 cells. Thus, the in vitro model reveals that T-B cell membrane interactions through surface molecules different from CD40-CD40L can trigger somatic hypermutation (Denepoux et al., T cells can induce somatic mutation in B cell receptor-engaged BL2 Burkitt's lymphoma cells independently of CD40-CD40 ligand interactions. J Immunol 164(3):1306-13, 2000).

A hybridoma-derived monoclonal antibody, produced by immunization with the Burkitt's tumor-derived B-lymphoblastoid cell line, B35M, was previously shown to detect a 68,000 dalton surface membrane protein, BL2, on the surface of peripheral blood B cells, which is absent from thymocytes, T cells, and granulocytes. In a recent study, the expression and distribution of BL2 on benign and malignant human lymphoid cells was investigated. Indirect immunofluorescent assay with this monoclonal antibody demonstrated that BL2 is expressed by cells within the fetal liver and by a variable proportion of lymph node, tonsil, and spleen B cells, but not by T cells. The neoplastic cells isolated from 18 T-cell malignancies were BL2⁻. BL2 was heterogeneously expressed by a variable proportion of the malignant cells in 29/32 cases of B-chronic lymphocytic leukemia and 33/38 cases of B-cell lymphomas, but appeared to be lost in the terminal stages of B-cell differentiation, as myeloma plasma cells were BL2⁻. BL2 expression was not limited to B cells of a particular surface immunoglobulin isotype. Immunofluorescent staining for BL2 in cryostat tissue sections demonstrated that the majority, but not all, germinal center and interfollicular Ia⁺ (non-T) cells are BL2⁺. These findings suggested that BL2 is a B-cell lineage-specific differentiation marker that may be useful in the study of B-cell ontogeny and in defining subgroups of the B-cell malignancies (Knowles et al., A new human B-lymphocyte surface antigen (BL 2) detectable by a hybridoma monoclonal antibody: distribution on benign and malignant lymphoid cells. Blood 1983 Jul;62(1):191-9, 1983).

The protein similarity information, expression pattern, and map location for the NOV9 suggest that NOV9 may have important structural and/or physiological functions characteristic of the Immunoglobulin protein family. Therefore, the NOV9 nucleic acids and proteins of the

invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV9 compositions of the present invention will have efficacy for treatment of patients suffering from inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, leukemia or pancreatic cancer.; blood disorders; asthma; psoriasis; inflammatory skin disorders; vascular disorders, hypertension, skin disorders, renal disorders including Alport syndrome, immunological disorders, tissue injury, cancers, fibrosis disorders, bone diseases, Ehlers-Danlos syndrome type VI, VII, type IV, S-linked cutis laxa and Ehlers-Danlos syndrome type V, osteogenesis imperfecta, Immuno therapy of inflammatory and infectious diseases such as AIDS, treatment of Neurologic diseases, Brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, endocrine diseases, muscle disorders, wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, multiple sclerosis; and Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome. The NOV9 nucleic acid encoding Immunoglobulin-like protein, and the Immunoglobulin-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV10

NOV10 includes three novel Type II Cytokeratin-like proteins disclosed below. The disclosed proteins have been named NOV10a, NOV10b and NOV10c.

NOV10a

A disclosed NOV10a nucleic acid of 1782 nucleotides (also referred to GSAC055715.12_D) encoding a Type II Cytokeratin-like protein is shown in Table 10A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 63-65 and ending with a TAA codon at nucleotides 1710-1712. Putative untranslated regions

upstream from the initiation codon and downstream from the termination codon are underlined in Table 10A, and the start and stop codons are in bold letters.

Table 10A. NOV10a Nucleotide Sequence (SEQ ID NO:43)

CAGAACCTTTTGGGATTTTGCCTTCTCTCCCTCCCGCATCTGAGCTTTGTCTCCACCAGCAACATGAGCCGCCAATTCACC
TGCAAGTCGGGAGCTGCCGCCAAGGGGGCTTCAGTGGCTGCTCAGCTGTGCTCTCAGGGGGCAGCTCATCTCTCTCCG
GGCAGGGAGCAAAGGGCTCAGTGGGGCTTTGGCAGCCGAGCCTCGCAGGGAGCAAAGGGCTCAGTGGGGCTTTGGCA
GCCGAGCCTCTACAGCCTGGGGGTGTCCGAGCCTCAATGTGGCCAGTGGCAGCGGGAAGAGTGGAGGCTATGGATTT
GGCCGGGGCCGGCCAGTGGCTTTGCTGGAAGCATGTTGGCAGTGTGGCCCTGGGGCTGTGTGCCAACTGTATGCC
ACCTGGAGGCATCCACCAGGTTACCATCAATGAGAGCCTCTGGCCCCCTCAACGTGGAGCTGGACCCCAAGATCCAGA
AAGTGGCTGCCAGGAGCGAGAGCAGATCAAGGCTCTGAACAACAAGTTCGCTCTCATCGACAAGGTGGCGTTCTGT
GAGCAGCAGAACCAGGTAAGTGGAGACCAAGTGGGAGCTGCTGCAGCAGCTGGACCTGAACAAGTGAAGAACAACCTGGA
GCCCCATCTCGAGGGCTACATCAGCAACCTGCGGAAGCAGCTGGAGACGCTGTCTGGGGAAGGGTGGAGCTGGACTCGG
AGCTGAGGAATGTGCGGGACGTAGTGGAGGACTACAAGAAGAGGTATGAGGAGGAAATCAACAAGCGGACAGCAGCAGAG
AACAGATTTGTGCTGCTCAAGAAGGATGTGGATGCTGCTTACGCCAATAAGGTGGAAGTGCAGGCCAAGGTGGAATCCAT
GGACCAGGAGATCAAGTCTTCAGGTGTCTCTTGAAGCCGAGATCACTCAGATCCAGTCCACATCAGTGACATGTCTG
TCATCTGTCTCATGGACAACAACCGGAACCTAGACCTGGACAGCATCATTGACGAAGTCCGACCCAGTATGAGGAGATT
GCCCTTGAAGAGTAAGGCCGAGGCTGAGGCCCTGTACCAGACCAAGTTCCAAGAGCTTCAGCTGGCAGCTGGCAGGCATGG
GGACGACCTCAAAAACCAAGAATGAAATCTCGGAGCTCACTCGGCTCATCCAGAGAATCCGCTCAGAGATCGAGAAG
TGAAGAAGCAGGCTTCAACCTGGAGACAGCCATCGCTGATGCTGAGCAGCGGGGAGACAACGCCCTGAAGGATGCCCGG
GCCAAGCTGGACGAGCTGGAGGGCGCCCTGCACCAGGCCAAGGAGGAGCTGGCACGGATGCTGCGGAGTACCAGGAGCT
CATGAGCCTGAAGCTGGCCCTGGACATGGAGATCGCCACCTATCGCAAGCTACTGGAGAGCGAGGAGTGCAGGATGTCAG
GAGAATTTCCCTCCCTGTGTCAGCATCTCCATCATCAGCAGCACCAAGTGGCGGCAGTGTCACTGGCTATGGCGGTGCCAGT
GGTGTGCGCAGTGGCTTAGGCCTGGGTGGAGGAAGCAGCTACTCCTATGGCAGTGGTCTTGGCGTTGGAGGTGGCTTCA
TTCCAGCAGTGGCAGAGCCATTGGGGGTGGCCCTCAGCTCTGTTGAGGCGGCAGTTCACCATCAAGTACACCAACCTC
CCTCTCCAGCAGGAAGAGCTATAAGCACTAAGTGGCTGCTGAGCTCTCGGTCCACAGTCTCAGGCCCTCTCTGG
CTGCAGAGCCCTCTCTCAGGT

The disclosed NOV10a nucleic acid sequence, localized to chromosome 12, has 1255
of 1478 bases (84%) identical *Mus musculus* type II cyokeratin mRNA (gb:GENBANK-
ID:AB033744|acc:AB033744.1) ($E = 5.2e^{-231}$).

A disclosed NOV10a polypeptide (SEQ ID NO:44) encoded by SEQ ID NO:43 is 549
amino acid residues and is presented using the one-letter amino acid code in Table 10B.
Signal P, Psort and/or Hydropathy results predict that NOV10a does not contain a signal
peptide and is likely to be localized in the cytoplasm with a certainty of 0.4500.

Table 10B. Encoded NOV10a protein sequence (SEQ ID NO:44).

MSRQFTCKSGAAAKGGFSGCSAVLSGGSSSSFRAGSKGLSGGFSGRSRLAGSKGLSGGFSGRSRLSLGVRSLNVAAGSGK
SGGYGFGGRGRAGSFGAGSMFSGSVALGPVCPVCPGGIHQVTINESLLAPLNVELDPKIQKVAQEREQIKALNNKFASFI
DKVRFLEQQNVLETKWELLQQLDLNCKNNLEPILEGYISNLRKQLETLSGDRVRLDSELRNVRDVEDYKKRYEEIN
KRTAAENEFVLLKKDVDAAYANKVELQAKVESMDQEI KFRCLFEAEITQIQSHISDMSVILSMDNNRNLDLDSIIDVR
TQYEEIALKSKAEAEALYQTKFQELQLAAGRHDLDLKNTEISELTRLIQRIRSEIENVKKQASNLETAIDAEQRGDN
ALKDARAKLDELEGALHQAKEELARMLREYQELMSLKLALDMEIATYRKLESEECRMSGFPPSPVISIISSTSGGSVS
GYGGASGVGSLGLGGSSSYSGSGLGVGGFSSSGRAIGGLSSVGGSSSTIKYTTTSSSSRSKYKH

The NOV10a amino acid sequence has 440 of 519 amino acid residues (84%) identical
to, and 465 of 519 amino acid residues (89%) similar to, a *Mus musculus* 524 amino acid
residue Type II cyokeratin (ptnr:SPTREMBL-ACC:Q9R0H5) ($E = 4.6e^{-221}$).

NOV10a is expressed in at least the following tissues: skin, muscle, bone, cartilage,
Colon carcinoma, lung. This information was derived by determining the tissue sources of the
sequences that were included in the invention including but not limited to SeqCalling sources,
Public EST sources, Genomic Clone sources, Literature sources, and/or RACE sources. In
addition, NOV10a is predicted to be expressed in the following tissues because of the

expression pattern of a closely related *Mus musculus* mRNA for type II cytokeratin (GENBANK-ID: gb:GENBANK-ID:AB033744 |acc:AB033744.1):skin, muscle, bone, cartilage, Colon carcinoma, lung.

NOV10b

5 A disclosed NOV10b nucleic acid of 1601 nucleotides (also referred to GSAC055715_C) encoding a Type II Cytokeratin-like protein is shown in Table 10C. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 66-68 and ending with a TGA codon at nucleotides 1599-1601. A putative untranslated region upstream from the initiation codon is underlined in Table 10C, and the start and stop codons are in bold letters.

Table 10C. NOV10b Nucleotide Sequence (SEQ ID NO:45)

CAGGAGGGATTATGCGGAGTTACGGTGAACAGACAAAAATCTCGCACCGGTACTTGGCAGCCATGAGCCGCCAACTG
ACCCATTTCCCCCGCGGGGAGCGCTGGGCTTCAGCGGTTGCTCCGCGGTCTCTTGGCGGGATCGGCAGCAGCTCCGC
CTCATTCCGGGCGCGGTCAAGGGCTCGGCCTCTTTGGCAGCAAGAGCCTCTCTGCGCTTGGGGGCGAGCGAAGCCTGG
CGCTCAGCGCTGCTGCACGGCGGGGCGGCGGCGCTGGGCGGCTTCGTGGGCACCGCTTGGCAGCGCGGGGCTGGGG
CCCAAGTGTCCCTCCGTGTGCCACCCGGGGGCATCCCTCAGGTACCGTCAACAAGAGCCTCTGGCCCCGCTCAACGT
GGAGATGGACCCGAGATCCAGAGGGTGCAGCGCCAGGAGCGGGAGCAGATCAAGGCGCTAAACAACAAGTTCGCGCTCT
TCATCGACAAGGTGCGGTTCCCTGGAGCAGCAGAATCAGGTGCTAGAGACCAAGTGGAACTCCTACAGCAGCTGGACTTG
AACAACTGCAGGAAGAACCTGGAGCCATTTATGAGGGCTACATCAGCAACCTGCAGAAGCAGCTGGAGATGCTGTCTGG
GGACGGGTGAGGCTGATTTCGAGCTGAGGAACATGCAGGATTGGTGGAGGACTACAAGAAGAGATATGAGGTGGAGA
TTACAGACGCACAGCTGCTGAGAATGAGTTTGTGGTGTCAAGAAGGACGTGGATGCTGCTTACATGAATAAGGTTGAG
CTCCAGGCCAAGGTGGACTCCTTGACAGATGAGATTAAATCTTCAAGTGCCTTTATGAAGGGGAGATCACTCAGATCCA
GTCCACATCAGCGACAGTCCATCGTCTGTCAATGGACAACACCGGGATCTGGACCTGGACAGCATCATTTGCCGAGG
TCCGTGCCAGTACGAGGAGATTGCCCTAAAGAGCAAGGCCGAGGCTGAGACCCTGTACCAGACCAAGATCCAGGAGCTG
CAGGTCAAGCAGGCCAGCATGGGGATGACCTCAAGCTCAGCAAGGCTGAAATCTCTGAGCTCAACCCGCTGATCCAGAG
GATCCGCTCAGAGATAGGAATGTGAAGAAGCAGTGTGCCGATCTGGAGACGGCCATCGCCGACGCTGAACAGCGGGGG
ACTGCGCCCTGAAAGATGCCCGGGCCAAGCTGGATGAGCTGGAGGGCGCCCTGCACCAGGCCAAGGAGGAGCTGGCAGG
ATGCTGCGTGAGTACCAGGAGCTCGTGAGCCTGAAGCTGGCCCTGGATATGGAGATCGCCACCTACCGCAAGCTGCTGGA
GAGCGAGGAGTGCAGGATGTCTGGCGAATATCCAAATCTGTGAGCATCTCCGTATCAGCAGCACCATGCTGGGGCAG
GAGGGGCTGGCTTCAGCATGGGCTTGGGCGCTCAAGCAGTTATAGCTACAAACTGCAGCTGCAGACGTCAAGACCAAA
GGCAGCTGTGGCAGTGAAGTCAAGGATCCCCTTGCCAAAACCTCGGGGAGCAGCTGTGCCACCAAAAAGGCTCCAGATG

A

The disclosed NOV10b nucleic acid sequence, localized to chromosome 12, has 1004 of 1224 bases (82%) identical *Mus musculus* type II cytokeratin mRNA (gb:GENBANK-ID:AB033744|acc:AB033744.1) ($E = 4.8e^{-176}$).

15 A disclosed NOV10b polypeptide (SEQ ID NO:46) encoded by SEQ ID NO:45 is 511 amino acid residues and is presented using the one-letter amino acid code in Table 10D. Signal P, Psort and/or Hydropathy results predict that NOV10b does not contain a signal peptide and is likely to be localized in the cytoplasm with a certainty of 0.4500.

Table 10D. Encoded NOV10b protein sequence (SEQ ID NO:46).

MSRQLTHFPRGERLGFSGCSAVLSGGIGSSSASFRARVKGSGSFGSKLSCLGGSRLALSAAARRGGRLGGFVGTAFG
SAGLGPKCPSVCPGGIPQVTVNKSLAPLNVMEDPEIQRVRAQEREQIKALNNKFASFDKVRFLQQNQVLETKWNLL
QQLDLNNCRKNLEPIYEGYISNLQKQLEMLSGDGVRLDSELNMQDLVEDYKKRYEVEINRRTAAENEFVVLKDDVDAAY
MNKVELQAKVDSLTDIEKFPKCLYEGETIQIQSHISDTSIVLSMDNNRDLDSIIAEVRAQYEEIALKSKAEATLYQT
KIQELQVTAGQHGDLLKLTAEISELNRLIQRIRSEIGNVKKQCADLETAIADAEQRGDCALKDARAKLDELEGALHQA
EELARMLREYQELVSLKLALDMEIATYRKLESEECRMSGEYPNSVSVISSTNAGAGGAGFSMGFGASSYSYKTA
DVKTKGSCGSELKDLAKTSGSSCATKKASR

The NOV10b amino acid sequence has 380 of 524 amino acid residues (72%) identical to, and 430 of 524 amino acid residues (82%) similar to, a *Mus musculus* 524 amino acid residue Type II cytokeratin (ptnr:SPTREMBL-ACC:Q9R0H5) ($E = 1.1e^{-185}$).

NOV10b is expressed in at least the following tissues: skin, muscle, bone, cartilage, Colon carcinoma, lung. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Genomic Clone sources, Literature sources, and/or RACE sources. In addition, NOV10b is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Mus musculus* mRNA for type II cytokeratin (GENBANK-ID: gb:GENBANK-ID:AB033744 |acc:AB033744.1):skin, muscle, bone, cartilage, Colon carcinoma, lung.

NOV10c

A disclosed NOV10c nucleic acid of 1606 nucleotides (also referred to GSAC055715_B) encoding a Type II Cytokeratin-like protein is shown in Table 10E. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TAG codon at nucleotides 1515-1517. A putative untranslated region downstream from the termination codon is underlined in Table 10E, and the start and stop codons are in bold letters.

Table 10E. NOV10c Nucleotide Sequence (SEQ ID NO:47)

ATG AGCCGCAATTACCTACAAGTCGGGAGCTGCTGCCAAGGGGGGCTTCAGCGCTGCTCCGCTGTGCTCTCAGGGG CAGCTCATCCTCCTACCGAGCAGGGGGCAAAGGGCTCAGTGGAGGCTTCAGCAGTCGGAGCCTTTACAGCCTGGGGGTG CCCGGAGCATCTCTTTCAATGTGGCCAGTGGCAGTGGGTGGGCAGGAGGCTATGGATTTGGCCGGGGCCGGCCAGTGGC TTTGCTGGCAGCATGTTTGGCAGTGTGGCCTTGGGGTCCGTGTGTCCTGTCGTGTGCCCCCGGGGTATCCATCAGGT CACCATCAACAAGAGCCTCCTGGCACCCCTGAACGTGGAGCTGGACCCTGAAATCCAGAAAGTGCGTGCCAGGAGCGGG AGCAGATCAAGGTGCTGAACAACAAGTTCGCCTCCTTCATTGACAAGGTGCGGTTCCTGGAGCAGCAGAACCAAGTGTCTG GAGACCAAGTGGGAGCTGTACAGCAGCTGGACCTGAACAAGTGAAGAATAACCTGGAGCCCATCCTTGAGGGCTACAT CAGCAACCTGCGGAAGCAGCTGGAGACGCTGTCTGGGGAAGGGTGAGGCTGGACTCGGAGCTGAGGAGCGTGCAGCAAG TGGTGGAGGACTACAAGAAGAGGTATGAAGAAGAAATAACAAGCGCACAACTGCTGAGAATGAATTTGTGGTCTTAAG AAGGACGTGGACGAGCTTACACGAGCAAAGTGGAGCTGCAGGCCAAGGTGGATGCCCTGGATGGAGAAATCAAGTCTT CAAGTGTCTGTACGAGGGGAGACTGCTCAGATCCAGTCCACATCAGCGACACGTCCATCATCTGTCCATGGACAACA ACCGGAACTGGACCTGGACAGCATCATTGCTGAGGTCCGTGCCAGTATGAGGAGATCGCCCGGAAGAGCAAGGCCGAG GCCGAGGCCCTGTACCAGACCAAGTTCAGGAGCTGCAGCTAGCAGCCGCCGCGCATGGGGATGACCTGAAACACACCAA AAATGAGATCTCAGAGCTGACCCGTCTCATCCAAGACTGCGCTCGGAGATTGAGAGTGTGAAGAAGCAGTGTGCCAACC TGGAGACGCCATCGCTGACGCCGAGCAGCGGGGGGACTGTGCCCTCAAGGATGCCAGGGCCAAGCTGGATGAGCTGGAG GGCGCCCTGCAGCAGGCCAAGGAGGAGCTGGCACGGATGCTGCGCGAGTACCAAGAGCTTTGAGCGTGAAGCTGTCCCT GGATATTGAGATCGCCACCTACCGCAAGCTGCTGGAGGGCGAGGAGTGAGGATGTCGGAGAAATATACCAACTCCGTGA GCATTTCCGTATCAACAGCTCCATGGCCGGGATGGCAGGCACAGGGGCTGGCTTTGGATTGAGCAATGCTGGCACCTAC GGCTACTGGCCAGCTCTGTGTCAGCGGGGCTACAGCATGCTGCCTGGGGGCTGTGTCACTGGCAGTGGAACTGTAGCCCC CCACACACCCAGAGGGTCAGCCCCACTGGAAGTTCCAGGGTGATCTGGGAGTGATAACCCAGTAATTGGAGGCCA GCAGGT
--

The disclosed NOV10c nucleic acid sequence, localized to chromosome 12, has 1271 of 1525 bases (83%) identical *Mus musculus* type II cytokeratin mRNA (gb:GENBANK-ID:AB033744|acc:AB033744.1) ($E = 5.0e^{-228}$).

A disclosed NOV10c polypeptide (SEQ ID NO:48) encoded by SEQ ID NO:47 is 521 amino acid residues and is presented using the one-letter amino acid code in Table 10F.

Signal P, Psort and/or Hydropathy results predict that NOV10c does not contain a signal peptide and is likely to be localized in the cytoplasm with a certainty of 0.4500.

Table 10F. Encoded NOV10c protein sequence (SEQ ID NO:48).

```
MSRQFTYKSGAAAKGGFSGCSAVLSCGGSSSSSYRAGGKLSGGFSSRSLSLGGARSISFNVASGSGWAGGYGFRGRASG
FAGSMFGSVALGSVCPSLCPGGIHOVTINKSLLAPLNVELDPEIQKVRAQEREQIKVLNNKFASFIDKVRFLQQNQVL
ETKWELLQQLDLNCKNNLEPILEGYISNLRKQLETLSGDRVRLDSELRSVREVVEDYKKRYEEEINKRTTAENEFVVLK
KDVDAAAYTSKVELQAKVDALDGEIKFFKCLYEGETAQIQSHISDTSIILSMDNNRNLDLDSIAEVRAQYEEIARKSKAE
AEALYQTKFQELQLAAGRHHGDDLKHTKNEISELTRLIQRLRSEIESVKKQCANLETAIADAEQRGDCALKDARAKLDELE
GALQQAKEELARMLREYQELLSVKLSLDIEIATYRKLLGEECRMSGEYTNVSISVINSSMAGMAGTGAGFGFSNAGTY
GYWPSSVSGGYSMLPGGCVTGSGNCSPTHPEGQPHWKFPG
```

The NOV10c amino acid sequence has 414 of 506 amino acid residues (81%) identical to, and 454 of 506 amino acid residues (89%) similar to, a *Mus musculus* 524 amino acid residue Type II cytokeratin (ptnr:SPTREMBL-ACC:Q9R0H5) ($E = 1.1e^{-212}$).

NOV10c is expressed in at least the following tissues: skin, mammary gland, and lung. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Genomic Clone sources, Literature sources, and/or RACE sources. In addition, NOV10c is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Mus musculus* mRNA for type II cytokeratin (GENBANK-ID: gb:GENBANK-ID:AB033744 |acc:AB033744.1): skin, mammary gland, and lung.

NOV10a, NOV10b and NOV10c are very closely homologous as is shown in the amino acid alignment in Table 10G.

Table 10G Amino Acid Alignment of NOV10a – NOV10c

	10	20	30	40	50
NOV10a	MSRQFTYKSGAAAKGGFSGCSAVLSCGGSSSSFRAGGKLSGGFSSRSLSLGGARSISFNVASGSGWAGGYGFRGRASG				
NOV10b	MSRQFTYKSGAAAKGGFSGCSAVLSCGGSSSSFRAGGKLSGGFSSRSLSLGGARSISFNVASGSGWAGGYGFRGRASG				
NOV10c	MSRQFTYKSGAAAKGGFSGCSAVLSCGGSSSSFRAGGKLSGGFSSRSLSLGGARSISFNVASGSGWAGGYGFRGRASG				
	60	70	80	90	100
NOV10a	LAGSKGLSGGFGSRSLSLGGARSISFNVASGSGWAGGYGFRGRASGFA				
NOV10b	LAGSKGLSGGFGSRSLSLGGARSISFNVASGSGWAGGYGFRGRASGFA				
NOV10c	LAGSKGLSGGFGSRSLSLGGARSISFNVASGSGWAGGYGFRGRASGFA				
	110	120	130	140	150
NOV10a	GSMFGSVALGSPVCPSPGGIHOVTINKSLLAPLNVELDPEIQKVRAQE				
NOV10b	GSMFGSVALGSPVCPSPGGIHOVTINKSLLAPLNVELDPEIQKVRAQE				
NOV10c	GSMFGSVALGSPVCPSPGGIHOVTINKSLLAPLNVELDPEIQKVRAQE				
	160	170	180	190	200
NOV10a	REQIKALNNKFASFIDKVRFLQQNQVLETKWELLQQLDLNCKNNLEPI				
NOV10b	REQIKALNNKFASFIDKVRFLQQNQVLETKWELLQQLDLNCKNNLEPI				
NOV10c	REQIKALNNKFASFIDKVRFLQQNQVLETKWELLQQLDLNCKNNLEPI				
	210	220	230	240	250
NOV10a	LEGYISNLRKQLETLSGDRVRLDSELNRVVDVVEDYKKRYEEEINKRTAA				
NOV10b	LEGYISNLRKQLETLSGDRVRLDSELNRVVDVVEDYKKRYEEEINKRTAA				
NOV10c	LEGYISNLRKQLETLSGDRVRLDSELNRVVDVVEDYKKRYEEEINKRTAA				
	260	270	280	290	300
NOV10a	ENEFVLLKDVDAAYANKVELQAKVESMDQEIKFELAEITQIQSHI				

NOV10b	ENEVVLKKVDAA Y MNKVELQAKVDSL T DEIKFFKCLYEGETIQISHI
NOV10b	ENEVVLKKVDAA Y T S KVELQAKVDA L LDGEIKFFKCLYEGETAQIQSHI
	310 320 330 340 350
NOV10a	SDMSVILSMDNNRNL D LDLSI I DEVRTQYEEIALKSKAEAEALYQTKFQEL
NOV10b	SDTSI V LSMDNNR R LDLSIIAEVRAQYEEIALKSKAEAE T LYQTK I QEL
NOV10b	SDTSIILSMDNNRNL D LDLSIIAEVRAQYEEI A RKSKAEAEALYQTKFQEL
	360 370 380 390 400
NOV10a	QLAAGRHGDDLK N TKNEISELTRLIQIRSEIENVKKQ A SNLETAIADAE
NOV10b	Q V TAG C HGDDLK L TKAEISELNRLIQIRSEI C NVKKQCADLETAIADAE
NOV10b	QLAAGRHGDDLK E TKNEISELTRLIQIR T RSEIESVKKQCANLETAIADAE
	410 420 430 440 450
NOV10a	QRGDNALKDARAKLDELEGALHQA E EELARMLREYQEL S SLKLALDMEIA
NOV10b	QRGDCALKDARAKLDELEGALHQA E EELARMLREYQEL V SLKLALDMEIA
NOV10b	QRGDCALKDARAKLDELEGAL Q AKEELARMLREYQEL S VKL S LD E IA
	460 470 480 490 500
NOV10a	TYRKLLSEECRMSGE P SPVSI S IISS T SGSVSGYGCA S GVCS C HLG
NOV10b	TYRKLLSEECRMSGE Y PNSVSI S SVIS T NAG-----ACGAGFS C FG
NOV10b	TYRKLL E CEECRMSGE Y TNSVSI S SVIN S S S MAG-----MAGTCAG C FGS
	510 520 530 540 550
NOV10a	GCSSSYSGSLGV C GG E SSSSGRAIGGLSSVCGSSST K Y T ITSS S SRK
NOV10b	ASSSY S YK T ---AAA-DVK T K C -----SCSELKD P LAKT S CGSSCATK
NOV10b	NAGTYG W P-SSVSGGY S MLP C -----GCVTSGN C SP H HP E GQPHW
NOV10a	S M KH
NOV10b	KASR
NOV10b	K E PG

Homologies to any of the above NOV10 proteins will be shared by the other NOV10 proteins insofar as they are homologous to each other as shown above. Any reference to NOV10 is assumed to refer to both of the NOV10 proteins in general, unless otherwise noted.

- 5 The disclosed NOV10a polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 10H.

Table 10H. BLAST results for NOV10a					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 15321302 ref XP_053295.1 (XM_053295)	keratin 6 irs [Homo sapiens]	523	384/425 (90%)	386/425 (90%)	0.0
gi 15321300 ref XP_053294.1 (XM_053294)	hypothetical protein XP_053294 [Homo sapiens]	441	354/368 (96%)	356/368 (96%)	1e-179
gi 9910294 ref NP_064340.1 (NM_019956)	keratin complex 2, gene 6g [Mus musculus]	524	359/424 (84%)	377/424 (88%)	1e-179
gi 15321298 ref XP_053296.1 (XM_053296)	hypothetical protein XP_053296 [Homo sapiens]	336	249/263 (94%)	251/263 (94%)	1e-133
gi 7161776 emb CAB76832.1 (Y19212)	cytokeratin [Homo sapiens]	551	257/432 (59%)	329/432 (75%)	1e-132

The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 10I.

Table 10I. ClustalW Analysis of NOV10

- 1) Novel NOV10a (SEQ ID NO:44)
- 2) [gi|15321302|ref|XP_053295.1|](#) (XM_053295) keratin 6 irs [Homo sapiens] (SEQ ID NO:123)
- 3) [gi|15321300|ref|XP_053294.1|](#) (XM_053294) hypothetical protein XP_053294 [Homo sapiens] (SEQ ID NO:124)
- 4) [gi|9910294|ref|NP_064340.1|](#) (NM_019956) keratin complex 2, gene 6g [Mus musculus] (SEQ ID NO:125)
- 5) [gi|15321298|ref|XP_053296.1|](#) (XM_053296) hypothetical protein XP_053296 [Homo sapiens] (SEQ ID NO:126)
- 6) [gi|7161776|emb|CAB76832.1|](#) (Y19212) cytokeratin [Homo sapiens] (SEQ ID NO:127)

		10	20	30	40	50
NOV10a		MSRQFTCKSGAAAKGFFSGCSAVLSG	---	G---	SSSSFRAGSKGLSGGFGS	
gi 15321302		MSRQFTCKSGAAAKGFFSGCSAVLSG	---	G---	SSSSFRAGSKGLSGGFGS	
gi 15321300		MSRQFTCKSGAAAKGFFSGCSAVLSG	---	G---	SSSSFRAGSKGLSGGFGS	
gi 9910294		MSRQFTCKSGAAAKGFFSGCSAVLSG	---	G---	SSSSFRAGSKGLSGGFGS	
gi 15321298		MSRQFTCKSGAAAKGFFSGCSAVLSG	---	G---	SSSSFRAGSKGLSGGFGS	
gi 7161776		MSRQSSITFQSGSRGFFSTTSAITPAAGRSRFS	SSV	VARSAACSCGLGRI		
		60	70	80	90	100
NOV10a		RSLAGSKGLSGGFGSRSLYSLGGVR	---	SIN	---	VAGSCSKSCGYGFCRCR
gi 15321302		RSLAGSKGLSGGFGSRSLYSLGGVR	---	SIN	---	VAGSCSKSCGYGFCRCR
gi 15321300		RSLAGSKGLSGGFGSRSLYSLGGVR	---	SIN	---	VAGSCSKSCGYGFCRCR
gi 9910294		RSLAGSKGLSGGFGSRSLYSLGGVR	---	SIN	---	VAGSCSKSCGYGFCRCR
gi 15321298		RSLAGSKGLSGGFGSRSLYSLGGVR	---	SIN	---	VAGSCSKSCGYGFCRCR
gi 7161776		SSAG	---	ASFGRSLYSLGGVR	---	SSVVARSAACSCGLGRI
		110	120	130	140	150
NOV10a		ASGF-AGSMFGSVALGPVCPVCPGGIHQVT	INESLLAPLNVELDP	KTQ		
gi 15321302		ASGF-AGSMFGSVALGPVCPVCPGGIHQVT	INESLLAPLNVELDP	KTQ		
gi 15321300		ASGF-AGSMFGSVALGPVCPVCPGGIHQVT	INESLLAPLNVELDP	KTQ		
gi 9910294		ASGF-AGSMFGSVALGPVCPVCPGGIHQVT	INESLLAPLNVELDP	KTQ		
gi 15321298		ASGF-AGSMFGSVALGPVCPVCPGGIHQVT	INESLLAPLNVELDP	KTQ		
gi 7161776		NSGF-AGSMFGSVALGPVCPVCPGGIHQVT	INESLLAPLNVELDP	KTQ		
		160	170	180	190	200
NOV10a		KVRAQEREQIKALNNKFASFIDKVRFL	EQNQVLET	KWELLQQLDLNNCK		
gi 15321302		KVRAQEREQIKALNNKFASFIDKVRFL	EQNQVLET	KWELLQQLDLNNCK		
gi 15321300		KVRAQEREQIKALNNKFASFIDKVRFL	EQNQVLET	KWELLQQLDLNNCK		
gi 9910294		KVRAQEREQIKALNNKFASFIDKVRFL	EQNQVLET	KWELLQQLDLNNCK		
gi 15321298		KVRAQEREQIKALNNKFASFIDKVRFL	EQNQVLET	KWELLQQLDLNNCK		
gi 7161776		KVRAQEREQIKALNNKFASFIDKVRFL	EQNQVLET	KWELLQQLDLNNCK		
		210	220	230	240	250
NOV10a		NNLEPILEGYISNLRKQLETLSGDRVRL	DSSELNRV	DDVVEDYKKRYEEI		
gi 15321302		NNLEPILEGYISNLRKQLETLSGDRVRL	DSSELNRV	DDVVEDYKKRYEEI		
gi 15321300		NNLEPILEGYISNLRKQLETLSGDRVRL	DSSELNRV	DDVVEDYKKRYEEI		
gi 9910294		NNLEPILEGYISNLRKQLETLSGDRVRL	DSSELNRV	DDVVEDYKKRYEEI		
gi 15321298		NNLEPILEGYISNLRKQLETLSGDRVRL	DSSELNRV	DDVVEDYKKRYEEI		
gi 7161776		NNLEPILEGYISNLRKQLETLSGDRVRL	DSSELNRV	DDVVEDYKKRYEEI		
		260	270	280	290	300
NOV10a		NKRTAAENEFVLLKKDVAAYANKVELQAKV	SMDOEIKFFKCLFEABIT			
gi 15321302		NKRTAAENEFVLLKKDVAAYANKVELQAKV	SMDOEIKFFKCLFEABIT			
gi 15321300		NKRTAAENEFVLLKKDVAAYANKVELQAKV	SMDOEIKFFKCLFEABIT			
gi 9910294		NKRTAAENEFVLLKKDVAAYANKVELQAKV	SMDOEIKFFKCLFEABIT			
gi 15321298		NKRTAAENEFVLLKKDVAAYANKVELQAKV	SMDOEIKFFKCLFEABIT			
gi 7161776		NKRTAAENEFVLLKKDVAAYANKVELQAKV	SMDOEIKFFKCLFEABIT			
		310	320	330	340	350
NOV10a		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 15321302		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 15321300		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 9910294		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 15321298		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 7161776		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
		360	370	380	390	400
NOV10a		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 15321302		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 15321300		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 9910294		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 15321298		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			
gi 7161776		QIQSHISDMSVILSMDNNRNLDLDSI	IDEVRIQYEEIALKSKAEAEALYC			

NOV10a	TKFQELQLAAGRHGDDLKNTKN-EISELTRLIQRIRSEIENVKKQASNLE
gi 15321302	TKFQELQLAAGRHGDDLKNTKN-EISELTRLIQRIRSEIENVKKQASNLE
gi 15321300	TKFQELQLAAGRHGDDLKNTKN-EISELTRLIQRIRSEIENVKKQASNLE
gi 9910294	TKFQELQLAAGRHGDDLKNTKN-EITELTRFIQRIRSEIENAKKQASNLE
gi 15321298	TKFQELQLAAGRHGDDLKNTKLCGEPPTHTPIN-----
gi 7161776	TKFQELQVLAGRHGDDLKNTKQ-EISEMNRMIQRIRAEIDSVKKQCSSLO
410 420 430 440 450	
NOV10a	TAIADAEQRGDNALKDARAKLDELEGALHQAKEELARMLREYQELMSLKL
gi 15321302	TAIADAEQRGDNALKDARAKLDELEGALHQAKEELARMLREYQELMSLKL
gi 15321300	TAIADAEQRGDNALKDARAKLDELEGALHQAKEELARMLREYQELMSLKL
gi 9910294	TAIADAEQRGDSALKDARAKLDELEGALHQAKEELARMLREYQELMSLKL
gi 15321298	-----SLAVMPQLH--HQPFRSWLPAFL--L-----C
gi 7161776	TAIADAEQRGELALKDARAKLVLEBALQAKQDMARELREYQELMNIKL
460 470 480 490 500	
NOV10a	ALDMEIATYRKLLSEECRMSGEEFSPVVISIISSTSGGSVSGYGGASGV
gi 15321302	ALDMEIATYRKLLSEECRMSGEEFSPVVISIISSTSGGSVYGFPRSMVS
gi 15321300	ALDMEIATYRKLLSEECRMSGEEFSPVVISIISSTSGGSVYGFPRSMVS
gi 9910294	ALDMEIATYRKLLSEECRMSGEEFSPVVISIISSTSGGSVYGFPRSTVS
gi 15321298	PASSAVANYSAGLPG-----SLPKAPHTLC-----PSIVP
gi 7161776	ALDMEIATYRKLLSEECRMSGEEFSPVVISIISSTSGGSVYGRGSSIGG
510 520 530 540 550	
NOV10a	CSGLLGGGSSSYSGSLGVCGGFSSSSCRAIGGGLSSVGGSSSTIKYTT
gi 15321302	C---GYVANSSNCISGVCSVRGGEGRRSASAN-DYKDTLKGSS-----
gi 15321300	C---GYVANSSNCISGVCSVRGGEGRRSASAN-DYKDTLKGSS-----
gi 9910294	C---GYVANSSNCISGVCSVRGGEGRRSASAN-DYKDTLKGSS-----
gi 15321298	A-----YARSWLCV-----
gi 7161776	GN-LGLGGGSGYSFTTSGGHSLLAGLGGSGFSATSNRCLGGSGSSVKFVS
560	
NOV10a	TSSSSRRKSYKH
gi 15321302	LSAPSKKTSR-
gi 15321300	LSAPSKKTSR-
gi 9910294	LSTPSKKKGR-
gi 15321298	-----
gi 7161776	TSSSSRRKSYTH

Table 10J lists the domain description from DOMAIN analysis results against NOV10a. This indicates that the NOV10a sequence has properties similar to those of other proteins known to contain these domains.

Table 10J. Domain Analysis of NOV10a

gnl|Pfam|pfam00038, filament, Intermediate filament protein. (SEQ ID NO:206)
Length = 312 residues, 100.0% aligned
Score = 291 bits (745), Expect = 7e-80

NOV10a	144	QEREQIKALNNKFASFIDKVRFLQQNQVLETKWELLQQLDLNNCKNNLEPILEGYISNL	203
00038	1	NEKEQMQLNDRLASVIDKVRFLQQNKELEVKIEELRQ-KQAPSVSRLYSLYTEIEEL	59
NOV10a	204	RKQLETLSGDRVRLDSELNRVDRVVEDYKKRYEEEINKRTAAENEFVLLKKDVDAAYANK	263
00038	60	RRQIDQLTNERARLQLEIDNLREAAEDFRKKYEDBINLRQEAENDLVGLRKDLDEATLAR	119
NOV10a	264	VELQAKVESMDQEIKFFRCLFEAEITQIQSHISDMSVILSMDNNRNLDDLSIIDEVRTQY	323
00038	120	VDLENKVESLQEELEFLKKNHEEEVKELQAAIQD-TNVNEMDAARKLDLTALREIRAQY	178
NOV10a	324	EEIALKSKAEAEALYQTKFQELQLAAGRHGDDLKNTKNEISELTRLIQRIRSEIENVKKQ	383
00038	179	EETAKNRQEAEEWYKSKLEELQTAAARNGEALRSAKEEITELRRQIQSLEIELQSLKAQ	238

NOV10a	384	ASNLETAIADAEQRGDNALKDARAKLDELEGALHQAEEELARMLREYQELMSLKLALDME	443
		++ + + + + + + + + + + +	
00038	239	NASLERQLAELEERYEELRQYQALISQLEEEELQQLREEMARQLREYQELLDVKLALDIE	298
NOV10a	444	IATYRKLESEECR	457
00038	299	IATYRKLEGEESR	312

Cytokeratins are constituent proteins of intermediate filaments (IFs) that form heterotypic tetrameric IF subunits containing two polypeptide chains of each of the two cytokeratin subfamilies, i.e. the acidic (type I) and the basic (type II). To locate the molecular domains involved in the formation of these heterotypic complexes, a binding assay was developed. The results obtained indicate that: (1) the binding between cytokeratin polypeptides of the complementary type is stronger and more selective than interactions of cytokeratins with other IF and non-IF proteins; (2) both the head and the tail portions of the proteins are not required for heterotypic complex formation; (3) the complementarity information located in the alpha-helical portions of the rod domain, and in short sequences immediately flanking them, is sufficient to discriminate between the two types of cytokeratins and to secure the formation of heterotypic cytokeratin complexes; (4) both coils 1 and 2 of the rod can contribute to this association; and (5) the formation of the heterotypic cytokeratin complex is not critically dependent upon ionic interactions. These results are further compatible with the concept that the heterotypic binding takes place between cytokeratin homodimer coiled-coils (Hatzfeld et al., Cytokeratin domains involved in heterotypic complex formation determined by in-vitro binding assays. J Mol Biol 197(2):237-55, 1987).

Human liver parenchymal cells have a very simple cytokeratin composition and express only one cytokeratin pair: cytokeratin 8 (a type II cytokeratin, molecular weight 52 kD) and cytokeratin 18 (a type I cytokeratin, molecular weight 45 kD). Intrahepatic bile duct cells contain in addition to cytokeratins 8 and 18 also cytokeratins 7 (a type II cytokeratin, molecular weight 54 kD) and cytokeratin 19 (a type I cytokeratin, molecular weight 40 kD) (Van Eyken et al., Immunocytochemistry of cytokeratins in primary human liver tumors. APMIS Suppl 23:77-85 1991).

Three monoclonal antibodies, 1C7, 2D7 and 6B10, directed against cytokeratins of human esophagus were isolated and characterized by one- and two-dimensional gel electrophoresis and by immunohistochemical staining on sections of human epithelial tissues. In immunoblot experiments, antibodies of clones 1C7 (IgG2a) and 2D7 (IgG2b) react only with cytokeratin no. 13 of the acidic (type I) subfamily of cytokeratin polypeptides (Mr 54000; pI 5.1); antibodies of clone 6B10 (IgG1) detect only cytokeratin no. 4 (Mr 59000; pI 7.3) of the basic (type II) cytokeratin subfamily and allows the detection of this protein and possible

degradation products at high sensitivity. These monoclonal antibodies are the first examples of antibodies specific for individual cytokeratin polypeptides characteristic of certain complex epithelia. They allow the identification of distinct minor populations of cells present in certain complex and glandular epithelia and in tumors derived therefrom which hitherto have not been distinguished. The possible reasons for the occurrence of cell type heterogeneity of cytokeratin expression in complex epithelia and in some carcinomas are discussed (van Muijen et al., Cell type heterogeneity of cytokeratin expression in complex epithelia and carcinomas as demonstrated by monoclonal antibodies specific for cytokeratins nos. 4 and 13. *Exp Cell Res* 162(1):97-113, 1986).

Studies have analyzed the possibility that cytoskeletal proteins may be the target of forskolin in living Caco-2 cells. It was shown that forskolin initiates dramatic changes in the spatial organization of the cytokeratin network that correlate with an increased phosphorylation of cytokeratin molecules, whereas microtubules, microfilaments and vimentin remain mainly unaffected. Indirect immunofluorescence studies showed that the cytokeratin network is redistributed from the cell periphery to the cytoplasm. Biochemical experiments indicate that forskolin doesn't interfere with the cytokeratin profile, since the three cytokeratins normally found in intestine (CK 8, CK 18, CK 19) are similarly expressed in both control and forskolin-Caco-2 cells. Analysis of ³²P-labeled cytokeratin extracted from the two cell populations demonstrates that forskolin quantitatively increases the phosphorylation of type I cytokeratin (CK 18 and CK 19), whereas the phosphorylation of type II cytokeratin (CK 8) is altered both quantitatively and qualitatively with the emergence of a new phosphorylation site (Baricault et al., The network organization and the phosphorylation of cytokeratins are concomitantly modified by forskolin in the enterocyte-like differentiated Caco-2 cell line. *J Cell Sci* 107 (Pt 10):2909-18, 1994).

By using the subtractive hybridization method, two complementary DNA clones differently expressed in rat normal esophageal epithelium and squamous cell carcinoma induced by administration of precursors of N-nitrososarcosine ethyl ester were isolated. A rat homologue of the human 50-kDa type I cytokeratin 14 was cloned for the first time and shown to be expressed preferentially in squamous cell papillomas and carcinomas, whereas it was weakly expressed or absent in normal squamous epithelial cells and in hyperplastic lesions. A rat homologue of the mouse 57-kDa type II cytokeratin showed strong expression in both normal and tumor tissues. These results are well consistent with the reported alteration of keratin subspecies in human esophageal cancers, therefore, encouraging us to use this experimental system as a model for human esophageal carcinogenesis (Wang et al.,

Identification of cytokeratin subspecies altered in rat experimental esophageal tumors by subtractive cloning. *Cancer Lett* 108(1):119-27, 1996).

5 The protein similarity information, expression pattern, and map location for the NOV10 suggest that NOV10 may have important structural and/or physiological functions characteristic of the Type II Cytokeratin protein family. Therefore, the NOV10 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV10 compositions of the present invention will have efficacy for treatment of patients suffering from inflammatory and infectious diseases such as AIDS; cancer, Neurologic
10 diseases, Brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, endocrine diseases, muscle disorders, wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer),
15 anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and
20 dyskinesias, such as Huntington's disease. The NOV10 nucleic acid encoding Type II Cytokeratin-like protein, and the Type II Cytokeratin-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOVX Nucleic Acids and Polypeptides

25 One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (*e.g.*, NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term
30 "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

The term “probes”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, *e.g.*, 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

30 The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments,

the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (*e.g.*, brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47 as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, *et al.*, (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15,

17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, or a complement thereof.

Oligonucleotides may be chemically synthesized and may also be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID
5 NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47,
or a portion of this nucleotide sequence (*e.g.*, a fragment that can be used as a probe or primer
or a fragment encoding a biologically-active portion of an NOVX polypeptide). A nucleic
acid molecule that is complementary to the nucleotide sequence shown NOS:1, 3, 5, 7, 9, 11,
13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 or 47 is one that is sufficiently
10 complementary to the nucleotide sequence shown NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23,
25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 or 47 that it can hydrogen bond with little or no
mismatches to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19,
21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, thereby forming a stable duplex.

As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base
15 pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means
the physical or chemical interaction between two polypeptides or compounds or associated
polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van
der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct
or indirect. Indirect interactions may be through or due to the effects of another polypeptide or
20 compound. Direct binding refers to interactions that do not take place through, or due to, the
effect of another polypeptide or compound, but instead are without other substantial chemical
intermediates.

Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic
acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific
25 hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of
amino acids, respectively, and are at most some portion less than a full length sequence.
Fragments may be derived from any contiguous portion of a nucleic acid or amino acid
sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed
from the native compounds either directly or by modification or partial substitution. Analogs
30 are nucleic acid sequences or amino acid sequences that have a structure similar to, but not
identical to, the native compound but differs from it in respect to certain components or side
chains. Analogs may be synthetic or from a different evolutionary origin and may have a
similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid
sequences or amino acid sequences of a particular gene that are derived from different species.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. *See e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

A “homologous nucleic acid sequence” or “homologous amino acid sequence,” or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for an NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, *e.g.*, frog, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

An NOVX polypeptide is encoded by the open reading frame ("ORF") of an NOVX
30 nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated
into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop
codon. An ORF that represents the coding sequence for a full protein begins with an ATG
"start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or
TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with

or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a *bona fide* cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47; or an anti-sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47; or of a naturally occurring mutant of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47.

Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express an NOVX protein, such as by measuring a level of an NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

“A polypeptide having a biologically-active portion of an NOVX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-active portion of NOVX" can be prepared by isolating a portion SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, that encodes a polypeptide having an NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of NOVX.

NOVX Nucleic Acid and Polypeptide Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27,

29, 31, 33, 35, 37, 39, 41, 43, 45 and 47 due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide
5 sequence encoding a protein having an amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48.

In addition to the human NOVX nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes
10 in the amino acid sequences of the NOVX polypeptides may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding an NOVX protein, preferably a vertebrate NOVX protein. Such
15 natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from the human SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their
20 homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the
30 nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under

stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T_m , 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, corresponds to a naturally-occurring nucleic acid molecule. As used herein,

a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known within the art. *See, e.g.*, Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (*e.g.*, as employed for cross-species hybridizations). *See, e.g.*, Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. *Proc Natl Acad Sci USA* 78: 6789-6792.

Conservative Mutations

In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48. A "non-essential"

Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48; more preferably at least about 70% homologous SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48; still more preferably at least about 80% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48; even more preferably at least about 90% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48; and most preferably at least about 95% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48.

25 An isolated nucleic acid molecule encoding an NOVX protein homologous to the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

30 Mutations can be introduced into SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with

an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved “strong” residues or fully conserved “weak” residues. The “strong” group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the “weak” group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and an NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (*e.g.* avidin proteins).

In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (*e.g.*, regulation of insulin release).

Antisense Nucleic Acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33,

35, 37, 39, 41, 43, 45 and 47, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (*e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of an NOVX protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, or antisense nucleic acids complementary to an NOVX nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (*e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an NOVX protein to thereby inhibit expression of the protein (*e.g.*, by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (*e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific

double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other. See, e.g., Gaultier, *et al.*, 1987. *Nucl. Acids Res.* **15**: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (See, e.g., Inoue, *et al.* 1987. *Nucl. Acids Res.* **15**: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, *et al.*, 1987. *FEBS Lett.* **215**: 327-330.

Ribozymes and PNA Moieties

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. *Nature* 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for an NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of an NOVX cDNA disclosed herein (*i.e.*, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an NOVX-encoding mRNA. See, e.g., U.S. Patent 4,987,071 to Cech, *et al.* and U.S. Patent 5,116,742 to Cech, *et al.* NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991. *Anticancer Drug Des.* **6**: 569-84; Helene, *et al.* 1992. *Ann. N.Y. Acad. Sci.* **660**: 27-36; Maher, 1992. *Bioassays* **14**: 807-15.

In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, *et al.*, 1996. *Bioorg Med*

Chem 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, *et al.*, 1996. *supra*; Perry-O'Keefe, *et al.*, 1996. *Proc. Natl. Acad. Sci. USA* 93: 14670-14675.

PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S₁ nucleases (See, Hyrup, *et al.*, 1996. *supra*); or as probes or primers for DNA sequence and hybridization (See, Hyrup, *et al.*, 1996, *supra*; Perry-O'Keefe, *et al.*, 1996. *supra*).

In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (see, Hyrup, *et al.*, 1996. *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, *et al.*, 1996. *supra* and Finn, *et al.*, 1996. *Nucl Acids Res* 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. See, e.g., Mag, *et al.*, 1989. *Nucl Acid Res* 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. See, e.g., Finn, *et al.*, 1996. *supra*. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, e.g., Petersen, *et al.*, 1975. *Bioorg. Med. Chem. Lett.* 5: 1119-11124.

1001515-11301

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (*see, e.g.*, Letsinger, *et al.*, 1989. *Proc. Natl. Acad. Sci. U.S.A.* 86: 6553-6556; Lemaitre, *et al.*, 1987. *Proc. Natl. Acad. Sci.* 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (*see, e.g.*, PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (*see, e.g.*, Krol, *et al.*, 1988. *BioTechniques* 6:958-976) or intercalating agents (*see, e.g.*, Zon, 1988. *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

NOVX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48 while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

In general, an NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (*e.g.*, the amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of an NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of an NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

In an embodiment, the NOVX protein has an amino acid sequence shown SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, and retains the functional activity of the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, and retains the functional activity of the NOVX proteins of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48.

Determining Homology Between Two or More Sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. *See*, Needleman and Wunsch, 1970. *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47.

1 The term "sequence identity" refers to the degree to which two polynucleotide or
polypeptide sequences are identical on a residue-by-residue basis over a particular region of
comparison. The term "percentage of sequence identity" is calculated by comparing two
optimally aligned sequences over that region of comparison, determining the number of
5 positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of
nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the
number of matched positions by the total number of positions in the region of comparison (*i.e.*,
the window size), and multiplying the result by 100 to yield the percentage of sequence
identity. The term "substantial identity" as used herein denotes a characteristic of a
10 polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80
percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent
sequence identity, more usually at least 99 percent sequence identity as compared to a
reference sequence over a comparison region.

Chimeric and Fusion Proteins

15 The invention also provides NOVX chimeric or fusion proteins. As used herein, an
NOVX "chimeric protein" or "fusion protein" comprises an NOVX polypeptide operatively-
linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having
an amino acid sequence corresponding to an NOVX protein SEQ ID NOS:2, 4, 6, 8, 10, 12,
14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, whereas a "non-NOVX
20 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein
that is not substantially homologous to the NOVX protein, *e.g.*, a protein that is different from
the NOVX protein and that is derived from the same or a different organism. Within an
NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of an NOVX
protein. In one embodiment, an NOVX fusion protein comprises at least one biologically-
25 active portion of an NOVX protein. In another embodiment, an NOVX fusion protein
comprises at least two biologically-active portions of an NOVX protein. In yet another
embodiment, an NOVX fusion protein comprises at least three biologically-active portions of
an NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to
indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with
30 one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the
NOVX polypeptide.

In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the
NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase)

sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

In another embodiment, the fusion protein is an NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is an NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an NOVX ligand and an NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction *in vivo*. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of an NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with an NOVX ligand.

An NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (*see, e.g.*, Ausubel, *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). An NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

NOVX Agonists and Antagonists

The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (*e.g.*, discrete point mutation or truncation of the NOVX protein).

- 5 An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific
- 10 biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

- Variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics)
- 15 or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (*e.g.*, truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example,
- 20 enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical
- 25 synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. *See, e.g.*, Narang, 1983. *Tetrahedron* 39: 3;
- 30 Itakura, *et al.*, 1984. *Annu. Rev. Biochem.* 53: 323; Itakura, *et al.*, 1984. *Science* 198: 1056; Ike, *et al.*, 1983. *Nucl. Acids Res.* 11: 477.

Polypeptide Libraries

In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent

selection of variants of an NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S₁ nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. *Proc. Natl. Acad. Sci. USA* 89: 7811-7815; Delgrave, et al., 1993. *Protein Engineering* 6:327-331.

Anti-NOVX Antibodies

Also included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab}, F_{ab}' and F_{(ab)2} fragments, and an F_{ab} expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated NOVX-related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX-related protein that is located on the surface of the protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of the human NOVX-related protein sequence will indicate which regions of a NOVX-related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, *e.g.*, Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, *Antibodies: A Laboratory Manual*, Harlow and Lane, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE*, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., *MONOCLONAL ANTIBODY PRODUCTION TECHNIQUES AND APPLICATIONS*, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by

the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *Nature* 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human

immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the
5 corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically
10 two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).
15

Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein.
20 Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by
25 using human hybridomas (see Cote, et al., 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991);
30 Marks et al., *J. Mol. Biol.*, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This

approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (*Bio/Technology* 10, 779-783 (1992)); Lonberg et al. (*Nature* 368 856-859 (1994)); Morrison (*Nature* 368, 812-13 (1994)); Fishwild et al., (*Nature Biotechnology* 14, 845-51 (1996)); Neuberger (*Nature Biotechnology* 14, 826
5 (1996)); and Lonberg and Huszar (*Intern. Rev. Immunol.* 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in
10 the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full
15 complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively
20 from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

25 An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain
30 locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a

nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

- 5 In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

F_{ab} Fragments and Single Chain Antibodies

- 10 According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective
- 15 identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_{(ab')₂} fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_{(ab')₂} fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing
- 20 agent and (iv) F_v fragments.

Bispecific Antibodies

- Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is
- 25 any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

- Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random
- 30 assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by

affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, 1991 *EMBO J.*, 10:3655-3659.

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.*, *Science* 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., *J. Exp. Med.* 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (scFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another

bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention.

- 5 Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
- 10 For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

Effector Function Engineering

- 15 It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody
- 20 can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).
- 25

Immunoconjugates

- The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
- 30

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain

(from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Anti-NOVX antibodies may be used in methods known within the art relating to the localization and/or quantitation of an NOVX protein (e.g., for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for NOVX

proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds (hereinafter "Therapeutics").

5 An anti-NOVX antibody (*e.g.*, monoclonal antibody) can be used to isolate an NOVX polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-NOVX antibody can facilitate the purification of natural NOVX polypeptide from cells and of recombinantly-produced NOVX polypeptide expressed in host cells. Moreover, an anti-NOVX antibody can be used to detect NOVX protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the NOVX
10 protein. Anti-NOVX antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent
15 materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example
20 of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

NOVX Recombinant Expression Vectors and Host Cells

25 Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA
30 segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San

Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. *Gene* 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (see, e.g., Wada, *et al.*, 1992. *Nucl. Acids Res.* 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1 (Baldari, *et al.*, 1987. *EMBO J.* 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. *Cell* 30: 933-943), pJRY88 (Schultz *et al.*, 1987. *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (Invitrogen Corp, San Diego, Calif.).

5 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian
cells using a mammalian expression vector. Examples of mammalian expression vectors
include pCDM8 (Seed, 1987. *Nature* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987. *EMBO*
J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are
often provided by viral regulatory elements. For example, commonly used promoters are
10 derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable
expression systems for both prokaryotic and eukaryotic cells see, *e.g.*, Chapters 16 and 17 of
Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring
Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the α -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA

1001515 "11301
molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes *see, e.g.,* Weintraub, *et al.*, "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.,* DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.,* resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a

selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

5 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

Transgenic NOVX Animals

15 The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

25 A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (*e.g.*, by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The

human NOVX cDNA sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA
5 (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as
10 mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of
15 NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at
20 least a portion of an NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (*e.g.*, the cDNA of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID
25 NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47 can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out"
30 vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion

of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. *See, e.g., Thomas, et al., 1987. Cell 51: 503* for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (*e.g., by electroporation*) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. *See, e.g., Li, et al., 1992. Cell 69: 915.*

The selected cells are then injected into a blastocyst of an animal (*e.g., a mouse*) to form aggregation chimeras. *See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152.* A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol. 2: 823-829*; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, *See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 6232-6236.* Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae*. *See, O'Gorman, et al., 1991. Science 251:1351-1355.* If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.*

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, *et al., 1997. Nature 385: 810-813.* In brief, a cell (*e.g., a somatic cell*) from the transgenic animal can be isolated and induced to exit the

growth cycle and enter G₀ phase. The quiescent cell can then be fused, *e.g.*, through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The
5 offspring borne of this female foster animal will be a clone of the animal from which the cell (*e.g.*, the somatic cell) is isolated.

Pharmaceutical Compositions

The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs
10 and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like,
15 compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be
20 used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its
25 intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (*i.e.*, topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine,
30 propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral

preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, an NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier

10 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

20 The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent No. 5,328,470) or by stereotactic injection (*see, e.g.*, Chen, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express NOVX protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (*e.g.*, in a biological sample) or a genetic lesion in an NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (*e.g.*; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention

can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, *supra*.

5 Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, *e.g.*, NOVX protein expression or NOVX protein activity.

10 The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. *See, e.g.*, Lam, 1997. *Anticancer Drug Design* 12: 145.

A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, *e.g.*, nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, *et al.*, 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, *et al.*, 1994. *Proc. Natl. Acad. Sci. U.S.A.* 91: 11422; Zuckermann, *et al.*, 1994. *J. Med. Chem.* 37: 2678; Cho, *et al.*, 1993. *Science* 261: 1303; Carrell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, *et al.*, 1994. *J. Med. Chem.* 37: 1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor,

1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, *et al.*, 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to an NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell.

Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule. As used herein, a "target molecule" is a molecule with which an NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses

an NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. An NOVX target molecule can be a non-NOVX molecule or an NOVX protein or polypeptide of the invention. In one embodiment, an NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

Determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular Ca^{2+} , diacylglycerol, IP_3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising an NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the NOVX protein

or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to an NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate an NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, *supra*.

In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of an NOVX target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins

can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, *supra*. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (*i.e.*, statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate

compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

In yet another aspect of the invention, the NOVX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos, *et al.*, 1993. *Cell* 72: 223-232; Madura, *et al.*, 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, *et al.*, 1993. *Biotechniques* 14: 920-924; Iwabuchi, *et al.*, 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, *et al.*, 1983. *Science* 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in

metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases.

5 However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, *see*, Verma, *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

10 Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations
15 during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, *e.g.*, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes
20 and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, *e.g.*, Egeland, *et al.*, 1987. *Nature*, 325: 783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is
25 observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete
30 sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Tissue Typing

The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with

one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine

The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a

1001515-11301
disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in an NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX in clinical trials.

These and other agents are described in further detail in the following sections.

Diagnostic Assays

An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions

to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

FOOTNOTES

An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of NOVX mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

5 The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

Prognostic Assays

10 The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

20 Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (*e.g.*, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

The methods of the invention can also be used to detect genetic lesions in an NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g.*, Landegran, *et al.*, 1988. *Science* 241: 1077-1080; and Nakazawa, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (*see*, Abravaya, *et al.*, 1995. *Nucl. Acids Res.* 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (*see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878*), transcriptional amplification system (*see, Kwoh, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177*); Q β Replicase

(see, Lizardi, *et al*, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

5 In an alternative embodiment, mutations in an NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in
10 the sample DNA. Moreover, the use of sequence specific ribozymes (*see, e.g.*, U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high-density arrays containing
15 hundreds or thousands of oligonucleotides probes. *See, e.g.*, Cronin, *et al.*, 1996. *Human Mutation* 7: 244-255; Kozal, *et al.*, 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, *et al.*, *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base
20 changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the
25 other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and
30 Gilbert, 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (*see, e.g.*, Naeve, *et al.*, 1995. *Biotechniques* 19: 448), including sequencing by mass spectrometry (*see, e.g.*, PCT

International Publication No. WO 94/16101; Cohen, *et al.*, 1996. *Adv. Chromatography* 36: 127-162; and Griffin, *et al.*, 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or
5 RNA/DNA heteroduplexes. *See, e.g.*, Myers, *et al.*, 1985. *Science* 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will
10 exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S₁ nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched
15 regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. *See, e.g.*, Cotton, *et al.*, 1988. *Proc. Natl. Acad. Sci. USA* 85: 4397; Saleeba, *et al.*, 1992. *Methods Enzymol.* 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more
20 proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. *See, e.g.*, Hsu, *et al.*, 1994. *Carcinogenesis* 15: 1657-1662. According to
25 an exemplary embodiment, a probe based on an NOVX sequence, *e.g.*, a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. *See, e.g.*, U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify
30 mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. *See, e.g.*, Orita, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA*: 86: 2766; Cotton, 1993. *Mutat. Res.* 285: 125-144; Hayashi, 1992. *Genet. Anal. Tech. Appl.* 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured

and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. *See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.*

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). *See, e.g., Myers, et al., 1985. Nature 313: 495.* When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. *See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.*

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. *See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230.* Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; *see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448*) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (*see, e.g., Prossner, 1993. Tibtech. 11: 238*). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. *See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1.* It is anticipated that in certain embodiments

amplification may also be performed using *Taq* ligase for amplification. *See, e.g.,* Barany, 1991. *Proc. Natl. Acad. Sci. USA* 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

5 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.,* in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an NOVX gene.

10 Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

Pharmacogenomics

15 Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (*e.g.,* NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's
20 Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (*i.e.,* the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may
25 be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.,* drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to
30 determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See *e.g.*, Eichelbaum, 1996. *Clin. Exp. Pharmacol. Physiol.*, 23: 983-985; Linder, 1997. *Clin. Chem.*, 43: 254-266. In general, two types of pharmacogenetic conditions can be

5 differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main

10 clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and

15 cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For

20 example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by

25 its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate

30 agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when

treating a subject with an NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trials of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trials of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates NOVX activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining

one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Osteodystrophy, and other diseases, disorders and conditions of the like.

These methods of treatment will be discussed more fully, below.

Disease and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to

Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an NOVX protein, a peptide, an NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of an NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering an NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

Stimulation of NOVX activity is desirable *in situations* in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immuné associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

Determination of the Biological Effect of the Therapeutic

In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo*

testing, any of the animal model system known in the art may be used prior to administration to human subjects.

Prophylactic and Therapeutic Uses of the Compositions of the Invention

5 The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders
10 associated with chronic diseases and various cancers.

As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease,
15 anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (*i.e.*, some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or
20 diagnostic methods.

25 The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

Examples

EXAMPLE 1: Identification of NOVX Nucleic Acids

TblastN using CuraGen Corporation's sequence file for polypeptides or homologs was
30 run against the Genomic Daily Files made available by GenBank or from files downloaded from the individual sequencing centers. Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for

example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

The novel NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. PCR primer sequences were used for obtaining different clones. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

Physical clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both

public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

Example 2: Identification of Single Nucleotide Polymorphisms in NOVX nucleic acid sequences

Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.

SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.

Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The

sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation's human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools™ program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.

The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein.

When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence.

Example 3. Quantitative expression analysis of clones in various cells and tissues

The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoinflammatory diseases), Panel CNSD.01 (containing samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer's diseased brains).

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β -actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix

Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.

In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 µg of total RNA were performed in a volume of 20 µl and incubated for 60 minutes at 42°C. This reaction can be scaled up to 50 µg of total RNA in a final volume of 100 µl. sscDNA samples are then normalized to reference nucleic acids as described previously, using 1X TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

Probes and primers were designed for each assay according to Applied Biosystems *Primer Express* Software package (version 1 for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM, primer melting temperature (T_m) range = 58°-60° C, primer optimal T_m = 59° C, maximum primer difference = 2° C, probe does not have 5' G, probe T_m must be 10° C greater than primer T_m , amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthesgen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200nM.

PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 48° C for 30 minutes followed by amplification/PCR cycles as follows: 95° C 10 min, then 40 cycles of 95° C for 15 seconds, 60° C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1X TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification was performed as follows: 95° C 10 min, then 40 cycles of 95° C for 15 seconds, 60° C for 1 minute. Results were analyzed and processed as described previously.

Panels 1, 1.1, 1.2, and 1.3D

The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:

ca. = carcinoma,
 * = established from metastasis,
 met = metastasis,
 s cell var = small cell variant,
 non-s = non-sm = non-small,
 squam = squamous,
 pl. eff = pl effusion = pleural effusion,
 glioma = glioma,
 astro = astrocytoma, and
 neuro = neuroblastoma.

General_screening_panel_v1.4

The plates for Panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panel 1.4 are

broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer.

- 5 Cell lines used in Panel 1.4 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panel 1.4 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal
10 skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.

15 **Panels 2D and 2.2**

- The plates for Panels 2D and 2.2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from
20 human malignancies and in cases where indicated many malignant tissues have "matched margins" obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in the results below. The tumor tissue and the "matched margins" are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI or CHTN). This analysis provides a gross
25 histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated "NAT", for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from
30 autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

Panel 3D

The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally
5 obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of
10 cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.

Panels 4D, 4R, and 4.1D

Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples)
15 composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). Intestinal tissue for
20 RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human
25 umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at
30 approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS

(Hyclone), 100 μ M non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μ g/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco).with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μ g/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10^{-5} M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GM-CSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μ g/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were

placed in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and plated at 10^6 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μ g/ml anti-CD28 (Pharmingen) and 3 μ g/ml anti-CD3 (OKT3, ATCC) in
 5 PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and IL-2.
 10 The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco)
 15 and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resuspended at 10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM
 20 Hepes (Gibco). To activate the cells, we used PWM at 5 μ g/ml or anti-CD40 (Pharmingen) at approximately 10 μ g/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μ g/ml anti-CD28 (Pharmingen) and 2 μ g/ml OKT3 (ATCC),
 25 and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, MD) were cultured at 10^5 - 10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μ g/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μ g/ml) were
 30 used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5

days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 µg/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×10^5 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10^5 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 µg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately 10^7 cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at -20 degrees C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 µl of RNase-free water and 35 µl buffer (Promega) 5 µl DTT, 7 µl RNasin and 8 µl DNase were added. The tube was incubated at 37 degrees C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at -80 degrees C.

AI_comprehensive panel_v1.0

The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, MD). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.

Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.

Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebid and two were on phenobarbital.

Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-1 anti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:

AI = Autoimmunity
Syn = Synovial
Normal = No apparent disease
Rep22 /Rep20 = individual patients
RA = Rheumatoid arthritis
Backus = From Backus Hospital

OA = Osteoarthritis
 (SS) (BA) (MF) = Individual patients
 Adj = Adjacent tissue
 Match control = adjacent tissues
 -M = Male
 -F = Female
 COPD = Chronic obstructive pulmonary disease

Panels 5D and 5I

The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

In the Gestational Diabetes study subjects are young (18 - 40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:

Patient 2	Diabetic Hispanic, overweight, not on insulin
Patient 7-9	Nondiabetic Caucasian and obese (BMI>30)
Patient 10	Diabetic Hispanic, overweight, on insulin
Patient 11	Nondiabetic African American and overweight
Patient 12	Diabetic Hispanic on insulin

Adipocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells *Science* Apr 2 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:

Donor 2 and 3 U	Mesenchymal Stem cells	Undifferentiated Adipose
-----------------	------------------------	--------------------------

Donor 2 and 3 AM Adipose
Donor 2 and 3 AD Adipose

AdiposeMidway Differentiated
Adipose Differentiated

Human cell lines were generally obtained from ATCC (American Type Culture
Collection), NCI or the German tumor cell bank and fall into the following tissue groups:
kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2
cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all
cultured under standard recommended conditions and RNA extracted using the standard
procedures. All samples were processed at CuraGen to produce single stranded cDNA.

Panel 5I contains all samples previously described with the addition of pancreatic islets
from a 58 year old female patient obtained from the Diabetes Research Institute at the
University of Miami School of Medicine. Islet tissue was processed to total RNA at an
outside source and delivered to CuraGen for addition to panel 5I.

In the labels employed to identify tissues in the 5D and 5I panels, the following
abbreviations are used:

GO Adipose = Greater Omentum Adipose
SK = Skeletal Muscle
UT = Uterus
PL = Placenta
AD = Adipose Differentiated
AM = Adipose Midway Differentiated
U = Undifferentiated Stem Cells

Panel CNSD.01

The plates for Panel CNSD.01 include two control wells and 94 test samples
comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard
Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24
hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor.
All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear
associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains two brains from
each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's
disease, Progressive Supranuclear Palsy, Depression, and "Normal controls". Within each of
these brains, the following regions are represented: cingulate gyrus, temporal pole, globus
pallidus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal
cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all
brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by

neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

PSP = Progressive supranuclear palsy
Sub Nigra = Substantia nigra
Glob Palladus= Globus palladus
Temp Pole = Temporal pole
Cing Gyr = Cingulate gyrus
BA 4 = Brodman Area 4

15 **Panel CNS_Neurodegeneration_V1.0**

The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from "Normal controls" who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0 = no evidence of plaques, 3 = severe AD senile plaque load). Within each of these brains, the following regions are represented:

hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a "control" region within AD patients. Not all brain regions are represented in all cases.

In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:

AD = Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy

- 5 Control = Control brains; patient not demented, showing no neuropathology
 Control (Path) = Control brains; patient not demented but showing severe AD-like pathology
 SupTemporal Ctx = Superior Temporal Cortex
 Inf Temporal Ctx = Inferior Temporal Cortex

10 **NOV1a: Membrane Protein/neuropilin/metalloproteinase-like**

Expression of the NOV1a gene (SC40376139) was assessed using the primer-probe set Ag2229 described in Table 11. Results from RTQ-PCR runs are shown in Tables 12 and 13.

Table 11. Probe Name Ag2229

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5' - ACCAAATTTGGTGAAGGAGATT - 3'	58.9	22	700	128
Probe	TET-5' - CAACAATTCGTGTGATCAAATATAGTCCTG-3' - TAMRA	65.5	30	722	129
Reverse	5' - CCATCTTCAAATCCACAATGAA - 3'	59.8	22	773	130

15

Table 12. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	tm4184t_ag2229		tm4184t_ag2229
Liver adenocarcinoma	0.0	Kidney (fetal)	1.0
Pancreas	0.0	Renal ca. 786-0	6.6
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	0.0
Adrenal gland	0.0	Renal ca. RXF 393	0.0
Thyroid	0.0	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.0
Pituitary gland	0.0	Renal ca. TK-10	0.0
Brain (fetal)	24.0	Liver	0.0
Brain (whole)	13.8	Liver (fetal)	0.0
Brain (amygdala)	19.5	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	4.6	Lung	0.0
Brain (hippocampus)	100.0	Lung (fetal)	0.0
Brain (substantia nigra)	6.6	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	18.2	Lung ca. (small cell) NCI-H69	9.4
Cerebral Cortex	82.4	Lung ca. (s.cell var.) SHP-77	36.3
Spinal cord	5.0	Lung ca. (large cell) NCI-H460	0.0
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.0
CNS ca. (glio/astro) U-118-MG	1.6	Lung ca. (non-s.cell) NCI-H23	0.0

CNS ca. (astro) SW1783	0.0	Lung ca (non-s.cell) HOP-62	0.0
CNS ca.* (neuro; met) SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio) SNB-19	0.0	Mammary gland	0.0
CNS ca. (glio) U251	0.0	Breast ca.* (pl. effusion) MCF-7	1.6
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.0	Breast ca.* (pl. effusion) T47D	6.4
Heart	0.0	Breast ca. BT-549	0.0
Fetal Skeletal	0.0	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.0	Ovarian ca. OVCAR-4	0.0
Spleen	0.0	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	3.3
Colorectal	0.0	Ovarian ca. IGROV-1	0.0
Stomach	0.0	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	0.0	Uterus	0.0
Colon ca. SW480	0.0	Placenta	0.0
Colon ca.* (SW480 met)SW620	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	2.1
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	4.2
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	1.7
Bladder	0.0	Melanoma LOX IMV1	0.0
Trachea	0.0	Melanoma* (met) SK-MEL-5	15.4
Kidney	0.0	Adipose	0.0

Table 13. Panel CNS_neurodegeneration_v1.0

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	tm7007t_ag2229_a1_s2		tm7007t_ag2229_a1_s2
AD 1 Hippo	0.9	Control (Path) 3 Temporal Ctx	2.3
AD 2 Hippo	30.7	Control (Path) 4 Temporal Ctx	13.8
AD 3 Hippo	1.3	AD 1 Occipital Ctx	4.3
AD 4 Hippo	1.5	AD 2 Occipital Ctx (Missing)	1.2
AD 5 hippo	19.4	AD 3 Occipital Ctx	1.2
AD 6 Hippo	17.0	AD 4 Occipital Ctx	5.5
Control 2 Hippo	18.4	AD 5 Occipital Ctx	1.8
Control 4 Hippo	1.4	AD 6 Occipital Ctx	17.5
Control (Path) 3 Hippo	0.6	Control 1 Occipital Ctx	0.0

AD 1 Temporal Ctx	3.5	Control 2 Occipital Ctx	41.5
AD 2 Temporal Ctx	10.2	Control 3 Occipital Ctx	3.5
AD 3 Temporal Ctx	0.8	Control 4 Occipital Ctx	1.9
AD 4 Temporal Ctx	3.3	Control (Path) 1 Occipital Ctx	100.0
AD 5 Inf Temporal Ctx	10.1	Control (Path) 2 Occipital Ctx	3.1
AD 5 Sup Temporal Ctx	2.8	Control (Path) 3 Occipital Ctx	0.9
AD 6 Inf Temporal Ctx	21.5	Control (Path) 4 Occipital Ctx	3.3
AD 6 Sup Temporal Ctx	30.3	Control 1 Parietal Ctx	1.5
Control 1 Temporal Ctx	5.5	Control 2 Parietal Ctx	3.5
Control 2 Temporal Ctx	22.2	Control 3 Parietal Ctx	7.6
Control 3 Temporal Ctx	4.5	Control (Path) 1 Parietal Ctx	47.8
Control 4 Temporal Ctx	2.7	Control (Path) 2 Parietal Ctx	11.4
Control (Path) 1 Temporal Ctx	29.1	Control (Path) 3 Parietal Ctx	1.8
Control (Path) 2 Temporal Ctx	15.5	Control (Path) 4 Parietal Ctx	30.0

Panel 1.3D Summary Expression of the NOV1 gene appears to be brain-specific. Highest expression is detected in the hippocampus (CT=33) and the cerebral cortex, two regions that degenerate in Alzheimer's disease. Thus, this gene would be useful for distinguishing brain tissue from non-neural tissue, and may be beneficial as a drug target in neurodegenerative disease. Please see Panel_CNS_neurodegeneration for further discussion of potential utility in the central nervous system.

Panel 2D Summary Expression of the NOV1 gene is low/undetectable (Ct values >35) in all samples in this panel. (Data not shown.)

Panel 4D Summary Expression of the NOV1 gene is low/undetectable (Ct values >35) in all samples in this panel. (Data not shown.)

Panel CNS_1 Summary Expression of the NOV1 gene is low/undetectable (Ct values >35) in all samples in this panel. (Data not shown.)

Panel CNS_neurodegeneration_v1.0 Summary The NOV1 gene is expressed at low but significant levels in the brain, as is seen in Panel 1.3D, with highest expression in the occipital cortex from the brain of a control patient (CT=32.2). Importantly, once the CT values are corrected for RNA quality/amount per well, there appears to be a down-regulation in the temporal cortex of the Alzheimer's diseased (AD) brain (in 5 of 6 diseased brains), a region that is known to undergo severe neurodegeneration. Conversely, in the occipital cortex, where neurodegeneration is not observed in AD, this gene does not appear to be differentially regulated. Neuropilins act as receptors for semaphorins, which mediate axon repulsion during neurodevelopment as well as neuroapoptosis. Thus, the downregulation of the expression of this gene may be critically involved in the neurodegeneration seen in Alzheimer's disease. Therefore, selective antagonism of this receptor may slow neurodegeneration in this disease or

enhance the compensatory synaptogenesis process. Furthermore, the NOV1 gene product may be useful in any clinical situation involving neuronal death, such as Parkinson's or Huntington's disease, spinocerebellar ataxia, head or spinal cord trauma, or stroke (Zhang et al., Up-regulation of neuropilin-1 in neovasculature after focal cerebral ischemia in the adult rat. J Cereb Blood Flow Metab. 21(5):541-9, 2001; Ziv et al., Semaphorins as mediators of neuronal apoptosis. J Neurochem. 73(3):961-71, 1999).

NOV2: Fibrillin-like protein

Expression of the NOV2a gene (GMAC022146_A) and variants NOV2b (153568997), NOV2c (CG88987-01), NOV2d (CG88987-02), NOV2e (CG88987-03) and NOV2f (CG88987-05) was assessed using the primer-probe sets Ag72, Ag390, Ag671, Ag766, Ag1211, Ag1928, Ag1938, Ag2233, Ag2241, Ag4154, and Ag4334 described in Tables 11-24. Please note that not all probe and primer sets match all the sequences. Table 25 provides a complete summary of the probe and primer sets that correspond to each sequence, where the "X" represents a match between the sequence and the probe and primer set. Results from RTQ-PCR runs are shown in Tables 26-35.

Table 14. Probe Name Ag72

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-CAGCGGAAAGACCCAGCA-3'		18	64	131
Probe	FAM-5'-CGCCCGTTGGGACAGACTCCC-3'-TAMRA		21	94	132
Reverse	5'-GATGTGAACGAGTGTGAGTCCTTC-3'		24	117	133

Table 15. Probe Name Ag390

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-ACCAATGTCATCGGAGGCTT-3'		20	175	134
Probe	FAM-5'-TCAAAGCCGTGACACAGGCACA-3'-TAMRA		23	199	135
Reverse	5'-GATGTCCTCGCAGGTCATCAT-3'		21	232	136

Table 16. Probe Name Ag671

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-ACTAACGGCGTCTGTGTCAA-3'	59.4	20	37	137
Probe	FAM-5'-CCTTTGGCTACAGCCTGGACTTCACT-3'-TAMRA	68.6	26	86	138
Reverse	5'-GTCTGTGTCCACACAGTTGATG-3'	59.1	22	114	139

Table 17. Probe Name Ag766

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-TGCTACTACCTGCCTGGATATG-3'	59.3	22	839	140
Probe	TET-5'-CAAGCCATGTACCTTCCTCTGCAAAA-3'-	68.2	26	881	141

	TAMRA				
Reverse	5'-GACAGCTGCACAGGAACTG-3'	59.6	20	917	142

Table 18. Probe Name Ag1211

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-CCCCTTGACATTGATGAGTGT-3'	59.8	21	367	143
Probe	FAM-5'-AGATCCCCGCCATCTGTGCCAAT-3'-TAMRA	71.7	23	392	144
Reverse	5'-ACTCCCGATCTGGTTTATGC-3'	59	20	422	145

Table 19. Probe Name Ag1928

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-AATACCGAGGGCTCCTACCT-3'	59.1	20	566	146
Probe	FAM-5'-ACCTGTCCAGCCGGCTACACCT-3'-TAMRA	71.1	23	590	147
Reverse	5'-CATTCATTGTCTCTCGACACA-3'	59.6	22	630	148

Table 20. Probe Name Ag1938

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GCCCTGGCAACTCTAATATTG-3'	58.7	21	941	149
Probe	TET-5'-CACTGCTACCTGAACCAGACCATTG-3'-TAMRA	68.8	26	963	150
Reverse	5'-ATTGAGACACAGGTTGGTGAAG-3'	59.1	22	1002	151

Table 21. Probe Name Ag2233

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-CATGCATTTCTGACCTTGCT-3'	58.9	20	101	152
Probe	FAM-5'-CCCACTCAAAGCTTTCAAGGGCTCT-3'-TAMRA	69.4	26	124	153
Reverse	5'-GTCATGCAGCTTTTGCTCAT-3'	59	20	166	154

Table 22. Probe Name Ag2241

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-CCACAGTGACTTGCCACATT-3'	59.6	20	9500	155
Probe	TET-5'-CCCCATTGGAGAATGCTTTTATATCA-3'-TAMRA	65.8	27	9524	156
Reverse	5'-AGGCAGGCAGACTTAACC-3'	59.3	19	9580	157

Table 23. Probe Name Ag4154

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-CTGTGAGGATATTGACGAATGC-3'	59.6	22	4867	158
Probe	FAM-5'-TCCACACACTCCGGCATCTGTGG-3'-TAMRA	71.8	23	4889	159
Reverse	5'-AGTTCCCCAGGGTGTGTAG-3'	58.9	20	4924	160

Table 24. Probe Name Ag4334

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-CTGTGAGGATATTGACGAATGC-3'	59.6	22	4407	161
Probe	FAM-5'-TCCACACACTCCGGCATCTGTGG-3'-TAMRA	71.8	23	4429	162
Reverse	5'-TAGTTCCCCAGGGTGTGTAG-3'	59	21	4464	163

Table 25.

	GMAC022146_A	153568997	CG88987-01	CG88987-02	CG88987-03	CG88987-05
Ag72	X	X	X	X	X	X
Ag390		X	X	X	X	X
Ag671	X		X	X		
Ag766	X	X	X	X	X	X
Ag1211	X	X	X	X	X	X
Ag1928						X
Ag1938	X	X	X	X	X	X
Ag2233	X	X	X			
Ag2241	X	X	X	X		X
Ag4154	X	X	X	X	X	X
Ag4334	X	X	X	X	X	X

Table 26. Panel 1

Tissue Name	Relative Expression(%)		Relative Expression(%)	
	tm407f	tm486f	tm208f	tm362f
Endothelial cells	0	0	0	0.1
Endothelial cells (treated)	0	0	0.1	0
Pancreas	0	0	0	0
Pancreatic ca. CAPAN 2	0	0.8	0.3	0
Adrenal gland	0	0	0.1	0
Thyroid	7.4	5.1	4.5	0
Salivary gland	5.9	1.3	2.8	0.3
Pituitary gland	0	0.1	0	0
Brain (fetal)	100	60.7	100	96.6
Brain (whole)	3	3.6	0	0
Brain (amygdala)	0.8	1.1	0.5	0.1
Brain (cerebellum)	1.4	0.3	0.1	0
Brain (hippocampus)	2.8	1	0.7	0.2
Brain (substantia nigra)	7.3	0.9	0.4	0
Brain (thalamus)	2	1.1	0.4	0.1
Brain (hypothalamus)	5.6	1.7	2	0.2
Spinal cord	1.2	1.2	0.2	0
CNS ca. (glio/astro) U87-MG	0	0	0	0
CNS ca. (glio/astro) U-118-MG	0	0.1	0	0
CNS ca. (astro) SW1783	0	0.1	0	0.1
CNS ca. * (neuro; met) SK-N-AS	0	0	0	0
CNS ca. (astro) SF-539	0	0	0	0
CNS ca. (astro) SNB-75	0	0	0	0
CNS ca. (glio) SNB-19	2.7	2.3	1.4	0
CNS ca. (glio) U251	0	0.8	0.5	0
CNS ca. (glio) SF-295	0	0	0	0
Heart	0	0.5	0.1	0
Skeletal muscle	0	0.1	0	0.2
Bone marrow	0	0	0	0
Thymus	1.9	0	1.8	0

Spleen	0	0	0.3	0
Lymph node	0	0.1	0.1	0
Colon (ascending)	0.8	1.4	1.5	0.1
Stomach	0	0.2	0.1	0
Small intestine	0	0.1	0	0
Colon ca. SW480	0	2.5	0	0
Colon ca.* (SW480 met)SW620	0.2	3	0.5	0
Colon ca. HT29	0	0	0.1	0
Colon ca. HCT-116	2.7	6.5	0	0
Colon ca. CaCo-2	21.9	17.4	7.4	6
Colon ca. HCT-15	2	1.4	1.3	0.1
Colon ca. HCC-2998	0	2.7	0.4	0
Gastric ca.* (liver met) NCI-N87	91.4	51.8	38.4	100
Bladder	0	0.5	0	0
Trachea	0	1.2	0	0
Kidney	7.6	3.1	3.7	2.4
Kidney (fetal)	46.7	8.7	16.5	0
Renal ca. 786-0	0	0	0	0.1
Renal ca. A498	0	0	0	0
Renal ca. RXF 393	0	0	0	0
Renal ca. ACHN	0	0	0	0
Renal ca. UO-31	0	0.1	0.1	0
Renal ca. TK-10	0	0	0.4	0
Liver	0.1	0.2	0	0
Liver (fetal)	0	0.4	0.7	0
Liver ca. (hepatoblast) HepG2	14.7	29.7	3.9	3.1
Lung	7.7	0	1.4	14.9
Lung (fetal)	81.8	100	49.7	38.2
Lung ca. (small cell) LX-1	1.6	8.1	1	0
Lung ca. (small cell) NCI-H69	0	2.2	0.8	0
Lung ca. (s.cell var.) SHP-77	0.3	1.9	0	0
Lung ca. (large cell)NCI-H460	0	0.1	0	0.1
Lung ca. (non-sm. cell) A549	0.1	0.1	0.1	0
Lung ca. (non-s.cell) NCI-H23	0	2	0	0
Lung ca (non-s.cell) HOP-62	0	0	0	0.1
Lung ca. (non-s.cl) NCI-H522	1.3	0.7	0.7	0
Lung ca. (squam.) SW 900	0	1.7	0.3	0
Lung ca. (squam.) NCI-H596	0	0.6	0	0
Mammary gland	0.2	2.4	0.8	0
Breast ca.* (pl. effusion) MCF-7	0	0.2	0.2	0
Breast ca.* (pl.ef) MDA-MB-231	0	0.1	0	0
Breast ca.* (pl. effusion) T47D	3.6	5.1	2.9	0
Breast ca. BT-549	0	0.1	0	0
Breast ca. MDA-N	0	46.7	0.6	0
Ovary	0.3	1.7	2	0

Ovarian ca. OVCAR-3	7.5	18.8	4.9	0.6
Ovarian ca. OVCAR-4	8.8	5.4	3.3	7.4
Ovarian ca. OVCAR-5	0	0.7	1.3	0.5
Ovarian ca. OVCAR-8	0	1.4	0.1	0
Ovarian ca. IGROV-1	0	1.6	0.4	0
Ovarian ca. * (ascites) SK-OV-3	0	0.1	0.3	0
Uterus	8.5	2	5.3	0.3
Placenta	0	0	0	0
Prostate	0.3	0.5	1.5	0
Prostate ca. * (bone met)PC-3	0	0.1	0	0
Testis	6.2	1.5	4.2	0
Melanoma Hs688(A).T	0	0	0	0
Melanoma* (met) Hs688(B).T	0	0.2	0.2	0
Melanoma UACC-62	0	0	0	0
Melanoma M14	0	0.1	1.7	0
Melanoma LOX IMVI	0	0	0.2	0
Melanoma* (met) SK-MEL-5	0	0.1	0	0
Melanoma SK-MEL-28	0	0	0	0

Table 27. Panel 1.1

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.1tm808f_ag671		1.1tm808f_ag671
Adrenal gland	0.0	Renal ca. UO-31	0.0
Bladder	0.0	Renal ca. RXF 393	0.0
Brain (amygdala)	0.0	Liver	0.0
Brain (cerebellum)	0.0	Liver (fetal)	0.0
Brain (hippocampus)	0.0	Liver ca. (hepatoblast) HepG2	4.3
Brain (substantia nigra)	0.5	Lung	0.0
Brain (thalamus)	0.0	Lung (fetal)	70.7
Cerebral Cortex	0.0	Lung ca (non-s.cell) HOP-62	0.0
Brain (fetal)	100.0	Lung ca. (large cell)NCI-H460	0.0
Brain (whole)	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
CNS ca. (astro) SF-539	0.0	Lung ca. (non-sm. cell) A549	0.0
CNS ca. (astro) SNB-75	0.0	Lung ca. (s.cell var.) SHP-77	0.0
CNS ca. (astro) SW1783	0.0	Lung ca. (small cell) LX-1	0.5
CNS ca. (glio) U251	0.0	Lung ca. (small cell) NCI-H69	0.0
CNS ca. (glio) SF-295	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (glio) SNB-19	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio/astro) U87-MG	0.0	Lymph node	0.0
CNS ca. * (neuro; met) SK-N-AS	0.0	Spleen	0.0
Mammary gland	0.0	Thymus	0.0
Breast ca. BT-549	0.0	Ovary	0.0
Breast ca. MDA-N	0.0	Ovarian ca. IGROV-1	0.0

Breast ca.* (pl. effusion) T47D	0.2	Ovarian ca. OVCAR-3	20.3
Breast ca.* (pl. effusion) MCF-7	0.0	Ovarian ca. OVCAR-4	4.5
Breast ca.* (pl.ef) MDA-MB-231	0.0	Ovarian ca. OVCAR-5	0.0
Small intestine	0.0	Ovarian ca. OVCAR-8	0.0
Colorectal	0.0	Ovarian ca.* (ascites) SK-OV-3	0.0
Colon ca. HT29	0.0	Pancreas	0.0
Colon ca. CaCo-2	9.9	Pancreatic ca. CAPAN 2	0.0
Colon ca. HCT-15	0.0	Pituitary gland	0.6
Colon ca. HCT-116	0.0	Placenta	0.0
Colon ca. HCC-2998	0.0	Prostate	0.0
Colon ca. SW480	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca.* (SW480 met)SW620	0.0	Salivary gland	0.5
Stomach	0.0	Trachea	0.2
Gastric ca.* (liver met) NCI-N87	66.0	Spinal cord	0.1
Heart	0.0	Testis	0.0
Fetal Skeletal	1.0	Thyroid	4.1
Skeletal muscle	0.0	Uterus	0.0
Endothelial cells	0.0	Melanoma M14	0.0
Heart (fetal)	0.0	Melanoma LOX IMVI	0.0
Kidney	15.3	Melanoma UACC-62	0.0
Kidney (fetal)	11.5	Melanoma SK-MEL-28	0.0
Renal ca. 786-0	0.0	Melanoma* (met) SK-MEL-5	0.0
Renal ca. A498	0.0	Melanoma Hs688(A).T	0.0
Renal ca. ACHN	0.0	Melanoma* (met) Hs688(B).T	0.0
Renal ca. TK-10	0.0		

Table 28. Panel 1.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.2tm915t_ag766		1.2tm915t_ag766
Endothelial cells	0.0	Renal ca. 786-0	0.0
Heart (fetal)	0.0	Renal ca. A498	0.0
Pancreas	0.3	Renal ca. RXF 393	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. ACHN	0.0
Adrenal Gland (new lot*)	0.0	Renal ca. UO-31	0.0
Thyroid	9.3	Renal ca. TK-10	0.0
Salivary gland	6.2	Liver	0.5
Pituitary gland	6.7	Liver (fetal)	2.4
Brain (fetal)	100.0	Liver ca. (hepatoblast) HepG2	6.5
Brain (whole)	3.7	Lung	3.7
Brain (amygdala)	2.2	Lung (fetal)	60.3
Brain (cerebellum)	0.0	Lung ca. (small cell) LX-1	3.7
Brain (hippocampus)	5.4	Lung ca. (small cell) NCI-H69	0.0
Brain (thalamus)	2.1	Lung ca. (s.cell var.) SHP-77	0.2
Cerebral Cortex	2.5	Lung ca. (large cell)NCI-H460	0.0

Spinal cord	2.0	Lung ca. (non-sm. cell) A549	0.0
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.1
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca (non-s.cell) HOP-62	0.0
CNS ca. (astro) SW1783	0.0	Lung ca. (non-s.cl) NCI-H522	1.2
CNS ca. * (neuro; met) SK-N-AS	0.0	Lung ca. (squam.) SW 900	0.3
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (astro) SNB-75	0.0	Mammary gland	2.3
CNS ca. (glio) SNB-19	0.6	Breast ca.* (pl. effusion) MCF-7	0.0
CNS ca. (glio) U251	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl. effusion) T47D	2.0
Heart	1.2	Breast ca. BT-549	0.0
Skeletal Muscle (new lot*)	0.6	Breast ca. MDA-N	0.0
Bone marrow	0.0	Ovary	0.5
Thymus	0.6	Ovarian ca. OVCAR-3	11.2
Spleen	0.0	Ovarian ca. OVCAR-4	6.2
Lymph node	0.0	Ovarian ca. OVCAR-5	0.1
Colorectal	0.0	Ovarian ca. OVCAR-8	0.2
Stomach	0.1	Ovarian ca. IGROV-1	1.0
Small intestine	0.3	Ovarian ca. * (ascites) SK-OV-3	0.0
Colon ca. SW480	0.6	Uterus	0.0
Colon ca.* (SW480 met)SW620	1.3	Placenta	0.0
Colon ca. HT29	0.0	Prostate	3.1
Colon ca. HCT-116	1.6	Prostate ca.* (bone met)PC-3	0.0
Colon ca. CaCo-2	7.6	Testis	3.8
83219 CC Well to Mod Diff (ODO3866)	0.0	Melanoma Hs688(A).T	0.0
Colon ca. HCC-2998	0.7	Melanoma* (met) Hs688(B).T	0.0
Gastric ca.* (liver met) NCI-N87	50.7	Melanoma UACC-62	0.0
Bladder	0.0	Melanoma M14	0.0
Trachea	2.5	Melanoma LOX IMVI	0.0
Kidney	9.0	Melanoma* (met) SK-MEL-5	0.0
Kidney (fetal)	29.3		

Table 29. Panel 1.3D

Tissue Name	Relative Expression(%)		Relative Expression(%)
	1.3Dtm2819f_ag 1211	1.3Dtm2843f_ag 1211	1.3dtm4344f_ag 2233
Liver adenocarcinoma	30.6	39.0	14.2
Pancreas	0.0	0.4	0.0
Pancreatic ca. CAPAN 2	0.0	0.0	0.0
Adrenal gland	0.7	0.0	0.0
Thyroid	2.8	5.7	4.4
Salivary gland	0.7	2.7	1.3
Pituitary gland	4.2	4.2	0.0
Brain (fetal)	47.6	49.7	100.0
Brain (whole)	1.5	0.7	2.2

Liver	0.0	0.0	0.0
Liver (fetal)	1.4	1.8	0.3
Liver ca. (hepatoblast) HepG2	12.2	4.8	9.5
Lung	6.7	1.8	5.1
Lung (fetal)	100.0	92.0	25.5
Lung ca. (small cell) LX-1	1.5	2.6	0.9
Lung ca. (small cell) NCI-H69	0.0	0.0	0.0
Lung ca. (s.cell var.) SHP-77	0.0	0.3	0.0
Lung ca. (large cell) NCI-H460	0.0	0.0	0.0
Lung ca. (non-sm. cell) A549	0.6	0.0	0.0
Lung ca. (non-s.cell) NCI-H23	1.0	0.0	0.0
Lung ca (non-s.cell) HOP-62	0.0	0.5	0.0
Lung ca. (non-s.cl) NCI-H522	0.3	0.2	0.0
Lung ca. (squam.) SW 900	0.3	0.6	1.8
Lung ca. (squam.) NCI-H596	0.0	0.0	0.0
Mammary gland	4.1	2.6	0.8
Breast ca.* (pl. effusion) MCF-7	0.0	0.0	0.0
Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0	0.0
Breast ca.* (pl. effusion) T47D	1.5	0.7	1.5
Breast ca. BT-549	0.0	0.0	1.6
Breast ca. MDA-N	0.0	0.0	0.0
Ovary	1.4	4.6	1.7
Ovarian ca. OVCAR-3	15.3	12.9	7.9
Ovarian ca. OVCAR-4	0.5	0.8	0.9
Ovarian ca. OVCAR-5	0.0	0.0	0.7
Ovarian ca. OVCAR-8	0.4	0.4	0.0
Ovarian ca. IGROV-1	0.3	0.4	0.0
Ovarian ca.* (ascites) SK-OV-3	0.0	0.0	0.0
Uterus	0.0	0.2	0.0
Placenta	0.0	0.0	0.0
Prostate	0.0	0.3	0.0
Prostate ca.* (bone met) PC-3	0.0	0.0	0.0
Testis	1.2	0.8	1.7
Melanoma Hs688(A).T	0.0	0.0	0.0
Melanoma* (met) Hs688(B).T	0.0	0.0	0.0
Melanoma UACC-62	0.0	0.0	0.0
Melanoma M14	0.0	0.0	0.0
Melanoma LOX IMVI	0.0	0.0	0.0
Melanoma* (met) SK-MEL-5	0.0	0.0	0.0
Adipose	0.4	0.4	0.0

Table 30. Panel General _screening_panel_v1.4

Tissue Name	Relative Expression(%)	Relative Expression(%)	Relative Expression(%)
	1.4x4tm7291f _ag1928_a2	1.4tm7578f _ag4154	1.4x4tm7676f _ag4334_b2

D6005-01_Human adipose	0.0	0.0	0.1
112193_Metastatic melanoma	0.0	0.0	0.0
112192_Metastatic melanoma	0.0	0.0	0.0
95280_Epidermis (metastatic melanoma)	0.0	0.0	0.0
95279_Epidermis (metastatic melanoma)	0.0	0.0	0.0
Melanoma (met)_SK-MEL-5	0.0	0.0	0.0
112196_Tongue (oncology)	0.0	0.0	0.0
113461_Testis Pool	0.0	0.7	0.3
Prostate ca.(bone met)_PC-3	0.0	0.0	0.0
113455_Prostate Pool	0.0	0.3	0.5
103396_Placenta	0.0	0.3	0.1
113463_Uterus Pool	0.0	0.0	0.0
Ovarian carcinoma_OVCAR-3	15.8	8.0	6.9
Ovarian carcinoma(ascites)_SK-OV-3	0.0	0.0	0.0
95297_Adenocarcinoma (ovary)	3.9	3.0	2.2
Ovarian carcinoma_OVCAR-5	0.0	0.7	0.9
Ovarian carcinoma_IGROV-1	0.0	1.3	0.5
Ovarian carcinoma_OVCAR-8	0.0	0.2	0.1
103368_Ovary	0.0	0.1	0.1
MCF7_breast carcinoma(pleural effusion)	0.0	0.1	0.2
Breast ca. (pleural effusion)_MDA-MB-231	0.0	0.0	0.1
112189_ductal cell carcinoma(breast)	0.0	0.0	0.0
Breast ca. (pleural effusion)_T47D	2.3	1.8	1.5
Breast carcinoma_MDA-N	0.0	0.0	0.0
113452_Breast Pool	0.0	0.7	0.4
103398_Trachea	0.0	3.9	2.1
112354_lung	0.0	0.1	0.2
103374_Fetal Lung	29.0	44.1	44.5
94921_Small cell carcinoma of the lung	0.0	0.0	0.0
Lung ca.(small cell)_LX-1	0.0	6.0	4.3
94919_Small cell carcinoma of the lung	6.0	5.6	3.9
Lung ca.(s.cell var.)_SHP-77	0.0	0.4	0.5
95268_Lung (Large cell carcinoma)	0.0	0.0	0.0
94920_Small cell carcinoma of the lung	0.0	0.0	0.0
Lung ca.(non-s.cell)_NCI-H23	0.0	1.0	0.7
Lung ca.(large cell)_NCI-H460	0.0	0.0	0.0
Lung ca.(non-s.cell)_HOP-62	0.0	0.0	0.0
Lung ca.(non-s.cl)_NCI-H522	0.0	0.5	0.9
103392_Liver	0.0	0.0	0.0
103393_Fetal Liver	0.0	1.6	1.6
Liver ca.(hepatoblast)_HepG2	13.2	7.3	4.2
113465_Kidney Pool	0.0	0.1	0.1
103373_Fetal Kidney	9.4	33.2	25.4
Renal ca. 786-0	0.0	0.0	0.0
112188_renal cell carcinoma	0.0	0.0	0.0

Renal ca. _ACHN	0.0	0.0	0.0
112190_Renal cell carcinoma	0.0	0.0	0.0
Renal ca. _TK-10	5.1	2.8	1.3
Bladder	0.0	0.3	0.2
Gastric ca.(liver met) _NCI-N87	28.8	83.5	80.5
112197_Stomach	3.6	4.7	3.0
94938_Colon Adenocarcinoma	0.0	0.0	0.0
Colon ca. _SW480	1.2	8.8	3.7
Colon ca.(SW480 met) _SW620	0.0	2.6	0.9
Colon ca. _HT29	0.0	0.0	0.0
Colon ca. _HCT-116	2.3	4.0	4.4
Colon ca. _CaCo-2	23.0	17.7	11.7
83219_CC Well to Mod Diff (ODO3866)	0.0	0.0	0.0
94936_Colon Adenocarcinoma	0.0	0.6	0.1
94930_Colon	0.0	0.0	0.0
94935_Colon Adenocarcinoma	0.0	0.0	0.0
113468_Colon Pool	0.0	0.0	0.1
113457_Small Intestine Pool	0.0	0.4	0.1
113460_Stomach Pool	0.0	1.6	0.7
113467_Bone Marrow Pool	0.0	0.0	0.0
103371_Fetal Heart	0.0	0.9	0.7
113451_Heart Pool	0.0	0.3	0.1
113466_Lymph Node Pool	0.0	0.7	0.4
103372_Fetal Skeletal Muscle	2.7	6.8	3.6
113456_Skeletal Muscle Pool	0.0	0.9	0.1
113459_Spleen Pool	0.0	0.0	0.1
113462_Thymus Pool	0.0	2.7	1.5
CNS ca. (glio/astro) _U87-MG	0.0	0.0	0.0
CNS ca. (glio/astro) _U-118-MG	0.0	0.0	0.0
CNS ca. (neuro;met) _SK-N-AS	0.0	0.0	0.0
95264_Brain astrocytoma	0.0	0.0	0.0
CNS ca. (astro) _SNB-75	0.0	0.0	0.0
CNS ca. (glio) _SNB-19	0.0	1.1	0.4
CNS ca. (glio) _SF-295	0.0	0.1	0.0
113447_Brain (Amygdala) Pool	0.0	0.3	0.5
103382_Brain (cerebellum)	0.0	0.6	0.6
64019-1_brain(fetal)	100.0	100.0	100.0
113448_Brain (Hippocampus) Pool	0.0	1.1	0.2
113464_Cerebral Cortex Pool	0.0	0.5	0.5
113449_Brain (Substantia nigra) Pool	0.0	0.6	0.3
113450_Brain (Thalamus) Pool	0.0	0.2	0.7
103384_Brain (whole)	0.0	1.6	3.3
113458_Spinal Cord Pool	0.0	0.9	0.5
103375_Adrenal Gland	0.0	0.0	0.0
113454_Pituitary gland Pool	0.0	0.2	1.1

103397_Salivary Gland	0.0	2.6	0.8
103369_Thyroid (female)	2.2	7.7	4.2
Pancreatic ca. CAPAN2	0.0	0.4	0.3
113453_Pancreas Pool	0.0	1.2	0.1

Table 31. Panel 2.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2.2x4tm6426t_ag2241_a2		2.2x4tm6426t_ag2241_a2
Normal Colon GENPAK 061003	0.0	83793 Kidney NAT (OD04348)	0.0
97759 Colon cancer (OD06064)	3.1	98938 Kidney malignant cancer (OD06204B)	1.9
97760 Colon cancer NAT (OD06064)	0.0	98939 Kidney normal adjacent tissue (OD06204E)	0.0
97778 Colon cancer (OD06159)	0.0	85973 Kidney Cancer (OD04450-01)	0.0
97779 Colon cancer NAT (OD06159)	0.0	85974 Kidney NAT (OD04450-03)	2.0
98861 Colon cancer (OD06297-04)	0.0	Kidney Cancer Clontech 8120613	0.0
98862 Colon cancer NAT (OD06297-015)	0.0	Kidney NAT Clontech 8120614	0.0
83237 CC Gr.2 ascend colon (ODO3921)	0.0	Kidney Cancer Clontech 9010320	0.0
83238 CC NAT (ODO3921)	0.0	Kidney NAT Clontech 9010321	1.4
97766 Colon cancer metastasis (OD06104)	0.0	Kidney Cancer Clontech 8120607	0.0
97767 Lung NAT (OD06104)	3.6	Kidney NAT Clontech 8120608	0.0
87472 Colon mets to lung (OD04451-01)	0.0	Normal Uterus GENPAK 061018	0.0
87473 Lung NAT (OD04451-02)	0.0	Uterus Cancer GENPAK 064011	0.0
Normal Prostate Clontech A+ 6546-1 (8090438)	0.0	Normal Thyroid Clontech A+ 6570-1 (7080817)	0.0
84140 Prostate Cancer (OD04410)	0.0	Thyroid Cancer GENPAK 064010	0.0
84141 Prostate NAT (OD04410)	0.0	Thyroid Cancer INVITROGEN A302152	0.0
Normal Ovary Res. Gen.	0.0	Thyroid NAT INVITROGEN A302153	0.0
98863 Ovarian cancer (OD06283-03)	0.0	Normal Breast GENPAK 061019	0.0
98865 Ovarian cancer NAT/fallopian tube (OD06283-07)	0.0	84877 Breast Cancer (OD04566)	0.0
Ovarian Cancer GENPAK 064008	0.0	Breast Cancer Res. Gen. 1024	0.0
97773 Ovarian cancer (OD06145)	0.0	85975 Breast Cancer (OD04590-01)	0.0
97775 Ovarian cancer NAT (OD06145)	0.0	85976 Breast Cancer Mets (OD04590-03)	0.0
98853 Ovarian cancer (OD06455-03)	0.0	87070 Breast Cancer Metastasis (OD04655-05)	0.0
98854 Ovarian NAT (OD06455-07) Fallopian tube	0.0	GENPAK Breast Cancer 064006	0.0
Normal Lung GENPAK 061010	0.0	Breast Cancer Clontech 9100266	0.0
92337 Invasive poor diff. lung adeno (ODO4945-01)	0.0	Breast NAT Clontech 9100265	0.0
92338 Lung NAT (ODO4945-03)	0.0	Breast Cancer INVITROGEN	0.0

		A209073	
84136 Lung Malignant Cancer (OD03126)	0.0	Breast NAT INVITROGEN A2090734	0.0
84137 Lung NAT (OD03126)	0.0	97763 Breast cancer (OD06083)	0.0
90372 Lung Cancer (OD05014A)	0.0	97764 Breast cancer node metastasis (OD06083)	0.0
90373 Lung NAT (OD05014B)	0.0	Normal Liver GENPAK 061009	1.8
97761 Lung cancer (OD06081)	0.0	Liver Cancer Research Genetics RNA 1026	0.0
97762 Lung cancer NAT (OD06081)	0.0	Liver Cancer Research Genetics RNA 1025	0.0
85950 Lung Cancer (OD04237-01)	0.0	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	4.0
85970 Lung NAT (OD04237-02)	0.0	Paired Liver Tissue Research Genetics RNA 6004-N	0.0
83255 Ocular Mel Met to Liver (ODO4310)	0.0	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	0.0
83256 Liver NAT (ODO4310)	0.0	Paired Liver Tissue Research Genetics RNA 6005-N	0.0
84139 Melanoma Mets to Lung (OD04321)	0.0	Liver Cancer GENPAK 064003	0.0
84138 Lung NAT (OD04321)	0.0	Normal Bladder GENPAK 061001	0.0
Normal Kidney GENPAK 061008	0.0	Bladder Cancer Research Genetics RNA 1023	0.0
83786 Kidney Ca, Nuclear grade 2 (OD04338)	0.0	Bladder Cancer INVITROGEN A302173	0.0
83787 Kidney NAT (OD04338)	0.0	Normal Stomach GENPAK 061017	30.4
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	100.0	Gastric Cancer Clontech 9060397	0.0
83789 Kidney NAT (OD04339)	0.0	NAT Stomach Clontech 9060396	0.0
83790 Kidney Ca, Clear cell type (OD04340)	0.0	Gastric Cancer Clontech 9060395	0.0
83791 Kidney NAT (OD04340)	0.0	NAT Stomach Clontech 9060394	0.0
83792 Kidney Ca, Nuclear grade 3 (OD04348)	0.0	Gastric Cancer GENPAK 064005	0.0

Table 32. Panel 2D

Tissue Name	Relative Expression(%)	
	2Dtm2820f_ag1211	2Dtm2841f_ag1211
Normal Colon GENPAK 061003	0.5	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	0.1
83220 CC NAT (ODO3866)	0.0	0.3
83221 CC Gr.2 rectosigmoid (ODO3868)	0.0	0.0
83222 CC NAT (ODO3868)	0.0	0.0
83235 CC Mod Diff (ODO3920)	0.0	0.0
83236 CC NAT (ODO3920)	0.1	0.0
83237 CC Gr.2 ascend colon (ODO3921)	0.0	0.3
83238 CC NAT (ODO3921)	0.0	0.3
83241 CC from Partial Hepatectomy (ODO4309)	0.2	0.0
83242 Liver NAT (ODO4309)	0.0	0.0
87472 Colon mets to lung (OD04451-01)	0.0	0.0

87473 Lung NAT (OD04451-02)	0.4	0.2
Normal Prostate Clontech A+ 6546-1	3.3	4.5
84140 Prostate Cancer (OD04410)	0.4	0.6
84141 Prostate NAT (OD04410)	1.2	0.6
87073 Prostate Cancer (OD04720-01)	2.1	3.5
87074 Prostate NAT (OD04720-02)	3.4	6.0
Normal Lung GENPAK 061010	10.8	10.9
83239 Lung Met to Muscle (ODO4286)	0.0	0.3
83240 Muscle NAT (ODO4286)	0.0	0.5
84136 Lung Malignant Cancer (OD03126)	1.0	0.9
84137 Lung NAT (OD03126)	6.1	5.9
84871 Lung Cancer (OD04404)	1.4	0.6
84872 Lung NAT (OD04404)	3.2	6.7
84875 Lung Cancer (OD04565)	0.0	0.0
84876 Lung NAT (OD04565)	4.9	4.0
85950 Lung Cancer (OD04237-01)	12.8	20.9
85970 Lung NAT (OD04237-02)	5.9	4.8
83255 Ocular Mel Met to Liver (ODO4310)	0.0	0.0
83256 Liver NAT (ODO4310)	0.0	0.0
84139 Melanoma Mets to Lung (OD04321)	0.0	0.2
84138 Lung NAT (OD04321)	2.9	3.0
Normal Kidney GENPAK 061008	6.3	8.6
83786 Kidney Ca, Nuclear grade 2 (OD04338)	0.0	0.0
83787 Kidney NAT (OD04338)	3.3	5.3
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	0.0	0.0
83789 Kidney NAT (OD04339)	4.0	5.2
83790 Kidney Ca, Clear cell type (OD04340)	0.2	0.0
83791 Kidney NAT (OD04340)	6.6	3.6
83792 Kidney Ca, Nuclear grade 3 (OD04348)	0.0	0.0
83793 Kidney NAT (OD04348)	3.4	2.1
87474 Kidney Cancer (OD04622-01)	0.0	0.0
87475 Kidney NAT (OD04622-03)	0.9	1.2
85973 Kidney Cancer (OD04450-01)	0.0	0.2
85974 Kidney NAT (OD04450-03)	7.9	5.4
Kidney Cancer Clontech 8120607	0.0	0.0
Kidney NAT Clontech 8120608	2.3	1.5
Kidney Cancer Clontech 8120613	100.0	100.0
Kidney NAT Clontech 8120614	4.2	8.1
Kidney Cancer Clontech 9010320	0.0	0.0
Kidney NAT Clontech 9010321	3.0	1.0
Normal Uterus GENPAK 061018	0.0	0.0
Uterus Cancer GENPAK 064011	0.4	0.0
Normal Thyroid Clontech A+ 6570-1	7.1	7.0
Thyroid Cancer GENPAK 064010	19.3	19.2
Thyroid Cancer INVITROGEN A302152	5.9	4.5

Thyroid NAT INVITROGEN A302153	5.8	3.6
Normal Breast GENPAK 061019	2.1	1.6
84877 Breast Cancer (OD04566)	0.5	0.8
85975 Breast Cancer (OD04590-01)	0.2	0.0
85976 Breast Cancer Mets (OD04590-03)	0.2	0.0
87070 Breast Cancer Metastasis (OD04655-05)	1.0	1.1
GENPAK Breast Cancer 064006	0.4	0.5
Breast Cancer Res. Gen. 1024	2.0	3.1
Breast Cancer Clontech 9100266	0.7	1.0
Breast NAT Clontech 9100265	0.6	0.3
Breast Cancer INVITROGEN A209073	1.1	0.9
Breast NAT INVITROGEN A2090734	0.8	0.5
Normal Liver GENPAK 061009	0.0	0.3
Liver Cancer GENPAK 064003	7.3	8.1
Liver Cancer Research Genetics RNA 1025	0.0	0.3
Liver Cancer Research Genetics RNA 1026	0.4	0.6
Paired Liver Cancer Tissue Research Genetics RNA 6004-T	0.0	0.0
Paired Liver Tissue Research Genetics RNA 6004-N	0.1	0.0
Paired Liver Cancer Tissue Research Genetics RNA 6005-T	0.2	0.7
Paired Liver Tissue Research Genetics RNA 6005-N	0.2	0.0
Normal Bladder GENPAK 061001	0.1	0.2
Bladder Cancer Research Genetics RNA 1023	0.1	0.0
Bladder Cancer INVITROGEN A302173	2.0	1.0
87071 Bladder Cancer (OD04718-01)	0.0	0.0
87072 Bladder Normal Adjacent (OD04718-03)	0.0	0.0
Normal Ovary Res. Gen.	0.9	2.1
Ovarian Cancer GENPAK 064008	7.5	8.1
87492 Ovary Cancer (OD04768-07)	0.6	0.3
87493 Ovary NAT (OD04768-08)	0.0	0.0
Normal Stomach GENPAK 061017	0.0	0.0
Gastric Cancer Clontech 9060358	0.1	0.3
NAT Stomach Clontech 9060359	0.0	0.2
Gastric Cancer Clontech 9060395	0.0	0.2
NAT Stomach Clontech 9060394	0.2	0.0
Gastric Cancer Clontech 9060397	0.1	0.2
NAT Stomach Clontech 9060396	0.2	0.0
Gastric Cancer GENPAK 064005	0.1	0.0

Table 33. Panel 4D

Tissue Name	Relative Expression(%)	Relative Expression(%)
	4dx4tm4491t ag1938	4dx4tm4230f ag2233 b2
93768_Secondary Th1_anti-CD28/anti-CD3	0.0	0.0
93769_Secondary Th2_anti-CD28/anti-CD3	0.0	0.0
93770_Secondary Tr1_anti-CD28/anti-CD3	0.0	0.0

93573_Secondary Th1_resting day 4-6 in IL-2	0.0	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	0.0
93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	0.0
93568_primary Th1_anti-CD28/anti-CD3	0.0	0.0
93569_primary Th2_anti-CD28/anti-CD3	0.0	0.0
93570_primary Tr1_anti-CD28/anti-CD3	0.0	0.0
93565_primary Th1_resting dy 4-6 in IL-2	0.0	0.0
93566_primary Th2_resting dy 4-6 in IL-2	0.0	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	0.0	0.0
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0.0	0.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0.0	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.0	0.0
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.0	0.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	0.0
93354_CD4_none	0.0	0.0
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0
93103_LAK cells_resting	0.0	0.0
93788_LAK cells_IL-2	0.0	0.0
93787_LAK cells_IL-2+IL-12	0.0	0.0
93789_LAK cells_IL-2+IFN gamma	0.0	0.0
93790_LAK cells_IL-2+ IL-18	0.0	0.0
93104_LAK cells_PMA/ionomycin and IL-18	0.0	0.0
93578_NK Cells IL-2_resting	0.0	0.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0
93112_Mononuclear Cells (PBMCs)_resting	0.0	0.0
93113_Mononuclear Cells (PBMCs)_PWM	0.0	0.0
93114_Mononuclear Cells (PBMCs)_PHA-L	0.0	0.0
93249_Ramos (B cell)_none	0.0	0.0
93250_Ramos (B cell)_ionomycin	0.0	0.0
93349_B lymphocytes_PWM	0.0	0.0
93350_B lymphocytes_CD40L and IL-4	0.0	0.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	0.0
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	0.0	0.0
93356_Dendritic Cells_none	0.0	0.0
93355_Dendritic Cells_LPS 100 ng/ml	0.0	0.0
93775_Dendritic Cells_anti-CD40	0.0	0.0
93774_Monocytes_resting	0.0	0.0
93776_Monocytes_LPS 50 ng/ml	0.0	0.0
93581_Macrophages_resting	0.0	0.0
93582_Macrophages_LPS 100 ng/ml	0.0	0.0
93098_HUVEC (Endothelial)_none	0.0	0.0
93099_HUVEC (Endothelial)_starved	0.0	0.0
93100_HUVEC (Endothelial)_IL-1b	0.0	0.0

93779_HUVEC (Endothelial)_IFN gamma	0.0	0.0
93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0	0.0
93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0	0.0
93781_HUVEC (Endothelial)_IL-11	0.0	62.8
93583_Lung Microvascular Endothelial Cells_none	0.0	0.0
93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
92662_Microvascular Dermal endothelium_none	0.0	0.0
92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0	0.0
93347_Small Airway Epithelium_none	0.0	0.0
93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
92668_Coronary Artery SMC_resting	0.0	0.0
92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
93107_astrocytes_resting	0.0	0.0
93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	8.3	0.0
92666_KU-812 (Basophil)_resting	0.0	0.0
92667_KU-812 (Basophil)_PMA/ionoycin	0.0	0.0
93579_CCD1106 (Keratinocytes)_none	0.0	0.0
93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0	0.0
93791_Liver Cirrhosis	0.0	46.4
93792_Lupus Kidney	0.0	0.0
93577_NCI-H292	0.0	0.0
93358_NCI-H292_IL-4	0.0	0.0
93360_NCI-H292_IL-9	0.0	0.0
93359_NCI-H292_IL-13	0.0	0.0
93357_NCI-H292_IFN gamma	0.0	0.0
93777_HPAEC_-	0.0	0.0
93778_HPAEC_IL-1 beta/TNA alpha	0.0	0.0
93254_Normal Human Lung Fibroblast_none	0.0	0.0
93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0	0.0
93257_Normal Human Lung Fibroblast_IL-4	0.0	0.0
93256_Normal Human Lung Fibroblast_IL-9	0.0	0.0
93255_Normal Human Lung Fibroblast_IL-13	0.0	0.0
93258_Normal Human Lung Fibroblast_IFN gamma	0.0	0.0
93106_Dermal Fibroblasts CCD1070_resting	0.0	0.0
93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	0.0	0.0
93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0	0.0
93772_dermal fibroblast_IFN gamma	0.0	0.0
93771_dermal fibroblast_IL-4	0.0	0.0
93260_IBD Colitis 2	0.0	0.0
93261_IBD Crohns	0.0	0.0
735010_Colon_normal	0.0	47.3
735019_Lung_none	50.3	55.5
64028-1_Thymus_none	100.0	100.0

64030-1_Kidney_none	57.7	0.0
---------------------	------	-----

Table 34. Panel 4.1D

Tissue Name	Relative Expression(%)	Relative Expression(%)
	4.1dx4tm6273 f_ag4154_b1	4.1dx4tm6627 f_ag4334_b1
93768_Secondary Th1_anti-CD28/anti-CD3	0.0	0.0
93769_Secondary Th2_anti-CD28/anti-CD3	0.0	0.0
93770_Secondary Tr1_anti-CD28/anti-CD3	0.0	0.0
93573_Secondary Th1_resting day 4-6 in IL-2	0.0	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	0.0
93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	0.0
93568_primary Th1_anti-CD28/anti-CD3	0.0	0.0
93569_primary Th2_anti-CD28/anti-CD3	0.0	0.0
93570_primary Tr1_anti-CD28/anti-CD3	0.0	0.0
93565_primary Th1_resting dy 4-6 in IL-2	0.0	12.1
93566_primary Th2_resting dy 4-6 in IL-2	0.0	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	0.0	0.0
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0.0	0.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0.0	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.0	0.0
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.0	0.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	0.0
93354_CD4_none	0.0	0.0
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0
93103_LAK cells_resting	0.0	0.0
93788_LAK cells_IL-2	0.0	0.0
93787_LAK cells_IL-2+IL-12	0.0	0.0
93789_LAK cells_IL-2+IFN gamma	0.0	0.0
93790_LAK cells_IL-2+ IL-18	0.0	0.0
93104_LAK cells_PMA/ionomycin and IL-18	0.0	0.0
93578_NK Cells IL-2_resting	0.0	0.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0
93112_Mononuclear Cells (PBMCs)_resting	0.0	0.0
93113_Mononuclear Cells (PBMCs)_PWM	0.0	0.0
93114_Mononuclear Cells (PBMCs)_PHA-L	0.0	0.0
93249_Ramos (B cell)_none	0.0	0.0
93250_Ramos (B cell)_ionomycin	0.0	0.0
93349_B lymphocytes_PWM	0.0	0.0
93350_B lymphocytes_CD40L and IL-4	0.0	0.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	0.0
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	0.0	0.0
93356_Dendritic Cells_none	0.0	0.0

93355_Dendritic Cells_LPS 100 ng/ml	0.0	0.0
93775_Dendritic Cells_anti-CD40	0.0	0.0
93774_Monocytes_resting	0.0	0.0
93776_Monocytes_LPS 50 ng/ml	0.0	0.0
93581_Macrophages_resting	0.0	0.0
93582_Macrophages_LPS 100 ng/ml	0.0	0.0
93098_HUVEC (Endothelial)_none	0.0	0.0
93099_HUVEC (Endothelial)_starved	0.0	0.0
93100_HUVEC (Endothelial)_IL-1b	0.0	0.0
93779_HUVEC (Endothelial)_IFN gamma	0.0	0.0
93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0	0.0
93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0	0.0
93781_HUVEC (Endothelial)_IL-11	0.0	0.0
93583_Lung Microvascular Endothelial Cells_none	0.0	0.0
93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
92662_Microvascular Dermal endothelium_none	0.0	0.0
92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0	0.0
93347_Small Airway Epithelium_none	0.0	0.0
93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
92668_Coronary Artery SMC_resting	0.0	0.0
92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
93107_astrocytes_resting	0.0	0.0
93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
92666_KU-812 (Basophil)_resting	0.0	0.0
92667_KU-812 (Basophil)_PMA/ionoycin	0.0	0.0
93579_CCD1106 (Keratinocytes)_none	0.0	0.0
93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0	0.0
93791_Liver Cirrhosis	0.0	0.0
93577_NCI-H292	0.0	0.0
93358_NCI-H292_IL-4	0.0	0.0
93360_NCI-H292_IL-9	0.0	0.0
93359_NCI-H292_IL-13	0.0	0.0
93357_NCI-H292_IFN gamma	0.0	0.0
93777_HPAEC_-	0.0	0.0
93778_HPAEC_IL-1 beta/TNA alpha	0.0	0.0
93254_Normal Human Lung Fibroblast_none	0.0	0.0
93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0	0.0
93257_Normal Human Lung Fibroblast_IL-4	0.0	0.0
93256_Normal Human Lung Fibroblast_IL-9	0.0	0.0
93255_Normal Human Lung Fibroblast_IL-13	0.0	0.0
93258_Normal Human Lung Fibroblast_IFN gamma	1.8	0.0
93106_Dermal Fibroblasts CCD1070_resting	0.0	0.0
93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	0.0	0.0

93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0	0.0
93772_dermal fibroblast_IFN gamma	0.0	0.0
93771_dermal fibroblast_IL-4	0.0	0.0
93892_Dermal fibroblasts_none	0.0	0.0
99202_Neutrophils_TNFa+LPS	0.0	0.0
99203_Neutrophils_none	0.0	0.0
735010_Colon_normal	0.0	0.0
735019_Lung_none	30.4	64.2
64028-1_Thymus_none	26.5	48.7
64030-1_Kidney_none	100.0	100.0

Table 35. Panel CNS_neurodegeneration_v1.0

Tissue Name	Relative Expression(%) tm7244f_ ag4154_a2_s1	Relative Expression(%) tm7852f_ ag4334_b1_s2
AD 1 Hippo	4.0	12.0
AD 2 Hippo	0.0	5.3
AD 3 Hippo	5.5	5.6
AD 4 Hippo	37.6	0.0
AD 5 Hippo	24.3	4.9
AD 6 Hippo	2.8	0.0
Control 2 Hippo	19.7	15.6
Control 4 Hippo	6.0	0.0
Control (Path) 3 Hippo	4.2	8.0
AD 1 Temporal Ctx	0.0	7.7
AD 2 Temporal Ctx	36.6	15.9
AD 3 Temporal Ctx	3.6	0.0
AD 4 Temporal Ctx	50.5	23.3
AD 5 Inf Temporal Ctx	23.6	30.0
AD 5 Sup Temporal Ctx	16.9	19.3
AD 6 Inf Temporal Ctx	6.4	8.0
AD 6 Sup Temporal Ctx	26.8	8.2
Control 1 Temporal Ctx	10.5	18.0
Control 2 Temporal Ctx	17.8	30.7
Control 3 Temporal Ctx	0.0	26.7
Control 3 Temporal Ctx	22.5	5.5
Control (Path) 1 Temporal Ctx	92.5	42.0
Control (Path) 2 Temporal Ctx	21.1	29.9
Control (Path) 3 Temporal Ctx	0.0	0.0
Control (Path) 4 Temporal Ctx	100.0	10.9
AD 1 Occipital Ctx	0.0	6.8
AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 3 Occipital Ctx	0.0	0.0
AD 4 Occipital Ctx	2.4	3.9
AD 5 Occipital Ctx	2.1	0.0

AD 6 Occipital Ctx	7.3	3.7
Control 1 Occipital Ctx	0.0	8.2
Control 2 Occipital Ctx	11.2	29.4
Control 3 Occipital Ctx	14.4	0.0
Control 4 Occipital Ctx	12.7	4.6
Control (Path) 1 Occipital Ctx	62.6	100.0
Control (Path) 2 Occipital Ctx	7.5	4.2
Control (Path) 3 Occipital Ctx	4.5	0.0
Control (Path) 4 Occipital Ctx	9.7	10.7
Control 1 Parietal Ctx	8.4	6.9
Control 2 Parietal Ctx	13.5	14.2
Control 3 Parietal Ctx	8.6	6.9
Control (Path) 1 Parietal Ctx	29.2	28.7
Control (Path) 2 Parietal Ctx	8.7	12.5
Control (Path) 3 Parietal Ctx	7.0	0.0
Control (Path) 4 Parietal Ctx	51.3	12.8

Panel 1 Summary Ag72/Ag390 Multiple runs with two different probe and primer sets show highest expression of the NOV2 gene in the fetal brain (CTs=25-27), fetal lung and a cell line derived from a gastric cancer. Thus, the expression of this gene could be used to distinguish fetal brain tissue from adult brain tissue and fetal lung from adult lung.

Significant expression is also seen in fetal kidney, when compared to expression in the adult kidney. Therefore, the expression of this gene could also be used to distinguish fetal kidney tissue from adult kidney tissue.

Panel 1.1 Summary Ag671 Highest expression of the NOV2 gene is seen in the fetal brain (CT=26.2), a result that is repeated in Panel 1. Significant expression is also seen in fetal lung and skeletal muscle (CTs=26.7-32.8) when compared to expression in the adult tissues. In addition, low, but significant expression is seen in the gastric cancer cell line (NCI-N87) and in adult and fetal kidney. Thus, the expression of this gene could be used to distinguish fetal brain tissue from other tissues in the panel. In addition, the expression of this gene could be used to distinguish fetal lung and skeletal muscle tissue from adult lung and skeletal muscle tissue.

Panel 1.2 Summary Ag766 Highest expression of the NOV2 gene in this panel is in the fetal brain (CT=27). Low, but significant expression is also seen in other brain samples including the amygdala, hippocampus, thalamus, and cerebral cortex. The higher levels of expression present in the fetal brain when compared to expression in the adult brain suggest an ongoing role in CNS processes.

There is also substantial expression in samples derived from a gastric cancer cell line (NCI-N87), fetal lung tissue and adult and fetal kidney tissue. This expression profile is

concordant with the expression seen in Panels 1, and 1.1. Of note is the difference in expression between fetal lung (CT=27.7) and its adult counterpart (CT=31.8). Thus, the expression of this gene could be used to distinguish fetal lung tissue from adult lung tissue.

Panel 1.3D Summary Ag1211/Ag2233 Three runs with two different probe and primer sets show highest expression in the fetal brain, lung and skeletal muscle (CTs=30). There is also substantial expression in samples derived from a gastric cancer cell line (NCI-N87). Thus, the expression of this gene could be used to distinguish fetal skeletal muscle or fetal lung from their respective adult tissue counterparts.

Ag2241 Expression of the NOV2 gene is low/undetectable (Ct values >35) in all samples in this panel. (Data not shown.)

Panel General_screening_panel_v1.0 Summary Ag1928/Ag4154/Ag4334 Multiple runs with different probe and primer sets show highest expression of the NOV2 gene in the fetal brain (CTs=26-33), indicating a probable developmental role for the NOV2 gene in the CNS. This finding is consistent with the expression seen in Panels 1, 1.1, 1.2 and 1.3D. There is also significant expression in the fetal kidney and lung and in the gastric cancer cell line (NCI-N87). Thus, the expression of this gene could be used to distinguish fetal brain tissue from adult brain. In addition, the expression of this gene could be used to distinguish fetal kidney tissue from adult kidney tissue and fetal lung tissue from adult lung tissue.

Panel 2.2. Summary Ag2241 The expression of the NOV2 gene appears to be exclusive to a sample derived from a kidney cancer. Thus, the expression of this gene could be used to distinguish this sample from others in the panel, including its normal adjacent tissue. Moreover, therapeutic modulation of this gene or its protein product, through the use of small molecule drugs, antibodies or protein therapeutics, may be useful in the treatment of kidney cancer.

Panel 2D Summary Ag1211 Two runs using the same probe and primer produce results that are in excellent agreement, with highest expression of the NOV2 gene in a kidney cancer (CTs=29.5). This expression profile is in concordance with the expression seen in Panel 2.2. Significant expression is also seen in a thyroid cancer sample and a series of normal adjacent tissues derived from kidney and lung cancer cases. Thus, the expression of this gene could be used to distinguish this kidney cancer sample from others in the panel, including its normal adjacent tissue. In addition, low levels of expression could be used to distinguish normal adjacent tissue from adjacent malignant tissue. Moreover, therapeutic modulation of this gene or its protein product, through the use of small molecule drugs, antibodies or protein therapeutics, might be of benefit in the treatment of kidney cancer.

Panel 4D Summary Ag1938/Ag2233 Expression of the NOV2 gene is limited to a few samples in this panel, with highest expression seen in the thymus. This expression is consistent in two runs with two different probe and primer sets (CTs= 33-34). Significant expression is also seen in the normal lung, a result that is replicated in Panel 4.1D and Panels 1, 1.2, and 1.3D. Please see Panel 4.1D for potential utility of this gene in the treatment of autoinflammatory related disease.

Ag1928/Ag2241 Expression of the NOV2 gene is low/undetectable (Ct values >35) in all samples in this panel. (Data not shown.)

Panel 4.1 D Summary Ag4154/Ag4334 Two experiments with two different probes and primers both show highest expression of the NOV2 gene in the kidney (CTs=33-34). There is also low but significant expression in normal lung and thymus. The expression in normal kidney is consistent with the expression seen in Panels 1, 1.1, 1.2, 1.3D and Panel 4. The expression of low levels of the NOV2 gene product, a secreted fibrillin-related homolog, in the normal lung, thymus, and kidney suggest that it could be used as a protein or antibody therapeutic to reduce or eliminate symptoms of patients with connective tissue diseases of the lung, thymus and kidney. These diseases include Marfan syndrome, ankylosing spondylitis, Sjogren's syndrome, and relapsing polychondritis.

Panel CNS_neurodegeneration_v1.0 Summary Ag4154/Ag4334 Expression of the NOV2 gene is restricted to a few samples with highest expression in the cerebral cortex of a control patient. This gene does not appear to be expressed in the brains of patients with Alzheimer's disease. Please see Panel 1 for discussion of potential utility in the CNS.

Ag2241 Expression of the NOV2 gene is low/undetectable (Ct values >35) in all samples in this panel. (Data not shown.)(Tanoue, Pulmonary involvement in collagen vascular disease: a review of the pulmonary manifestations of the Marfan syndrome, ankylosing spondylitis, Sjogren's syndrome, and relapsing polychondritis. 7:62-77, 1992; Kanwar et al., Isolation of rat fibrillin-1 cDNA and its relevance in metanephric development. 275 (5 Pt 2):F710-23, 1998).

NOV3: KIAA1589-like

Expression of the NOV3 gene (GSAL442663.1_A) was assessed using the primer-probe set Ag1550 described in Table 36. Results from RTQ-PCR runs are shown in Table 37.

Table 36. Probe Name Ag1550

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-TGGAAATACTGGTGATGGAAAG-3'	59	22	900	164

Probe	FAM-5' -TCAACCACACTTTCTTTTATGGTCGTG-3' -TAMRA	66.2	27	932	165
Reverse	5' -TCGGGGAGGTTTAAAGACTT-3'	59.1	21	959	166

Table 37. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.3Dtm2584f_ag1550		1.3Dtm2584f_ag1550
Liver adenocarcinoma	20.2	Kidney (fetal)	10.9
Pancreas	4.7	Renal ca. 786-0	12.9
Pancreatic ca. CAPAN 2	4.7	Renal ca. A498	24.0
Adrenal gland	15.1	Renal ca. RXF 393	10.4
Thyroid	11.4	Renal ca. ACHN	21.9
Salivary gland	4.5	Renal ca. UO-31	9.6
Pituitary gland	8.0	Renal ca. TK-10	4.8
Brain (fetal)	9.5	Liver	3.2
Brain (whole)	15.0	Liver (fetal)	12.8
Brain (amygdala)	15.8	Liver ca. (hepatoblast) HepG2	12.7
Brain (cerebellum)	6.7	Lung	10.3
Brain (hippocampus)	30.6	Lung (fetal)	12.8
Brain (substantia nigra)	6.8	Lung ca. (small cell) LX-1	5.7
Brain (thalamus)	14.1	Lung ca. (small cell) NCI-H69	9.2
Cerebral Cortex	45.1	Lung ca. (s.cell var.) SHP-77	12.6
Spinal cord	8.4	Lung ca. (large cell)NCI-H460	2.2
CNS ca. (glio/astro) U87-MG	30.4	Lung ca. (non-sm. cell) A549	4.6
CNS ca. (glio/astro) U-118-MG	42.9	Lung ca. (non-s.cell) NCI-H23	11.5
CNS ca. (astro) SW1783	16.8	Lung ca (non-s.cell) HOP-62	11.2
CNS ca.* (neuro; met) SK-N-AS	23.2	Lung ca. (non-s.cl) NCI-H522	11.5
CNS ca. (astro) SF-539	15.5	Lung ca. (squam.) SW 900	17.1
CNS ca. (astro) SNB-75	55.1	Lung ca. (squam.) NCI-H596	4.0
CNS ca. (glio) SNB-19	1.5	Mammary gland	27.0
CNS ca. (glio) U251	12.8	Breast ca.* (pl. effusion) MCF-7	34.4
CNS ca. (glio) SF-295	9.2	Breast ca.* (pl.ef) MDA-MB-231	24.8
Heart (fetal)	33.7	Breast ca.* (pl. effusion) T47D	31.4
Heart	3.3	Breast ca. BT-549	33.0
Fetal Skeletal	100.0	Breast ca. MDA-N	21.2
Skeletal muscle	7.7	Ovary	36.1
Bone marrow	11.8	Ovarian ca. OVCAR-3	19.8
Thymus	12.1	Ovarian ca. OVCAR-4	5.3
Spleen	10.4	Ovarian ca. OVCAR-5	12.9
Lymph node	8.1	Ovarian ca. OVCAR-8	11.2
Colorectal	11.3	Ovarian ca. IGROV-1	2.5
Stomach	17.3	Ovarian ca.* (ascites) SK-OV-3	10.6
Small intestine	9.1	Uterus	11.0
Colon ca. SW480	14.9	Placenta	14.8

Colon ca.* (SW480 met)SW620	6.2	Prostate	6.4
Colon ca. HT29	2.5	Prostate ca.* (bone met)PC-3	41.8
Colon ca. HCT-116	5.2	Testis	15.2
Colon ca. CaCo-2	9.2	Melanoma Hs688(A).T	45.7
83219 CC Well to Mod Diff (ODO3866)	11.3	Melanoma* (met) Hs688(B).T	44.1
Colon ca. HCC-2998	5.6	Melanoma UACC-62	12.5
Gastric ca.* (liver met) NCI-N87	32.8	Melanoma M14	7.6
Bladder	6.9	Melanoma LOX IMVI	3.7
Trachea	14.2	Melanoma* (met) SK-MEL-5	26.4
Kidney	7.1	Adipose	5.8

Panel 1.3D Summary The NOV3 gene, a KIAA1589 homolog, is ubiquitously expressed in this panel, with highest expression seen in fetal skeletal muscle (CT=29).

Expression of the gene appears to be much higher in fetal skeletal muscle than in adult skeletal muscle (CT=32.6). In addition, expression of the gene appears to be higher in fetal heart (CT=30.5) than in adult heart (CT=33.9). Thus, expression of this gene could be used to distinguish between adult and fetal sources of heart and skeletal muscle. In addition, the higher levels of expression of the NOV3 gene in fetal heart and skeletal muscle when compared to the levels of expression in adult tissue, suggests that the protein encoded by the NOV3 gene may be involved in the development of these tissues. Therefore, therapeutic modulation of this gene or its protein product may be effective in the treatment of diseases that affect the heart, such as atherosclerosis, hypertension, or aortic stenosis. Furthermore, the therapeutic modulation of this gene or gene product, through replacement therapy, could be used as a regenerative therapy for muscle disease.

Among tissues involved in central nervous system function, this gene is expressed at moderate levels in all brain regions examined. The NOV3 gene encodes a protein with a putative zinc-finger motif. Since these proteins are known to interact with nucleic acids, this suggests that the NOV3 gene product may play a potential role in transcription. Thus, therapeutic modulation of the NOV3 gene product may be used to regulate the transcription of disease-related proteins such as ataxin, huntingtin, or various apoptosis cascade proteins.

NOV4: WD40 motif protein

Expression of the NOV4 gene (GSAL442663.1_B) was assessed using the primer-probe sets Ag1551 and Ag3362 described in Tables 38 and 39. Results from RTQ-PCR runs are shown in Tables 40-44.

Table 38. Probe Name Ag1551

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GGCTCCAAGTATGGTATCATCA-3'	58.9	22	636	167
Probe	TET-5'-TCTGAAGACCCCTACGCTCAAGGTGT-3'-TAMRA	69.1	26	668	168
Reverse	5'-TGAAGTAGAGGTTTTCGTGCAT-3'	58.9	22	696	169

Table 39. Probe Name Ag3362

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GTCGGGCAGGACCTTTACT-3'	59.2	19	1474	170
Probe	FAM-5'-TCCTACAGCTAATTCTGCAGGGCACA-3'-TAMRA	68.8	26	1498	171
Reverse	5'-TACGCTTTACTCCCGTAAGTCA-3'	59	22	1543	172

Table 40. Panel 1.3D

Tissue Name	Relative Expression(%) 1.3Dtm2585t _ag1551	Tissue Name	Relative Expression(%) 1.3Dtm2585t _ag1551
Liver adenocarcinoma	23.2	Kidney (fetal)	10.7
Pancreas	9.4	Renal ca. 786-0	20.2
Pancreatic ca. CAPAN 2	8.0	Renal ca. A498	40.3
Adrenal gland	8.4	Renal ca. RXF 393	26.1
Thyroid	17.3	Renal ca. ACHN	75.3
Salivary gland	11.1	Renal ca. UO-31	36.6
Pituitary gland	7.2	Renal ca. TK-10	31.6
Brain (fetal)	11.7	Liver	1.8
Brain (whole)	24.8	Liver (fetal)	8.7
Brain (amygdala)	17.8	Liver ca. (hepatoblast) HepG2	68.8
Brain (cerebellum)	5.5	Lung	9.9
Brain (hippocampus)	37.6	Lung (fetal)	20.0
Brain (substantia nigra)	5.4	Lung ca. (small cell) LX-1	22.1
Brain (thalamus)	17.0	Lung ca. (small cell) NCI-H69	52.5
Cerebral Cortex	36.1	Lung ca. (s.cell var.) SHP-77	41.8
Spinal cord	13.6	Lung ca. (large cell)NCI-H460	10.9
CNS ca. (glio/astro) U87-MG	43.2	Lung ca. (non-sm. cell) A549	22.1
CNS ca. (glio/astro) U-118-MG	55.5	Lung ca. (non-s.cell) NCI-H23	11.1
CNS ca. (astro) SW1783	45.4	Lung ca (non-s.cell) HOP-62	16.8
CNS ca.* (neuro; met) SK-N-AS	39.5	Lung ca. (non-s.cl) NCI-H522	27.4
CNS ca. (astro) SF-539	33.0	Lung ca. (squam.) SW 900	5.3
CNS ca. (astro) SNB-75	74.2	Lung ca. (squam.) NCI-H596	17.1
CNS ca. (glio) SNB-19	0.4	Mammary gland	47.3
CNS ca. (glio) U251	5.9	Breast ca.* (pl. effusion) MCF-7	100.0
CNS ca. (glio) SF-295	22.8	Breast ca.* (pl.ef) MDA-MB-231	67.4
Heart (fetal)	15.6	Breast ca.* (pl. effusion) T47D	25.9
Heart	1.2	Breast ca. BT-549	57.8
Fetal Skeletal	60.7	Breast ca. MDA-N	58.2

Skeletal muscle	5.6	Ovary	21.2
Bone marrow	5.6	Ovarian ca. OVCAR-3	24.5
Thymus	10.2	Ovarian ca. OVCAR-4	10.5
Spleen	12.8	Ovarian ca. OVCAR-5	19.1
Lymph node	21.2	Ovarian ca. OVCAR-8	11.7
Colorectal	8.4	Ovarian ca. IGROV-1	8.9
Stomach	33.7	Ovarian ca. * (ascites) SK-OV-3	46.3
Small intestine	17.9	Uterus	17.2
Colon ca. SW480	76.3	Placenta	28.1
Colon ca.* (SW480 met)SW620	14.7	Prostate	9.5
Colon ca. HT29	7.6	Prostate ca.* (bone met)PC-3	81.2
Colon ca. HCT-116	19.3	Testis	34.4
Colon ca. CaCo-2	32.5	Melanoma Hs688(A).T	72.7
83219 CC Well to Mod Diff (ODO3866)	19.9	Melanoma* (met) Hs688(B).T	73.7
Colon ca. HCC-2998	30.8	Melanoma UACC-62	11.6
Gastric ca.* (liver met) NCI-N87	71.2	Melanoma M14	14.1
Bladder	10.9	Melanoma LOX IMVI	12.2
Trachea	15.8	Melanoma* (met) SK-MEL-5	18.7
Kidney	5.7	Adipose	4.9

Table 41. Panel General_screening_panel_v1.0

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	tm7276f_ ag3362_b2		tm7276f_ ag3362_b2
D6005-01_Human adipose	6.3	Renal ca. TK-10	44.4
112193_Metastatic melanoma	17.6	Bladder	9.4
112192_Metastatic melanoma	18.3	Gastric ca.(liver met)_NCI-N87	21.7
95280_Epidermis (metastatic melanoma)	17.2	112197_Stomach	17.6
95279_Epidermis (metastatic melanoma)	13.6	94938_Colon Adenocarcinoma	5.8
Melanoma (met)_SK-MEL-5	19.6	Colon ca. SW480	34.7
112196_Tongue (oncology)	14.6	Colon ca.(SW480 met)_SW620	14.2
113461_Testis Pool	4.0	Colon ca. HT29	7.3
Prostate ca.(bone met)_PC-3	90.8	Colon ca. HCT-116	14.3
113455_Prostate Pool	4.1	Colon ca. CaCo-2	19.8
103396_Placenta	11.4	83219_CC Well to Mod Diff (ODO3866)	3.6
113463_Uterus Pool	2.1	94936_Colon Adenocarcinoma	9.4
Ovarian carcinoma_OVCAR-3	17.5	94930_Colon	8.9
Ovarian carcinoma(ascites)_SK- OV-3	47.1	94935_Colon Adenocarcinoma	13.3
95297_Adenocarcinoma (ovary)	14.7	113468_Colon Pool	5.7
Ovarian carcinoma_OVCAR-5	31.8	113457_Small Intestine Pool	10.2
Ovarian carcinoma_IGROV-1	12.9	113460_Stomach Pool	6.2
Ovarian carcinoma_OVCAR-8	6.7	113467_Bone Marrow Pool	1.3

103368_Ovary	12.6	103371_Fetal Heart	1.1
MCF7_breast carcinoma(pleural effusion)	76.2	113451_Heart Pool	3.4
Breast ca. (pleural effusion)_MDA-MB-231	30.3	113466_Lymph Node Pool	8.7
112189_ductal cell carcinoma(breast)	65.7	103372_Fetal Skeletal Muscle	2.3
Breast ca. (pleural effusion)_T47D	100.0	113456_Skeletal Muscle Pool	9.4
Breast carcinoma_MDA-N	33.6	113459_Spleen Pool	4.6
113452_Breast Pool	4.6	113462_Thymus Pool	7.4
103398_Trachea	7.7	CNS ca. (glio/astro)_U87-MG	34.0
112354_lung	4.9	CNS ca. (glio/astro)_U-118-MG	27.3
103374_Fetal Lung	7.1	CNS ca. (neuro;met)_SK-N-AS	16.1
94921_Small cell carcinoma of the lung	9.3	95264_Brain astrocytoma	14.3
Lung ca.(small cell)_LX-1	15.9	CNS ca. (astro)_SNB-75	60.8
94919_Small cell carcinoma of the lung	4.9	CNS ca. (glio)_SNB-19	13.9
Lung ca.(s.cell var.)_SHP-77	16.5	CNS ca. (glio)_SF-295	28.6
95268_Lung (Large cell carcinoma)	27.2	113447_Brain (Amygdala) Pool	5.3
94920_Small cell carcinoma of the lung	4.1	103382_Brain (cerebellum)	5.0
Lung ca.(non-s.cell)_NCI-H23	15.1	64019-1_brain(fetal)	16.5
Lung ca.(large cell)_NCI-H460	9.6	113448_Brain (Hippocampus) Pool	5.5
Lung ca.(non-s.cell)_HOP-62	7.6	113464_Cerebral Cortex Pool	8.7
Lung ca.(non-s.cl)_NCI-H522	18.2	113449_Brain (Substantia nigra) Pool	8.3
103392_Liver	0.0	113450_Brain (Thalamus) Pool	6.3
103393_Fetal Liver	7.3	103384_Brain (whole)	7.0
Liver ca.(hepatoblast)_HepG2	29.7	113458_Spinal Cord Pool	5.6
113465_Kidney Pool	17.7	103375_Adrenal Gland	6.3
103373_Fetal Kidney	4.6	113454_Pituitary gland Pool	0.8
Renal ca. 786-0	17.2	103397_Salivary Gland	5.6
112188_renal cell carcinoma	5.1	103369_Thyroid (female)	9.8
Renal ca._ACHN	17.4	Pancreatic ca._CAPAN2	11.8
112190_Renal cell carcinoma	11.1	113453_Pancreas Pool	9.2

Table 42. Panel 2.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2.2x4tm6351t_a g1551_b1		2.2x4tm6351t_a g1551_b1
Normal Colon GENPAK 061003	26.8	83793_Kidney NAT (OD04348)	100.0
97759 Colon cancer (OD06064)	19.2	98938 Kidney malignant cancer (OD06204B)	24.5
97760 Colon cancer NAT (OD06064)	28.5	98939 Kidney normal adjacent tissue (OD06204E)	10.9
97778 Colon cancer (OD06159)	8.9	85973 Kidney Cancer (OD04450-01)	51.3

97779 Colon cancer NAT (OD06159)	13.2	85974 Kidney NAT (OD04450-03)	24.0
98861 Colon cancer (OD06297-04)	8.9	Kidney Cancer Clontech 8120613	7.0
98862 Colon cancer NAT (OD06297-015)	24.3	Kidney NAT Clontech 8120614	19.3
83237 CC Gr.2 ascend colon (ODO3921)	15.6	Kidney Cancer Clontech 9010320	4.0
83238 CC NAT (ODO3921)	12.7	Kidney NAT Clontech 9010321	7.3
97766 Colon cancer metastasis (OD06104)	3.9	Kidney Cancer Clontech 8120607	38.9
97767 Lung NAT (OD06104)	6.8	Kidney NAT Clontech 8120608	5.9
87472 Colon mets to lung (OD04451-01)	37.3	Normal Uterus GENPAK 061018	7.6
87473 Lung NAT (OD04451-02)	14.9	Uterus Cancer GENPAK 064011	13.6
Normal Prostate Clontech A+ 6546-1 (8090438)	11.5	Normal Thyroid Clontech A+ 6570-1 (7080817)	10.9
84140 Prostate Cancer (OD04410)	7.9	Thyroid Cancer GENPAK 064010	3.8
84141 Prostate NAT (OD04410)	11.2	Thyroid Cancer INVITROGEN A302152	35.1
Normal Ovary Res. Gen.	13.6	Thyroid NAT INVITROGEN A302153	4.0
98863 Ovarian cancer (OD06283-03)	9.3	Normal Breast GENPAK 061019	27.5
98865 Ovarian cancer NAT/fallopian tube (OD06283-07)	16.2	84877 Breast Cancer (OD04566)	13.7
Ovarian Cancer GENPAK 064008	19.0	Breast Cancer Res. Gen. 1024	24.2
97773 Ovarian cancer (OD06145)	6.6	85975 Breast Cancer (OD04590-01)	26.0
97775 Ovarian cancer NAT (OD06145)	20.4	85976 Breast Cancer Mets (OD04590-03)	46.5
98853 Ovarian cancer (OD06455-03)	13.6	87070 Breast Cancer Metastasis (OD04655-05)	47.8
98854 Ovarian NAT (OD06455-07) Fallopian tube	6.9	GENPAK Breast Cancer 064006	32.9
Normal Lung GENPAK 061010	13.6	Breast Cancer Clontech 9100266	18.8
92337 Invasive poor diff. lung adeno (ODO4945-01)	8.8	Breast NAT Clontech 9100265	5.1
92338 Lung NAT (ODO4945-03)	11.5	Breast Cancer INVITROGEN A209073	3.0
84136 Lung Malignant Cancer (OD03126)	6.2	Breast NAT INVITROGEN A2090734	33.1
84137 Lung NAT (OD03126)	7.2	97763 Breast cancer (OD06083)	59.8
90372 Lung Cancer (OD05014A)	8.1	97764 Breast cancer node metastasis (OD06083)	37.3
90373 Lung NAT (OD05014B)	11.2	Normal Liver GENPAK 061009	19.4
97761 Lung cancer (OD06081)	10.9	Liver Cancer Research Genetics RNA 1026	3.0
97762 Lung cancer NAT (OD06081)	8.5	Liver Cancer Research Genetics RNA 1025	18.1
85950 Lung Cancer (OD04237-01)	10.1	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	12.0
85970 Lung NAT (OD04237-02)	12.1	Paired Liver Tissue Research Genetics RNA 6004-N	3.2
83255 Ocular Mel Met to Liver (ODO4310)	41.2	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	8.8
83256 Liver NAT (ODO4310)	3.6	Paired Liver Tissue Research	22.7

		Genetics RNA 6005-N	
84139 Melanoma Mets to Lung (OD04321)	20.2	Liver Cancer GENPAK 064003	20.5
84138 Lung NAT (OD04321)	3.5	Normal Bladder GENPAK 061001	19.7
Normal Kidney GENPAK 061008	13.4	Bladder Cancer Research Genetics RNA 1023	7.4
83786 Kidney Ca, Nuclear grade 2 (OD04338)	49.3	Bladder Cancer INVITROGEN A302173	15.4
83787 Kidney NAT (OD04338)	4.6	Normal Stomach GENPAK 061017	39.3
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	38.0	Gastric Cancer Clontech 9060397	9.4
83789 Kidney NAT (OD04339)	19.1	NAT Stomach Clontech 9060396	7.2
83790 Kidney Ca, Clear cell type (OD04340)	7.8	Gastric Cancer Clontech 9060395	14.1
83791 Kidney NAT (OD04340)	12.5	NAT Stomach Clontech 9060394	28.5
83792 Kidney Ca, Nuclear grade 3 (OD04348)	5.2	Gastric Cancer GENPAK 064005	15.9

Table 43. Panel 4D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	4dtm4721t_ag1551		4dtm4721t_ag1551
93768_Secondary Th1_anti-CD28/anti-CD3	12.4	93100_HUVEC (Endothelial)_IL-1b	3.5
93769_Secondary Th2_anti-CD28/anti-CD3	7.9	93779_HUVEC (Endothelial)_IFN gamma	10.7
93770_Secondary Tr1_anti-CD28/anti-CD3	9.2	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	10.2
93573_Secondary Th1_resting day 4-6 in IL-2	2.0	93101_HUVEC (Endothelial)_TNF alpha + IL4	11.0
93572_Secondary Th2_resting day 4-6 in IL-2	3.5	93781_HUVEC (Endothelial)_IL-11	3.2
93571_Secondary Tr1_resting day 4-6 in IL-2	3.3	93583_Lung Microvascular Endothelial Cells_none	12.0
93568_primary Th1_anti-CD28/anti-CD3	15.9	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	15.8
93569_primary Th2_anti-CD28/anti-CD3	8.7	92662_Microvascular Dermal endothelium_none	6.0
93570_primary Tr1_anti-CD28/anti-CD3	21.3	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	9.2
93565_primary Th1_resting dy 4-6 in IL-2	20.6	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	1.9
93566_primary Th2_resting dy 4-6 in IL-2	9.7	93347_Small Airway Epithelium_none	8.8
93567_primary Tr1_resting dy 4-6 in IL-2	11.3	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	19.6
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	8.7	92668_Coronary Artery SMC_resting	12.5
93352_CD45RO CD4	13.6	92669_Coronary Artery	4.7

lymphocyte_anti-CD28/anti-CD3		SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	11.0	93107_astrocytes_resting	9.5
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	16.2	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	8.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	6.8	92666_KU-812 (Basophil)_resting	36.3
93354_CD4_none	4.5	92667_KU-812 (Basophil)_PMA/ionomycin	51.4
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	6.2	93579_CCD1106 (Keratinocytes)_none	15.3
93103_LAK cells_resting	5.8	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	2.0
93788_LAK cells_IL-2	11.1	93791_Liver Cirrhosis	1.4
93787_LAK cells_IL-2+IL-12	11.7	93792_Lupus Kidney	1.6
93789_LAK cells_IL-2+IFN gamma	19.9	93577_NCI-H292	14.5
93790_LAK cells_IL-2+ IL-18	16.5	93358_NCI-H292_IL-4	14.9
93104_LAK cells_PMA/ionomycin and IL-18	7.0	93360_NCI-H292_IL-9	26.8
93578_NK Cells_IL-2_resting	5.7	93359_NCI-H292_IL-13	12.6
93109_Mixed Lymphocyte Reaction_Two Way MLR	8.0	93357_NCI-H292_IFN gamma	21.8
93110_Mixed Lymphocyte Reaction_Two Way MLR	6.4	93777_HPAEC_-	5.6
93111_Mixed Lymphocyte Reaction_Two Way MLR	2.9	93778_HPAEC_IL-1 beta/TNA alpha	8.1
93112_Mononuclear Cells (PBMcs)_resting	3.3	93254_Normal Human Lung Fibroblast_none	6.9
93113_Mononuclear Cells (PBMcs)_PWM	24.1	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	3.5
93114_Mononuclear Cells (PBMcs)_PHA-L	4.7	93257_Normal Human Lung Fibroblast_IL-4	28.9
93249_Ramos (B cell)_none	33.4	93256_Normal Human Lung Fibroblast_IL-9	27.7
93250_Ramos (B cell)_ionomycin	100.0	93255_Normal Human Lung Fibroblast_IL-13	13.1
93349_B lymphocytes_PWM	63.3	93258_Normal Human Lung Fibroblast_IFN gamma	22.7
93350_B lymphocytes_CD40L and IL-4	22.7	93106_Dermal Fibroblasts CCD1070_resting	20.3
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	14.5	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	36.3
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	7.2	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	8.7
93356_Dendritic Cells_none	6.0	93772_dermal fibroblast_IFN gamma	8.4
93355_Dendritic Cells_LPS 100 ng/ml	2.5	93771_dermal fibroblast_IL-4	17.1
93775_Dendritic Cells_anti-CD40	4.2	93260_IBD Colitis 2	0.8
93774_Monocytes_resting	4.6	93261_IBD Crohns	0.8
93776_Monocytes_LPS 50 ng/ml	0.6	735010_Colon_normal	14.8

93581_Macrophages_resting	7.8	735019_Lung_none	4.4
93582_Macrophages_LPS 100 ng/ml	0.5	64028-1_Thymus_none	14.4
93098_HUVEC (Endothelial)_none	8.7	64030-1_Kidney_none	6.2
93099_HUVEC (Endothelial)_starved	10.7		

Table 44. Panel CNS_neurodegeneration_V1.0

Tissue Name	Relative Expression(%)	Relative Expression(%)
	tm6962t_ ag1551_b1_s2	tm7090f_ ag3362_a1
AD 1 Hippo	19.0	9.9
AD 2 Hippo	33.6	33.3
AD 3 Hippo	8.2	4.3
AD 4 Hippo	10.7	16.5
AD 5 hippo	72.1	97.0
AD 6 Hippo	40.3	43.2
Control 2 Hippo	27.0	29.1
Control 4 Hippo	7.8	16.6
Control (Path) 3 Hippo	4.7	3.8
AD 1 Temporal Ctx	12.9	7.1
AD 2 Temporal Ctx	37.4	23.2
AD 3 Temporal Ctx	9.3	5.6
AD 4 Temporal Ctx	17.7	20.1
AD 5 Inf Temporal Ctx	79.0	100.0
AD 5 SupTemporal Ctx	35.4	44.0
AD 6 Inf Temporal Ctx	30.2	30.9
AD 6 Sup Temporal Ctx	35.8	69.8
Control 1 Temporal Ctx	12.1	9.1
Control 2 Temporal Ctx	42.8	59.1
Control 3 Temporal Ctx	18.0	11.7
Control 4 Temporal Ctx	9.7	8.2
Control (Path) 1 Temporal Ctx	78.6	56.2
Control (Path) 2 Temporal Ctx	45.4	34.2
Control (Path) 3 Temporal Ctx	8.4	0.0
Control (Path) 4 Temporal Ctx	37.9	24.3
AD 1 Occipital Ctx	15.2	2.0
AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 3 Occipital Ctx	4.8	5.4
AD 4 Occipital Ctx	19.4	24.7
AD 5 Occipital Ctx	12.2	24.5
AD 6 Occipital Ctx	45.3	31.8
Control 1 Occipital Ctx	2.6	0.9
Control 2 Occipital Ctx	70.2	89.8
Control 3 Occipital Ctx	14.9	12.6

Control 4 Occipital Ctx	10.3	6.3
Control (Path) 1 Occipital Ctx	100.0	65.4
Control (Path) 2 Occipital Ctx	12.7	15.9
Control (Path) 3 Occipital Ctx	1.8	2.0
Control (Path) 4 Occipital Ctx	14.9	11.6
Control 1 Parietal Ctx	9.3	2.8
Control 2 Parietal Ctx	25.9	39.4
Control 3 Parietal Ctx	19.5	23.5
Control (Path) 1 Parietal Ctx	61.1	69.7
Control (Path) 2 Parietal Ctx	22.2	14.9
Control (Path) 3 Parietal Ctx	2.3	0.9
Control (Path) 4 Parietal Ctx	60.1	38.9

Panel 1.3D Summary Ag1551 The NOV4 gene is widely expressed in this panel, with highest expression in the breast cancer cell line MCF-7 (CT=29). Of note is the difference in expression between the fetal and adult heart and skeletal muscle, with higher expression seen in the tissues derived from the fetal source (CTs=30-32) than in tissues derived from the adult (CTs=34-36). Thus, expression of the NOV4 gene could be used to distinguish between fetal and adult heart and skeletal muscle. In general, expression of the NOV4 gene appears to be greater in the cancer cell lines and fetal cells than in the samples derived from normal tissues. Since normal cultured cell lines and fetal cells are highly proliferative, this observation may indicate that the expression of the NOV4 gene might be used to distinguish proliferating cells over resting or quiescent cells.

Among tissues involved in central nervous system function, this gene is expressed at moderate levels in all brain regions examined. The NOV4 gene encodes a protein with a putative WD40 motif, which is known to interact with the G protein beta subunit (Gbeta), suggesting a role in signal transduction. Several neurotransmitter receptors are GPCRs, including the dopamine receptor family, the serotonin receptor family, the GABAB receptor, muscarinic acetylcholine receptors, and others; thus this molecule may mediate signaling via a neurotransmitter receptor. Targeting various neurotransmitter receptors (dopamine, serotonin) has proven to be an effective therapy in psychiatric illnesses such as schizophrenia, bipolar disorder and depression. Therefore, therapeutic modulation of this gene or its protein product may be beneficial in one or more of these diseases, as may antagonism of the protein encoded by the gene.

Among tissues with metabolic function, the NOV4 gene is expressed in adipose, adrenal gland, adult and fetal heart, adult and fetal liver, pancreas, pituitary and thyroid. This putative nuclear protein may be important for the pathogenesis and/or treatment of disease in

any or all of these tissues, including obesity and diabetes.

Panel General_screening_panel_v1.0 Summary Ag3362 The NOV4 gene is widely expressed in this panel, with highest expression in the breast cancer cell line T47D (CT=29).

Significant expression is also seen in cell lines derived from prostate, breast and ovarian

5 cancers. In general, expression of the NOV4 gene appears to be greater in the cancer cell lines than in normal tissue, an observation that is consistent with the results from Panel 1.3D. Thus, the expression of this gene could be used to distinguish these cell line types from others in the panel.

Panel 2.2 Summary Ag1551 Highest expression of the NOV4 gene is seen in normal
10 kidney tissue adjacent to malignant kidney tissue. Thus, the expression of this gene could be used to distinguish this sample from others in the panel.

Panel 4D Summary Ag1551 The NOV4 gene is widely expressed in this panel, a pattern detected in the other panels as well, with highest expression in the ionomycin activated B cell line (Ramos) (CT=28.6). Significant expression is also detected in normal B
15 lymphocytes, a B cell line (Ramos), and in normal B cells activated by pokeweed mitogen. Cytoplasmic and nuclear localization (PSORT) suggests that this G protein-beta-WD40 motif protein homolog may be used as a target for small molecule drug discovery. Activated B lymphocytes are important antigen presenting cells that participate in the stimulation of the immune response in numerous settings. Inhibitory small molecule drugs that reduce the
20 function of activated B cells may reduce or eliminate symptoms in patients with autoimmune and inflammatory diseases such as lupus erythematosus, Crohn's disease, ulcerative colitis, asthma, psoriasis, and rheumatoid arthritis.

Please note that data from one run with the probe and primer set Ag3362 is not included because the amp plot corresponding to the run indicates that there were problems
25 with the experiment.

Panel CNS_neurodegeneration_V1.0 Summary Ag1551/Ag336 Highest expression of the the NOV4 gene is seen in the occipital cortex of a control patient and the temporal cortex of an Alzheimer's patient. While the NOV4 gene does not appear to be preferentially expressed in Alzheimer's disease, this panel confirms expression of the NOV4 gene at
30 moderate/high levels in the brain in an additional set of individuals. Please see Panel 1.3D for discussion of potential utility of this gene in the central nervous system (Zhu et al., Transcription activating property of autoantigen SG2NA and modulating effect of WD-40 repeats. Exp Cell Res. 269(2):312-21, 2001).

NOV5a and NOV5b: Novel Opioid Binding Cell Adhesion Molecule

Expression of the NOV5a gene (139785504) and the NOV5b variant (139785504_da1) was assessed using the primer-probe sets Ag3090 and Ag3092 described in Tables 45 and 46. Results from RTQ-PCR runs are shown in Tables 47-50.

5 Table 45. Probe Name Ag3090

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5' -ATGACAGACTGCTGAGCAGC-3'	59.3	20	706	173
Probe	FAM-5' -AAGGCCTGAAGGTGCAGACGGAG-3' -TAMRA	70	23	736	174
Reverse	5' -CGTTGGCAAAGAGAAGCAT-3'	59	19	789	175

Table 46. Probe Name Ag3092

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5' -ATGACAGACTGCTGAGCAGC-3'	59.3	20	707	176
Probe	FAM-5' -AAGGCCTGAAGGTGCAGACGGAG-3' -TAMRA	70	23	737	177
Reverse	5' -CGTTGGCAAAGAGAAGCAT-3'	59	19	772	178

Table 47. Panel 1.3D

Tissue Name	Relative Expression(%)	Relative Expression(%)
	1.3dx4tm5823 f_ag3090_a2	1.3dx4tm5472 f_ag3092_b1
Liver adenocarcinoma	0.3	0.0
Pancreas	0.0	0.0
Pancreatic ca. CAPAN 2	0.0	0.0
Adrenal gland	1.5	0.0
Thyroid	0.0	0.0
Salivary gland	0.0	0.0
Pituitary gland	3.4	0.2
Brain (fetal)	100.0	53.3
Brain (whole)	29.4	51.5
Brain (amygdala)	31.8	50.9
Brain (cerebellum)	93.5	71.4
Brain (hippocampus)	41.1	91.1
Brain (substantia nigra)	27.0	24.5
Brain (thalamus)	20.3	100.0
Cerebral Cortex	89.4	37.4
Spinal cord	16.4	7.9
CNS ca. (glio/astro) U87-MG	0.0	0.0
CNS ca. (glio/astro) U-118-MG	0.0	0.0
CNS ca. (astro) SW1783	0.0	0.0
CNS ca. * (neuro; met) SK-N-AS	2.2	3.2
CNS ca. (astro) SF-539	0.0	0.0
CNS ca. (astro) SNB-75	1.4	0.0
CNS ca. (glio) SNB-19	0.0	0.2
CNS ca. (glio) U251	0.8	0.0
CNS ca. (glio) SF-295	0.0	0.1

Heart (fetal)	0.0	0.1
Heart	0.0	0.0
Fetal Skeletal	0.0	5.2
Skeletal muscle	0.2	0.0
Bone marrow	0.0	0.0
Thymus	0.0	1.6
Spleen	0.3	1.6
Lymph node	0.0	0.0
Colorectal	1.7	0.1
Stomach	0.0	0.0
Small intestine	0.5	0.0
Colon ca. SW480	0.0	0.0
Colon ca. * (SW480 met)SW620	0.4	0.0
Colon ca. HT29	0.5	0.1
Colon ca. HCT-116	0.0	0.2
Colon ca. CaCo-2	0.5	0.0
83219 CC Well to Mod Diff (ODO3866)	5.8	0.9
Colon ca. HCC-2998	0.7	1.0
Gastric ca.* (liver met) NCI-N87	0.3	0.0
Bladder	0.0	0.0
Trachea	0.0	0.0
Kidney	0.0	0.0
Kidney (fetal)	13.3	4.4
Renal ca. 786-0	0.2	0.0
Renal ca. A498	0.0	0.1
Renal ca. RXF 393	0.1	0.0
Renal ca. ACHN	0.0	0.0
Renal ca. UO-31	0.0	0.0
Renal ca. TK-10	0.5	0.0
Liver	0.0	0.8
Liver (fetal)	1.2	0.0
Liver ca. (hepatoblast) HepG2	21.2	5.4
Lung	0.0	0.0
Lung (fetal)	1.8	2.1
Lung ca. (small cell) LX-1	0.0	0.0
Lung ca. (small cell) NCI-H69	0.2	0.0
Lung ca. (s.cell var.) SHP-77	1.6	0.0
Lung ca. (large cell)NCI-H460	0.0	2.0
Lung ca. (non-sm. cell) A549	0.8	0.0
Lung ca. (non-s.cell) NCI-H23	21.3	10.1
Lung ca (non-s.cell) HOP-62	0.0	0.0
Lung ca. (non-s.cl) NCI-H522	26.9	3.7
Lung ca. (squam.) SW 900	0.0	0.1
Lung ca. (squam.) NCI-H596	0.0	0.0
Mammary gland	0.0	0.0

Breast ca.* (pl. effusion) MCF-7	0.0	0.0
Breast ca.* (pl.ef) MDA-MB-231	0.5	0.0
Breast ca.* (pl. effusion) T47D	0.0	0.0
Breast ca. BT-549	0.0	0.1
Breast ca. MDA-N	0.4	0.0
Ovary	8.9	2.0
Ovarian ca. OVCAR-3	0.0	0.0
Ovarian ca. OVCAR-4	1.1	0.0
Ovarian ca. OVCAR-5	0.4	0.0
Ovarian ca. OVCAR-8	0.5	0.4
Ovarian ca. IGROV-1	0.0	0.1
Ovarian ca.* (ascites) SK-OV-3	0.0	2.6
Uterus	0.0	0.0
Placenta	0.0	0.0
Prostate	0.0	0.3
Prostate ca.* (bone met)PC-3	0.2	0.1
Testis	5.9	15.0
Melanoma Hs688(A).T	0.0	0.0
Melanoma* (met) Hs688(B).T	0.0	0.0
Melanoma UACC-62	0.0	0.1
Melanoma M14	0.0	0.1
Melanoma LOX IMVI	0.0	0.0
Melanoma* (met) SK-MEL-5	0.0	0.0
Adipose	3.1	0.8

Table 48. Panel 4D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	4dx4tm5038f_a g3092_b2		4dx4tm5038f_a g3092_b2
93768_Secondary Th1_anti-CD28/anti-CD3	0.0	93100_HUVEC (Endothelial)_IL-1b	0.0
93769_Secondary Th2_anti-CD28/anti-CD3	100.0	93779_HUVEC (Endothelial)_IFN gamma	0.0
93770_Secondary Tr1_anti-CD28/anti-CD3	0.0	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0
93573_Secondary Th1_resting day 4-6 in IL-2	0.0	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	93781_HUVEC (Endothelial)_IL-11	0.0
93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	93583_Lung Microvascular Endothelial Cells_none	0.0
93568_primary Th1_anti-CD28/anti-CD3	6.2	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	4.9
93569_primary Th2_anti-CD28/anti-CD3	0.0	92662_Microvascular Dermal endothelium_none	0.0
93570_primary Tr1_anti-CD28/anti-CD3	0.0	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0

93565_primary Th1_resting dy 4-6 in IL-2	0.0	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0
93566_primary Th2_resting dy 4-6 in IL-2	0.0	93347_Small Airway Epithelium_none	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	0.0	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	2.9	92668_Coronary Artery SMC_resting	24.7
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	5.3	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.0	93107_astrocytes_resting	0.0
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.0	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	92666_KU-812 (Basophil)_resting	25.9
93354_CD4_none	0.0	92667_KU-812 (Basophil) PMA/ionomycin	23.4
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	14.2	93579_CCD1106 (Keratinocytes)_none	0.0
93103_LAK cells_resting	0.0	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0
93788_LAK cells_IL-2	0.0	93791_Liver Cirrhosis	25.4
93787_LAK cells_IL-2+IL-12	0.0	93792_Lupus Kidney	0.0
93789_LAK cells_IL-2+IFN gamma	15.3	93577_NCI-H292	0.0
93790_LAK cells_IL-2+ IL-18	0.0	93358_NCI-H292_IL-4	0.0
93104_LAK cells_PMA/ionomycin and IL-18	3.6	93360_NCI-H292_IL-9	0.0
93578_NK Cells_IL-2_resting	0.0	93359_NCI-H292_IL-13	0.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	0.0	93357_NCI-H292_IFN gamma	0.0
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.0	93777_HPAEC_-	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	14.6	93778_HPAEC_IL-1 beta/TNA alpha	2.2
93112_Mononuclear Cells (PBMCs)_resting	4.2	93254_Normal Human Lung Fibroblast_none	0.0
93113_Mononuclear Cells (PBMCs)_PWM	14.2	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0
93114_Mononuclear Cells (PBMCs)_PHA-L	37.1	93257_Normal Human Lung Fibroblast_IL-4	0.0
93249_Ramos (B cell)_none	0.0	93256_Normal Human Lung Fibroblast_IL-9	0.0
93250_Ramos (B cell)_ionomycin	0.0	93255_Normal Human Lung Fibroblast_IL-13	0.0
93349_B lymphocytes_PWM	2.6	93258_Normal Human Lung Fibroblast_IFN gamma	0.0
93350_B lymphocytes_CD40L and IL-4	0.0	93106_Dermal Fibroblasts CCD1070_resting	0.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	0.0

93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	37.9	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0
93356_Dendritic Cells_none	0.0	93772_dermal fibroblast_IFN gamma	0.0
93355_Dendritic Cells_LPS 100 ng/ml	17.3	93771_dermal fibroblast_IL-4	0.0
93775_Dendritic Cells_anti-CD40	0.0	93260_IBD Colitis 2	0.0
93774_Monocytes_resting	0.0	93261_IBD Crohns	0.0
93776_Monocytes_LPS 50 ng/ml	0.0	735010_Colon_normal	52.3
93581_Macrophages_resting	0.0	735019_Lung_none	58.3
93582_Macrophages_LPS 100 ng/ml	5.0	64028-1_Thymus_none	0.0
93098_HUVEC (Endothelial)_none	0.0	64030-1_Kidney_none	0.0
93099_HUVEC (Endothelial)_starved	0.0		

Table 49. Panel CNS_1

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	cns1x4tm6194 f_ag3092_b2		cns1x4tm6194 f_ag3092_b2
102633_BA4 Control	25.5	102605_BA17 PSP	10.2
102641_BA4 Control2	26.5	102612_BA17 PSP2	11.5
102625_BA4 Alzheimer's2	6.8	102637_Sub Nigra Control	52.7
102649_BA4 Parkinson's	25.0	102645_Sub Nigra Control2	60.1
102656_BA4 Parkinson's2	84.7	102629_Sub Nigra Alzheimer's2	4.1
102664_BA4 Huntington's	16.0	102660_Sub Nigra Parkinson's2	90.9
102671_BA4 Huntington's2	39.4	102667_Sub Nigra Huntington's	66.9
102603_BA4 PSP	20.0	102674_Sub Nigra Huntington's2	64.5
102610_BA4 PSP2	21.8	102614_Sub Nigra PSP2	7.2
102588_BA4 Depression	13.8	102592_Sub Nigra Depression	3.6
102596_BA4 Depression2	7.9	102599_Sub Nigra Depression2	11.0
102634_BA7 Control	54.8	102636_Glob Palladus Control	13.6
102642_BA7 Control2	100.0	102644_Glob Palladus Control2	9.3
102626_BA7 Alzheimer's2	7.2	102620_Glob Palladus Alzheimer's	10.0
102650_BA7 Parkinson's	16.9	102628_Glob Palladus Alzheimer's2	0.0
102657_BA7 Parkinson's2	35.3	102652_Glob Palladus Parkinson's	28.2
102665_BA7 Huntington's	20.5	102659_Glob Palladus Parkinson's2	16.1
102672_BA7 Huntington's2	27.6	102606_Glob Palladus PSP	1.6
102604_BA7 PSP	12.1	102613_Glob Palladus PSP2	4.1
102611_BA7 PSP2	13.9	102591_Glob Palladus Depression	1.8
102589_BA7 Depression	8.1	102638_Temp Pole Control	14.1
102632_BA9 Control	7.8	102646_Temp Pole Control2	26.2
102640_BA9 Control2	53.8	102622_Temp Pole Alzheimer's	1.8
102617_BA9 Alzheimer's	3.5	102630_Temp Pole Alzheimer's2	8.8
102624_BA9 Alzheimer's2	13.0	102653_Temp Pole Parkinson's	13.6

102648_BA9 Parkinson's	25.0	102661_Temp Pole Parkinson's2	33.6
102655_BA9 Parkinson's2	35.4	102668_Temp Pole Huntington's	19.8
102663_BA9 Huntington's	44.2	102607_Temp Pole PSP	3.7
102670_BA9 Huntington's2	19.8	102615_Temp Pole PSP2	3.8
102602_BA9 PSP	10.1	102600_Temp Pole Depression2	0.2
102609_BA9 PSP2	2.1	102639_Cing Gyr Control	43.5
102587_BA9 Depression	7.3	102647_Cing Gyr Control2	41.3
102595_BA9 Depression2	25.5	102623_Cing Gyr Alzheimer's	2.0
102635_BA17 Control	46.7	102631_Cing Gyr Alzheimer's2	12.6
102643_BA17 Control2	52.4	102654_Cing Gyr Parkinson's	18.3
102627_BA17 Alzheimer's2	14.0	102662_Cing Gyr Parkinson's2	7.7
102651_BA17 Parkinson's	26.5	102669_Cing Gyr Huntington's	20.8
102658_BA17 Parkinson's2	38.5	102676_Cing Gyr Huntington's2	13.1
102666_BA17 Huntington's	44.2	102608_Cing Gyr PSP	0.0
102673_BA17 Huntington's2	13.7	102616_Cing Gyr PSP2	1.7
102590_BA17 Depression	6.0	102594_Cing Gyr Depression	7.6
102597_BA17 Depression2	28.0	102601_Cing Gyr Depression2	2.3

Table 50. Panel CNS_neurodegeneration_V1.0

Tissue Name	Relative Expression(%) tm7048f_ ag3090_a2_s2	Relative Expression(%) tm7048f_ ag3092_b2_s1
AD 1 Hippo	15.6	21.3
AD 2 Hippo	28.0	33.7
AD 3 Hippo	6.0	9.7
AD 4 Hippo	9.0	13.5
AD 5 hippo	49.9	69.4
AD 6 Hippo	38.4	41.1
Control 2 Hippo	34.5	43.2
Control 4 Hippo	11.8	13.5
Control (Path) 3 Hippo	6.3	17.7
AD 1 Temporal Ctx	11.1	12.9
AD 2 Temporal Ctx	24.3	24.9
AD 3 Temporal Ctx	6.1	6.6
AD 4 Temporal Ctx	18.1	25.8
AD 5 Inf Temporal Ctx	34.6	51.3
AD 5 SupTemporal Ctx	19.4	25.9
AD 6 Inf Temporal Ctx	34.7	30.8
AD 6 Sup Temporal Ctx	33.4	28.3
Control 1 Temporal Ctx	14.1	12.1
Control 2 Temporal Ctx	79.3	52.5
Control 3 Temporal Ctx	14.4	20.2
Control 4 Temporal Ctx	15.4	13.6
Control (Path) 1 Temporal Ctx	39.4	58.3
Control (Path) 2 Temporal Ctx	34.7	46.7

Control (Path) 3 Temporal Ctx	4.4	4.9
Control (Path) 4 Temporal Ctx	34.1	49.6
AD 1 Occipital Ctx	18.3	20.0
AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 3 Occipital Ctx	11.4	14.8
AD 4 Occipital Ctx	23.0	26.3
AD 5 Occipital Ctx	11.0	64.9
AD 6 Occipital Ctx	69.7	14.5
Control 1 Occipital Ctx	7.5	12.4
Control 2 Occipital Ctx	75.4	100.0
Control 3 Occipital Ctx	22.1	30.9
Control 4 Occipital Ctx	5.7	7.3
Control (Path) 1 Occipital Ctx	53.1	57.6
Control (Path) 2 Occipital Ctx	11.4	19.6
Control (Path) 3 Occipital Ctx	5.8	7.0
Control (Path) 4 Occipital Ctx	22.7	26.2
Control 1 Parietal Ctx	10.2	14.8
Control 2 Parietal Ctx	24.1	30.3
Control 3 Parietal Ctx	30.4	33.3
Control (Path) 1 Parietal Ctx	100.0	84.8
Control (Path) 2 Parietal Ctx	25.1	33.2
Control (Path) 3 Parietal Ctx	5.4	8.4
Control (Path) 4 Parietal Ctx	54.8	57.5

Panel 1.3D Summary Ag3090/Ag3092 Two experiments with two different probe and primer sets produce results that are in very good agreement, with highest expression of the NOV5A gene in regions of the brain, specifically the thalamus and fetal brain (CTS=29-30). Indeed, the NOV5A gene shows a highly brain-preferential expression, and is expressed at high levels in all brain regions examined. The protein encoded by the NOV5A gene is a homolog of opioid-binding cell adhesion molecule (OBCAM), which is believed to be involved in axonal outgrowth. In addition, this molecule may be involved in the synaptic machinery. The limited ability of the CNS to regenerate after injury is the major impediment to the treatment of stroke, spinal cord and head trauma, and neurodegenerative diseases. Therefore, selective modulation of this gene or its protein product may be useful in enhancing neuroregeneration in any or all of these clinical conditions.

Panel 2.2 Summary Ag3090/Ag3092 Expression of the NOV5A gene is low/undetectable (Ct values >35) in all samples in this panel. (Data not shown.)

Panel 4D Summary Ag3092 Expression of the NOV5A gene is limited to a sample derived from secondary Th2 cells (Ct=34.2). This expression profile suggests that the NOV5A gene product may be useful as a protein therapeutic or a target for the generation of therapeutic

antibodies that reduce or eliminate the symptoms in patients with one or more diseases related to the functions of Th2 cells, including asthma and allergies.

Ag3090 Expression of the NOV5A gene is low/undetectable (Ct values >35) in all samples in this panel. (Data not shown.)

- 5 **Panel CNS_1 Summary Ag3092** Highest expression of the NOV5A gene is seen in the parietal cortex (Brodman's Area 7) of a control patient (CT=31.2). The gene is also widely expressed across many regions of the brain in many disease states. Please see Panel 1.3D for discussion of potential utility in the central nervous system.

- 10 **Panel CNS_neurodegeneration_V1.0 Ag3090/Ag3092** Two experiments with two different probe and primer sets produce results that are in very good agreement, with highest expression in the occipital cortex and the parietal cortex of a control patient (CT=30.3). While the expression of this gene does not appear to be specific to Alzheimer's disease, the results of this panel confirm expression of the NOV5A gene at moderate/high level in the brain in an independent set of individuals. Please see Panel 1.3D for a discussion of potential utility in the
- 15 central nervous system. (Hachisuka et al., Localization of opioid-binding cell adhesion molecule (OBCAM) in adult rat brain. Brain Res. 842(2):482-6, 1999; Hachisuka et al., Developmental expression of opioid-binding cell adhesion molecule (OBCAM) in rat brain. Brain Res Dev Brain Res 122(2):183-91, 2000).

NOV5d: Opioid Binding Cell Adhesion Molecule

- 20 Expression of the NOV5d gene (CG51027-05) was assessed using the primer-probe set Ag565 described in Table 51. Results from RTQ-PCR runs are shown in Tables 52-54.

Table 51. Probe Name Ag565

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5' -CACCAGCCGTACACCACTCA-3'		20	166	179
Probe	TET-5' -CCACGTCCCTGCCGCGTT-3' -TAMRA		19	201	180
Reverse	5' -TCACAGGCGACGAGATGTTC-3'		20	222	181

- 25 Table 52. Panel 1.1

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.1tm760t_ag565		1.1tm760t_ag565
Adrenal gland	2.7	Renal ca. UO-31	0.1
Bladder	0.5	Renal ca. RXF 393	0.2
Brain (amygdala)	10.7	Liver	3.2
Brain (cerebellum)	100.0	Liver (fetal)	0.8
Brain (hippocampus)	27.4	Liver ca. (hepatoblast) HepG2	0.0

Brain (substantia nigra)	73.2	Lung	0.0
Brain (thalamus)	44.1	Lung (fetal)	0.9
Cerebral Cortex	51.8	Lung ca. (non-s.cell) HOP-62	6.6
Brain (fetal)	48.3	Lung ca. (large cell)NCI-H460	0.0
Brain (whole)	41.2	Lung ca. (non-s.cell) NCI-H23	10.7
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cl) NCI-H522	50.0
CNS ca. (astro) SF-539	0.0	Lung ca. (non-sm. cell) A549	0.1
CNS ca. (astro) SNB-75	0.0	Lung ca. (s.cell var.) SHP-77	0.7
CNS ca. (astro) SW1783	0.1	Lung ca. (small cell) LX-1	0.0
CNS ca. (glio) U251	0.0	Lung ca. (small cell) NCI-H69	2.3
CNS ca. (glio) SF-295	0.0	Lung ca. (squam.) SW 900	0.4
CNS ca. (glio) SNB-19	0.0	Lung ca. (squam.) NCI-H596	1.3
CNS ca. (glio/astro) U87-MG	0.0	Lymph node	0.0
CNS ca.* (neuro; met) SK-N-AS	9.3	Spleen	0.0
Mammary gland	0.8	Thymus	0.0
Breast ca. BT-549	0.0	Ovary	6.2
Breast ca. MDA-N	0.0	Ovarian ca. IGROV-1	0.0
Breast ca.* (pl. effusion) T47D	0.2	Ovarian ca. OVCAR-3	0.1
Breast ca.* (pl. effusion) MCF-7	0.0	Ovarian ca. OVCAR-4	0.2
Breast ca.* (pl.ef) MDA-MB-231	0.0	Ovarian ca. OVCAR-5	0.3
Small intestine	1.8	Ovarian ca. OVCAR-8	5.8
Colorectal	0.0	Ovarian ca.* (ascites) SK-OV-3	0.1
Colon ca. HT29	0.0	Pancreas	1.2
Colon ca. CaCo-2	0.0	Pancreatic ca. CAPAN 2	0.0
Colon ca. HCT-15	0.0	Pituitary gland	11.3
Colon ca. HCT-116	0.0	Placenta	0.0
Colon ca. HCC-2998	0.0	Prostate	2.9
Colon ca. SW480	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca.* (SW480 met)SW620	0.0	Salivary gland	0.0
Stomach	0.4	Trachea	0.0
Gastric ca.* (liver met) NCI-N87	0.0	Spinal cord	10.7
Heart	0.1	Testis	5.7
Fetal Skeletal	0.0	Thyroid	0.1
Skeletal muscle	0.0	Uterus	0.1
Endothelial cells	0.0	Melanoma M14	0.1
Heart (fetal)	0.8	Melanoma LOX IMVI	0.0
Kidney	0.0	Melanoma UACC-62	0.1
Kidney (fetal)	4.7	Melanoma SK-MEL-28	0.0
Renal ca. 786-0	0.0	Melanoma* (met) SK-MEL-5	0.3
Renal ca. A498	0.0	Melanoma Hs688(A).T	0.0
Renal ca. ACHN	0.0	Melanoma* (met) Hs688(B).T	0.1
Renal ca. TK-10	0.0		

Table 53. Panel 4.1D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
-------------	------------------------	-------------	------------------------

	4.1dx4tm6519 t_ag565_a1		4.1dx4tm6519 t_ag565_a1
93768_Secondary Th1_anti-CD28/anti-CD3	0.0	93100_HUVEC (Endothelial)_IL-1b	0.0
93769_Secondary Th2_anti-CD28/anti-CD3	0.0	93779_HUVEC (Endothelial)_IFN gamma	0.0
93770_Secondary Tr1_anti-CD28/anti-CD3	1.9	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0
93573_Secondary Th1_resting day 4-6 in IL-2	0.0	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	93781_HUVEC (Endothelial)_IL-11	0.0
93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	93583_Lung Microvascular Endothelial Cells_none	0.0
93568_primary Th1_anti-CD28/anti-CD3	0.0	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93569_primary Th2_anti-CD28/anti-CD3	3.1	92662_Microvascular Dermal endothelium_none	0.0
93570_primary Tr1_anti-CD28/anti-CD3	0.0	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93565_primary Th1_resting dy 4-6 in IL-2	2.4	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0
93566_primary Th2_resting dy 4-6 in IL-2	0.0	93347_Small Airway Epithelium_none	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	0.0	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.3
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0.0	92668_Coronary Artery SMC_resting	0.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0.0	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.0	93107_astrocytes_resting	7.9
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.0	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	2.8
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	92666_KU-812 (Basophil)_resting	0.0
93354_CD4_none	0.0	92667_KU-812 (Basophil)_PMA/ionomycin	4.5
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.0	93579_CCD1106 (Keratinocytes)_none	0.0
		93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	5.3
93103_LAK cells_resting	2.4	93791_Liver Cirrhosis	2.3
93788_LAK cells_IL-2	0.0	93577_NCI-H292	0.0
93787_LAK cells_IL-2+IL-12	0.0		
93789_LAK cells_IL-2+IFN gamma	0.0	93358_NCI-H292_IL-4	0.0
93790_LAK cells_IL-2+ IL-18	0.0	93360_NCI-H292_IL-9	0.0
93104_LAK cells_PMA/ionomycin and IL-18	6.0	93359_NCI-H292_IL-13	0.0
93578_NK Cells_IL-2_resting	1.9	93357_NCI-H292_IFN gamma	0.0

93109_Mixed Lymphocyte Reaction_Two Way MLR	1.4	93777_HPAEC_-	0.0
93110_Mixed Lymphocyte Reaction_Two Way MLR	1.2	93778_HPAEC_IL-1 beta/TNA alpha	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.0	93254_Normal Human Lung Fibroblast_none	0.0
93112_Mononuclear Cells (PBMCs)_resting	2.2	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	2.1
93113_Mononuclear Cells (PBMCs)_PWM	0.0	93257_Normal Human Lung Fibroblast_IL-4	0.0
93114_Mononuclear Cells (PBMCs)_PHA-L	0.8	93256_Normal Human Lung Fibroblast_IL-9	0.0
93249_Ramos (B cell)_none	0.0	93255_Normal Human Lung Fibroblast_IL-13	0.0
93250_Ramos (B cell)_ionomycin	0.0	93258_Normal Human Lung Fibroblast_IFN gamma	0.0
93349_B lymphocytes_PWM	0.0	93106_Dermal Fibroblasts CCD1070_resting	0.0
93350_B lymphocytes_CD40L and IL-4	1.0	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	0.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	18.2	93772_dermal fibroblast_IFN gamma	0.0
93356_Dendritic Cells_none	0.0	93771_dermal fibroblast_IL-4	0.0
93355_Dendritic Cells_LPS 100 ng/ml	0.0	93892_Dermal fibroblasts_none	0.0
93775_Dendritic Cells_anti-CD40	0.0	99202_Neutrophils_TNFa+LPS	0.0
93774_Monocytes_resting	0.0	99203_Neutrophils_none	0.0
93776_Monocytes_LPS 50 ng/ml	0.0	735010_Colon_normal	1.6
93581_Macrophages_resting	0.0	735019_Lung_none	1.4
93582_Macrophages_LPS 100 ng/ml	0.0	64028-1_Thymus_none	31.4
93098_HUVEC (Endothelial)_none	0.0	64030-1_Kidney_none	100.0
93099_HUVEC (Endothelial)_starved	0.0		

Table 54. Panel CNS_neurodegeneration_v1.0

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	tm6933t_ag565_b1_s2		tm6933t_ag565_b1_s2
106655_4951 Hippo	19.7	106677_4624 BA21	3.2
106657_4986 Hippo	36.4	106681_4640 BA21	35.3
106652_4933 Hippo	8.0	106654_4951 BA17	12.6
106649_4901 Hippo	7.7	cns_water	0.0
110138_3087 hippo	91.7	106651_4933 BA17	7.3
110121_3027 Hippo	41.1	106648_4901 BA17	20.6
106670_4971 Hippo	48.3	110123_3027 Occ Ctx	10.9
106666_4867 Hippo	6.9	110140_3087 occ ctx	56.3

106680_4624 Hippo	3.3	106659_4595 BA17	1.9
106653_4951 BA21	9.6	106668_4971 BA17	100.0
106656_4986 BA21	29.4	106662_4737 BA17	11.0
106650_4933 BA21	4.0	106665_4867 BA17	7.5
106647_4901 BA21	14.4	106675_3975 BA17	82.9
110136_3087 inf temp ctx	49.8	106672_3954 BA17	10.5
110137_3087 sup temp ctx	27.3	106678_4624 BA17	0.9
110118_3027 Inf Temp Ctx	25.1	106682_4640 BA17	20.9
110119_3027 Sup Temp Ctx	40.8	106660_4595 BA7	5.6
106658_4595 BA21	5.1	113670_106669 pool	20.3
106667_4971 BA21	82.8	106663_4737 BA7	24.8
106661_4737 BA21	19.6	106676_3975 BA7	97.3
106664_4867 BA21	7.9	106673_3954 BA7	26.4
106674_3975 BA21	77.6	106679_4624 BA7	2.9
106671_3954 BA21	38.0	106683_4640 BA7	55.7

Panel 1.1 Summary The NOV5D gene is expressed most highly in the cerebellum (CT=22). Indeed, this gene shows a highly brain-preferential expression, and is expressed at high levels in all brain regions examined. The protein encoded by the NOV5D gene is a homolog of opioid-binding cell adhesion molecule (OBCAM), which is believed to be involved in axonal outgrowth. In addition, this molecule may be involved in the synaptic machinery. The limited ability of the CNS to regenerate after injury is the major impediment to treatment of stroke, spinal cord and head trauma, and neurodegenerative diseases. Therefore, selective modulation of this gene or its protein product may be useful in enhancing neuroregeneration in any or all of these clinical conditions.

There is also significant expression in tissue derived from fetal heart and kidney (CTs=26-29) when compared to the level of expression in the adult source of these tissues (CTs=32-37). Thus, expression of this gene could be used to differentiate between the adult and fetal sources of heart and kidney tissue.

The NOV5D gene encodes a putative intracellular protein with moderate expression in many metabolic tissues including adrenal, adult and fetal liver, pancreas, pituitary and thyroid. Therefore, this protein may be important for the pathogenesis and/or treatment of disease in any or all of these tissues, including obesity and diabetes.

Panel General_screening_panel_v1.4 Summary Please note that data from this experiment is not included because the amp plot corresponding to the run indicates that there were problems with the run.

Panel 4.1D Summary Expression is limited to a few samples in this panel, with highest expression in the kidney (CT=30.4) and thymus. Moderate expression is seen dibutyryl

–cAMP-differentiated and phorbol ester plus ionomycin-activated eosinophil cell line EOL-1, with low but significant levels of expression detected in unstimulated astrocytes. This expression profile suggests that the NOV5D gene product, an opioid-binding cell adhesion molecule homolog, may be useful as a therapeutic protein to reduce or eliminate symptoms resulting from diseases of the thymus and kidney. Furthermore, the protein encoded by the NOV5D gene may also reduce or eliminate allergies in which activated eosinophils play a role and may be effective in the treatment of multiple sclerosis where astrocytes present antigens to T lymphocytes.

Panel CNS_neurodegeneration_v1.0 Summary The NOV5D gene is widely expressed in this panel, with highest expression detected in the occipital cortex of a control brain (CT=29.1). The expression seen across all regions of the brain is in agreement with the expression seen in Panel 1.1. While the expression of this gene does not appear to be specific to Alzheimer's disease, this panel confirms expression at the moderate/high level in the brain in an additional set of individuals. Please see Panel 1.1 for discussion of potential utility in the central nervous system (Hachisuka et al., Localization of opioid-binding cell adhesion molecule (OBCAM) in adult rat brain. Brain Res. 842(2):482-6, 1999; Hachisuka et al., Developmental expression of opioid-binding cell adhesion molecule (OBCAM) in rat brain. Brain Res Dev Brain Res 122(2):183-91, 2000).

NOV6: Triacylglycerol lipase-like

Expression of the NOV6a gene (SC122982104_A) and the NOV6b variant (CG58608-02) was assessed using the primer-probe sets Ag2179 and Ag3927 described in Tables 55 and 56. Please note that only the probe and primer set Ag3927 match the CG58608-02 sequence. Results from RTQ-PCR runs are shown in Table 57.

Table 55. Probe Name Ag2179

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-AAATGGAAGTCAATAGGCAACA-3'	58.6	22	739	182
Probe	TET-5'-AAGACTTCTTGCCTAAACCTCATTTAAAA-3'-TAMRA	63.7	30	761	183
Reverse	5'-ACACAGCTTTGAACCAATGAAT-3'	58.6	22	792	184

Table 56. Probe Name Ag3927

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GTCCTGATCTGAACTTGGTTCA-3'	59.2	22	980	185
Probe	TET-5'-CAGACAACGCTCCATTATACAACATGACA-3'-TAMRA	66.9	30	1009	186
Reverse	5'-TTACCATTCCAAATGCAGTTG-3'	59.9	22	1052	187

Table 57. Panel General screening panel_v1.4

Tissue Name	Relative Expression(%)
	tm7491t_ag3927
D6005-01_Human adipose	1.5
112193_Metastatic melanoma	1.6
112192_Metastatic melanoma	0.0
95280_Epidermis (metastatic melanoma)	0.0
95279_Epidermis (metastatic melanoma)	1.5
Melanoma (met)_SK-MEL-5	0.0
112196_Tongue (oncology)	0.0
113461_Testis Pool	100.0
Prostate ca.(bone met)_PC-3	0.0
113455_Prostate Pool	1.0
103396_Placenta	0.0
113463_Uterus Pool	0.0
Ovarian carcinoma_OVCAR-3	2.1
Ovarian carcinoma(ascites)_SK-OV-3	0.0
95297_Adenocarcinoma (ovary)	0.0
Ovarian carcinoma_OVCAR-5	11.8
Ovarian carcinoma_IGROV-1	6.2
Ovarian carcinoma_OVCAR-8	8.8
103368_Ovary	1.2
MCF7_breast carcinoma(pleural effusion)	5.0
Breast ca. (pleural effusion)_MDA-MB-231	0.0
112189_ductal cell carcinoma(breast)	3.1
Breast ca. (pleural effusion)_T47D	0.0
Breast carcinoma_MDA-N	0.0
113452_Breast Pool	2.1
103398_Trachea	7.8
112354_lung	0.0
103374_Fetal Lung	2.7
94921_Small cell carcinoma of the lung	0.0
Lung ca.(small cell)_LX-1	5.7
94919_Small cell carcinoma of the lung	0.0
Lung ca.(s.cell var.)_SHP-77	0.0
95268_Lung (Large cell carcinoma)	0.0
94920_Small cell carcinoma of the lung	0.0
Lung ca.(non-s.cell)_NCI-H23	2.5
Lung ca.(large cell)_NCI-H460	0.0
Lung ca.(non-s.cell)_HOP-62	0.0
Lung ca.(non-s.cl)_NCI-H522	2.7
103392_Liver	0.0
103393_Fetal Liver	0.0

113450_Brain (Thalamus) Pool	9.0
103384_Brain (whole)	1.2
113458_Spinal Cord Pool	3.0
103375_Adrenal Gland	0.0
113454_Pituitary gland Pool	0.0
103397_Salivary Gland	0.9
103369_Thyroid (female)	24.7
Pancreatic ca. CAPAN2	1.4
113453_Pancreas Pool	1.8

Panel General_screening_panel_v1.4 Summary Ag3927 Expression of the NOV6a gene in this panel is limited to samples originating from the testis (CT=33) and the kidney. Thus, expression of this gene could be used to distinguish testis and kidney tissue from the other tissues in this panel.

Ag2179 Expression of the NOV6a gene is low/undetectable (Ct values >35) in all samples in Panels 1.3D, 2D, 4D, and CNS_neurodegeneration_v1.0. (Data not shown.)

NOV7a: IGE Receptor Beta Subunit

Expression of the NOV7a gene (SC126624027_A) was assessed using the primer-probe set Ag2178 described in Table 58. Results from RTQ-PCR runs are shown in Table 59.

Table 58. Probe Name Ag2178

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5' - TTGAGAAAGGCAGAGAAATGAA - 3'	59.1	22	85	188
Probe	TET-5' - CAATAATGCTGAAAGTCATCAATGTAATCA - 3' - TAMRA	64.2	30	112	189
Reverse	5' - ACTGTCCTGTCTTGGGAATTT - 3'	59	22	142	190

Table 59. Panel 1.3D

Tissue Name	Relative Expression(%) 1.3dx4tm5487 t_ag2178_b1	Tissue Name	Relative Expression(%) 1.3dx4tm5487 t_ag2178_b1
Liver adenocarcinoma	0.0	Kidney (fetal)	0.0
Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	0.0
Adrenal gland	0.0	Renal ca. RXF 393	0.0
Thyroid	0.0	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.0
Pituitary gland	0.0	Renal ca. TK-10	0.0
Brain (fetal)	0.0	Liver	0.0
Brain (whole)	0.0	Liver (fetal)	0.0
Brain (amygdala)	0.0	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	0.0	Lung	0.0

Brain (hippocampus)	0.0	Lung (fetal)	0.0
Brain (substantia nigra)	0.0	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	0.0	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	0.0	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	0.0	Lung ca. (large cell)NCI-H460	0.0
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.0
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (astro) SW1783	0.0	Lung ca (non-s.cell) HOP-62	0.0
CNS ca.* (neuro; met) SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio) SNB-19	0.0	Mammary gland	0.0
CNS ca. (glio) U251	0.0	Breast ca.* (pl. effusion) MCF-7	0.0
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.0	Breast ca.* (pl. effusion) T47D	0.0
Heart	0.0	Breast ca. BT-549	0.0
Fetal Skeletal	0.0	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.0	Ovarian ca. OVCAR-4	0.0
Spleen	0.0	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	0.0
Colorectal	0.0	Ovarian ca. IGROV-1	0.0
Stomach	0.0	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	0.0	Uterus	0.0
Colon ca. SW480	0.0	Placenta	0.0
Colon ca.* (SW480 met)SW620	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	100.0
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	0.0	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	0.0

Panel 1.3D Summary Expression of the NOV7a gene is restricted to the testis (CT=32.9). Thus, the expression of this gene could be used to distinguish testis tissue from the other samples on the panel.

- 5 Expression of the NOV7a gene is low/undetectable (Ct values >35) in all samples in Panels 2D and 4D. (Data not shown.)

NOV8: Munc18-like

Expression of the NOV8 gene (SC138745558_A) was assessed using the primer-probe set Ag2177 described in Table 60. Results from RTQ-PCR runs are shown in Tables 61-64.

Table 60. Probe Name Ag2177

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-TCCAGTGTTCAAAGCTTCTTTC-3'	58.6	22	937	191
Probe	FAM-5'-CCCAAGCAAATTTGTCCTTATCACCG-3'-TAMRA	68.9	26	983	192
Reverse	5'-CGAGCTTTCCAAATGTATCAAG-3'	58.9	22	1014	193

5

Table 61. Panel 1.3D

Tissue Name	Relative Expression(%) 1.3dtm4176f_ ag2177	Tissue Name	Relative Expression(%) 1.3dtm4176f_ ag2177
Liver adenocarcinoma	14.6	Kidney (fetal)	8.4
Pancreas	3.3	Renal ca. 786-0	1.3
Pancreatic ca. CAPAN 2	7.4	Renal ca. A498	13.1
Adrenal gland	9.8	Renal ca. RXF 393	0.9
Thyroid	13.4	Renal ca. ACHN	11.1
Salivary gland	3.3	Renal ca. UO-31	24.7
Pituitary gland	16.8	Renal ca. TK-10	6.7
Brain (fetal)	8.1	Liver	1.9
Brain (whole)	13.9	Liver (fetal)	6.5
Brain (amygdala)	16.0	Liver ca. (hepatoblast) HepG2	0.4
Brain (cerebellum)	7.6	Lung	12.0
Brain (hippocampus)	72.7	Lung (fetal)	6.8
Brain (substantia nigra)	6.0	Lung ca. (small cell) LX-1	1.6
Brain (thalamus)	16.2	Lung ca. (small cell) NCI-H69	14.8
Cerebral Cortex	45.1	Lung ca. (s.cell var.) SHP-77	14.3
Spinal cord	8.4	Lung ca. (large cell) NCI-H460	8.0
CNS ca. (glio/astro) U87-MG	28.7	Lung ca. (non-sm. cell) A549	12.1
CNS ca. (glio/astro) U-118-MG	34.4	Lung ca. (non-s.cell) NCI-H23	18.9
CNS ca. (astro) SW1783	14.8	Lung ca. (non-s.cell) HOP-62	13.1
CNS ca.* (neuro; met) SK-N-AS	56.3	Lung ca. (non-s.cl) NCI-H522	10.4
CNS ca. (astro) SF-539	14.2	Lung ca. (squam.) SW 900	4.7
CNS ca. (astro) SNB-75	21.5	Lung ca. (squam.) NCI-H596	6.3
CNS ca. (glio) SNB-19	7.9	Mammary gland	14.4
CNS ca. (glio) U251	8.1	Breast ca.* (pl. effusion) MCF-7	4.4
CNS ca. (glio) SF-295	22.4	Breast ca.* (pl.ef) MDA-MB-231	39.8
Heart (fetal)	12.0	Breast ca.* (pl. effusion) T47D	6.2
Heart	2.8	Breast ca. BT-549	100.0
Fetal Skeletal	42.0	Breast ca. MDA-N	10.4
Skeletal muscle	4.6	Ovary	31.0
Bone marrow	5.8	Ovarian ca. OVCAR-3	6.7
Thymus	5.6	Ovarian ca. OVCAR-4	4.5

Spleen	9.0	Ovarian ca. OVCAR-5	8.0
Lymph node	4.5	Ovarian ca. OVCAR-8	2.1
Colorectal	13.9	Ovarian ca. IGROV-1	0.9
Stomach	7.4	Ovarian ca.* (ascites) SK-OV-3	13.3
Small intestine	8.4	Uterus	10.8
Colon ca. SW480	8.1	Placenta	10.4
Colon ca.* (SW480 met)SW620	2.5	Prostate	4.0
Colon ca. HT29	0.5	Prostate ca.* (bone met)PC-3	4.1
Colon ca. HCT-116	5.6	Testis	14.2
Colon ca. CaCo-2	0.1	Melanoma Hs688(A).T	10.6
83219 CC Well to Mod Diff (ODO3866)	6.7	Melanoma* (met) Hs688(B).T	4.2
Colon ca. HCC-2998	39.8	Melanoma UACC-62	3.7
Gastric ca.* (liver met) NCI-N87	1.4	Melanoma M14	3.9
Bladder	3.5	Melanoma LOX IMVI	4.5
Trachea	12.9	Melanoma* (met) SK-MEL-5	9.5
Kidney	5.1	Adipose	7.2

Table 62. Panel 2D

Tissue Name	Relative Expression(%) 2dtm4177f_ag2 177	Tissue Name	Relative Expression(%) 2dtm4177f_ag2 177
Normal Colon GENPAK 061003	80.1	Kidney NAT Clontech 8120608	24.7
83219 CC Well to Mod Diff (ODO3866)	9.1	Kidney Cancer Clontech 8120613	31.9
83220 CC NAT (ODO3866)	16.3	Kidney NAT Clontech 8120614	31.2
83221 CC Gr.2 rectosigmoid (ODO3868)	12.5	Kidney Cancer Clontech 9010320	31.6
83222 CC NAT (ODO3868)	6.3	Kidney NAT Clontech 9010321	43.2
83235 CC Mod Diff (ODO3920)	7.7	Normal Uterus GENPAK 061018	12.3
83236 CC NAT (ODO3920)	21.6	Uterus Cancer GENPAK 064011	35.8
83237 CC Gr.2 ascend colon (ODO3921)	27.7	Normal Thyroid Clontech A+ 6570-1	26.2
83238 CC NAT (ODO3921)	23.5	Thyroid Cancer GENPAK 064010	43.5
83241 CC from Partial Hepatectomy (ODO4309)	25.7	Thyroid Cancer INVITROGEN A302152	23.2
83242 Liver NAT (ODO4309)	24.1	Thyroid NAT INVITROGEN A302153	37.9
87472 Colon mets to lung (OD04451-01)	10.3	Normal Breast GENPAK 061019	35.1
87473 Lung NAT (OD04451-02)	18.7	84877 Breast Cancer (OD04566)	37.4
Normal Prostate Clontech A+ 6546-1	9.4	85975 Breast Cancer (OD04590- 01)	53.6
84140 Prostate Cancer (OD04410)	41.8	85976 Breast Cancer Mets (OD04590-03)	42.9
84141 Prostate NAT (OD04410)	36.3	87070 Breast Cancer Metastasis (OD04655-05)	45.7
87073 Prostate Cancer (OD04720- 01)	33.2	GENPAK Breast Cancer 064006	19.9
87074 Prostate NAT (OD04720- 02)	64.2	Breast Cancer Res. Gen. 1024	42.3

Normal Lung GENPAK 061010	71.2	Breast Cancer Clontech 9100266	46.3
83239 Lung Met to Muscle (ODO4286)	36.1	Breast NAT Clontech 9100265	32.8
83240 Muscle NAT (ODO4286)	22.8	Breast Cancer INVITROGEN A209073	26.6
84136 Lung Malignant Cancer (OD03126)	48.0	Breast NAT INVITROGEN A2090734	23.5
84137 Lung NAT (OD03126)	53.6	Normal Liver GENPAK 061009	9.4
84871 Lung Cancer (OD04404)	31.6	Liver Cancer GENPAK 064003	6.2
84872 Lung NAT (OD04404)	26.2	Liver Cancer Research Genetics RNA 1025	10.7
84875 Lung Cancer (OD04565)	11.6	Liver Cancer Research Genetics RNA 1026	11.0
84876 Lung NAT (OD04565)	11.5	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	12.2
85950 Lung Cancer (OD04237-01)	66.0	Paired Liver Tissue Research Genetics RNA 6004-N	12.2
85970 Lung NAT (OD04237-02)	23.2	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	9.5
83255 Ocular Mel Met to Liver (ODO4310)	23.7	Paired Liver Tissue Research Genetics RNA 6005-N	5.3
83256 Liver NAT (ODO4310)	17.9	Normal Bladder GENPAK 061001	30.4
84139 Melanoma Mets to Lung (OD04321)	42.3	Bladder Cancer Research Genetics RNA 1023	11.0
84138 Lung NAT (OD04321)	42.0	Bladder Cancer INVITROGEN A302173	16.3
Normal Kidney GENPAK 061008	85.3	87071 Bladder Cancer (OD04718-01)	56.6
83786 Kidney Ca, Nuclear grade 2 (OD04338)	100.0	87072 Bladder Normal Adjacent (OD04718-03)	44.1
83787 Kidney NAT (OD04338)	49.7	Normal Ovary Res. Gen.	19.3
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	38.2	Ovarian Cancer GENPAK 064008	31.6
83789 Kidney NAT (OD04339)	59.5	87492 Ovary Cancer (OD04768-07)	34.6
83790 Kidney Ca, Clear cell type (OD04340)	68.8	87493 Ovary NAT (OD04768-08)	8.2
83791 Kidney NAT (OD04340)	50.7	Normal Stomach GENPAK 061017	25.3
83792 Kidney Ca, Nuclear grade 3 (OD04348)	13.5	Gastric Cancer Clontech 9060358	12.2
83793 Kidney NAT (OD04348)	25.9	NAT Stomach Clontech 9060359	22.4
87474 Kidney Cancer (OD04622-01)	23.5	Gastric Cancer Clontech 9060395	30.8
87475 Kidney NAT (OD04622-03)	9.1	NAT Stomach Clontech 9060394	24.8
85973 Kidney Cancer (OD04450-01)	45.1	Gastric Cancer Clontech 9060397	18.4
85974 Kidney NAT (OD04450-03)	37.4	NAT Stomach Clontech 9060396	12.4
Kidney Cancer Clontech 8120607	30.6	Gastric Cancer GENPAK 064005	31.2

Table 63. Panel 4D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	4dtm4178f_ag2177		4dtm4178f_ag2177
93768 Secondary Th1 anti-	11.6	93100 HUVEC (Endothelial) IL-	25.0

CD28/anti-CD3		Ib	
93769_Secondary Th2_anti-CD28/anti-CD3	42.9	93779_HUVEC (Endothelial)_IFN gamma	52.1
93770_Secondary Tr1_anti-CD28/anti-CD3	39.8	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	35.1
93573_Secondary Th1_resting day 4-6 in IL-2	16.7	93101_HUVEC (Endothelial)_TNF alpha + IL4	41.8
93572_Secondary Th2_resting day 4-6 in IL-2	24.8	93781_HUVEC (Endothelial)_IL-11	19.1
93571_Secondary Tr1_resting day 4-6 in IL-2	19.2	93583_Lung Microvascular Endothelial Cells_none	40.6
93568_primary Th1_anti-CD28/anti-CD3	44.4	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	37.6
93569_primary Th2_anti-CD28/anti-CD3	43.2	92662_Microvascular Dermal endothelium_none	58.2
93570_primary Tr1_anti-CD28/anti-CD3	60.7	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	35.1
93565_primary Th1_resting dy 4-6 in IL-2	84.7	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	31.6
93566_primary Th2_resting dy 4-6 in IL-2	55.5	93347_Small Airway Epithelium_none	17.7
93567_primary Tr1_resting dy 4-6 in IL-2	42.0	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	72.2
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	31.0	92668_Coronary Artery SMC_resting	38.4
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	37.6	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	21.0	93107_astrocytes_resting	27.9
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	24.0	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	17.2
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	22.1	92666_KU-812 (Basophil)_resting	22.8
93354_CD4_none	14.5	92667_KU-812 (Basophil)_PMA/ionomycin	49.0
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	30.1	93579_CCD1106 (Keratinocytes)_none	13.8
93103_LAK cells_resting	38.7	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	5.6
93788_LAK cells_IL-2	29.5	93791_Liver Cirrhosis	7.9
93787_LAK cells_IL-2+IL-12	21.6	93792_Lupus Kidney	4.6
93789_LAK cells_IL-2+IFN gamma	38.7	93577_NCI-H292	48.6
93790_LAK cells_IL-2+ IL-18	49.3	93358_NCI-H292_IL-4	63.3
93104_LAK cells_PMA/ionomycin and IL-18	17.4	93360_NCI-H292_IL-9	66.4
93578_NK Cells_IL-2_resting	25.3	93359_NCI-H292_IL-13	34.6
93109_Mixed Lymphocyte Reaction_Two Way MLR	31.6	93357_NCI-H292_IFN gamma	31.6
93110_Mixed Lymphocyte Reaction_Two Way MLR	15.7	93777_HPAEC_-	32.5

93111_Mixed Lymphocyte Reaction Two Way MLR	17.1	93778_HPAEC_IL-1 beta/TNA alpha	41.8
93112_Mononuclear Cells (PBMCs)_resting	10.0	93254_Normal Human Lung Fibroblast_none	37.6
93113_Mononuclear Cells (PBMCs)_PWM	66.9	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	24.0
93114_Mononuclear Cells (PBMCs)_PHA-L	35.8	93257_Normal Human Lung Fibroblast_IL-4	71.7
93249_Ramos (B cell)_none	27.2	93256_Normal Human Lung Fibroblast_IL-9	55.5
93250_Ramos (B cell)_ionomycin	62.0	93255_Normal Human Lung Fibroblast_IL-13	41.8
93349_B lymphocytes_PWM	76.8	93258_Normal Human Lung Fibroblast_IFN gamma	61.1
93350_B lymphocytes_CD40L and IL-4	58.2	93106_Dermal Fibroblasts CCD1070_resting	57.8
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	29.3	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	95.3
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	20.9	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	31.0
93356_Dendritic Cells_none	24.8	93772_dermal fibroblast_IFN gamma	32.8
93355_Dendritic Cells_LPS 100 ng/ml	20.6	93771_dermal fibroblast_IL-4	70.2
93775_Dendritic Cells_anti-CD40	28.9	93260_IBD Colitis 2	2.2
93774_Monocytes_resting	30.4	93261_IBD Crohns	2.8
93776_Monocytes_LPS 50 ng/ml	21.9	735010_Colon_normal	30.1
93581_Macrophages_resting	51.8	735019_Lung_none	29.7
93582_Macrophages_LPS 100 ng/ml	18.3	64028-1_Thymus_none	49.3
93098_HUVEC (Endothelial)_none	52.9	64030-1_Kidney_none	35.6
93099_HUVEC (Endothelial)_starved	100.0		

Table 64. Panel CNS_neurodegeneration_v1.0

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	tm6900f_ag2177_a1s1		tm6900f_ag2177_a1s1
AD 1 Hippo	0.0	Control (Path) 3 Temporal Ctx	4.5
AD 2 Hippo	21.5	Control (Path) 4 Temporal Ctx	34.0
AD 3 Hippo	5.6	AD 1 Occipital Ctx	13.8
AD 4 Hippo	6.8	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	66.5	AD 3 Occipital Ctx	6.4
AD 6 Hippo	34.0	AD 4 Occipital Ctx	29.1
Control 2 Hippo	38.5	AD 5 Occipital Ctx	45.7
Control 4 Hippo	11.4	AD 6 Occipital Ctx	0.1
Control (Path) 3 Hippo	0.0	Control 1 Occipital Ctx	4.5
AD 1 Temporal Ctx	11.4	Control 2 Occipital Ctx	69.7
AD 2 Temporal Ctx	38.6	Control 3 Occipital Ctx	16.1
AD 3 Temporal Ctx	4.8	Control 4 Occipital Ctx	8.2

AD 4 Temporal Ctx	0.0	Control (Path) 1 Occipital Ctx	70.8
AD 5 Inf Temporal Ctx	100.0	Control (Path) 2 Occipital Ctx	0.0
AD 5 Sup Temporal Ctx	30.4	Control (Path) 3 Occipital Ctx	4.2
AD 6 Inf Temporal Ctx	58.9	Control (Path) 4 Occipital Ctx	12.6
AD 6 Sup Temporal Ctx	36.5	Control 1 Parietal Ctx	7.8
Control 1 Temporal Ctx	9.7	Control 2 Parietal Ctx	28.9
Control 2 Temporal Ctx	57.5	Control 3 Parietal Ctx	0.0
Control 3 Temporal Ctx	14.4	Control (Path) 1 Parietal Ctx	82.8
Control 3 Temporal Ctx	7.6	Control (Path) 2 Parietal Ctx	24.3
Control (Path) 1 Temporal Ctx	58.9	Control (Path) 3 Parietal Ctx	4.0
Control (Path) 2 Temporal Ctx	30.2	Control (Path) 4 Parietal Ctx	33.8

Panel 1.3D Summary Expression of the NOV8 gene is ubiquitous among the samples in this panel, with highest expression in a sample derived from a breast cancer cell line (BT-549) (CT=27.4). In addition, there is substantial expression in a neuroblastoma cell line (SK-N-AS). Of note is the difference in expression between the sample of fetal skeletal muscle and its adult counterpart. Thus, the expression of this gene could be used to distinguish skeletal muscle from fetal and adult sources.

In addition, there is substantial expression of this gene in the hippocampus and cerebral cortex. Munc 18 appears to be critically involved in the process of synaptic vesicle docking prior to neurotransmitter release. Since the NOV8 gene product is a Munc 18 homolog, inhibition of the function of this protein may have therapeutic benefit in any disease in which selective decreases of neurotransmission has been shown to ameliorate symptomology (e.g., epilepsy or other seizure disorders, schizophrenia, bipolar disorder or anxiety).

The NOV8 gene encodes a putative intracellular protein with moderate expression in many metabolic tissues including adipose, adrenal gland, adult and fetal heart, adult and fetal liver, adult and fetal skeletal muscle, pancreas, pituitary and thyroid. Thus, this protein may be important for the pathogenesis and/or treatment of disease in any or all of these tissues, including obesity and diabetes.

Panel 2D Summary Expression of the NOV8 gene is ubiquitous among the samples in this panel, with highest expression in a kidney cancer sample (CT=27.1). Thus, the expression of this gene could be used to distinguish between this kidney cancer and the other samples in the panel.

Panel 4D Summary The NOV8 gene is widely expressed among the samples in this panel, with highest expression in endothelial (HUVEC) cells (CT=26.7). Significantly, expression of the NOV8 gene is higher in activated B cells than in resting B cells. Small molecule drugs that inhibit the function of the NOV8 gene product may reduce the function of activated B cells and may reduce or eliminate the symptoms in patients with autoimmune and

inflammatory diseases such as lupus erythematosus, Crohn's disease, ulcerative colitis, asthma, psoriasis, and rheumatoid arthritis.

Panel CNS_neurodegeneration_v1.0 Summary The NOV8 gene is widely expressed among the samples in this panel, with highest expression in the temporal cortex of an Alzheimer's patient (CT=26.6). While the expression of this gene does not appear to be specific to Alzheimer's disease, this panel confirms expression at the moderate/high level in the brain in an additional set of individuals (Voets et al., Munc18-1 promotes large dense-core vesicle docking. Neuron. 31(4):581-91, 2001).

NOV9: Immunoglobulin-like

Expression of the NOV9a gene (SC138673511_A) and the NOV9b variant (CG106625-02) was assessed using the primer-probe set Ag2176 described in Table 65. Results from RTQ-PCR runs are shown in Tables 66-70.

Table 65. Probe Name Ag2176

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GGATAACGGCACCTACACTTG-3'	59.5	21	1006	194
Probe	TET-5'-AGGCGTCCAATAAGCACGGCCAT-3'-TAMRA	71.4	23	1029	195
Reverse	5'-CAGGGTCGTAGACCACAAGTAC-3'	58.7	22	1067	196

Table 66. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.3dtm4274t_ag2176		1.3dtm4274t_ag2176
Liver adenocarcinoma	6.4	Kidney (fetal)	3.6
Pancreas	1.5	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.4	Renal ca. A498	3.3
Adrenal gland	4.5	Renal ca. RXF 393	0.1
Thyroid	1.0	Renal ca. ACHN	1.0
Salivary gland	1.3	Renal ca. UO-31	2.8
Pituitary gland	8.7	Renal ca. TK-10	1.7
Brain (fetal)	13.6	Liver	0.6
Brain (whole)	28.5	Liver (fetal)	0.7
Brain (amygdala)	35.4	Liver ca. (hepatoblast) HepG2	2.5
Brain (cerebellum)	9.8	Lung	1.3
Brain (hippocampus)	100.0	Lung (fetal)	1.6
Brain (substantia nigra)	21.8	Lung ca. (small cell) LX-1	0.4
Brain (thalamus)	48.0	Lung ca. (small cell) NCI-H69	1.8
Cerebral Cortex	10.2	Lung ca. (s.cell var.) SHP-77	2.3
Spinal cord	24.1	Lung ca. (large cell) NCI-H460	0.7
CNS ca. (glio/astro) U87-MG	0.3	Lung ca. (non-sm. cell) A549	1.2
CNS ca. (glio/astro) U-118-MG	0.3	Lung ca. (non-s.cell) NCI-H23	1.0

CNS ca. (astro) SW1783	0.4	Lung ca (non-s.cell) HOP-62	1.5
CNS ca.* (neuro; met) SK-N-AS	2.8	Lung ca. (non-s.cl) NCI-H522	1.9
CNS ca. (astro) SF-539	0.2	Lung ca. (squam.) SW 900	1.5
CNS ca. (astro) SNB-75	7.4	Lung ca. (squam.) NCI-H596	0.1
CNS ca. (glio) SNB-19	4.9	Mammary gland	4.3
CNS ca. (glio) U251	2.4	Breast ca.* (pl. effusion) MCF-7	0.8
CNS ca. (glio) SF-295	3.0	Breast ca.* (pl.ef) MDA-MB-231	0.3
Heart (fetal)	2.1	Breast ca.* (pl. effusion) T47D	0.5
Heart	0.8	Breast ca. BT-549	3.4
Fetal Skeletal	4.6	Breast ca. MDA-N	0.3
Skeletal muscle	0.3	Ovary	1.4
Bone marrow	0.3	Ovarian ca. OVCAR-3	1.0
Thymus	0.3	Ovarian ca. OVCAR-4	1.0
Spleen	0.4	Ovarian ca. OVCAR-5	2.3
Lymph node	0.2	Ovarian ca. OVCAR-8	0.4
Colorectal	0.3	Ovarian ca. IGROV-1	0.6
Stomach	2.6	Ovarian ca.* (ascites) SK-OV-3	1.6
Small intestine	2.5	Uterus	2.0
Colon ca. SW480	11.0	Placenta	0.1
Colon ca.* (SW480 met)SW620	0.6	Prostate	4.7
Colon ca. HT29	0.4	Prostate ca.* (bone met)PC-3	0.8
Colon ca. HCT-116	1.5	Testis	2.1
Colon ca. CaCo-2	0.9	Melanoma Hs688(A).T	0.1
83219 CC Well to Mod Diff (ODO3866)	0.3	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	1.0	Melanoma UACC-62	1.1
Gastric ca.* (liver met) NCI-N87	1.5	Melanoma M14	0.0
Bladder	0.4	Melanoma LOX IMVI	0.0
Trachea	6.8	Melanoma* (met) SK-MEL-5	0.7
Kidney	2.6	Adipose	0.1

Table 67. Panel 2D

Tissue Name	Relative Expression(%) 2dtm4275t _ag2176	Tissue Name	Relative Expression(%) 2dtm4275t _ag2176
Normal Colon GENPAK 061003	31.0	Kidney NAT Clontech 8120608	45.7
83219 CC Well to Mod Diff (ODO3866)	6.7	Kidney Cancer Clontech 8120613	46.3
83220 CC NAT (ODO3866)	10.0	Kidney NAT Clontech 8120614	66.0
83221 CC Gr.2 rectosigmoid (ODO3868)	1.4	Kidney Cancer Clontech 9010320	11.2
83222 CC NAT (ODO3868)	6.7	Kidney NAT Clontech 9010321	100.0
83235 CC Mod Diff (ODO3920)	3.4	Normal Uterus GENPAK 061018	5.0
83236 CC NAT (ODO3920)	3.2	Uterus Cancer GENPAK 064011	16.5
83237 CC Gr.2 ascend colon (ODO3921)	6.5	Normal Thyroid Clontech A+ 6570-1	12.5
83238 CC NAT (ODO3921)	8.8	Thyroid Cancer GENPAK 064010	6.2
83241 CC from Partial	5.2	Thyroid Cancer INVITROGEN	1.0

Hepatectomy (ODO4309)		A302152	
83242 Liver NAT (ODO4309)	8.2	Thyroid NAT INVITROGEN A302153	14.7
87472 Colon mets to lung (OD04451-01)	6.8	Normal Breast GENPAK 061019	27.7
87473 Lung NAT (OD04451-02)	4.9	84877 Breast Cancer (OD04566)	17.4
Normal Prostate Clontech A+ 6546-1	61.6	85975 Breast Cancer (OD04590- 01)	35.6
84140 Prostate Cancer (OD04410)	37.6	85976 Breast Cancer Mets (OD04590-03)	38.2
84141 Prostate NAT (OD04410)	29.7	87070 Breast Cancer Metastasis (OD04655-05)	23.7
87073 Prostate Cancer (OD04720- 01)	28.7	GENPAK Breast Cancer 064006	10.2
87074 Prostate NAT (OD04720- 02)	67.8	Breast Cancer Res. Gen. 1024	34.2
Normal Lung GENPAK 061010	14.0	Breast Cancer Clontech 9100266	17.8
83239 Lung Met to Muscle (ODO4286)	3.1	Breast NAT Clontech 9100265	19.9
83240 Muscle NAT (ODO4286)	5.2	Breast Cancer INVITROGEN A209073	41.8
84136 Lung Malignant Cancer (OD03126)	14.6	Breast NAT INVITROGEN A2090734	25.2
84137 Lung NAT (OD03126)	6.3	Normal Liver GENPAK 061009	2.4
84871 Lung Cancer (OD04404)	21.9	Liver Cancer GENPAK 064003	1.2
84872 Lung NAT (OD04404)	8.2	Liver Cancer Research Genetics RNA 1025	3.4
84875 Lung Cancer (OD04565)	13.5	Liver Cancer Research Genetics RNA 1026	2.8
84876 Lung NAT (OD04565)	3.7	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	7.3
85950 Lung Cancer (OD04237-01)	35.1	Paired Liver Tissue Research Genetics RNA 6004-N	1.0
85970 Lung NAT (OD04237-02)	9.2	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	1.9
83255 Ocular Mel Met to Liver (ODO4310)	6.7	Paired Liver Tissue Research Genetics RNA 6005-N	2.1
83256 Liver NAT (ODO4310)	6.2	Normal Bladder GENPAK 061001	15.8
84139 Melanoma Mets to Lung (OD04321)	60.7	Bladder Cancer Research Genetics RNA 1023	4.0
84138 Lung NAT (OD04321)	7.5	Bladder Cancer INVITROGEN A302173	13.2
Normal Kidney GENPAK 061008	35.1	87071 Bladder Cancer (OD04718- 01)	29.5
83786 Kidney Ca, Nuclear grade 2 (OD04338)	85.9	87072 Bladder Normal Adjacent (OD04718-03)	4.7
83787 Kidney NAT (OD04338)	28.7	Normal Ovary Res. Gen.	16.6
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	6.8	Ovarian Cancer GENPAK 064008	26.4
83789 Kidney NAT (OD04339)	64.6	87492 Ovary Cancer (OD04768- 07)	9.5
83790 Kidney Ca, Clear cell type (OD04340)	2.8	87493 Ovary NAT (OD04768-08)	3.0
83791 Kidney NAT (OD04340)	27.2	Normal Stomach GENPAK 061017	15.9
83792 Kidney Ca, Nuclear grade 3 (OD04348)	2.7	Gastric Cancer Clontech 9060358	2.8

83793 Kidney NAT (OD04348)	14.9	NAT Stomach Clontech 9060359	9.6
87474 Kidney Cancer (OD04622-01)	8.7	Gastric Cancer Clontech 9060395	21.5
87475 Kidney NAT (OD04622-03)	9.9	NAT Stomach Clontech 9060394	10.5
85973 Kidney Cancer (OD04450-01)	36.9	Gastric Cancer Clontech 9060397	25.7
85974 Kidney NAT (OD04450-03)	16.6	NAT Stomach Clontech 9060396	5.1
Kidney Cancer Clontech 8120607	20.2	Gastric Cancer GENPAK 064005	6.9

Table 68. Panel 4D

Tissue Name	Relative Expression(%)	
	4dx4tm4234t ag2176_a2	4dtm4276t ag2176
93768_Secondary Th1_anti-CD28/anti-CD3	0.8	0.9
93769_Secondary Th2_anti-CD28/anti-CD3	0.6	0.7
93770_Secondary Tr1_anti-CD28/anti-CD3	0.8	1.7
93573_Secondary Th1_resting day 4-6 in IL-2	0.2	1.3
93572_Secondary Th2_resting day 4-6 in IL-2	0.2	0.3
93571_Secondary Tr1_resting day 4-6 in IL-2	0.3	1.4
93568_primary Th1_anti-CD28/anti-CD3	0.4	0.8
93569_primary Th2_anti-CD28/anti-CD3	0.0	0.9
93570_primary Tr1_anti-CD28/anti-CD3	0.4	0.2
93565_primary Th1_resting dy 4-6 in IL-2	0.9	2.2
93566_primary Th2_resting dy 4-6 in IL-2	0.4	0.9
93567_primary Tr1_resting dy 4-6 in IL-2	0.1	0.7
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0.8	1.6
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0.6	0.5
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.7	0.8
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.4	0.3
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	1.1
93354_CD4_none	0.1	0.2
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.6	0.2
93103_LAK cells_resting	0.7	1.0
93788_LAK cells_IL-2	0.3	0.5
93787_LAK cells_IL-2+IL-12	0.4	0.4
93789_LAK cells_IL-2+IFN gamma	0.4	0.2
93790_LAK cells_IL-2+ IL-18	0.6	0.9
93104_LAK cells_PMA/ionomycin and IL-18	0.3	1.5
93578_NK Cells IL-2_resting	0.2	1.2
93109_Mixed Lymphocyte Reaction_Two Way MLR	0.6	1.1
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.4	0.2
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.5	0.2
93112_Mononuclear Cells (PBMCs)_resting	0.1	0.1
93113_Mononuclear Cells (PBMCs)_PWM	0.7	1.2
93114_Mononuclear Cells (PBMCs)_PHA-L	0.2	0.5
93249_Ramos (B cell)_none	0.0	0.0
93250_Ramos (B cell)_ionomycin	0.0	0.3
93349_B lymphocytes_PWM	0.8	0.6

93350_B lymphocytes_CD40L and IL-4	1.1	0.3
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.8	0.8
93248_EOL-1 (Eosinophil)_dbcAMP/PMA/ionomycin	8.9	11.6
93356_Dendritic Cells_none	0.7	0.0
93355_Dendritic Cells_LPS 100 ng/ml	0.8	0.2
93775_Dendritic Cells_anti-CD40	0.9	0.4
93774_Monocytes_resting	0.7	0.5
93776_Monocytes_LPS 50 ng/ml	0.5	0.4
93581_Macrophages_resting	0.0	0.8
93582_Macrophages_LPS 100 ng/ml	0.4	0.2
93098_HUVEC (Endothelial)_none	1.3	2.3
93099_HUVEC (Endothelial)_starved	2.8	6.0
93100_HUVEC (Endothelial)_IL-1b	1.0	1.8
93779_HUVEC (Endothelial)_IFN gamma	3.6	6.9
93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.6	0.4
93101_HUVEC (Endothelial)_TNF alpha + IL4	1.6	2.6
93781_HUVEC (Endothelial)_IL-11	6.4	3.2
93583_Lung Microvascular Endothelial Cells_none	2.5	5.0
93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	1.3	1.6
92662_Microvascular Dermal endothelium_none	5.3	4.9
92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	1.2	3.3
93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	1.7	7.3
93347_Small Airway Epithelium_none	2.3	3.2
93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	6.3	7.9
92668_Coronary Artery SMC_resting	0.5	1.7
92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.9	3.5
93107_astrocytes_resting	100.0	100.0
93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	70.6	65.5
92666_KU-812 (Basophil)_resting	0.9	0.6
92667_KU-812 (Basophil)_PMA/ionomycin	2.7	1.5
93579_CCD1106 (Keratinocytes)_none	3.5	2.4
93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.8	3.6
93791_Liver Cirrhosis	1.1	1.5
93792_Lupus Kidney	2.7	2.1
93577_NCI-H292	8.7	9.6
93358_NCI-H292_IL-4	10.3	14.3
93360_NCI-H292_IL-9	10.4	15.5
93359_NCI-H292_IL-13	7.9	14.0
93357_NCI-H292_IFN gamma	6.8	10.9
93777_HPAEC_-	2.4	3.8
93778_HPAEC_IL-1 beta/TNA alpha	2.1	3.1
93254_Normal Human Lung Fibroblast_none	1.7	1.4
93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	2.1	0.4
93257_Normal Human Lung Fibroblast_IL-4	1.2	2.8

102631_Cing Gyr Alzheimer's2	11.6	102615_Temp Pole PSP2	4.0
102649_BA4 Parkinson's	31.4	102616_Cing Gyr PSP2	10.3
102650_BA7 Parkinson's	13.4	102588_BA4 Depression	10.9
102648_BA9 Parkinson's	21.8	102589_BA7 Depression	8.3
102651_BA17 Parkinson's	37.8	102587_BA9 Depression	6.2
102652_Glob Palladus Parkinson's	60.3	102590_BA17 Depression	15.7
102653_Temp Pole Parkinson's	23.3	102591_Glob Palladus Depression	9.4
102654_Cing Gyr Parkinson's	35.4	102592_Sub Nigra Depression	18.2
102656_BA4 Parkinson's2	44.2	102594_Cing Gyr Depression	13.4
102657_BA7 Parkinson's2	26.2	102596_BA4 Depression2	5.8
102655_BA9 Parkinson's2	29.4	102595_BA9 Depression2	4.5
102658_BA17 Parkinson's2	34.7	102597_BA17 Depression2	21.1
102659_Glob Palladus Parkinson's2	26.5	102599_Sub Nigra Depression2	15.0
102660_Sub Nigra Parkinson's2	95.6	102600_Temp Pole Depression2	9.0
102661_Temp Pole Parkinson's2	19.7	102601_Cing Gyr Depression2	22.5

Table 70. Panel CNS neurodegeneration_V1.0

Tissue Name	Relative Expression(%) tm7006t_ ag2176_b1_s1	Tissue Name	Relative Expression(%) tm7006t_ ag2176_b1_s1
AD 1 Hippo	15.4	Control (Path) 3 Temporal Ctx	7.2
AD 2 Hippo	42.7	Control (Path) 4 Temporal Ctx	22.1
AD 3 Hippo	7.0	AD 1 Occipital Ctx	16.7
AD 4 Hippo	10.4	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	63.1	AD 3 Occipital Ctx	6.4
AD 6 Hippo	68.0	AD 4 Occipital Ctx	27.4
Control 2 Hippo	47.6	AD 5 Occipital Ctx	57.8
Control 4 Hippo	19.3	AD 6 Occipital Ctx	18.3
Control (Path) 3 Hippo	6.6	Control 1 Occipital Ctx	6.3
AD 1 Temporal Ctx	16.8	Control 2 Occipital Ctx	80.9
AD 2 Temporal Ctx	41.3	Control 3 Occipital Ctx	15.8
AD 3 Temporal Ctx	5.5	Control 4 Occipital Ctx	16.1
AD 4 Temporal Ctx	23.2	Control (Path) 1 Occipital Ctx	100.0
AD 5 Inf Temporal Ctx	96.7	Control (Path) 2 Occipital Ctx	8.3
AD 5 Sup Temporal Ctx	55.1	Control (Path) 3 Occipital Ctx	6.6
AD 6 Inf Temporal Ctx	57.5	Control (Path) 4 Occipital Ctx	9.7
AD 6 Sup Temporal Ctx	60.0	Control 1 Parietal Ctx	13.2
Control 1 Temporal Ctx	9.6	Control 2 Parietal Ctx	32.2
Control 2 Temporal Ctx	51.3	Control 3 Parietal Ctx	23.8
Control 3 Temporal Ctx	17.4	Control (Path) 1 Parietal Ctx	68.7
Control 3 Temporal Ctx	17.3	Control (Path) 2 Parietal Ctx	28.2
Control (Path) 1 Temporal Ctx	51.9	Control (Path) 3 Parietal Ctx	6.4
Control (Path) 2 Temporal Ctx	28.7	Control (Path) 4 Parietal Ctx	29.5

Panel 1.3D Summary Expression of the NOV9A gene is ubiquitous among the samples in this panel, with highest expression seen in the hippocampus (CT=25.1). The highly

brain-preferential pattern of expression of this gene indicates a role in normal adult brain function. Please see Panel CNS_1 for further discussion of potential utility in the central nervous system.

Among tissues with metabolic function, the NOV9A gene has moderate expression in a variety of metabolic tissues including adrenal gland, adult and fetal heart, adult and fetal liver, adult and fetal skeletal muscle, pancreas and thyroid. Thus, this gene product may be a protein therapeutic for the treatment of diseases that affect these tissues, including obesity and diabetes.

Panel 2D Summary The NOV9A gene is widely expressed among the samples in this panel, with highest expression detected in normal kidney tissue adjacent to a kidney cancer (CT=28.7). In addition, other tissue samples derived from normal margin to kidney cancers appear to express this gene. Thus, the expression of this gene could be used to distinguish normal kidney tissue adjacent to malignant kidney. Moreover, therapeutic modulation of the expression or function of this gene or gene product, through the use of small molecule drugs, antibodies or protein therapeutics, might be of benefit in the treatment of kidney cancer.

Panel 4D Summary The results from two experiments with the same probe and primer set are in very good agreement, with highest expression in astrocytes (CTs=27-28). Furthermore, expression of the NOV9A gene, which encodes a putative immunoglobulin domain containing protein, is higher in activated astrocytes when compared to resting astrocytes. Activated astrocytes play a role in the pathogenesis of multiple sclerosis (See reference 1). Thus, the NOV9A gene product could be used as a protein therapeutic for the reduction or elimination of the symptoms in patients suffering from multiple sclerosis.

Panel CNS_1 Summary This gene appears to be widely expressed across all regions of the brain and in all disease states represented in this panel. Apparent reduced expression in the primary motor strip (BA4 region) of an Alzheimer's brain suggests an association of the function of the NOV9A gene product with this neurodegenerative pathology. In addition, a less pronounced, but still evident, decreased expression of the NOV9A gene in the primary motor strip (BA4) of Huntington's disease brains suggests a possible general role in neurodegeneration in this brain region. The combination of brain-preferential expression and dysregulation in neurodegenerative diseases seen in this panel indicates potential utility of the NOV9A gene product as a specific mediator of CNS disorders. Therefore, agents that modulate the action of the protein encoded by the NOV9A gene may have utility in the treatment of CNS disorders.

CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio) SNB-19	0.0	Mammary gland	0.0
CNS ca. (glio) U251	0.0	Breast ca.* (pl. effusion) MCF-7	0.0
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.0	Breast ca.* (pl. effusion) T47D	0.0
Heart	0.0	Breast ca. BT-549	0.0
Fetal Skeletal	1.5	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.8	Ovarian ca. OVCAR-4	0.0
Spleen	0.0	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	0.0
Colorectal	1.0	Ovarian ca. IGROV-1	0.0
Stomach	0.0	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	0.0	Uterus	0.0
Colon ca. SW480	100.0	Placenta	0.0
Colon ca.* (SW480 met)SW620	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	1.7
Colon ca. CaCo-2	5.1	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	1.2
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	0.0	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	0.5

Table 73. Panel 4D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	4dtm4365f_ ag1858		4dtm4365f_ ag1858
93768_Secondary Th1_anti- CD28/anti-CD3	0.0	93100_HUVEC (Endothelial)_IL- 1b	0.0
93769_Secondary Th2_anti- CD28/anti-CD3	0.0	93779_HUVEC (Endothelial)_IFN gamma	0.0
93770_Secondary Tr1_anti- CD28/anti-CD3	0.0	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0
93573_Secondary Th1_resting day 4-6 in IL-2	0.0	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	93781_HUVEC (Endothelial)_IL- 11	0.0
93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	93583_Lung Microvascular Endothelial Cells_none	0.0
93568_primary Th1_anti- CD28/anti-CD3	0.0	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93569_primary Th2_anti- CD28/anti-CD3	11.0	92662_Microvascular Dermal endothelium_none	0.0

93570_primary Tr1_anti-CD28/anti-CD3	0.0	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93565_primary Th1_resting dy 4-6 in IL-2	3.5	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0
93566_primary Th2_resting dy 4-6 in IL-2	1.6	93347_Small Airway Epithelium_none	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	9.0	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	20.4
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0.0	92668_Coronary Artery SMC_resting	0.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0.0	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.0	93107_astrocytes_resting	0.0
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.0	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	10.3
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	92666_KU-812 (Basophil)_resting	0.0
93354_CD4_none	2.0	92667_KU-812 (Basophil)_PMA/ionomycin	0.0
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.0	93579_CCD1106 (Keratinocytes)_none	0.0
93103_LAK cells_resting	0.0	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0
93788_LAK cells_IL-2	1.4	93791_Liver Cirrhosis	33.0
93787_LAK cells_IL-2+IL-12	20.3	93792_Lupus Kidney	2.4
93789_LAK cells_IL-2+IFN gamma	0.0	93577_NCI-H292	71.7
93790_LAK cells_IL-2+ IL-18	0.0	93358_NCI-H292_IL-4	0.0
93104_LAK cells_PMA/ionomycin and IL-18	0.0	93360_NCI-H292_IL-9	0.0
93578_NK Cells_IL-2_resting	0.0	93359_NCI-H292_IL-13	0.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	0.0	93357_NCI-H292_IFN gamma	0.0
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.0	93777_HPAEC_-	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.0	93778_HPAEC_IL-1 beta/TNA alpha	0.0
93112_Mononuclear Cells (PBMCs)_resting	0.0	93254_Normal Human Lung Fibroblast_none	0.0
93113_Mononuclear Cells (PBMCs)_PWM	0.0	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0
93114_Mononuclear Cells (PBMCs)_PHA-L	0.0	93257_Normal Human Lung Fibroblast_IL-4	0.0
93249_Ramos (B cell)_none	0.0	93256_Normal Human Lung Fibroblast_IL-9	0.0
93250_Ramos (B cell)_ionomycin	0.0	93255_Normal Human Lung Fibroblast_IL-13	100.0
93349_B lymphocytes_PWM	0.0	93258_Normal Human Lung Fibroblast_IFN gamma	0.0
93350_B lymphocytes_CD40L and IL-4	0.0	93106_Dermal Fibroblasts CCD1070_resting	0.0

92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	0.0
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionom ycin	0.0	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0
93356_Dendritic Cells_none	0.0	93772_dermal fibroblast_IFN gamma	0.0
93355_Dendritic Cells_LPS 100 ng/ml	0.0	93771_dermal fibroblast_IL-4	0.0
93775_Dendritic Cells_anti-CD40	0.0	93260_IBD Colitis 2	0.0
93774_Monocytes_resting	10.6	93261_IBD Crohns	0.0
93776_Monocytes_LPS 50 ng/ml	0.0	735010_Colon_normal	7.5
93581_Macrophages_resting	0.0	735019_Lung_none	29.1
93582_Macrophages_LPS 100 ng/ml	0.0	64028-1_Thymus_none	0.0
93098_HUVEC (Endothelial)_none	0.0	64030-1_Kidney_none	74.2
93099_HUVEC (Endothelial)_starved	0.0		

Panel 1.3D Summary Expression of the NOV10A gene is limited to a sample derived from a colon cancer cell line (CT=31.4) in this panel. Of note is the difference between SW480 cells and the genetically related metastatic variant, SW620, which showed much lower expression of this gene. Thus, the expression of this gene could be used to distinguish SW480 cells from the rest of the samples on the panel, and specifically the SW620 metastatic variant.

Panel 2.2 Summary Expression of the NOV10A gene is low/undetectable (Ct values >35) in all samples in Panels 2.2. (Data not shown.)

Panel 4D Summary Expression of the NOV10A gene in panel 4D is limited to IL-13 stimulated lung fibroblasts (CT=33.5) and the mucoepidermoid cell line NCI-H292. The NOV10A gene, a basic cytokeratin homolog, may be useful as a small molecule target for the discovery of therapeutics to reduce or eliminate the symptoms of lung diseases such as asthma, emphysema, and chronic obstructive pulmonary disease. Furthermore, the NOV10A gene product may be useful as a diagnostic marker for the cells in these diseases.

NOV10b: Type II Cytokeratin

Expression of the NOV10b gene (GSAC055715_C) was assessed using the primer-probe set Ag1857 described in Table 74. Results from RTQ-PCR runs are shown in Tables 75-77.

Table 74. Probe Name Ag1857

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-ATCAGGTGCTAGAGACCAAGTG-3'	58.5	22	514	200
Probe	TET-5'-CCTCCTACAGCAGCTGGACTTGAACA-3'-TAMRA	68.8	26	539	201
Reverse	5'-ATAAATGGGCTCCAGGTTCTT-3'	59	21	573	202

Table 75. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.3dtm4357t _ag1857		1.3dtm4357t _ag1857
Liver adenocarcinoma	0.0	Kidney (fetal)	0.3
Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.3	Renal ca. A498	0.0
Adrenal gland	0.6	Renal ca. RXF 393	0.0
Thyroid	0.0	Renal ca. ACHN	0.0
Salivary gland	2.6	Renal ca. UO-31	0.0
Pituitary gland	0.0	Renal ca. TK-10	0.0
Brain (fetal)	0.0	Liver	0.7
Brain (whole)	0.3	Liver (fetal)	0.3
Brain (amygdala)	0.0	Liver ca. (hepatoblast) HepG2	0.3
Brain (cerebellum)	0.4	Lung	6.7
Brain (hippocampus)	0.0	Lung (fetal)	0.8
Brain (substantia nigra)	0.0	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	0.0	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	0.6	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	0.0	Lung ca. (large cell)NCI-H460	0.0
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.0
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (astro) SW1783	0.0	Lung ca (non-s.cell) HOP-62	0.0
CNS ca.* (neuro; met) SK-N-AS	0.3	Lung ca. (non-s.cl) NCI-H522	0.0
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio) SNB-19	0.0	Mammary gland	0.0
CNS ca. (glio) U251	0.0	Breast ca.* (pl. effusion) MCF-7	0.0
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.0	Breast ca.* (pl. effusion) T47D	0.0
Heart	0.0	Breast ca. BT-549	0.9
Fetal Skeletal	0.9	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	2.5	Ovarian ca. OVCAR-3	0.0
Thymus	1.8	Ovarian ca. OVCAR-4	0.0
Spleen	6.8	Ovarian ca. OVCAR-5	0.0
Lymph node	19.9	Ovarian ca. OVCAR-8	0.0
Colorectal	0.0	Ovarian ca. IGROV-1	0.4
Stomach	2.6	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	22.5	Uterus	0.0
Colon ca. SW480	0.9	Placenta	0.5
Colon ca.* (SW480 met)SW620	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	100.0
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0

83219 CC Well to Mod Diff (ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMV1	0.0
Trachea	3.8	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	0.3

Table 76. Panel 2D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2dtm4358t _ag1857		2dtm4358t _ag1857
Normal Colon GENPAK 061003	0.0	Kidney NAT Clontech 8120608	0.0
83219 CC Well to Mod Diff (ODO3866)	6.2	Kidney Cancer Clontech 8120613	5.0
83220 CC NAT (ODO3866)	11.4	Kidney NAT Clontech 8120614	0.0
83221 CC Gr.2 rectosigmoid (ODO3868)	0.0	Kidney Cancer Clontech 9010320	0.0
83222 CC NAT (ODO3868)	0.0	Kidney NAT Clontech 9010321	0.0
83235 CC Mod Diff (ODO3920)	5.6	Normal Uterus GENPAK 061018	0.0
83236 CC NAT (ODO3920)	0.0	Uterus Cancer GENPAK 064011	0.0
83237 CC Gr.2 ascend colon (ODO3921)	0.0	Normal Thyroid Clontech A+ 6570-1	4.3
83238 CC NAT (ODO3921)	50.0	Thyroid Cancer GENPAK 064010	10.7
83241 CC from Partial Hepatectomy (ODO4309)	11.6	Thyroid Cancer INVITROGEN A302152	4.8
83242 Liver NAT (ODO4309)	0.0	Thyroid NAT INVITROGEN A302153	3.9
87472 Colon mets to lung (OD04451-01)	0.0	Normal Breast GENPAK 061019	6.0
87473 Lung NAT (OD04451-02)	0.0	84877 Breast Cancer (OD04566)	0.0
Normal Prostate Clontech A+ 6546-1	0.0	85975 Breast Cancer (OD04590-01)	0.0
84140 Prostate Cancer (OD04410)	0.0	85976 Breast Cancer Mets (OD04590-03)	0.0
84141 Prostate NAT (OD04410)	0.0	87070 Breast Cancer Metastasis (OD04655-05)	85.3
87073 Prostate Cancer (OD04720-01)	0.0	GENPAK Breast Cancer 064006	5.5
87074 Prostate NAT (OD04720-02)	0.0	Breast Cancer Res. Gen. 1024	46.3
Normal Lung GENPAK 061010	97.3	Breast Cancer Clontech 9100266	92.7
83239 Lung Met to Muscle (ODO4286)	4.5	Breast NAT Clontech 9100265	100.0
83240 Muscle NAT (ODO4286)	0.0	Breast Cancer INVITROGEN A209073	19.2
84136 Lung Malignant Cancer (OD03126)	7.0	Breast NAT INVITROGEN A2090734	0.0
84137 Lung NAT (OD03126)	17.6	Normal Liver GENPAK 061009	11.7
84871 Lung Cancer (OD04404)	6.5	Liver Cancer GENPAK 064003	0.0
84872 Lung NAT (OD04404)	0.0	Liver Cancer Research Genetics RNA 1025	0.0
84875 Lung Cancer (OD04565)	0.0	Liver Cancer Research Genetics RNA 1026	0.0

84876 Lung NAT (OD04565)	11.2	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	0.0
85950 Lung Cancer (OD04237-01)	0.0	Paired Liver Tissue Research Genetics RNA 6004-N	9.6
85970 Lung NAT (OD04237-02)	0.0	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	0.0
83255 Ocular Mel Met to Liver (ODO4310)	0.0	Paired Liver Tissue Research Genetics RNA 6005-N	0.0
83256 Liver NAT (ODO4310)	0.0	Normal Bladder GENPAK 061001	1.4
84139 Melanoma Mets to Lung (OD04321)	0.0	Bladder Cancer Research Genetics RNA 1023	36.3
84138 Lung NAT (OD04321)	0.0	Bladder Cancer INVITROGEN A302173	68.3
Normal Kidney GENPAK 061008	42.6	87071 Bladder Cancer (OD04718-01)	0.0
83786 Kidney Ca, Nuclear grade 2 (OD04338)	0.0	87072 Bladder Normal Adjacent (OD04718-03)	0.0
83787 Kidney NAT (OD04338)	7.1	Normal Ovary Res. Gen.	0.0
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	15.0	Ovarian Cancer GENPAK 064008	5.9
83789 Kidney NAT (OD04339)	0.0	87492 Ovary Cancer (OD04768-07)	0.0
83790 Kidney Ca, Clear cell type (OD04340)	0.0	87493 Ovary NAT (OD04768-08)	0.0
83791 Kidney NAT (OD04340)	0.0	Normal Stomach GENPAK 061017	0.0
83792 Kidney Ca, Nuclear grade 3 (OD04348)	0.0	Gastric Cancer Clontech 9060358	0.0
83793 Kidney NAT (OD04348)	8.1	NAT Stomach Clontech 9060359	0.0
87474 Kidney Cancer (OD04622-01)	0.0	Gastric Cancer Clontech 9060395	4.2
87475 Kidney NAT (OD04622-03)	0.0	NAT Stomach Clontech 9060394	13.3
85973 Kidney Cancer (OD04450-01)	0.0	Gastric Cancer Clontech 9060397	0.0
85974 Kidney NAT (OD04450-03)	0.0	NAT Stomach Clontech 9060396	0.0
Kidney Cancer Clontech 8120607	0.0	Gastric Cancer GENPAK 064005	24.3

Table 77. Panel 4D

Tissue Name	Relative Expression(%) 4dtm4359t _ag1857	Tissue Name	Relative Expression(%) 4dtm4359t _ag1857
93768_Secondary Th1_anti-CD28/anti-CD3	0.0	93100_HUVEC (Endothelial)_IL-1b	0.0
93769_Secondary Th2_anti-CD28/anti-CD3	0.0	93779_HUVEC (Endothelial)_IFN gamma	0.0
93770_Secondary Tr1_anti-CD28/anti-CD3	0.0	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0
93573_Secondary Th1_resting day 4-6 in IL-2	1.6	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.9	93781_HUVEC (Endothelial)_IL-11	0.0
93571_Secondary Tr1_resting day 4-6 in IL-2	4.9	93583_Lung Microvascular Endothelial Cells_none	1.9
93568_primary Th1_anti-CD28/anti-CD3	0.0	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml)	0.0

		and IL1b (1 ng/ml)	
93569_primary Th2_anti-CD28/anti-CD3	0.0	92662_Microvascular Dermal endothelium_none	1.6
93570_primary Tr1_anti-CD28/anti-CD3	0.0	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93565_primary Th1_resting dy 4-6 in IL-2	100.0	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0
93566_primary Th2_resting dy 4-6 in IL-2	42.3	93347_Small Airway Epithelium_none	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	15.0	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	1.8	92668_Coronary Artery SMC_resting	1.9
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	9.2	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	2.2	93107_astrocytes_resting	0.0
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	6.3	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	92666_KU-812 (Basophil)_resting	3.5
93354_CD4_none	81.2	92667_KU-812 (Basophil)_PMA/ionomycin	1.9
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	10.0	93579_CCD1106 (Keratinocytes)_none	0.0
93103_LAK cells_resting	9.6	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0
93788_LAK cells_IL-2	18.4	93791_Liver Cirrhosis	7.0
93787_LAK cells_IL-2+IL-12	1.8	93792_Lupus Kidney	0.8
93789_LAK cells_IL-2+IFN gamma	2.3	93577_NCI-H292	0.0
93790_LAK cells_IL-2+ IL-18	3.9	93358_NCI-H292_IL-4	0.0
93104_LAK cells_PMA/ionomycin and IL-18	0.7	93360_NCI-H292_IL-9	0.0
93578_NK Cells_IL-2_resting	13.6	93359_NCI-H292_IL-13	0.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	19.5	93357_NCI-H292_IFN gamma	0.0
93110_Mixed Lymphocyte Reaction_Two Way MLR	1.0	93777_HPAEC_-	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	10.2	93778_HPAEC_IL-1 beta/TNA alpha	0.0
93112_Mononuclear Cells (PBMCs)_resting	32.1	93254_Normal Human Lung Fibroblast_none	0.0
93113_Mononuclear Cells (PBMCs)_PWM	2.2	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0
93114_Mononuclear Cells (PBMCs)_PHA-L	3.1	93257_Normal Human Lung Fibroblast_IL-4	0.0
93249_Ramos (B cell)_none	0.0	93256_Normal Human Lung Fibroblast_IL-9	0.0
93250_Ramos (B cell)_ionomycin	0.0	93255_Normal Human Lung Fibroblast_IL-13	0.0
93349_B lymphocytes_PWM	0.0	93258_Normal Human Lung	0.0

		Fibroblast_IFN gamma	
93350_B lymphocytes_CD40L and IL-4	1.0	93106_Dermal Fibroblasts CCD1070_resting	0.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	1.8
93248_EOL-1 (Eosinophil)_dbcAMP/PMA/ionomycin	0.0	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0
93356_Dendritic Cells_none	1.0	93772_dermal fibroblast_IFN gamma	0.0
93355_Dendritic Cells_LPS 100 ng/ml	0.0	93771_dermal fibroblast_IL-4	0.7
93775_Dendritic Cells_anti-CD40	0.0	93260_IBD Colitis 2	0.0
93774_Monocytes_resting	2.7	93261_IBD Crohns	2.2
93776_Monocytes_LPS 50 ng/ml	0.0	735010_Colon_normal	8.0
93581_Macrophages_resting	4.8	735019_Lung_none	2.8
93582_Macrophages_LPS 100 ng/ml	0.0	64028-1_Thymus_none	0.0
93098_HUVEC (Endothelial)_none	0.0	64030-1_Kidney_none	17.2
93099_HUVEC (Endothelial)_starved	0.0		

Panel 1.3D Summary Expression of the NOV10b gene is highest in the testis (CT=29.4), with low but significant expression also detected in the lung, lymph node and small intestine. Thus, the expression of the NOV10b gene could be used to distinguish testis from the other samples in the panel.

Panel 2D Summary Expression of the NOV10b gene is highest in a sample from normal breast tissue adjacent to a breast cancer (CT=32.9) with low but significant expression also detected in the breast cancer, bladder cancer, normal lung tissue, and a sample derived from normal tissue adjacent to a colon cancer. Thus, the expression of the NOV10b gene could be used to distinguish these tissue samples from the rest of the samples in the panel.

Panel 4D Summary Expression of the NOV10b gene is highest in resting Th1 lymphocytes (CT=30.7), with significant expression also seen in resting Th2 cells. Lower levels of expression levels are detected in activated Th1 and Th2 cells. The NOV10b gene encodes a basic cytokeratin homolog and may be useful as a small molecule target for the discovery of therapeutics that can reduce or eliminate the symptoms of autoimmune and inflammatory diseases such as lupus erythematosus, Crohn's disease, ulcerative colitis, asthma, psoriasis, and rheumatoid arthritis. Furthermore, the NOV10b gene product may be useful as a diagnostic marker for Th1 and Th2 lymphocytes.

The NOV10b gene and the NOV10c gene (please see next entry) that encode these cytokeratin homologs are both found in the cytokeratin locus on chromosome 12. However, while all cytokeratins to date have been identified as epithelial cell markers, these novel gene

products are expressed in a restricted subset of T lymphocytes, as seen from the expression profile in Panel 4D. CLUSTALW alignment of these two novel lymphocyte cytokeratins is shown in Table 10G and demonstrates similarity along the entire length of the proteins.

NOV10c: Type II Cytokeratin

- 5 Expression of the NOV10c gene (GSAC055715_B) was assessed using the primer-probe set Ag1856 described in Table 78. Results from RTQ-PCR runs are shown in Tables 79-81.

Table 78. Probe Name Ag1856

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-AGCTGTCCCTGGATATTGAGAT-3'	59.1	22	1271	203
Probe	FAM-5'-CACCTACCGCAAGCTGCTGGAGG-3'-TAMRA	71.2	23	1296	204
Reverse	5'-TGGTATATTCTCCGGACATCCT-3'	59.7	22	1330	205

10

Table 79. Panel 1.3D

Tissue Name	Relative Expression(%) 1.3dtm4360f _ag1856	Tissue Name	Relative Expression(%) 1.3dtm4360f _ag1856
Liver adenocarcinoma	0.0	Kidney (fetal)	0.0
Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	3.3
Adrenal gland	2.4	Renal ca. RXF 393	0.0
Thyroid	0.0	Renal ca. ACHN	0.0
Salivary gland	7.1	Renal ca. UO-31	0.0
Pituitary gland	0.0	Renal ca. TK-10	0.0
Brain (fetal)	0.0	Liver	0.0
Brain (whole)	2.8	Liver (fetal)	3.2
Brain (amygdala)	0.0	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	0.0	Lung	52.9
Brain (hippocampus)	1.7	Lung (fetal)	13.0
Brain (substantia nigra)	0.0	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	0.0	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	0.0	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	1.2	Lung ca. (large cell)NCI-H460	0.0
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.0
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (astro) SW1783	0.0	Lung ca (non-s.cell) HOP-62	0.0
CNS ca.* (neuro; met) SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio) SNB-19	0.0	Mammary gland	1.5
CNS ca. (glio) U251	0.0	Breast ca.* (pl. effusion) MCF-7	0.0

CNS ca. (glio) SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.0	Breast ca.* (pl. effusion) T47D	0.0
Heart	0.0	Breast ca. BT-549	0.0
Fetal Skeletal	2.1	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	14.4	Ovarian ca. OVCAR-3	0.0
Thymus	42.3	Ovarian ca. OVCAR-4	0.0
Spleen	36.3	Ovarian ca. OVCAR-5	0.0
Lymph node	59.0	Ovarian ca. OVCAR-8	0.0
Colorectal	2.7	Ovarian ca. IGROV-1	0.0
Stomach	5.7	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	100.0	Uterus	0.0
Colon ca. SW480	0.0	Placenta	3.0
Colon ca.* (SW480 met)SW620	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	2.0
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	21.3	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	0.0

Table 80. Panel 2D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2dtm4361f_ag1856		2dtm4361f_ag1856
Normal Colon GENPAK 061003	0.0	Kidney NAT Clontech 8120608	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	Kidney Cancer Clontech 8120613	0.0
83220 CC NAT (ODO3866)	19.5	Kidney NAT Clontech 8120614	0.0
83221 CC Gr.2 rectosigmoid (ODO3868)	0.0	Kidney Cancer Clontech 9010320	0.0
83222 CC NAT (ODO3868)	0.0	Kidney NAT Clontech 9010321	0.0
83235 CC Mod Diff (ODO3920)	0.0	Normal Uterus GENPAK 061018	0.0
83236 CC NAT (ODO3920)	2.7	Uterus Cancer GENPAK 064011	0.0
83237 CC Gr.2 ascend colon (ODO3921)	0.0	Normal Thyroid Clontech A+ 6570-1	6.7
83238 CC NAT (ODO3921)	13.2	Thyroid Cancer GENPAK 064010	0.0
83241 CC from Partial Hepatectomy (ODO4309)	12.5	Thyroid Cancer INVITROGEN A302152	0.0
83242 Liver NAT (ODO4309)	0.0	Thyroid NAT INVITROGEN A302153	0.0
87472 Colon mets to lung (OD04451-01)	12.6	Normal Breast GENPAK 061019	6.8
87473 Lung NAT (OD04451-02)	0.0	84877 Breast Cancer (OD04566)	0.0
Normal Prostate Clontech A+ 6546-1	0.0	85975 Breast Cancer (OD04590-01)	0.0

84140 Prostate Cancer (OD04410)	0.0	85976 Breast Cancer Mets (OD04590-03)	18.7
84141 Prostate NAT (OD04410)	7.5	87070 Breast Cancer Metastasis (OD04655-05)	85.9
87073 Prostate Cancer (OD04720-01)	0.0	GENPAK Breast Cancer 064006	6.2
87074 Prostate NAT (OD04720-02)	0.0	Breast Cancer Res. Gen. 1024	0.0
Normal Lung GENPAK 061010	55.9	Breast Cancer Clontech 9100266	62.0
83239 Lung Met to Muscle (ODO4286)	0.0	Breast NAT Clontech 9100265	100.0
83240 Muscle NAT (ODO4286)	0.0	Breast Cancer INVITROGEN A209073	0.0
84136 Lung Malignant Cancer (OD03126)	0.0	Breast NAT INVITROGEN A2090734	0.0
84137 Lung NAT (OD03126)	10.7	Normal Liver GENPAK 061009	0.0
84871 Lung Cancer (OD04404)	6.7	Liver Cancer GENPAK 064003	0.0
84872 Lung NAT (OD04404)	11.0	Liver Cancer Research Genetics RNA 1025	0.0
84875 Lung Cancer (OD04565)	0.0	Liver Cancer Research Genetics RNA 1026	0.0
84876 Lung NAT (OD04565)	20.4	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	0.0
85950 Lung Cancer (OD04237-01)	0.0	Paired Liver Tissue Research Genetics RNA 6004-N	0.0
85970 Lung NAT (OD04237-02)	5.0	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	0.0
83255 Ocular Mel Met to Liver (ODO4310)	0.0	Paired Liver Tissue Research Genetics RNA 6005-N	0.0
83256 Liver NAT (ODO4310)	0.0	Normal Bladder GENPAK 061001	0.0
84139 Melanoma Mets to Lung (OD04321)	0.0	Bladder Cancer Research Genetics RNA 1023	31.2
84138 Lung NAT (OD04321)	8.5	Bladder Cancer INVITROGEN A302173	41.5
Normal Kidney GENPAK 061008	6.7	87071 Bladder Cancer (OD04718-01)	0.0
83786 Kidney Ca, Nuclear grade 2 (OD04338)	0.0	87072 Bladder Normal Adjacent (OD04718-03)	18.6
83787 Kidney NAT (OD04338)	0.0	Normal Ovary Res. Gen.	0.0
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	0.0	Ovarian Cancer GENPAK 064008	4.2
83789 Kidney NAT (OD04339)	0.0	87492 Ovary Cancer (OD04768-07)	0.0
83790 Kidney Ca, Clear cell type (OD04340)	0.0	87493 Ovary NAT (OD04768-08)	0.0
83791 Kidney NAT (OD04340)	0.0	Normal Stomach GENPAK 061017	6.7
83792 Kidney Ca, Nuclear grade 3 (OD04348)	6.5	Gastric Cancer Clontech 9060358	0.0
83793 Kidney NAT (OD04348)	17.2	NAT Stomach Clontech 9060359	0.0
87474 Kidney Cancer (OD04622-01)	0.0	Gastric Cancer Clontech 9060395	0.0
87475 Kidney NAT (OD04622-03)	0.0	NAT Stomach Clontech 9060394	6.0
85973 Kidney Cancer (OD04450-01)	0.0	Gastric Cancer Clontech 9060397	0.0
85974 Kidney NAT (OD04450-03)	8.0	NAT Stomach Clontech 9060396	0.0
Kidney Cancer Clontech 8120607	0.0	Gastric Cancer GENPAK 064005	5.3

282

93104_LAK cells_PMA/ionomycin and IL-18	1.0	93360_NCI-H292_IL-9	0.0
93578_NK Cells IL-2_resting	17.1	93359_NCI-H292_IL-13	0.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	20.7	93357_NCI-H292_IFN gamma	0.0
93110_Mixed Lymphocyte Reaction_Two Way MLR	4.6	93777_HPAEC_-	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	9.7	93778_HPAEC_IL-1 beta/TNA alpha	0.0
93112_Mononuclear Cells (PBMcs)_resting	36.9	93254_Normal Human Lung Fibroblast_none	0.0
93113_Mononuclear Cells (PBMcs)_PWM	0.7	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0
93114_Mononuclear Cells (PBMcs)_PHA-L	0.8	93257_Normal Human Lung Fibroblast_IL-4	0.0
93249_Ramos (B cell)_none	0.0	93256_Normal Human Lung Fibroblast_IL-9	0.0
93250_Ramos (B cell)_ionomycin	0.0	93255_Normal Human Lung Fibroblast_IL-13	0.0
93349_B lymphocytes_PWM	0.0	93258_Normal Human Lung Fibroblast_IFN gamma	0.0
93350_B lymphocytes_CD40L and IL-4	0.0	93106_Dermal Fibroblasts CCD1070_resting	0.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	1.7
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	0.0	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0
93356_Dendritic Cells_none	0.7	93772_dermal fibroblast_IFN gamma	0.0
93355_Dendritic Cells_LPS 100 ng/ml	0.0	93771_dermal fibroblast_IL-4	0.0
93775_Dendritic Cells_anti-CD40	0.0	93260_IBD Colitis 2	0.0
93774_Monocytes_resting	1.2	93261_IBD Crohns	0.3
93776_Monocytes_LPS 50 ng/ml	0.6	735010_Colon_normal	2.8
93581_Macrophages_resting	3.7	735019_Lung_none	1.7
93582_Macrophages_LPS 100 ng/ml	0.0	64028-1_Thymus_none	0.0
93098_HUVEC (Endothelial)_none	0.0	64030-1_Kidney_none	19.5
93099_HUVEC (Endothelial)_starved	0.0		

Panel 1.3D Summary Highest expression of the NOV10c gene is detected in the small intestine (CT=31.4). The expression of this gene is highest in a sample derived from small intestine. In addition, this gene has an expression pattern restricted to lymph node, bone marrow, spleen, thymus, trachea, adult lung and fetal lung tissue. Thus the expression of this gene could be used to distinguish these tissues from other tissues in the panel.

Panel 2D Summary Highest expression of the NOV10c gene is seen in normal breast tissue adjacent to a breast cancer (CT=31.8). Low, but significant expression is also seen in normal lung tissue, as is seen in panel 1.3D and in some breast cancer samples. Thus, the

expression of this gene could be used to distinguish these tissue samples from the rest of the samples in the panel. Moreover, therapeutic modulation of the expression of this gene or the function of its protein product, through the use of small molecule drugs, antibodies or protein therapeutics, might be of benefit for the treatment of breast cancer.

- 5 **Panel 4D Summary** Highest expression of the gene is seen in untreated CD4 cells (CT=28.8). Significant expression is also seen in resting Th1 and Th2 lymphocytes, with lower levels of expression in activated Th1 and Th2 cells. The NOV10c gene encodes a cytokeratin homolog and may be useful as a small molecule target for the discovery of
- 10 therapeutics that can reduce or eliminate the symptoms of autoimmune and inflammatory diseases such as lupus erythematosus, Crohn's disease, ulcerative colitis, asthma, psoriasis, and rheumatoid arthritis. Furthermore, the NOV10c gene may be useful as a diagnostic marker for Th1 and Th2 lymphocytes.

10015145-111301

OTHER EMBODIMENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims.

10015115-11301
TOCTE 5115101